IL300525A

IL300525A - Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists

Info

Publication number: IL300525A
Application number: IL300525A
Authority: IL
Original assignee: Viva Star Biosciences Ltd
Priority date: 2020-08-11
Filing date: 2021-10-09
Publication date: 2023-04-01
Also published as: WO2022034568A1; JP2023544476A; MX2023001812A; EP4196220A1; KR20240068583A; CA3191452A1; AU2021323515A1; CN116669727A

Description

WO 2022/034568 PCT/IB2021/059266 TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS FIELD id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1"

[0001]This application relates to novel substituted azacyclohexyl acetic acid compounds and analogues, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPAR).

BACKGROUND id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2"

[0002]Lysophosphatidic acid (LPA) is a small glycerolphospholipid (1- or 2-acyl-sn-glycerol 3- phosphate) with a molecular weight of 430 - 480 Dalton, consisting of a glycerol backbone which is esterified with a phosphate group and a fatty acid with variable chain length and degree of saturation (Yang and Chen, World J Gastroenterol 24:4132-4151, 2018). LPA can be formed from precursor molecules in plasma, serum or tissues (membrane phospholipids) via several pathways: (1) hydrolysis of the choline group off lysophosphatidylcholine by lysophospholipase D (lysoPLD or autotaxin); (2) hydrolysis of a fatty acyl chain from phosphatidic acid to produce 2-acyl or 1- acyl LPA by phospholipase Al or A2; and (3) de novo synthesis from glycerol-3-phosphate by acyltransferases (Kihara et al., Experimental Cell Res 333:171-177, 2015). In tissues or cells, LPA represents a mixture of 1- or 2-acyl-sn-glycerol 3-phosphates. [0003]Lysophosphatidic acid (LPA) acts as a signaling molecule and exerts its effects by binding to G protein-coupled receptors, termed LPA receptors (LPAR). To date, there are six identified LPA receptors (LPAR1-6), which are expressed in various tissues and/or cells. LPA, through binding to its receptors, plays important roles in pathophysiological processes, such as autoimmune diseases, fibrotic diseases, cancer, inflammation, neuropathic pain, etc. (Budd and Qian, Future Med Chem 5:1935-52, 2013; Valdes-Rives and Gonzalez-Arenas, Mediators Inflamm 2017:9173090, 2017; Lopane et al., Biochim Biophys Acta Rev Cancer 1868:277-282, 2017; Ueda H. Pain 158 Suppl !:S55-S65, 2017). [0004]Fibrosis is a reparative (or "healing ") process characterized by the excessive accumulation of extracellular matrix (ECM). When tissue injury (caused by infections, autoimmune reactions, mechanical injuries, etc.) is chronic, a sustained production of pro-fibrotic mediators leads to an uncontrolled healing process, and the replacement of injured cells occurs with connective tissues WO 2022/034568 PCT/IB2021/059266 associated with over production of ECM (Weiskirchen et al., Molecular Aspects Med. 65:2-15, 2019). Because it alters organs ’ architecture and function, fibrosis is tightly associated with and often responsible for morbidity and mortality. It is estimated that 45% of all deaths in the developed world are attributed to some type of chronic fibrosis, such as idiopathic pulmonary fibrosis, systemic sclerosis, liver cirrhosis, chronic cardiovascular diseases, progressive kidney diseases (kidney fibrosis) or diabetes (Wynn T.A. Nat. Rev. Immunol. 4:583-594, 2004). [0005]The profibrotic action of LPA via binding to its receptor LPAR1 has been established in lung, liver and other organs or tissues with two main characteristics: 1) the existence of a positive correlation between the apparition of fibrosis markers and the increased production of LPA associated with an increased expression of the LPAR1; 2) the attenuation of fibrosis in LPAR1-/- mice or by treatment with LPAR antagonists (Rancoule et al., Expert Opin. Investig. Drugs 20:657- 667, 2011). For example, in the bleomycin model of pulmonary fibrosis, LPA levels increased significantly in the bronchoaveolar lavage fluid following lung injury, and mice lacking the LPARgene (LPAR1-/- mice) were remarkably protected from fibrosis and mortality (Tager et al., Nat. Med. 14:45-54, 2008). Treatment with small molecule LPAR1 antagonists could reduce the lung fibrosis in the bleomycin mouse model (Swanet et al., Br. J. Pharmacol. 160:1699-1713, 2010). More recently, in a chemical-induced cirrhosis and HCC rat model, the expression of Laprl was markedly increased in hepatic stellate cells, while lysoPLD (autotaxin) was higher in hepatocytes (Nakagawa et al., Cancer Cell. 30:879-890, 2016). Transcriptome analysis of human and rat liver tissues indicated that the LPA pathway via the activation of LPAR1 was a functional driver of cirrhosis and HCC. Consequently, inhibition of LPAR1 and lysoPLD by chemical inhibitors attenuated fibrosis progression and reduced HCC nodules in the cirrhosis-driven HCC rat model W. SUMMARY id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6"

[0006]In one aspect, the present invention relates to a compound of formula (I) WO 2022/034568 PCT/IB2021/059266 or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups; L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is C(=O)NR9R10, C(=O)OR10, or a ring selected from a 5- or 6-membered heteroaryl group or a 5- or 6-membered heterocyclyl group, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or an oxo group attached to a ring member, and wherein the ring is substituted with (R3)n and one R4; X1 is N, O or CR6a; X2 is N or NR6; X3 is N, NR6 or CR6, wherein the dashed circle denotes bonds forming a five-membered aromatic ring; Y1, Y2, Y3 and Y4 are each independently N or CR5, provided that at least one but no more than two of Y1, Y2, Y3 and Y4 are N; Z is CH2 or O; R1 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- calkyl-OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-ealkyl-NR aRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; R2 is (CR7R7)q-R8; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)p- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered WO 2022/034568 PCT/IB2021/059266 heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- 6alkyl-OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- ealkyl-NR aRb; each occurrence of R6a and R6 is independently hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or twoR 7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; R8 is C(=O)OR7, C(=O)NRaRb, CN, C(=O)NHC(=O)R7, C(=O)NHS(=O)2R7,H n ׳'N C(=O)NHS(=O)R7, S(=O)2R7, P(=O)(OH)2, or N ; each occurrence of R9 and R10is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2- 6alkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R12 at each occurrence is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring WO 2022/034568 PCT/IB2021/059266 containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; m is 1, or 2; n is 0, 1, or 2; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4. id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7"

[0007]The invention also relates to a pharmaceutical composition comprising a compound of formula (I), its manufacture and use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi). Accordingly, the compounds of formula (I) are useful for treatment of pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, demal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis.

DETAILED DESCRIPTION id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8"

[0008]In one aspect, the present technology provides compounds, and their pharmaceutically acceptable forms, including, but not limited to, salts, hydrates, solvates, isomers, sterioisomers, enantiomers, prodmgs, and isotopically labeled derivatives thereof. [0009]In another aspect, the present technology provides methods of treating and/or managing various diseases and disorders, which comprises administering to a patient a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, enantiomers, prodmgs, and isotopically labeled derivatives) thereof. Non-limiting examples of diseases and disorders are described herein. [0010]In another aspect, the present technology provides methods of preventing various diseases and disorders, which comprises administering to a patient in need of such prevention a prophylactically effective amount of a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, prodmgs, and isotopically labeled derivatives) thereof. Non-limiting examples of diseases and disorders are described herein.

WO 2022/034568 PCT/IB2021/059266 id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11"

[0011]In another aspect, the present technology, a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, prodrugs, and isotopically labeled derivatives) thereof, can be administered in combination with another drug ("second active agent") or treatment. Second active agents include small molecules and large molecules (e.g., proteins and antibodies). [0012]Also provided herein are pharmaceutical compositions (e.g., single unit dosage forms) that can be used in the methods provided herein. In one embodiment, pharmaceutical compositions comprise a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, prodrugs, and isotopically labeled derivatives) thereof, and optionally one or more second active agents. [0013]While specific embodiments have been discussed, the specification is illustrative only and not restrictive. Many variations of this disclosure will become apparent to those skilled in the art upon review of this specification. [0014]Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this specification pertains.

Definitions [0015]As used in the specification and claims, the singular form "a", "an" and "the" includes plural references unless the context clearly dictates otherwise. [0016]As used herein, "agent," "additional agent," "therapeutic agent, " or "second active agent" refers to a biological, pharmaceutical, or chemical compound or another moiety. Non-limiting examples include simple or complex organic or inorganic molecules, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, an antibody fragment, a vitamin, a vitamin derivative, a carbohydrate, a toxin, or a chemotherapeutic compound, and metabolites thereof. Various compounds can be synthesized, for example, small molecules and oligomers (e.g., oligopeptides and oligonucleotides), and synthetic organic compounds based on various core structures. In addition, various natural sources can provide active compounds, such as plant or animal extracts, and the like. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of this disclosure. [0017]"Administration " of a disclosed compound encompasses the delivery to a subject of a compound as described herein, or a prodrug or other pharmaceutically acceptable derivative thereof, using any suitable formulation or route of administration, as discussed herein.

WO 2022/034568 PCT/IB2021/059266 id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18"

[0018]The term "co-administration," "administered in combination with," and their grammatical equivalents, as used herein, encompasses administration of two or more agents to the subject so that both agents and/or their metabolites are present in the subject at the same time. Co- administration includes simultaneous administration in separate compositions, administration at separate times in separate compositions, or administration in a composition in which both agents are present. [0019]The term "effective amount" or "therapeutically effective amount" refers to that amount of a compound or pharmaceutical composition described herein that is sufficient to affect the intended application including, but not limited to, disease treatment, as illustrated below. In some embodiments, the amount is that effective for detectable inhibition of LPA1, which, for example, can be determined in an LPA1 functional antagonist assay. The therapeutically effective amount can vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a response in target cells, e.g., reduction of cell migration. The specific dose will vary depending on, for example, the compounds chosen, the species of subject and their age/existing health conditions or risk for health conditions, the dosing regimen to be followed, the severity of the disease, whether it is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried. [0020]All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. [0021]As used herein, the terms "treatment", "treating", "palliating" "managing " and "ameliorating" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient can still be afflicted with the underlying disorder. For prophylactic benefit, the pharmaceutical compounds and/or compositions can be administered to a patient at risk of developing a disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.

WO 2022/034568 PCT/IB2021/059266 id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22"

[0022]The terms "preventing " and "prophylaxis " as used herein refer to administering a pharmaceutical compound or medicament or a composition including the pharmaceutical compound or medicament to a subject before a disease, disorder, or condition fully manifests itself, to forestall the appearance and/or reduce the severity of one or more symptoms of the disease, disorder or condition. The person of ordinary skill in the art recognizes that the term "prevent " is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a disease, disorder or condition, or a symptom thereof, and this is the sense that such terms are used in this disclosure. [0023]A "therapeutic effect," as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. [0024]The "subjects" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including rodents (e.g., mice, rats), cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including birds such as chickens, ducks, geese, quail, and/or turkeys. [0025]The term "in vivo" refers to an event that takes place in a subject ’s body. In vivo also includes events occurring in rodents, such as rats, mice, guinea pigs, and the like. [0026]The term "in vitro" refers to an event that takes places outside of a subject ’s body. For example, an in vitro assay encompasses any assay conducted outside of a subject. In vitro assays encompass cell-based assays in which cells, alive or dead, are employed. In vitro assays also encompass cell-free assays in which no intact cells are employed. [0027]As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. (incorporated by referene herein) describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds provided herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, WO 2022/034568 PCT/IB2021/059266 sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentane propionate, digluconate, dodecyl sulfate, ethane sulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemi sulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoracetic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, and the like. [0028]The salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, such as by reacting the free base or free acid of a parent compound with a suitable base or acid, respectively. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl) 4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt can be chosen from ammonium, potassium, sodium, calcium, and magnesium salts. [0029]As used herein, the term "solvate" refers to compounds that further include a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. The solvate can be of a disclosed compound or a pharmaceutically acceptable salt thereof. Where the solvent is water, the solvate is a "hydrate". Pharmaceutically acceptable solvates and hydrates are complexes that, for example, can include 1 to about 100, or 1 to about 10, or 1 to about 2, about WO 2022/034568 PCT/IB2021/059266 or about 4, solvent or water molecules. It will be understood that the term "compound" as used herein encompasses the compound and solvates of the compound, as well as mixtures thereof. [0030]In some embodiments, the pharmaceutically acceptable form is a prodrug. As used herein, the term "prodrug" refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable form of the compound. A prodrug can be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood). In certain cases, a prodrug has improved physical and/or delivery properties over the parent compound. Prodrugs can increase the bioavailability of the compound when administered to a subject (e.g., by permitting enhanced absorption into the blood following oral administration) or which enhance delivery to a biological compartment of interest (e.g., the brain or lymphatic system) relative to the parent compound. Exemplary prodrugs include derivatives of a disclosed compound with enhanced aqueous solubility or active transport through the gut membrane, relative to the parent compound. [0031]The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7- 9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein. Exemplary advantages of a prodrug can include, but are not limited to, its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it can enhance absorption from the digestive tract, or it can enhance drug stability for long-term storage. [0032]The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject. Prodrugs of an active compound, as described herein, can be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like. Other examples of prodrugs include compounds that comprise -NO, -NO2, -ONO, or -ONO2moieties. Prodrugs can typically be WO 2022/034568 PCT/IB2021/059266 prepared using well known methods, such as those described in Burger’s Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., Sth ed., 1995), and Design of Prodrugs (H. Bundgaard ed., Elselvier, New York, 1985). [0033]For example, if a disclosed compound or a pharmaceutically acceptable form of the compound contains a carboxylic acid functional group, a prodrug can comprise a pharmaceutically acceptable ester formed by the replacement of the hydrogen atom of the acid group with a group such as (Ci-s)alkyl, (C1-12)alkanoyloxymethyl, 1- (alkanoyl oxy )ethyl having from 4 to 9 carbon atoms, 1 -methyl-l-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxy carbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxy carbonyloxy)ethyl having from 4 to 7 carbon atoms, 1 -methyl- 1 -(alkoxy carbonyl oxy )ethyl having from 5 to 10 carbon atoms, N-(alkoxycarbonyl)aminom ethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C1-2)alkylamino(C2-3)alkyl (such as [3-dimethylaminoethyl), carbamoyl-(C1-2)alkyl, N,N-di(C1-2)alkylcarbamoyl-(C1-2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-3)alkyl . [0034]Similarly, if a disclosed compound contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (Ci- 6)alkanoyloxymethyl, l-((C1-6)alkanoyloxy)ethyl,l-methyl-l-((C1-6)alkanoyloxy)ethyl, (Ci- 6)alkoxycarbonyloxymethyl, N-(C1-6)alkoxycarbonylaminomethyl, succinoyl, (Ci- 6)alkanoyl, a- amino(C1-4)alkanoyl, arylacyl, and a-aminoacyl, or a-aminoacyl-a- aminoacyl, where each a- aminoacyl group is independently selected from the naturally occurring L-amino acids, - P(O)(OH)2, -P(O)(O(C1-6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate). [0035]If a disclosed compound incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R-carbonyl, RO- carbonyl, NRR‘ -carbonyl where R and R’ are each independently selected from (Ci-io)alkyl, (C3- ?)cycloalkyl, benzyl, a natural a-aminoacyl or natural a-aminoacyl-natural-a-aminoacyl,- C(OH)C(O)OY1 wherein Y1 is H, (C1-6)alkyl or benzyl;-C(OY 2)Y3 whereinY 2 is (C1-4)alkyl and Y3 is (C1-6)alkyl, carboxy(C1-6)alkyl, amino(C1-4)alkyl or mono-N- or di-N,N-(C1- 6)alkylaminoalkyl; and -C(Y4)Y5 wherein Y4 is H or methyl andY 5 is mono-N- or di-N-(C6)alkylamino, morpholino, piperidin-l-yl or pyrrolidin-l-yl. [0036]In some embodiments, the disclosed compounds may encompass an isomer. "Isomers" are different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. As used herein, the term "isomer" includes any WO 2022/034568 PCT/IB2021/059266 and all geometric isomers and stereoisomers. For example, "isomers" include geometric double bond cis- and trans-isomers, also termed E- and Z-isomers; R- and S-enantiomers; diastereomers, (d)-isomers and (l)-isomers, racemic mixtures thereof; and other mixtures thereof, as falling within the scope of this disclosure. [0037]Geometric isomers can be represented by the symbol ---- which denotes a bond that can be a single, double or triple bond as described herein. Provided herein are various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon- carbon double bond or arrangement of substituents around a carbocyclic ring. Substituents around a carbon-carbon double bond are designated as being in the "Z" or "E" configuration wherein the terms "Z" and "E" are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the "E" and "Z" isomers. [0038]Substituents around a carbon-carbon double bond alternatively can be referred to as "cis" or"trans," where "cis" represents substituents on the same side of the double bond and "trans" represents substituents on opposite sides of the double bond. The arrangement of substituents around a carbocyclic ring can also be designated as "cis" or "trans." The term "cis" represents substituents on the same side of the plane of the ring, and the term "trans" represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated "cis/trans." [0039]"Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is an enantiomer, the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry at each asymmetric atom, as (R)- or (S)-. The present chemical entities, pharmaceutical compositions and methods are meant to include all such possible isomers, including racemic mixtures, optically substantially pure forms and intermediate mixtures. Optically active (R)- and (S)-isomers can be prepared, for example, using chiral synthons or chiral reagents, or resolved using conventional techniques. [0040]A mixture of a pair of enantiomers in any proportion can be known as a "racemic" mixture. The term "(±)" is used to designate a racemic mixture where appropriate. In some embodiments, WO 2022/034568 PCT/IB2021/059266 a compound of the present technology is a racemic mixture of (S)- and (R)-isomers. In some embodiments, the racemic mixture has equal amounts of two enantiomers. [0041]In some embodiments, an enantiomer is provided partly or substantially free of the corresponding enantiomer, and may be referred to as "optically enriched, " "enantiomerically enriched, " "enantiomerically pure, " and "non-racemic, " as used interchangeably herein. The "enantiomeric excess" or "% enantiomeric excess" of such a composition can be calculated using the equation shown below. In the example shown below, a composition contains 90% of one enantiomer, e.g., the S enantiomer, and 10% of the other enantiomer, e.g., the R enantiomer.ee=(90-10)7100=80%.Thus, a composition containing 90% of one enantiomer and 10% of the other enantiomer is said to have an enantiomeric excess of 80%. In some embodiments, compositions described herein contain an enantiomeric excess of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% of the S enantiomer, or a range between and including any two of the foregoing values (e.g., 50-99.5% ee). In other words, the compositions contain an enantiomeric excess of the S enantiomer over the R enantiomer. In other embodiments, some compositions described herein contain an enantiomeric excess of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% of the R enantiomer or a range between any two of the foregoing values (e.g., 50-99.5% ee). In other words, the compositions contain an enantiomeric excess of the R enantiomer over the S enantiomer. Where the enrichment of one enantiomer is much greater than about 80% by weight, the compositions are referred to as "substantially enantiomerically enriched," "substantially enantiomerically pure" or a "substantially non-racemic" preparation. [0042]Enantiomers can be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC), the formation and crystallization of chiral salts, or prepared by asymmetric syntheses. See, for example, Enantiomers, Racemates and Resolutions (Jacques, Ed., Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Stereochemistry of Carbon Compounds (E. L. Eliel, Ed., McGraw- Hill, NY, 1962); and Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. EIM, Ed., Univ, of Notre Dame Press, Notre Dame, Ind. 1972). [0043]Optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids include, but are not limited to, tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid. The separation of WO 2022/034568 PCT/IB2021/059266 the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts affords separation of the isomers. Another method involves synthesis of covalent diastereoisomeric molecules by reacting disclosed compounds with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically enriched compound. Optically active compounds can also be obtained by using active starting materials. In some embodiments, these isomers can be in the form of a free acid, a free base, an ester or a salt. [0044]In any embodiments, the pharmaceutically acceptable form is a tautomer. As used herein, the term "tautomer" is a type of isomer that includes two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). "Tautomerization" includes prototropic or proton-shift tautomerization, which is considered a subset of acid-base chemistry. "Prototropic tautomerization" or"proton-shift tautomerization" involves the migration of a proton accompanied by changes in bond order. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Where tautomerization is possible (e.g., in solution), a chemical equilibrium of tautomers can be reached. Tautomerizations (i.e., the reaction providing a tautomeric pair) can be catalyzed by acid or base, or can occur without the action or presence of an external agent. Exemplary tautomerizations include, but are not limited to, keto-to-enol; amide-to-imide; lactam-to-lactim; enamine-to-imine; and enamine-to-(a different) enamine tautomerizations. A specific example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-01 and pyridin-4(lH)-one tautomers. [0045]Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by13C- or 14C-enriched carbon are within the scope of this disclosure. [0046]The disclosure also embraces pharmaceutically acceptable forms that are "isotopically labeled derivatives " which are compounds that are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated WO 2022/034568 PCT/IB2021/059266 into disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C 14c, 15N, 18o, 17O,31P, 32P,35S, 18F, and 36Cl, respectively. Certain isotopically-labeled disclosed compounds (e.g., those labeled with 3H and 4C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes can allow for ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) can afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). Isotopically labeled disclosed compounds can generally be prepared by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. In some embodiments, provided herein are compounds that can also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds. All isotopic variations of the compounds as disclosed herein, whether radioactive or not, are encompassed within the scope of the present disclosure. In some embodiments, radiolabeled compounds are useful for studying metabolism and/or tissue distribution of the compounds or to alter the rate or path of metabolism or other aspects of biological functioning. [0047]"Pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The pharmaceutically acceptable carrier or excipient does not destroy the pharmacological activity of the disclosed compound and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions as disclosed herein is contemplated. Non-limiting examples of pharmaceutically acceptable carriers and excipients include sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as polyethylene glycol and propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate; coloring agents; releasing agents; coating agents; sweetening, flavoring and perfuming agents; preservatives; antioxidants; ion exchangers; alumina; aluminum stearate; lecithin; self emulsifying dmg delivery systems (SEDDS) such as d-atocopherol WO 2022/034568 PCT/IB2021/059266 polyethyleneglycol 1000 succinate; surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices; serum proteins such as human serum albumin; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; cellulose-based substances; polyacrylates; waxes; and polyethylene-polyoxypropylene-block polymers. Cyclodextrins such as a-, P־, and y-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3- hydroxypropyl-cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. [0048]Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sansalito,1999; Smith and March March’s Advanced Organic Chemistry, Sth ed., John Wiley & Sons, Inc., NewYork, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., NewYork, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd ed., Cambridge University Press, Cambridge, 1987. [0049]Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value and sub-range falling within the range, unless otherwise indicated herein, and each separate value and sub-range is incorporated into the specification as if it were individually recited herein. For example, "C1-6 alkyl" is intended to encompass, Cl, C2, C3, C4, C5, C6, Cl-6, Cl-5, Cl-4, Cl-3, Cl-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl. [0050]"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., C1-10 alkyl). Whenever it appears herein, a numerical range such as "1 to 10" refers to each integer in the given range; e.g., "1 to 10 carbon atoms" means that the alkyl group can consist of 1, 2, 3, ,4 5, 6, 7, 8, 9, or 10 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated. In some embodiments, alkyl groups have to 10, 1 to 8, 1 to 6, or 1 to 3 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl groups; while WO 2022/034568 PCT/IB2021/059266 saturated branched alkyls include, but are not limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2- methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like. The alkyl is attached to the parent molecule by a single bond. Unless stated otherwise in the specification, an alkyl group may be optionally substituted by one or more of substituents disclosed herein. In a non-limiting embodiment, a substituted alkyl can be selected from fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxy ethyl, 3- hydroxypropyl, benzyl, and phenethyl. [0051]"Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from two to ten carbon atoms (i.e., C2-10 alkenyl). Whenever it appears herein, a numerical range such as "2 to 10" refers to each integer in the given range; e.g., "2 to 10 carbon atoms" means that the alkenyl group can consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In any embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to six carbon atoms (e.g., C2-6 alkenyl). The alkenyl is attached to the parent molecular structure by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i.e., allyl), but- 1-enyl, pent-l-enyl, penta-1,4-dienyl, and the like. The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), 2-methylprop-2-enyl (C4), butadienyl (C4) and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), 2,3-dimethyl-2-butenyl (C6) and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8) and the like. Unless stated otherwise in the specification, an alkenyl group may be optionally substituted by one or more of substituents disclosed herein. [0052]" Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to ten carbon atoms (i.e., C2-10 alkynyl). Whenever it appears herein, a numerical range such as "2 to 10" refers to each integer in the given range; e.g., "2 to 10 carbon atoms" means that the alkynyl group can consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In any embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl has two to six carbon atoms (e.g., C2-6 alkynyl). The alkynyl is attached to the parent molecular structure by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, 3-methyl-4-pentenyl, hexynyl, and the like. Unless stated otherwise in the specification, an alkynyl group may be optionally substituted by one or more of substituents disclosed herein.

WO 2022/034568 PCT/IB2021/059266 id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53"

[0053]"Alkoxy" refers to the group -O-alkyl, including from 1 to 10 carbon atoms of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t- butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. "Lower alkoxy" refers to alkoxy groups containing one to six carbons. In some embodiments, C1-4alkoxy is an alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms. Unless stated otherwise in the specification, an alkoxy group may be optionally substituted by one or more of substituents disclosed herein. The terms "alkenoxy" and "alkynoxy" mirror the above description of "alkoxy" wherein the prefix "alk" is replaced with "alken" or "alkyn" respectively, and the parent "alkenyl" or "alkynyl" terms are as described herein. [0054]"Aromatic" or "aryl" refers to a radical with 6 to 14 ring atoms (e.g., C6-14 aromatic or C6- aryl) which has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl). In some embodiments, the aryl is a C6-10 aryl group. For example, bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. In other embodiments, bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in"-yl" by removal of one hydrogen atom from the carbon atom with the free valence are named by adding idene" to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. Whenever it appears herein, a numerical range such as "to 14 aryl "refers to each integer in the given range; e.g., "6 to 14 ring atoms" means that the aryl group can consist of 6 ring atoms, 7 ring atoms, etc., up to and including 14 ring atoms. The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In a multi-ring group, only one ring is required to be aromatic, so groups such as indanyl are encompassed by the aryl definition. Non-limiting examples of aryl groups include phenyl, phenalenyl, naphthalenyl, tetrahydronaphthyl, phenanthrenyl, anthracenyl, fluorenyl, indolyl, indanyl, and the like. Unless stated otherwise in the specification, an aryl group may be optionally substituted by one or more of substituents disclosed herein. [0055]"Cycloalkyl" and "carbocyclyl" each refer to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated. Partially unsaturated cycloalkyl groups can be termed "cycloalkenyl" if the carbocycle contains at least one double bond, or "cycloalkynyl" if the carbocycle contains at least one triple bond. Cycloalkyl groups include groups having from 3 to 13 ring atoms (i.e., C3-13 cycloalkyl). Whenever it appears herein, a numerical range such as "3 to 10" refers to each integer in the given range; e.g., "3 to WO 2022/034568 PCT/IB2021/059266 carbon atoms" means that the cycloalkyl group can consist of 3 carbon atoms, 4 carbon atoms, carbon atoms, etc., up to and including 13 carbon atoms. The term "cycloalkyl" also includes bridged and spiro-fused cyclic structures containing no heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In some embodiments, "cycloalkyl" can be a C3-8 cycloalkyl radical. In some embodiments, "cycloalkyl" can be a C3-cycloalkyl radical. Illustrative examples of cycloalkyl groups include, but are not limited to the following moieties: C3-6 carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6) and the like. Examples of C3-7 carbocyclyl groups include norbornyl (C7). Examples of C3-8 carbocyclyl groups include the aforementioned C3-7 carbocyclyl groups as well as cycloheptyl(C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like. Examples of C3-13 carbocyclyl groups include the aforementioned C3-8 carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and the like. Unless stated otherwise in the specification, a cycloalkyl group may be optionally substituted by one or more of substituents disclosed herein. The terms "cycloalkenyl" and "cycloalkynyl" mirror the above description of "cycloalkyl" wherein the prefix "alk" is replaced with "alken" or "alkyn" respectively, and the parent "alkenyl" or "alkynyl" terms are as described herein. For example, a cycloalkenyl group can have 3 to 13 ring atoms, such as 5 to 8 ring atoms. In some embodiments, a cycloalkynyl group can have 5 to 13 ring atoms. [0056]"Halo", "halide", or, alternatively, "halogen" means fluoro, chloro, bromo or iodo. The terms "haloalkyl," "haloalkenyl," "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups or with combinations thereof, preferably substituted with one, two, or three halo groups. For example, the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2- trifluoroethyl, l-fluoromethyl-2-fluoroethyl, -O-CHF2, and the like. Each of the alkyl, alkenyl, alkynyl and alkoxy groups are as defined herein and can be optionally further substituted as defined herein. [0057]"Heteroaryl" or, alternatively, "heteroaromatic" refers to a refers to a radical of a 5-membered monocyclic or polycyclic (e.g., bicyclic, tricyclic, tetracyclic and the like) aromatic ring system (e.g., having 6, 10 or 14 7t electrons shared in a cyclic array) having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is WO 2022/034568 PCT/IB2021/059266 independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-18 membered heteroaryl"). Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. Whenever it appears herein, a numerical range such as "5 to 18" refers to each integer in the given range; e.g., "5 to 18 ring atoms" means that the heteroaryl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. In some instances, a heteroaryl can have 5 to 14 ring atoms. In some embodiments, the heteroaryl has, for example, bivalent radicals derived from univalent heteroaryl radicals whose names end in "-yl" by removal of one hydrogen atom from the atom with the free valence are named by adding "-ene" to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylene. [0058]For example, an N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. One or more heteroatom(s) in the heteroaryl radical can be optionally oxidized. One or more nitrogen atoms, if present, can also be optionally quaternized. Heteroaryl also includes ring systems substituted with one or more nitrogen oxide (-O-) substituents, such as pyridinyl N-oxides. The heteroaryl is attached to the parent molecular structure through any atom of the ring(s). [0059]"Heteroaryl" also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment to the parent molecular structure is either on the aryl or on the heteroaryl ring, or wherein the heteroaryl ring, as defined above, is fused with one or more cycloalkyl or heterocyclyl groups wherein the point of attachment to the parent molecular structure is on the heteroaryl ring. For polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl and the like), the point of attachment to the parent molecular structure can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur ("5-10 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur ("5-membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur ("5-6 membered heteroaryl"). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the WO 2022/034568 PCT/IB2021/059266 -6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur. [0060]Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, benzo[b][l,4] oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzopyranonyl, benzofurazanyl, benzothiazolyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[ 1,2- a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H- cyclopenta[4,5]thieno [2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6- dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H benzo[6,7]cyclohepta[ l,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furo [3,2 -c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d] pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10- hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano- 5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-lH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4- d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8- tetrahydrobenzo [4,5 ] thieno [2,3 -d]pyrimdinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno [2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno [2,3-c]pridinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise in the specification, a heteroaryl group may be optionally substituted by one or more of substituents disclosed herein. [0061]"Heterocyclyl", "heterocycloalkyl" or "heterocarbocyclyl" each refer to any 3 to 18- membered non-aromatic radical monocyclic or polycyclic moiety comprising at least one carbon atom and at least one heteroatom selected from nitrogen, oxygen, phosphorous and sulfur. A heterocyclyl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein the polycyclic ring systems can be a fused, bridged or spiro ring system. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. A heterocyclyl group can be saturated or partially unsaturated. Partially unsaturated heterocycloalkyl groups can be termed WO 2022/034568 PCT/IB2021/059266 "heterocycloalkenyl" if the heterocyclyl contains at least one double bond, or "heterocycloalkynyl" if the heterocyclyl contains at least one triple bond. Whenever it appears herein, a numerical range such as "5 to 18" refers to each integer in the given range; e.g., "5 to 18 ring atoms" means that the heterocyclyl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. For example, bivalent radicals derived from univalent heterocyclyl radicals whose names end in "-yl" by removal of one hydrogen atom from the atom with the free valence are named by adding "-ene" to the name of the corresponding univalent radical, e.g., a piperidine group with two points of attachment is a piperidylene. [0062]An N-containing heterocyclyl moiety refers to a non-aromatic group in which at least one of the ring atoms is a nitrogen atom. The heteroatom(s) in the heterocyclyl radical can be optionally oxidized. One or more nitrogen atoms, if present, can be optionally quaternized. Heterocyclyl also includes ring systems substituted with one or more nitrogen oxide (-O-) substituents, such as piperidinyl N-oxides. The heterocyclyl is attached to the parent molecular structure through any atom of any of the ring(s). [0063]"Heterocyclyl" also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment to the parent molecular structure is on the heterocyclyl ring. In some embodiments, a heterocyclyl group is a 5- membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-14 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 3-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("3-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-8 membered non- aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-8 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-6 membered heterocyclyl"). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen phosphorous and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous and sulfur. In WO 2022/034568 PCT/IB2021/059266 some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous and sulfur. [0064]"Heterocyclyl" may include one or more ketone group (-C(=O)-) as part of the ring. Examples of a ketone-contianing heterocycle include, without limitation, pyridin-2(lH)-one, pyrazin-2(lH)-one, pyrimidin-2(lH)-one, pyrimidin-4(3H)-one, pyridazin-3(2H)-one, pyridin- 4(lH)-one, imidazolidin-2-one, l,3-dihydro-2H-imidazol-2-one, 2,4-dihydro-3H-l,2,4-triazol-3- one, oxazol-2(3H)-one, and oxazolidin-2-one. A ketone-containing heterocyclyl is obtainable by removing a hydrogen atom from its corepsonding ketone-contianing heterocycle at any available N-H or C-H position. [0065]Exemplary 3-membered heterocyclyls containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyls containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyls containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyls containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl, thiazolidinyl, and dithiolanyl. Exemplary 5- membered heterocyclyls containing 3 heteroatoms include, without limitation, triazolinyl, diazolonyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6 membered heterocyclyl groups containing heteroatoms include, without limitation, piperazinyl, morpholinyl, thiomorpholinyl, dithianyl, dioxanyl, and triazinanyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl, benzothianyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, 3-lH-benzimidazol-2-one, (l-substituted)-2-oxo- benzimidazol-3-yl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2 -b]pyrrole, phenanthridinyl, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, lH-benzo[e] [l,4]diazepinyl, 1,4,5,7- tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo [3,2- b]pyranyl, 5,7-dihydro-4H-thieno [2,3-c]pyranyl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, WO 2022/034568 PCT/IB2021/059266 hydrofuro[2,3-b]pyridinyl, 4,5,6,7 tetrahydro- lH-pyrrolo[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, l,2,3,4-tetrahydro-l,6- naphthyridinyl, and the like. [0066]Unless stated otherwise in the specification, a heterocyclyl group may be optionally substituted by one or more of substituents disclosed herein. [0067]Where substituent groups are specified by their conventional chemical Formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., -CH2O- is equivalent to -OCH2-. [0068]A "leaving group or atom" is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable non-limiting examples of such groups unless otherwise specified include halogen atoms, mesyloxy, p- nitrobenzensulphonyloxy, trifluoromethyloxy, and tosyloxy groups. [0069]"Protecting group" has the meaning conventionally associated with it in organic synthesis, i.e., a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site and such that the group can readily be removed after the selective reaction is complete. Non-limiting embodiments of functional groups that can be masked with a protecting group include an amine, hydroxy, thiol, carboxylic acid, and aldehyde. For example, a hydroxy protected form is where at least one of the hydroxy groups present in a compound is protected with a hydroxy protecting group. A variety of protecting groups are disclosed, for example, Greene ’s Protective Groups in Organic Synthesis, Fifth Edition, Wiley (2014), incorporated herein by reference in its entirety. For additional background information on protecting group methodologies (materials, methods and strategies for protection and deprotection) and other synthetic chemistry transformations useful in producing the compounds described herein, see in R. Larock, Comprehensive organic Transformations, VCH Publishers (1989); Greene ’s Protective Groups in Organic Synthesis, Fifth Edition, Wiley (2014); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995). These references are incorporated herein by reference in their entirety. [0070]The terms "substituted" or "substitution" mean that at least one hydrogen present on a group atom (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution for the hydrogen results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a "substituted" group can have a substituent at one WO 2022/034568 PCT/IB2021/059266 or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. Substituents include one or more group(s) individually and independently selected from acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo (i.e., F, Cl, Br, I), haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, -Si(Ra)3 , -ORa, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)0Ra, -0C(0)N(Ra)2, -C(0)N(Ra)2, -N(Ra)C(0)0Ra, -N(Ra)C(0)Ra, -N(Ra)C(0)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tN(R a)2 (where t is 1 or 2), -P(=0)(Ra)(Ra), or -O-P(=O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroaryl alkyl, and each of these moi eties (other than hydrogen) can be optionally substituted with one or more substituents (up to six, valence permitting) selected from OH, NH2, oxo, halo, nitro, COOH, C(0)NH2 or cyano. For example, a cycloalkyl substituent can have a halide substituted at one or more ring carbons, and the like. The protecting groups that can form the protective derivatives of the above substituents are known to those of skill in the art and can be found in references such as Greene and Wuts, above. [0071]Suitable substituents include, but are not limited to, haloalkyl and trihaloalkyl, alkoxyalkyl, halophenyl, -M-heteroaryl, -M-heterocycle, -M-aryl, -M-0Ra, -M-SRa, -M-N(Ra)2, -M- 0C(0)N(Ra)2, -M-C(=NRa)N(Ra)2, -M-C(=NRa)0Ra, -M-P(0)(Ra)2, Si(Ra)3, -M-NRaC(0)Ra -M- NRaC(0)0Ra, -M-C(0)Ra, -M-C(=S)Ra, -M-C(=S)NRaRa, -M-C(0)N(Ra)2, -M-C(0)NRa-M- N(Ra)2, -M-NRaC(NRa)N(Ra)2, -M-NRaC(S)N(Ra)2, -M-S(0)2Ra, -M C(0)Ra, -M-0C(0)Ra, - MC(0)SRa, -M-S(O)2N(Ra)2,-C(O)-M-C(O)Ra, -MCO:Ra, -MC(=0)N(Ra)2, -M-C(=NH)N(Ra)2, and -M-0C(=NH)N(Ra)2 (wherein M is a C1-6 alkyl group). [0072]When a ring system (e.g., cycloalkyl, heterocyclyl, aryl, or heteroaryl) is substituted with several substituents varying within an expressly defined range, it is understood that the total number of substituents does not exceed the normal available valencies under the existing conditions. Thus, for example, a phenyl ring substituted with "p" substituents (where "p" ranges from 0 to 5) can have 0 to 5 substituents, whereas it is understood that a pyridinyl ring substituted with "p" substituents has several substituents ranging from 0 to 4. The maximum number of substituents that a group in the disclosed compounds can have can be easily determined. The substituted group encompasses only those combinations of substituents and variables that result in a stable or chemically feasible compound. A stable compound or chemically feasible compound is WO 2022/034568 PCT/IB2021/059266 one that, among other factors, has stability sufficient to permit its preparation and detection. In some embodiments, disclosed compounds are sufficiently stable that they are not substantially altered when kept at a temperature of 40° C or less, in the absence of moisture (e.g., less than about 10%, less than about 5%, less than about 2%, less than about 1%, or less than about 0.5%) or other chemically reactive conditions, for e.g., at least about 3 days, at least about a week, at least about weeks, at least about 4 weeks, or at least about 6 weeks. [0073]The terms "combine, combining, to combine, combination " refer to the action of adding at least one chemical substance to another chemical substance(s) either sequentially or simultaneously. In some embodiments, bringing these chemical substances together can result in transformation of the initial chemical substances into one or more different chemical substances. This transformation can occur through one or more chemical reactions, e.g., where covalent bonds are formed, broken, rearranged and the like. A non-limiting example can include hydrolysis of an ester into an alcohol and carboxylic acid which can result from the combination of the ester with a suitable base. In another non-limiting example, an aryl fluoride can be combined with an amine to provide an aryl amine through a substitution process. These terms also include changes in association of charged chemical substances and creation of charged chemical substances, such as, but not limited to, N-oxide formation, acid addition salt formation, basic addition salt formation, and the like. These terms include the creation and/or transformation of radical chemical substances and isotopically labeled chemical substances. [0074]The terms "convert, converting, to convert, conversion " refer to a subset of "combination " and its grammatical equivalents, where the action of one or more reagents transforms one or more functional groups on a chemical substance to another functional group(s). For example, a conversion includes, but is not limited to, transforming a nitro functional group on a chemical substance to an amine with a reducing agent. Conversions also include changes in charged chemical substances, radical chemical substances and isotopically labeled chemical substances. However, the term "convert " does not include alteration of conserved bonds in disclosed genuses and compounds.

Compounds [0075]In one aspect, the present invention relates to a compound of Formula (I): WO 2022/034568 PCT/IB2021/059266 or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: Z is CH2 or O; Y1, Y2, Y3 and Y4 are each independently N or CR5, provided that at least one but no more than two of Y1, Y2, Y3 and Y4 are N; X1 is N, O or CR6a; X2 is N or NR6; X3 is N, NR6 or CR6, wherein the dashed circle denotes bonds forming a five-membered aromatic ring; L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups; L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is C(=O)NR9R10, C(=O)OR10, or a ring selected from a 5- or 6-membered heteroaryl group or a 5- or 6-membered heterocyclyl group, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo group attached to a ring member, and wherein the ring is substituted with (R3)n and one R4; R1 at each occurrence is independently hy drogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, Ci- 6alkyl-OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-6alkyl-NR aRb, or 4-6- WO 2022/034568 PCT/IB2021/059266 membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; R2 is (CR7R7)q-R8; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)p- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- 6alkyl-OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- ealkyl-NR aRb; each occurrence of R6a and R6 is independently hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or twoR 7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; R8 is C(=O)OR7, C(=O)NRaRb, CN, C(=O)NHC(=O)R7, C(=O)NHS(=O)2R7,H y^N H z'n C(=O)NHS(=O)R7, S(=O)2R7, P(=O)(OH)2, or N'N ; each occurrence of R9 and R10 is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; WO 2022/034568 PCT/IB2021/059266 R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- ?cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)p-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R12 at each occurrence is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; m is 1, or 2; n is 0, 1, or 2; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4. id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76"

[0076]In some embodiments, the compound of Formula (I) includes a compound of Formula (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: WO 2022/034568 PCT/IB2021/059266 L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups; L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo (=0) attached to a ring member, and wherein the ring is substituted with (R3)n and one R4; X1 is N, or CR6a; Z is CH2 or O; R1 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-6alkyl-NR aRb, or 4-6-membered heterocylyl, or twoR 1 groups, together with the carbon atom to which they are attached, form C=O; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4 is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)p- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1- of halogen, C1-6alkyl, or C1-6alkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or R7 andR 7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; WO 2022/034568 PCT/IB2021/059266 R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- ?cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-?cycloalkyl, C2-6alkynyl, O(CH2)P-C3- ?cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or C1-6alkoxy; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1, and further provided that when L1 is CH2 optionally substituted with 1 or 2 methyl groups, w is 0. id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77"

[0077]In some embodiments, the compound of Formula I includes a compound of Formula (Ila) or (Ilaa): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: WO 2022/034568 PCT/IB2021/059266 L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo attached to a ring member, and wherein the ring is substituted with (R3)n and one R4; X1 is N, or CR6a; R1 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, C1-6alkyl- OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-ealkyl-NR aRb, or 4-6-membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4 is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)p- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1- of halogen, C1-6alkyl, or C1-6alkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or R7 andR 7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- WO 2022/034568 PCT/IB2021/059266 ?cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)p-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3. id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78"

[0078]In some embodiments, the compound of Formula I includes a compound of Formula (lib) or (Ilbb): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one WO 2022/034568 PCT/IB2021/059266 carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein the ring is substituted with (R3)n and one R4; X1 is N, or CR6a; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4 is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)p- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1- of halogen, C1-6alkyl, or C1-6alkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or R7 andR 7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be WO 2022/034568 PCT/IB2021/059266 optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3. id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79"

[0079]In some embodiments, the compound of Formula I includes a compound of Formula (lie) or (IIcc): (lie) oror a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring contains at least one carbon atom, at least one nitrogen atom, and optionally contains 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein the ring is substituted with (R3)n and one R4; X1 is N, or CR6a; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4 is hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, (CH2)P-C1- ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2- WO 2022/034568 PCT/IB2021/059266 6alkenyl-C3-7cycloalkyl, C2-6alkynyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or Ci- ealkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or R7 andR 7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or C1-6alkoxy; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3. id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80"

[0080]In some embodiments, the compound of Formula I includes a compound of Formula (lid) or (Ildd): WO 2022/034568 PCT/IB2021/059266 or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: * in Formula (Ildd) represents a chiral center with R or S configutation; L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo (=0) attached to a ring member, and wherein the ring is substituted with (R3)n and one R4; X1 is N, or CR6a; R1 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- calkyl-OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-ealkyl-NR aRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4 is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)p- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6- membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring WO 2022/034568 PCT/IB2021/059266 substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or two R7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- ?cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3. id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81"

[0081]In some embodiments, the compound of Formula I includes a compound of Formula (III): WO 2022/034568 PCT/IB2021/059266 or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: X1 is N, or CR6a; Z is CH2 or O; L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups; L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; R1 at each occurrence is independently hy drogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, Ci- 6alkyl-OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-6alkyl-NR aRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or two R7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; WO 2022/034568 PCT/IB2021/059266 each occurrence of R9 and R10 is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- ?cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)p-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R12 at each occurrence is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; R13 at each occurrence is independently C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; p at each occurrence is independently 1, 2, 3 or 4; q at each occurrence is independently 0, 1, 2, 3 or 4; t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1, and further provided that when L1 is CH2 optionally substituted with 1-2 methyl, w is 0.

WO 2022/034568 PCT/IB2021/059266 id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82"

[0082]In some embodiments, the compound of Formula I includes a compound of Formula (Illa) or (Illaa): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; X1 is N, or CR6a; R1 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- calkyl-OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-ealkyl-NR aRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- 6alkyl-OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- ealkyl-NR aRb; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or twoR 7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered WO 2022/034568 PCT/IB2021/059266 heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; R11 at each occurrence independently hydrogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or C1-6alkoxy; R12 at each occurrence is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; t is 0, 1, 2 or 3; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4. id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83"

[0083]In some embodiments, the compound of Formula I includes a compound of Formula (Illb) or (Ilbb) : WO 2022/034568 PCT/IB2021/059266 (Illb) or (Illbb)or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; X1 is N, or CR6a; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; each occurrence of R7is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or R7 andR 7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; WO 2022/034568 PCT/IB2021/059266 each occurrence of R11 is independently hydrogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2- 6alkynyl, C1-6alkoxy, (CH2)P-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- ?cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-?cycloalkyl, C2-6alkynyl, O(CH2)P-C3- ?cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or C1-6alkoxy; each occurrence of R12 is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; t is 0, 1, 2 or 3; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4. id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84"

[0084]In some embodiments, the compound of Formula I includes a compound of Formula (IIIc) or (IIIcc): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: WO 2022/034568 PCT/IB2021/059266 L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; X1 is N, or CR6a; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or R7 andR 7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R12 at each occurrence is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring WO 2022/034568 PCT/IB2021/059266 containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; t is 0, 1, 2 or 3; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4. id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85"

[0085]In some embodiments, the compound of Formula I includes a compound of Formula (Hid) or (Illdd): wherein: * in Formula (Illdd) represents a chiral center with R or S configutation;L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; X1 is N, or CR6a; R1 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- calkyl-OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-ealkyl-NR aRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; WO 2022/034568 PCT/IB2021/059266 R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, OH, C1-6alkyl- OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or C1-6alkyl- NRaRb; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; each occurrence of R7is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or R7 andR 7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; each occurrence of R11 is independently hydrogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2- 6alkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or C1-6alkoxy; each occurrence of R12 is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; t is 0, 1, 2 or 3; WO 2022/034568 PCT/IB2021/059266 p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4. id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86"

[0086]In any embodiments, Z is CH2. In certain other embodiments, Z is O. [0087]In any embodiments, L1 is a covalent bond. In certain other embodiments, L1 is CHoptionally substituted with 1-2 methyl. In yet other embodiments, L1 is CH2. [0088]In any embodiments, L1 is a covalent bond, and w is 1. In certain other embodiments, L1 is CH2 optionally substituted with 1-2 methyl, and w is 0. [0089]In any embodiments, each occurrence of R1 is independently hydrogen. In certain other embodiments, each occurrence of R1 is independently halogen. In yet other embodiments, m is 2, one R1 is hydrogen, and the other R1 is halogen. In yet other embodiments, m is 2, one R1 is hydrogen, and the other R1 is F. In yet other embodiments, each occurrence of R1 is independently F. [0090]In any embodiments, Y2 is N, and each of Y1, Y3 and Y4 is independently CR5. In certain other embodiments, Y1 is CR5, Y2 is N, and each of Y3 and Y4is independently CH. In yet other embodiments, Y1 is CR5, Y2 is N, Y3 is N, and Y4 CH.ww id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91"

[0091]In any embodiments, the moiety ■؟״־ in Formulae (II), (Ila), (Ilaa), (lib), (Ilbb), (lie), (IIcc), (lid), (Ildd), and (III), (Illa), (Illaa), (Illb), (Illbb), (IIIc), (IIIcc), (Hid), and (Illdd), is id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92"

[0092]In any embodiments, R5 is methyl or ethyl. In certain other embodiments, R5 is CHF2 or CF3. In yet other embodiments, R5 is hydrogen, or CN. [0093]In any embodiments, t is 0. In certain other embodiments, t is 1. In yet other embodiments, t is 2. In yet other embodiments, t is 3. [0094]In any embodiments, X1 is N, X2 is N, and X3 is NR6. In certain other embodiments, X1 is CH, X2 is N, and X3 is NR6. In yet other embodiments, X1 is O, X2 is N, and X3 is CR6. [0095]In any embodiments, R6 is hydrogen. In certain other embodiments, R6 is methyl. In yet other embodiments, R6is ethyl. In yet other embodiments, R6is cyclopropyl. [0096]In any embodiments, R6ais hydrogen. In certain other embodiments, R6ais methyl. In yet other embodiments, R6ais ethyl. In yet other embodiments, R6ais cyclopropyl.

WO 2022/034568 PCT/IB2021/059266 id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97"

[0097]In any embodiments, L2 is a covalent bond. In certain other embodiments, L2 is (CR7R7)P. In yet other embodiments, L2 is CH2. [0098]In any embodiments, L3 is a covalent bond. In certain other embodiments, L3 is O. In yet other embodiments, L3 is NR7. [0099]In any embodiments, each occurrence of R7 is independently hydrogen. In certain other embodiments, each occurrence of R7 is independently C1-4alkyl. In yet other embodiments, each occurrence of R7 is independently C3-5cycloalkyl. In yet other embodiments, each occurrence of R7 is independently hydrogen or methyl. [0100]In any embodiments, q is 0. In certain other embodiments, q is 1. In yet other embodiments, q is 2. [0101]In any embodiments, R8is COOH. [0102]In any embodiments, R9 is C1-4alkyl. In certain other embodiments, R9 is methyl. In yet other embodiments, R9 is ethyl. [0103]In any embodiments, R10 is C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3- ?cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6- membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11. In certain other embodiments, R10 is C1-6alkyl. R10 is (CH2)P-C3- ?cycloalkyl. In yet other embodiments, R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. [0104]In any embodiments, Qis C(=O)NR9R10.In certain other embodiments, Qis a ring (also referred to herein the "Q ring ") selected from the group consisting of 5-membered heteroaryl, 5- membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least on carbon atom, at least one nitrogen atom and optionally 1-3 heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or an oxo attached to a ring member, and wherein the ring is substituted with (R3)n and R4. id="p-105" id="p-105" id="p-105" id="p-105" id="p-105" id="p-105" id="p-105" id="p-105" id="p-105"

[0105]In any embodiments, Q is N , or WO 2022/034568 PCT/IB2021/059266 ׳N'N י and each of which is substituted with (R3)n and one R4 at any available carbon or nitrogen position. id="p-106" id="p-106" id="p-106" id="p-106" id="p-106" id="p-106" id="p-106" id="p-106" id="p-106"

[0106]In any embodiments, Q is substituted with (R3)n and one R4 at any availablecarbon position. or , and each of which is substituted with (R3)n and one R4 at anyavailable carbon or nitrogen position. [0108]In any embodiments, each occurrence of R3 is independently hydrogen, halogen, or Ci- 4alkyl. In certain other embodiments, each occurrence of R3 is independently C1-4alkyl. In yet other embodiments, each occurrence of R3is independently methyl. [0109]In any embodiments, n is 0. In certain other embodiments, n is 1. In yet other embodiments, n is 2. [0110]In any embodiments, R4is independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or Ci- ealkoxy. In certain other embodiments, R4 is independently (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11. In yet other embodiments, R4is independently C1-6alkyl, C2-6alkynyl, C1-6alkoxy, (CH2)P-C1-6alkoxy, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, or C2-6alkenyl-C3-7cycloalkyl. [0111]In any embodiments, each occurrence of R11 is independently hydrogen. In certain other embodiments, each occurrence of R11 is independently C1-6alkyl. In yet other embodiments, each occurrence of R11 is independently C1-6alkoxy. In yet other embodiments, each occurrence of R11 WO 2022/034568 PCT/IB2021/059266 is independently (CH2)P-C1-6alkox. In yet other embodiments, each occurrence of R11 is independently phenyl. In yet other embodiments, each occurrence of R11 is independently (CH2)p- phenyl. In yet other embodiments, each occurrence of R11 is independently C3-7cycloalkyl. In yet other embodiments, each occurrence of R11 is independently (CH2)P-C3-7cycloalkyl. In yet other embodiments, each occurrence of R11 is independently C2-6alkynyl-C3-7cycloalkyl. In yet other embodiments, each occurrence of R11 is independently O(CH2)P-C3-7cycloalkyl. In any embodiments, each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy. [0112]In any embodiments, each occurrence of R12 is independently hydrogen. In certain other embodiments, each occurrence of R12 is independently C1-4alkyl. In yet other embodiments, each occurrence of R12 is independently C3-7cycloalkyl. In yet other embodiments, R12 andR 12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring. [0113]In any embodiments, each occurrence of Ra and Rb is independently hydrogen. In certain other embodiments, each occurrence of Ra and Rb is independently C1-6alkyl. In yet other embodiments, each occurrence of R12 is independently C3-7cycloalkyl. In yet other embodiments, Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl. id="p-114" id="p-114" id="p-114" id="p-114" id="p-114" id="p-114" id="p-114" id="p-114" id="p-114"

[0114]In any embodiments, the moiety in Formula (II) and (III) is In certain other embodiments, the moiety in Formula (II) id="p-115" id="p-115" id="p-115" id="p-115" id="p-115" id="p-115" id="p-115" id="p-115" id="p-115"

[0115]In any embodiments, R13 is hydrogen. In certain other embodiments, R13 is methyl. In yet other embodiments, R13 is cyclopropyl.

WO 2022/034568 PCT/IB2021/059266 id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116"

[0116]In any embodiments, the compound is selected from: id="p-117" id="p-117" id="p-117" id="p-117" id="p-117" id="p-117" id="p-117" id="p-117" id="p-117"

[0117]In any embodiments, the compound is selected from: WO 2022/034568 PCT/IB2021/059266 id="p-118" id="p-118" id="p-118" id="p-118" id="p-118" id="p-118" id="p-118" id="p-118" id="p-118"

[0118]In any embodiments, the compound is selected from: id="p-119" id="p-119" id="p-119" id="p-119" id="p-119" id="p-119" id="p-119" id="p-119" id="p-119"

[0119]In any embodiments, the compound is selected from: WO 2022/034568 PCT/IB2021/059266 id="p-120" id="p-120" id="p-120" id="p-120" id="p-120" id="p-120" id="p-120" id="p-120" id="p-120"

[0120]In another aspect, the present invention relates to a pharmaceutical composition comprising a compound disclosed herein, and a pharmaceutically acceptable carrier.. [0121]In yet another aspect, the present invention relates to a method for treating a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi) in a subject in need thereof, comprising administering an effective amount of a compound disclosed herein to the subject. In some embodiments, the disease is pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, demal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis. [0122]In yet another aspect, the present invention relates to a process of making a compound of Formulae (I), (II), (Ila), (Ilaa), (lib), (Hbb), (lie), (IIcc), (lid), (Ildd), (III), (Illa), (Illaa), (Illb), (Illbb), (IIIc), (IIIcc), (Hid), and (Illdd), including each exemplified compound and intermediates described herein. [0123]In any embodiments, the present invention relates to an intermediate selected from: General Synthetic Methods [0124]The compounds of the present invention can be synthesized using the methods describled herein, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preffered methods include, but are not limited to, those exemplary schemes and working examples described below. All substituents are as defined hereinabove unless otherwise indicated. The reactions are performed in a solvent or solvent mixture appropriate to the reagents and materials employed and suitable for the transformations proposed. This will sometimes require a judgment to modify the order of syntheitic WO 2022/034568 PCT/IB2021/059266 steps or to select on particular process scheme over another in order to obtain a desired compound of the invention. [0125]It will be recongnized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account descrbing the many alternatives to the trained practitioner is by Greene et al., Greene ’s Protective Groups in Organic Synthesis, Fifth Edition, Wiley (2014). It will also be recongnized that the compound names referred to in the decriptions of Schemes 1-12are for convinience only, and do not necesrrily reflect the actual chemical names of those compounds.Scheme 1 (R1)m (CR7R7)qC(=O)O-PG2(R1) Buchwald Coupling reactionXt ‘-PG:X>tx3 u or Ullmann Reaction or SNArX= Br, I De-protection of alcohol 2'0-PG1 (CR7R7)qC(=O)O-PG2(R1)m (CR7R7)qC(=O)O-PG2 MsCI or PBr3 >V'4 0HX3 ؛- X (R1)m (CR7R7)qC(=O)O-PG2 (R1)m ,2 (CR7R7)qC(=O)O-PG2(R1)m(CR7R7)qC(=O)OHOHN*X7 d־ ״. rRx6 ؟ ؛ xXs 6 X^L’Xx^'x3X= Br, OMs Base, solventX4, X5, Xs and X7 are each independently N or CHx ’ ؛ x De-protection of acid 8 A X N N O y6 K 5 7 id="p-126" id="p-126" id="p-126" id="p-126" id="p-126" id="p-126" id="p-126" id="p-126" id="p-126"

[0126]Scheme 1describes the synthesis of carbonyl azine azole N-heteroaryl-azacyclohexyl acetic acids 8. PG1 and PG2 each represents a protecting group, and L2 is (CR7R7)P(e.g., CH2). The halo azine derivative 1is reacted with piperidine acetic ester 2under Buckwald conditions with appropriate catalyst (e.g. Pd(OAc)2/BINAP) or nucleophilic aromatic substitution reaction or Ullmann reaction to give the corresponding carbonyl azine N-heteroaryl-piperidine acetic carboxylate 3.Deprotection of the protected hydroxylmethyl azole 3provides the hydroxylmethyl azole 4,which is then reacted with MsCI (or PBr3) to give the mesylate (or Br) 5.Treatment of the mesylate (or Br) 5with 2-hydroxy azine 6in the presence of an appropriate base (e.g. K2CO3, nucleophilic substitution reactions) gives the corresponding carbonyl azine N-heteroaryl- WO 2022/034568 PCT/IB2021/059266 piperidine acetic carboxylate 7, which then undergoes ester deprotection to give the desired carbonyl azine L2-azole N-heteroaryl-azacyclohexyl acetic acids 8.

WO 2022/034568 PCT/IB2021/059266 Scheme 2 I 2O'PG1De-protection of alcohol MsCI or PBr3 Base, solvent X= Br, I (R1)m (CR7R7)qC(=O)O-PG2(R1)m Z /(CR7R7)qC(=O)O-PG2 (R1) -a De-protection of acidL2 J/R3)״ n 6 (CR7R7)aC(=O)OH d N 7 8 id="p-127" id="p-127" id="p-127" id="p-127" id="p-127" id="p-127" id="p-127" id="p-127" id="p-127"

[0127]Scheme 2describes an alternative synthetic route to the carbonyl azine N-heteroaryl- azacyclohexyl acetic acids 8. PG1 and PG2 each represents a protecting group, and L2 is (CR7R7)P (e.g., CH2). Deprotection of the protected hydroxylmethyl azole derivative 1 gives hydroxylmethyl azole 9, which is then reacted with MsCI (or PBr3) to give the mesylate (or Br) 10. Treatment of mesylate (or Br) 10 with 2-hydroxy azine in the presence of an appropriate base (e.g. K2CO3, nucleophilic substitution reactions) gives the corresponding N-substituted carbonyl azine 11. The halo azine derivative 11 is reacted with piperidine acetic carboxylate under Buckwald conditions with appropriately catalyst (e.g. Pd(OAc)2/BINAP) or nucleophilic aromatic substitution reaction or Ullmann reaction to give the corresponding piperidine acetic carboxylate 7, which then undergoes ester deprotection to give the desired carbonyl azine L2-azole N-heteroaryl- azacyclohexyl acetic acids 8.Scheme 3=O)O-PG2O 3HN 'X6x4-x R4 6a Base, solventX4 and X5 are each independently CH,CH2, N or NH, X6 is (CR7R7)qC(=O)O-PG2 -a De-protection of acid (R1)m (CR7R7)qC(=O)OH Y1^Y4 CH, CH2, N, NH, orOx4A-x5r4 d N WO 2022/034568 PCT/IB2021/059266 id="p-128" id="p-128" id="p-128" id="p-128" id="p-128" id="p-128" id="p-128" id="p-128" id="p-128"

[0128]Scheme 3describes the synthesis of N-substituted aza-heterocyclopentyl ketone N- heteroaryl-azacyclohexyl acetic acids 13.Treatment of the mesylate (or Br) 5with aza- heterocyclopentyl ketone 6ain the presence of an appropriate base (e.g. t-BuOK, nucleophilic substitution reactions) gives the corresponding N-substituted aza-cyclopentyl ketone 12,which then undergoes ester deprotection to give the desired N-substituted aza-cyclopentyl ketone-N- heteroaryl-azacyclohexyl acetic acids 13. Scheme 4 16 [0129]Scheme 4describes the synthesis of oxy-Q ring N-heteroaryl-azacyclohexyl acetic acid 16, wherein Q represents a 5-membered heteroaryl or heterocyclyl or 6-membered heteroaryl or heterocyclyl. Base-mediated SnAt reaction of hydroxyl methyl azole 4 with an appropriate halo- or methylsulfonyl-substitued Q ring 14 (X is halo or methyl sulfonyl) provides the oxy-Q ring N- heteroaryl piepridine acetic ester 15,which then undergoes ester deprotection to give the desired oxy-Q ring N-heteroaryl-azacyclohexyl acetic acids 16. Scheme 5 (R1)m 7 (CR7R7)qC(=O)O-PG2 CO N 2 Buchwald Coupling reaction or Ullmann Reaction or SNAr WO 2022/034568 PCT/IB2021/059266 id="p-130" id="p-130" id="p-130" id="p-130" id="p-130" id="p-130" id="p-130" id="p-130" id="p-130"

[0130]Scheme 5describes an alternative synthesis of oxy-Q ring N-heteroaryl-azacyclohexyl acetic acid 16,wherein Q represents a 5-membered heteroaryl or heterocyclyl or 6-membered heteroaryl or heterocyclyl. Base-mediated SnAt reaction of hydroxylmethyl azole 9with an appropriate halo- or methylsulfonyl-substitued Q ring 14(X is halo or methyl sulfonyl) provides the oxy-Q ring 17,which is reacted with piperidine ethyl ester derivative under Buckwald conditions with appropriately catalyst (e.g. Pd(OAc)2/BINAP) or nucleophilic aromatic substitution reaction or Ullmann reaction to give the corresponding oxy-Q ring N-heteroaryl piepridine acetic ester 15,which then undergoes ester deprotection to give the desired oxy-Q ring N-heteroaryl-azacyclohexyl acetic acids 16. Scheme 6 17 18 21 [0131]Scheme 6describes the synthesis of amino-Q ring N-heteroaryl-azacyclohexyl acetic acids 21.The hydroxylmethyl azole 4is reacted with MsCl with appropriately base (e.g. TEA) to give the corresponding mesylate 17.Displacement of the mesylate 17with NaN3 (or other azide reagent) gives azide 18,which then undergoes reduction (e.g. Staudinger reduction with PPh3/water) to give the amine 19.Amine 19is then reacted with halo- or methylsulfonyl-substitued Q ring 14(X is halo or methyl sulfonyl) in the presence of an appropriate base or via Pd catalyzed amination to give amino-azine piepridine acetic ester 20,which then undergoes ester deprotection to give the desired amino-Q ring N-heteroaryl-azacyclohexyl acetic acids 21.

WO 2022/034568 PCT/IB2021/059266 Scheme 7 id="p-132" id="p-132" id="p-132" id="p-132" id="p-132" id="p-132" id="p-132" id="p-132" id="p-132"

[0132]Scheme 7 describes the synthesis of oxy-azole N-heteroaryl-azacyclohexyl acetic acids 24. The hydroxylmethyl azole 4is reacted with an appropriate haloazole or methyl sulfonyl azole 22 (which is a 5-membered heteroaryl ring that contains at least one nitrogen and may contain additional 1-3 heteroatoms selected from N, O and S) in the presence of an appropriate base (nucleophilic aromatic substitution reaction) to give oxy-azole N-heteroaryl piepridine acetic ester 23,which then undergoes ester deprotection to give the desired oxy-azole N-heteroaryl- azacyclohexyl acetic acids 24. Scheme 8 id="p-133" id="p-133" id="p-133" id="p-133" id="p-133" id="p-133" id="p-133" id="p-133" id="p-133"

[0133]Scheme 8describes the synthesis of amino-azole N-heteroaryl-azacyclohexyl acetic acids 28.The hydroxylmethyl azole 4ais oxidized to the corresponding aldehyde 25(e.g. with Dess- Martin periodinane or Swern Oxidation). The aldehyde 25can then undergo reductive amination with an appropriate amino-azole 26(which is a 5-membered heteroaryl ring that contains at least one nitrogen and may contain additional 1-3 heteroatoms selected from N, O and S) to give amino WO 2022/034568 PCT/IB2021/059266 azole N-heteroaryl piepridine ecetic ester 27.Subsequent deprotection of ester 27provides the amino-azole N-heteroaryl-azacyclohexyl acetic acids 28. Scheme 29 Base, solventBuchwald Coupling reaction or Ullmann Reaction or SNAr (R1)m (CR7R7)qC(=O)O-PG2 De-protection of acid id="p-134" id="p-134" id="p-134" id="p-134" id="p-134" id="p-134" id="p-134" id="p-134" id="p-134"

[0134]Scheme 9describes the synthesis of alkylated-triazole N-heteroaryl-azacyclohexyl acetic acids 32.Treatment of the mesylate or Br-substitued compound 10with triazole 29in the presence of appropriate base gives the alkylated triazole 30.The halo-azine 30is then reacted with piperidine acetic ester 2under Buckwald conditions with appropriately catalyst (e.g. Pd(OAc)2/BINAP) to give the corresponding alkylated-triazole N-heteroaryl piepridine acetic ester 31,which then undergoes ester deprotection to give the desired alkylated-triazole N-heteroaryl-azacyclohexyl acetic acids 32.

WO 2022/034568 PCT/IB2021/059266 Scheme 10 id="p-135" id="p-135" id="p-135" id="p-135" id="p-135" id="p-135" id="p-135" id="p-135" id="p-135"

[0135]Scheme 10describes the synthesis of alkylated-tetrazole N-heteroaryl-azacyclohexyl acetic acids 36and 37.The hydroxylmethyl azole 4is reacted with tetrazole 33under Mitsunobu conditions to provide the regioisomeric tetrazoles 34and 35.Deprotection piepridine acetic ester 34and 35provides the regioisomeric alkylated-tetrazole N-heteroaryl-azacyclohexyl acetic acids 36and 37.

WO 2022/034568 PCT/IB2021/059266 Scheme 11 id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136"

[0136]Scheme 11describes the synthesis of carbamoyloxymethyl azole N-heteroaryl- azacyclohexyl acetic acids 41.The hydroxylmethyl azole 4is reacted with 4-nitrophenyl chloroformate in the presence of an appropriate base to give the corresponding 4-nitrophenyl carbonate 38,which is then reacted with an amine 39in the presence of an appropriate base to give the carbomate 40.Subsequent deprotection of ester 40provides the carbamoyloxymethyl azole N- heteroaryl-azacyclohexyl acetic acids 41.

WO 2022/034568 PCT/IB2021/059266 Scheme 12 X= Br, I catalyst MeOH co, TEA ReductionMsCI Base 49 W =OorNH [0137]Scheme 12describes the synthesis of l-azinemethyl-piperidine-3-carboxylic acids 48, 49 and 50. Carbonyl insertion of azine halide 1 in the presence of CO gas and appropriate catalyst in methanol gives azine carboxylate 42,which is then reduced with appropriate reductant to give azine methyl alcohol 43.Treatment of azine methyl alcohol 43with MsCI in the presence of appropriate base gives the corresponding mesylate 44. Alkylation piperidine carboxylate 45 with mesylate 44in the presence appropriate base affords azine methyl-piperidine-3 -carboxylate 46. Deprotection of azine methyl-piperidine-3-carboxylate 46gives hydroxylmethyl azole 47,which is then converted to corresponding acids 48, 49 and 50 using similar methods as described herein over several steps.Pharmaceutical Compositions and Methods id="p-138" id="p-138" id="p-138" id="p-138" id="p-138" id="p-138" id="p-138" id="p-138" id="p-138"

[0138]The compounds utilized in the methods described herein may be formulated together with a pharmaceutically acceptable carrier or adjuvant into pharmaceutically acceptable compositions WO 2022/034568 PCT/IB2021/059266 prior to be administered to a subject. In another embodiment, such pharmaceutically acceptable compositions further comprise additional therapeutic agents in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein. [0139]The term "pharmaceutically acceptable carrier or adjuvant " refers to a carrier or adjuvant that may be administered to a subject, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. [0140]Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as a-, P־ , and y-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-P-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein. [0141]The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. [0142]The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be WO 2022/034568 PCT/IB2021/059266 formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanedi 01. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer ’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. [0143]The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. [0144]The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols. [0145]Topical administration of the pharmaceutical compositions of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a WO 2022/034568 PCT/IB2021/059266 suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyl dodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention. [0146]The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. [0147]When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition. [0148]The compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the mode of WO 2022/034568 PCT/IB2021/059266 administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound. [0149]Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the subject ’s disposition to the disease, condition or symptoms, and the judgment of the treating physician. [0150]Upon improvement of a subject ’s condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Subjects may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms. [0151]The pharmaceutical compositions described above comprising a compound of Formula (I) may further comprise another therapeutic agent useful for treating a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi). In particular, such combination may be useful for treating pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, dernal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis (IFF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis. [0152]All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. [0153]The examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compounds of the present technology or salts, pharmaceutical compositions, derivatives, solvates, metabolites, prodrugs, racemic mixtures or tautomeric forms thereof. The examples herein are also presented in order to more fully illustrate the preferred aspects of the present technology. The examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims. The examples can include or incorporate any of the variations, aspects or aspects of the present technology described above. The variations, aspects or aspects described above may WO 2022/034568 PCT/IB2021/059266 also further each include or incorporate the variations of any or all other variations, aspects or aspects of the present technology.

EXAMPLES id="p-154" id="p-154" id="p-154" id="p-154" id="p-154" id="p-154" id="p-154" id="p-154" id="p-154"

[0154]Abbreviations used herein are as follows: Abbrv. Full Name Abbrv. Full Name anhy. anhydrous aq. aqueousmin minute(s) satd. saturatedmL milliliter hrs hoursmmol millimole(s) mol mole(s)MS mass spectrometry NMR nuclear magnetic resonanceTLC thin layer chromatography HPLC high-performance liquid chromatographyLCMS Liquid chromatography-mass spectrometryPPTS Pyridinium p-Toluenesulfonate DCE 1,2-di chloroethane CHC13 chloroformDCM dichloromethane DMF dimethylformamideEt2O diethyl ether EtOH ethyl alcoholEtOAc ethyl acetate MeOH methyl alcoholMeCN acetonitrile PE petroleum etherTHE tetrahydrofuran DMSO dimethyl sulfoxideAcOH acetic acid HC1 hydrochloric acidH2SO4 sulfuric acid NH4C1 ammonium chlorideKOH potassium hydroxide NaOH sodium hydroxideK2CO3 potassium carbonate Na2CO3 sodium carbonateTFA trifluoroacetic acid Na2SO4 sodium sulfateNaBH4 sodium borohydride NaHCO3 sodium bicarbonateLiHMDS lithiumhexamethyl di silyl ami deNaBH4 sodium borohydride Et3N or TEATriethylamine Py or Pyr pyridine TBAF Tetrabutylammonium fluorideMsCl Methanesulfonyl chlorideBnBr Benzyl bromide DHP 3,4-Dihydro-2H-pyranCbz carbobenzyloxy m-CPBA 3-Chloroperoxybenzoic acidDess- Martin1,1,1 -Triacetoxy- 1,1- Dihydro-1,2-Benziodoxol-3(1H)-On DIADDiisopropyl azodicarboxylate DMAP 4-(dimethylamino)pyridine DIPEA N,N-diisopropylethylamineTMSCHN2(Trimethylsilyl)diazomethane TMSCH2N3Trimethyl silylmethyl azide Ruphos 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenylRuPhosP d G3Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-l,r ־ biphenyl)(2'-amino-l,r ־biphenyl-2-yl)palladium(II) WO 2022/034568 PCT/IB2021/059266 General Conditions and Procedures id="p-155" id="p-155" id="p-155" id="p-155" id="p-155" id="p-155" id="p-155" id="p-155" id="p-155"

[0155]In the following examples, the chemical reagents were purchased from commercial sources (such as Alfa, Acros, Sigma Aldrich, TCI and Shanghai Chemical Reagent Company), and used without further purification. THF was continuously refluxed and freshly distilled from sodium and benzophenone under nitrogen, dichloromethane was continuously refluxed and freshly distilled from CaH2 under nitrogen. [0156]Flash chromatography was performed on an Ez Purifier III via column with silica gel particles of 200-300 mesh. Analytical and preparative thin layer chromatography plates (TEC) were HSGF 254 (0.15-0.2mm thickness, Shanghai Anbang Company, China). Nuclear magnetic resonance (NMR) spectra were recorded using Brucker AMX-300 or AMX-400 NMR (Brucker, Switzerland) at around 20 - 30 °C unless otherwise specified. The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublet of doublet; dt, doublet of triplets; bs, broad signal. Chemical shifts were reported in parts per million (ppm, 5) downfield from tetramethylsilane. Mass spectra were run with electrospray ionization (ESI) from a Waters LCT TOF Mass Spectrometer (Waters, USA). Compound purification was carried out as needed using a variety of traditional methods including, but not limited to, preparative chromatography under acidic, neutral, or basic conditions using either normal phase or reverse phase HPLC or flash columns or Prep-TLC plates. [0157] Preparative HPLC:unless otherwise described, the compounds were purified using a WATERS Fractionlynx system equipped with a YMC Pack Pro ds Column (5 pm, 120A, 50 x mm) and the following solvent system: H2O, AcCN, and 2% TFA in H2O. Specific elution gradients were based on the retention times obtained with an analytical LC-MS, however, in general all elution gradients of H2O and MeCN were run over a 7 minute run time with a flow rate of 35 mL/min. An autoblend method was used to ensure a concentration of 0.1 % TFA throughout each run. Specific elution gradients were based on the retention times obtained with an analytical LC-MS, however, in general, all elution gradients of H2O and MeCN were run over at 8 minute run time with a flow rate of 50 mL/min. [0158] Analytical LC-MS:analytical LC-MS was performed on a WATERS Acquity UPLC-MS instrument equipped with a ACQUITY UPLC BEH Ci8 Column (2.1 x 50 mm, 1 .7 un), a column temperature of 45 °C and using the following solvent system: Solvent A: 0.1 % HCOOH in H20; and Solvent B: 0.1 % HCOOH in AcCN. All compounds were run using the same elution gradient, i.e., 5% to 95% Solvent B over a 1 .5 min run time with a flow rate of 0.6 mL/min.

WO 2022/034568 PCT/IB2021/059266 id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159"

[0159] Preparative Chiral SFC Separation:stereoisomer mixtures were separated using a Berger Minigram SFC instrument on one of the following columns: ChiralPak AS-H (10 x 2mm), ChiralPak IA (10 x 250 mm), ChiralPak AD-H (21 x 250 mm), Phenomenex Lux-2 (21.2 x 250 mm), or ChiralPak IC (10 x 250 mm); eluting with either 0.1 % diethylamine in MeOH / CO2, or 0.1 % diethylamine in EtOH / CO2 or 0.1 % diethylamine in isopropanol / CO2 with a flow rate of 2.5 mL/min and a column temperature of 35°C. [0160] Analytical Chiral SFC Separation:stereoisomer mixtures or single enantiomers were analyzed using a JASCO analytical SFC instrument on one of the following columns: ChiralPak AS-H (4.6 x 250 mm), ChiralPak IA (4.6 x 250 mm), ChiralPak AD-H (4.6 x 250 mm), Phenomenex Lux-2 (4.6 x 250 mm), or ChiralPak IC (4.6 x 250 mm); eluting with either 0.1 % diethylamine in MeOH / C02, or 0.1 % diethylamine in EtOH / C02 or 0.1 % diethylamine in isopropanol / C02, with a flow rate of 6.0 imL/min and a column temperature of 35°C. Intermediate 1: 3-bromo-2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine Br Br Br Br Step 1: 3,6-dibromo-2-ethylpyridine [0161]To a solution of 3,6-dibromo-2-methylpyridine (75 g, 0.299 mol) in THE (1 L) was added NaHMDS (180 mL, 0.36 mol, 2M in THF) drop-wisely at -50 °C and the mixture was stirred at this temperature for 30 mins. Mel (46.5 mL, 0.75 mol) was added to the above mixture and the resulting mixture was stirred at -50 °C to room temperature for 16 hrs. The reaction mixture was quenched with saturated aq.NH4Cl solution (500 mL) at 0 °C, and extracted with EtOAc (2 x 5mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by silica column chromatography (PE: DCM=300: 1 to 200: 1) to give the title compound (47 g, 59.1% yield) as WO 2022/034568 PCT/IB2021/059266 yellow oil. 1H NMR (400 MHz, CD3OD) 5 7.61-7.59 (d, J = 8 Hz, 1H), 7.61-7.59 (d, J = 8.4 Hz, 1H), 2.94-2.88 (q, 2H), 1.38-1.27 (t, 3H). Step 2: 3-(5-bromo-6-ethylpyridin-2-yl)prop-2-yn-l-ol [0162]To a solution of 3,6-dibromo-2-ethylpyridine (47 g, 0.177 mol) in THF (0.65 L) was added prop-2-yn-l-ol (11.9 g, 0.212 mol), Cui (3.4 g, 17.7 mmol), DIPEA (35.1 mL, 0.212 mol) and Pd(PPh3)2C12 (12.4 g, 17.7 mmol) and the mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at r.t. for 16 hrs. The mixture was diluted with EtOAc (5m L) and filtered. The filtrate was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica column chromatography (DCM: EtOAc= 10: 1 to 4: 1) to give the title compound (40 g, 94.1% yield) as brown solid. LC/MS (ESI) m/z: 240/242 (M+H)+. Step 3: (4-(5-bromo-6-ethylpyridin-2-yl)-l-((trimethylsilyl)methyl)-lH-l,2,3-triazol-5- yl)methanol [0163]To a solution of intermediate 3-(5-bromo-6-ethylpyridin-2-yl)prop-2-yn-l-ol (20 g, 0.0mol) in THF (400 mL) was added Chlorocyclopentadienylbis(triphenylphosphine)ruthenium(II) (3.5 g, 4.16 mmol) and TMS-methyl azide (14 g, 0.108 mol) at 0 °C under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred at room temperature for hrs. The mixture was diluted with EtOAc (500 mL) and filtered. The filtrate was concentrated to dryness to give crude product, which was triturated with PE/EtOAc (1000 mL, 10/1 v/v) to give the title compound (28 g, 91.3% yield) as white solid. 1H NMR (400 MHz, CDC13) 5 8.03 - 8.(d, J = 8.4 Hz, 1H), 7.95-7.93 (d, J = 8.4 Hz, 1H), 6.77 - 6.74 (t, J = 6.8 Hz, 1H), 4.79 - 4.78 (d, J = 6.8 Hz, 1H), 3.80 (s, 3H), 3.03 - 3.01 (q, 1H), 1.34 - 1.30 (t, J= 7.6 Hz, 3H), 0.20 (s, 9H). Step 4: (4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol [0164]To a solution of (4-(5-bromo-6-ethylpyridin-2-yl)-l-((trimethylsilyl)methyl)-lH-l,2,3- triazol-5-yl)methanol (25 g, 67.7 mmol) in THF (300 mL) was added TBAF.3H:O (25.6 g, 81.mmol) and the mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc (500 mL), washed with saturated aq.NH4Cl solution (3 x 50 mL) and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica column chromatography (DCM: EtOAc= 8: 1 to 4: 1) to give the title compound (19 g, 94.4% yield) as gray solid. LC/MS (ESI) m/z: 297/299 (M+H)+. Step 5: 3-bromo-2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridine [0165]To the mixture of (4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methanol (25 g, 0.084 mol) and TosOH (2.2 g, 12.6 mmol) in DCM (300 mL) was added DHP WO 2022/034568 PCT/IB2021/059266 (10.6 g, 0.126 mol) at 0 °C and the mixture was stirred at room temperature for 16 hrs. The mixture was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica column chromatography (DCM: EtOAc= 8: 1) to give the title compound (30 g, 93.6% yield) as yellow solid. LC/MS (ESI) m/z: 381/383 (M+H)+. 1HNMR (4MHz, CDC13) 5 7.91 (d, J= 8.3 Hz, 1H), 7.86 (d, J= 8.3 Hz, 1H), 5.36 (dd, J= 36.5, 12.8 Hz, 2H), 4.75 - 4.67 (m, 1H), 4.16 (s, 3H), 3.88 - 3.80 (m, 1H), 3.55 - 3.46 (m, 1H), 3.00 (q, J= 7.5 Hz, 2H), 1.84 - 1.67 (m, 2H), 1.65 - 1.58 (m, 2H), 1.54 - 1.45 (m, 2H), 1.34 (t, J= 15 Hz, 3H). Intermediate 2: 3-bromo-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine id="p-166" id="p-166" id="p-166" id="p-166" id="p-166" id="p-166" id="p-166" id="p-166" id="p-166"

[0166]Intermediate 2was synthesized according the same sequence as was used for the synthesis of intermediate 1LC/MS (ESI) m/z: 367/369 (M+H)+. 1HNMR (400 MHz, CDC13) 5 7.73 (d, J = 8.3 Hz, 1H), 7.69 (d, J= 8.3 Hz, 1H), 5.15 (q, J= 12.7 Hz, 2H), 4.61 - 4.54 (m, 1H), 3.99 (s, 3H), 3.74 - 3.64 (m, 1H), 3.38 - 3.30 (m, 1H), 2.51 (s, 3H), 1.66 - 1.50 (m, 2H), 1.46 - 1.40 (m, 2H), 1.39- 1.32 (m, 2H). Intermediate 3: (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol Step 1: 2-ethyl-3-iodo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridine [0167]To a mixture of 3-bromo-2-ethyl-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine(7.2 g, 18.9 mmol) and Nai (14.2 g, 94.4 mmol) in l,4-dioxane(80 mL) was added N1,N2-diMethylethane-l,2-diaMine (1.55 g, 11.3 mmol) and Cui (1.80 g, 9.44 mmol) and the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 20 hrs. The mixture was filtered and the filter cake was washed with EtOAc (2x50 mL). The combined filtrate was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by silica gel chromatography (PE: EtOAc= 4: 1 to 1: 1) to give the title compound (6.1 g, 74.2%) as light yellow solid. LC/MS (ESI) (m/z): 429 (M+H)+. 1HNMR (400 MHz, CDC13) 5 8.11-8.09 (d, J= 8.4 Hz, 1H), 7.75-7.73 (d, J= 8.3 Hz, 1H), 5.42 - 5.29 (q, J WO 2022/034568 PCT/IB2021/059266 = 12.7 Hz, 2H), 4.72 - 4.70 (m, 1H), 4.16 (s, 3H), 3.84 - 3.82 (m, 1H), 3.56 - 3.49 (m, 1H), 3.02- 2.97 (q, J= 7.2 2H), 1.63 - 1.59 (m, 2H), 1.56 - 1.53 (m, 4H), 1.34 - 1.30 (t, J= 7.6 Hz, 3H). Step 2: (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl) methanol (6) [0168]To a solution of 2-ethyl-3-iodo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine (1.0 g, 2.34 mmol) inMeOH (10 mL) was added PPTS (0.59 g, 2.mmol) and the mixture was stirred at 60 °C for 16 hrs. The mixture was diluted with EtOAc, washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (698 mg, 86.9% yield) as white solid. LC/MS (ESI) m/z: 345 (M+H)+. Intermediate 4: 5-bromo-4-ethyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-pyrazol-4-yl)pyrimidine 1Step 1 Step 2 Step 34 3 intermediate 4 Step 1: 5-bromo-2-chloro-4-ethylpyrimidine id="p-169" id="p-169" id="p-169" id="p-169" id="p-169" id="p-169" id="p-169" id="p-169" id="p-169"

[0169]To a solution of 5-bromo-2-chloropyrimidine (60 g, 0.31 mol) in THE (600 mL) was added EtMgCl (186 mL, 0.37 mol, 2M in THF) drop-wisely at 10 °C under N2 atmosphere and the resulting mixture was stirred at this temperature for 1 hr. TEA (43 mL, 0.31 mol) was added to the mixture drop-wisely at 0 °C under N2 atmosphere. After stirring at 0 °C for 20 min, a solution of iodine (79.0 g, 0.31 mol) in THF (120 mL) was added and the resulting mixture was stirred at r.t. for 16 hrs. The reaction was quenched with water and extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with saturated aq.Na2SO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (EtOAc: PE= 0 to 200: 1) to give the title compound (35.3 g, 51.4% yield) as light yellow solid. 1H NMR (400 MHz, DMSO-d6) 5 8.87 (s, 1H), 2.89-2.83 (q, J= 7.5 Hz, 2H), 1.22- 1.18 (t, J= 7.5 Hz, 3H). Step 2: 5-bromo-4-ethyl-2-iodopyrimidine id="p-170" id="p-170" id="p-170" id="p-170" id="p-170" id="p-170" id="p-170" id="p-170" id="p-170"

[0170]To a solution of 5-bromo-2-chloro-4-ethylpyrimidine (20 g, 0.09 mol) in DCM (50 mL) was added aq.HI (200 mL, 57% wt) drop-wisely followed by Nai (30 g, 0.2 mol) at 0 °C and the mixture was stirred at 5 °C for 16 hrs. The reaction mixture was quenched with saturated aq.Na2S2O3 solution (100 mL) and extracted with DCM (2 x 200 mL). The combined organic layers WO 2022/034568 PCT/IB2021/059266 were concentrated under reduced pressure to give a colorless residue. The resulting residue was purified by silica gel column chromatography (PE: EtOAc= 4: 1) to give the title compound (25.g, 89.8% yield) as light yellow solid. 1HNMR (400 MHz, DMSO-d6) 5 8.64 (s, 1H), 2.82-2.75 (q, J = 7.5 Hz, 2H), 1.19-1.16 (t, J = 7.5 Hz, 3H). Step 3: 5-bromo-4-ethyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH- pyrazol-4-yl)pyrimidine id="p-171" id="p-171" id="p-171" id="p-171" id="p-171" id="p-171" id="p-171" id="p-171" id="p-171"

[0171]To a solution of 5-bromo-4-ethyl-2-iodopyrimidine (17.5 g, 55.9 mmol) and l-methyl-5- (((tetrahydro-2H-pyran-2-yl)oxy)methyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (15.8 g, 46.6 mmol, prepared as WO2014081619) in 1,4-dioxane (300 mL) and water (mb) were added Na2CO3 (9.9 g, 93.2 mmol), Pd(dppf)C12 (1.7 g, 2.3 mmol) in one portion under N2 atmosphere, the mixture was degassed under N2 for three times and stirred under N2 atmosphere at 75 °C for 16 hrs. The mixture was poured into ice-water and extracted with DCM (2 x 200 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to dryness. The resulting residue was purified by silica gel chromatography (PE: EtOAc= 10: 1) to give the title compound (12.7 g, 59.6% yield) as yellow solid. LC/MS (ESI) m/z: 381/383 (M+H)+. 1HNMR (400 MHz, DMSO-d6) 5 8.80 (s, 1H), 8.01 (s, 1H), 5.32-5.29 (d, J= 12 Hz, 1H), 5.14-5.11 (d, J= 12 Hz, 1H), 4.73-4.69 (m, 1H), 3.90 (s, 3H), 3.79-3.72 (m, 1H), 3.45-3.41 (m, 1H), 2.88-2.83 (q, J = 7.4 Hz, 2H), 1.68-1.55 (m, 2H), 1.55-1.42 (m, 4H), 1.28-1.(t, J = 7.5 Hz, 3H). Intermediate 5: methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate (intermediate 5A) bte P 1 Step 2 3A Step 3 intermediate 5 Step 1: benzyl 5-(2-diazoacetyl)-3,3-difluoropiperidine-l-carboxylate [0172]To a solution of l-((benzyloxy)carbonyl)-5,5-difluoropiperidine-3-carboxylic acid (51 g, 0.17 mol) in DCM (500 mL) was added DMF (2 mL) followed by drop-wise addition of (COC1)(43 g, 0.34 mol) at 0 °C and the mixture was stirred at 0 °C to r.t. for 2 hrs. The reaction was concentrated to dryness and the residue was co-evaporated with toluene for three times. The residue WO 2022/034568 PCT/IB2021/059266 was dissolved in THF (500 mL) and TMSCHN2 solution (250 mL, 0.5 mol, 2M in hexane) was added drop-wisely at 0 °C. The resulting mixture was stirred at r.t. for 16 hrs. The reaction was quenched with AcOH (60 mL) at 0 °C and the mixture was concentrated to dryness to give the title compound (55 g, 100% yield) as yellow oil, which was directly used to the next reaction without purification. LC/MS (ESI) m/z: 324 (M+H)+. Step 2: benzyl (S)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (3A) and benzyl (R)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (3B) [0173]To a solution of benzyl 5-(2-diazoacetyl)-3,3-difluoropiperidine-l-carboxylate (55 g, 0.mol) in MeOH (500 mL) was added CF3COOAg (7.4 g, 0.03mol) and TEA (67.6 g, 0.67mol) and the mixture was stirred at 20 °C for 2 hrs. The reaction mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc= 3: 1) to give the title compound (37 g, 62.9% yield) as light yellow oil. LC/MS (ESI) m/z: 328 (M+H)+. The two enantiomers were separated by chiral SEC to give benzyl (S)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l- carboxylate (peak 2, retention time: 4.414 min) (13.8 g, 24.8% yield) and benzyl (R)-3,3-difluoro- 5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (peak 1, retention time: 4.109 min) (16.1 g, 28.9% yield) as light yellow oil. 1HNMR (400 MHz, CDCI3) 5 7.41 - 7.28 (m, 5H), 5.15 (s, 2H), 4.25 - 3.94 (m, 2H), 3.66 (d, J =25.3 Hz, 3H), 3.30 - 3.12 (m, 1H), 2.91 - 2.67 (m, 1H), 2.42 - 2.23 (m, 4H), 1.75 - 1.60 (m, 1H). SFC condition: Column: ChiralPak IC-H, 250x4.6mm I.D., pm; Mobile phase: A for CO2 and B for Methanol (0.05% NH4OH); Gradient: B 5%-40%; Flow rate: 50 mL /min; Step 3: Methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate [0174]To a solution of benzyl (S)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l- carboxylate (4.2 g, 12.83 mmol) in EtOAc (40 mL) was added Pd/C (300 mg, 10% wt) at 0 °C. The mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (2.37 g, 95.6%) as off-white solid. LC/MS (ESI) (m/z): 194 (M+H)+. 1HNMR (400 MHz, CDCI3) 5 3.69 (s, 3H), 3.18 - 3.06 (m, 2H), 2.85 - 2.65 (m, 1H), 2.36 - 2.(m, 5H), 1.62- 1.48 (m, 1H). Intermediate 6: Methyl (R)-2-(5,5-difluoropiperidin-3-yl)acetate intermediate 6 WO 2022/034568 PCT/IB2021/059266 id="p-175" id="p-175" id="p-175" id="p-175" id="p-175" id="p-175" id="p-175" id="p-175" id="p-175"

[0175]The title compound was prepared from benzyl (R)-3,3-difluoro-5-(2-methoxy-2- oxoethyl)piperidine-l-carboxylate using the same procedure as methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate. LC/MS (ESI) (m/z): 194 (M+H)+. Intermediate 7: methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate Step 1: 2-((3S)-5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid [0176]To a mixture of 3-bromo-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridine (1.5 g, 4.1 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (790 mg, 4.1 mmol) in dry 1,4-dioxane (30 mL) was added Cs2CO(2.66 g, 8.2 mmol), RuPhos (381 mg, 0.82 mmol) and RuPhos-Pd-G3 (342 mg, 0.41 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 100 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (1.6 g, 81.7% yield) as light yellow solid. LC/MS (ESI) m/z: 480 (M+H)+. 1H NMR (400 MHz, CDC13) 5 7.97 (d, J= 8.3 Hz, 1H), 7.33 (d, J= 8.3 Hz, 1H), 5.38 - 5.26 (m, 2H), 4.(t, J = 3.2 Hz, 1H), 4.15 (s, 3H), 3.92 -3.85 (m, 1H), 3.70 (s, 3H), 3.57 -3.50 (m, 1H), 3.32 -3.(m, 2H), 3.03 - 2.93 (m, 1H), 2.63 - 2.53 (m, 2H), 2.57 (s, 3H), 2.44 - 2.41 (m, 2H), 2.35 - 2.(m, 1H), 1.84 - 1.77 (m, 1H), 1.75 - 1.67 (m, 2H), 1.62 - 1.55 (m, 2H), 1.54 - 1.45 (m, 2H). Step 2: methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)- 2-methylpyridin-3-yl)piperidin-3-yl)acetate [0177]To a solution of methyl 2-((3S)-5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (1.6 g, 3.mmol) in MeOH (20 mL) was added PPTS (1.6 g, 6.6 mmol) and the mixture was stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in EtOAc (mL). The mixture was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 60% EtOAc in PE) to give the title compound (1.2 g, 90.0% yield) as light yellow solid. LC/MS (ESI) m/z: 3 WO 2022/034568 PCT/IB2021/059266 (M+H)+. 1H NMR (400 MHz, CDCh)5 8.11 (d,J=8.4Hz, 1H), 7.44 (d, =8.4 Hz, 1H), 4.82 (s, 2H), 4.08 (s, 3H), 3.70 (s, 3H), 3.36 - 3.21 (m, 2H), 3.06 - 2.96 (m, 1H), 2.65- 2.56 (m, 2H), 2.(s, 3H), 2.46 - 2.40 (m, 2H), 2.37 - 2.28 (m, 1H), 1.78 - 1.70(m, 1H). Intermediate 8: methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate intermediate 8 [0178]Intermediate 8was synthesized according the same sequence as was used for the synthesis of intermediate7. LC/MS (ESI) m/z: 410 (M+H)+. 1H NMR (400 MHz, CDCI3) 5 8.12 (d, J= 8.Hz, 1H), 7.48 (d, J= 8.4 Hz, 1H), 4.84 (s, 2H), 4.08 (s, 3H), 3.70 (s, 3H), 3.30 - 3.17 (m, 2H), 3.- 2.99 (m, 1H), 2.99 - 2.93 (m, 2H), 2.63 - 2.58 (m, 2H), 2.48 - 2.38 (m, 2H), 2.36 - 2.28 (m, 1H), 1.74 - 1.63 (m, 1H), 1.34 (t, J= 7.5 Hz, 3H). Intermediate 9: methyl (S)-2-(l-(4-ethyl-2-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4- yl)pyrimidin-5-yl)-5,5-difluoropiperidin-3-yl)acetate Step 1: methyl 2-((3S)-5,5-difluoro-l-(4-methyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-pyrazol-4-yl)pyrimidin-5-yl)piperidin-3-yl)acetate [0179]To a solution of 5-bromo-4-ethyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy )methyl)- lH-pyrazol-4-yl)pyrimidine (420 mg, 1.1 mmol) in toluene(5 mL) were added methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (212 mg, 1.1 mmol), followed by the addition of Cs2CO3 (710 mg, 2.2 mmol), BINAP (135 mg, 0.20 mmol ) and Pd(OAc)2 (49 mg, 0.22 mmol ) under N2 atmosphere. The reaction was stirred under N2 atmosphere at 100 °C for 16 hrs. The mixture was dilute d with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (160 mg, 28.7% yield) as a yellow oil. LC-MS (ESI) m/z 494 (M+H)+. Step 2: methyl (S)-2-(l-(4-ethyl-2-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)pyrimidin- 5-yl)-5,5-difluoropiperidin-3-yl)acetate WO 2022/034568 PCT/IB2021/059266 id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180"

[0180]Intermediate 9was synthesized according the same sequence as was used for the synthesis of intermediate 5. LC/MS (ESI) m/z: 410 (M+H)+. Intermediate 10: ethyl (R)-2-(l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)piperidin-3-yl)acetate id="p-181" id="p-181" id="p-181" id="p-181" id="p-181" id="p-181" id="p-181" id="p-181" id="p-181"

[0181]Intermediate 10was synthesized from commercial available ethyl (R)-2-(piperidin-3- yl)acetate according the same sequence that was used for the synthesis of intermediate 7. LC/MS (ESI) m/z: 374 (M+H)+1H NMR (400 MHz, CDC13) 5 8.07 (d, J= 8.4 Hz, 1H), 7.43 (d, J= 8.Hz, 1H), 4.81 (s, 2H), 4.14 (q, J= 7.1 Hz, 2H), 4.07 (s, 3H), 3.21 - 3.14 (m, 1H), 3.09- 3.02 (m, 1H), 2.72- 2.67 (m, 1H), 2.57 (s, 3H), 2.48 - 2.39 (m, 1H), 2.35 - 2.26 (m, 3H), 1.93 - 1.86 (m, 1H), 1.84- 1.68 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H), 1.23-1.15 (m, 1H). Intermediate 11: ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-182" id="p-182" id="p-182" id="p-182" id="p-182" id="p-182" id="p-182" id="p-182" id="p-182"

[0182]Intermediate 11was synthesized from commercial available ethyl (R)-2-(piperidin-3- yl)acetate according the same sequence that was used for the synthesis of intermediate 7. LC/MS (ESI) m/z: 388 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.09 (d, J= 8.4 Hz, 1H), 7.47 (d, J= 8.Hz, 1H), 4.83 (s, 2H),4.14(q,J=7.5Hz, 2H), 4.08 (d, J = 6.8 Hz, 3H),3.12(d,J= 10.8 Hz, 1H), 3.05- 2.98 (m, 1H), 2.92 (q, J= 7.5 Hz, 2H), 2.73-2.67 (m, 1H), 2.50 - 2.40 (m, 1H), 2.35 - 2.(m, 3H), 1.95 - 1.85 (m, 1H), 1.84 - 1.80 (m, 1H), 1.79 - 1.71 (m, 1H), 1.33 (t, J= 15 Hz, 3H), 1.26 (t, J= 15, 0.7 Hz, 3H), 1.23-1.13 (m, 1H). Intermediate 12: Methyl 5,5-difluoro-l-((6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)-2-methylpyridin-3-yl)methyl)piperidine-3-carboxylate WO 2022/034568 PCT/IB2021/059266 Step 1: Methyl 2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)nicotinate [0183]To a solution of 3-bromo-2-methyl-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3- triazol-4-yl }pyridine (5.0 g, 13.6 mmol) in MeOH (50 mL) was added TEA (9.5 mL, 68.1 mmol) followed by Pd(dppf)C12 (1.0 g, 1.4 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under 60 psi of CO gas at 70 °C for 16 hrs. The mixture was filtered through Celite pad and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (3.8 g, 80.6% yield) as yellow solid. LC-MS (ESI) m/z 347 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.28 (d, J= 8.2 Hz, 1H), 8.(d, 8.2 Hz, 1H), 5.39 (dd, J= 29.2, 12.7 Hz, 2H), 4.77 - 4.75 (m, 1H), 4.17 (s, 3H), 3.93 (s,3H), 3.90 - 3.83 (m, 1H), 3.55 - 3.50 (m, 1H), 2.86 (s, 3H), 1.84 - 1.66 (m, 2H), 1.65 - 1.57 (m, 2H), 1.55 - 1.48 (m, 2H). Step 2: (2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol- 4-yl)pyridin-3-yl)methanol [0184]To a solution of Methyl 2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)nicotinate (1.50 g, 4.33 mmol) in THE (20 mL) was added LiBH4(5.20 mL, 10.40 mmol, 2M in THF) drop-wisely at 0 °C. After addition, the mixture was stirred at 55 °C for 3 hrs. The mixture was poured into saturated aq.NH4Cl solution and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (1.3 g, 94.3% yield) as light yellow solid. LC/MS (ESI) (m/z): 319 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.

WO 2022/034568 PCT/IB2021/059266 (d,J = 7.9Hz, 1H), 7.74 (d,J=8.0Hz, 1H),5.34(dd,J=33.4, 12.6 Hz, 2H), 4.80 -4.75 (m, 1H), 4.74 (s, 2H), 4.16 (s, 3H), 3.92 - 3.84 (m, 1H), 3.55 - 3.48 (m, 1H), 2.57 (s, 3H), 1.82 - 1.71 (m, 2H), 1.58- 1.48 (m, 4H). Step 3: 3-(chloromethyl)-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine [0185]To a solution of (2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methanol (1.3 g, 4.1 mmol) in DCM (30 mL) were added TEA (1.mL, 12.25 mmol) followed by drop-wise addition of MsCl (0.70 g, 6.1 mmol) at 0 °C. The reaction was stirred at r.t. for 2 hrs. The mixture was washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (1.7 g, 87.3% yield) as yellow solid. LC/MS (ESI) (m/z): 367(M+H)+. 1HNMR(400MHz, CDCI3) 8.03 (d, J= 8.0 Hz, 1H), 7.68 (d, J= 8.0 Hz, 1H), 5.35 (dd,J= 33.2, 12.7 Hz, 2H), 4.80 - 4.(m, 1H), 4.62 (s, 2H), 4.16 (s, 3H), 3.93 - 3.82 (m, 1H), 3.56 - 3.42 (m, 1H), 2.66 (s, 3H), 1.81 - 1.67 (m, 2H), 1.61 - 1.49 (m, 4H). Step 4: Methyl 5,5-difluoro-l-((2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)piperidine-3-carboxylate [0186]To the solution of 3-(chloromethyl)-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridine (935 mg, 2.78 mmol) in CH3CN (20 mL) was added methyl 5,5-difluoropiperidine-3-carboxylate (994 mg, 3.6 mmol) followed by DIPEA (1.2 mL, 7.mmol) and the reaction was stirred at 80 °C for 3.5 hrs. The mixture was diluted with EtOAc (mL) and was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (800 mg, 60.1% yield) as yellow oil. LC/MS (ESI) (m/z): 4(M+H)+. 1H NMR (400 MHz, CDC13) 5 7.98 (d, J= 7.9 Hz, 1H), 7.62 (d, J= 7.9 Hz, 1H), 5.43 - 5.30 (m, 2H), 4.78 - 4.76 (m, 1H), 4.15 (s, 3H), 3.93 - 3.85 (m, 1H), 3.68 (s, 3H), 3.65 - 3.57 (m, 2H), 3.56 - 3.49 (m, 1H), 3.12 - 3.01 (m, 2H), 2.92 - 2.85 (m, 1H), 2.81 - 2.75 (m, 1H), 2.58 (s, 3H), 2.42 - 2.35 (m, 1H), 2.32 - 2.22 (m, 1H), 1.93 - 1.86 (m, 1H), 1.82 - 1.66 (m, 2H), 1.62 - 1.48 (m, 4H). Step 5: Methyl 5,5-difluoro-l-((6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)methyl)piperidine-3-carboxylate [0187]To the solution of Methyl 5,5-difluoro-l-((2-methyl-6-(l-methyl-5-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)piperidine-3-carboxylate (8mg, 1.67 mmol) in MeOH (15 mL) was added PPTS (0.84 g, 3.34 mmol) and the reaction was WO 2022/034568 PCT/IB2021/059266 stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was diluted with EtOAc (10 mL). The mixture was washed with saturated aq.NaHCO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 60% EtOAc in PE) to give the title compound (620 mg, 94.0% yield) as yellow oil. LC/MS (ESI) (m/z): 396 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.14 (d, J= 8.0 Hz, 1H), 7.73 (d, J= 8.0 Hz, 1H), 4.85 (s, 2H), 4.09 (s, 3H), 3.69 (s, 3H), 3.62 (d, J= 3.2 Hz, 2H), 3.- 2.97 (m, 2H), 2.95 - 2.83 (m, 1H), 2.62 (s, 3H), 2.48 - 2.38 (m, 2H), 2.34 - 2.28 (m, 1H), 2.- 1.86 (m, 1H). Intermediate 13: methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate O^OX N-N intermediate 13 [0188]The title compound was prepared from 3-bromo-2-ethyl-6-(l-methyl-5-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridine using the same sequence as the synthesis of intermediate 12 LC/MS (ESI) (m/z): 410 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.13 (d, J = 8.0 Hz, 1H), 7.75 (d, J= 8.0 Hz, 1H), 4.85 (s, 2H), 4.10 (s, 3H), 3.69 (s, 3H), 3.64 (s, 2H), 3.12 - 3.00 (m, 2H), 2.94 - 2.88 (m, 2H), 2.44 - 2.37 (m, 2H), 2.33 - 2.27 m, 1H), 2.07 - 1.86 (m, 2H), 1.31 (t, J =7.6 Hz, 3H). Intermediate 14: 4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one Step 1: cyclopropyl(2-fluoro-3-methylpyridin-4-yl)methanol id="p-189" id="p-189" id="p-189" id="p-189" id="p-189" id="p-189" id="p-189" id="p-189" id="p-189"

[0189]To a solution of 2-fluoro-4-iodo-3-methylpyridine (4 g, 16.9 mmol) in THE (40 mL) was added i-Pr-MgCl (16.9 mmol, 8.4 mL, 2 M in THF) drop-wisely at 0 °C under N2 and the mixture was stirred at r.t. for 1 hr. Cyclopropanecarbaldehyde (1.18 g, 16.9 mmol) was added and the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with ice-water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash WO 2022/034568 PCT/IB2021/059266 chromatography (eluted with PE: EtOAc = 100: 1 to 10: 1) to give the title compound (2.37 g, 77.6% yield) as colorless oil. LC/MS (ESI) m/z: 182 (M+H)+. Step 2: 4-(cyclopropylmethyl)-2-fluoro-3-methylpyridine id="p-190" id="p-190" id="p-190" id="p-190" id="p-190" id="p-190" id="p-190" id="p-190" id="p-190"

[0190]To a solution of cyclopropyl(2-fluoro-3-methylpyridin-4-yl)methanol (810 mg, 4.47 mmol) in CH3CN (8 mL) were added Nai (2.68 g, 17.9 mmol) and TEA (2.61 g, 22.4 mmol) followed by drop-wise addition of Et3SiH (2.60 g, 22.4 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 16 hrs. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with EtOAc (2x15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 100: 1 to 10: 1) to give the title compound (420 mg, 56.9% yield) as colorless oil. LC/MS (ESI) m/z: 166 (M+H)+. Step 3: 4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one [0191]To a solution of 4-(cyclopropylmethyl)-2-fluoro-3-methylpyridine (420 mg, 2.54 mmol) in 1,4-dioxane (4.2 mL) and water (4.2 mL) was added aq.HCl (0.84 mL, 36% wt) and the mixture was stirred at 100 °C for 16 hrs. The mixture was diluted with water and extracted with DCM (2 x mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (322 mg, 77.6% yield) as light yellow solid. 1H NMR (400 MHz, DMSO-d6) 5 11.13 (s, 1H), 6.95 (d, J= 6.8 Hz, 1H), 5.97 (d, J= 6.Hz, 1H), 2.19 (d, J= 6.8 Hz, 2H), 1.75 (s, 3H), 0.78-0.67 (m, 1H), 0.32-0.23 (m, 2H), 0.02-0.(m, 2H). LC/MS (ESI) m/z: 164 (M+H)+. Intermediate 15: 4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one Pd(OH)2, H2 /0"Pd(dppf)CI 2, K3PO4 MeOH،، dioxane/H 2O,100°C 2 Step 1 Step 2 Step 1: 5-allyl-2-methoxypyridine [0192]To a solution of 5-bromo-2-methoxypyridine (4.2 g, 22.3 mmol) and 2-allyl-4,4,5,5- tetramethyl-l,3,2-dioxaborolane (5.63 g, 33.5 mmol) in 1,4-dioxane (42 mL) and water (8.4 mL) were added K3PO4 (14.23 g, 67.0 mmol), Pd(dppf)C12 (1.63 g, 2.23 mmol) under N2 atmosphere and the mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 100 °C for 2 hrs. The mixture was diluted EtOAc (50 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash aq.HBr ‘MEton, 85°C intermediate 15 Step 3 WO 2022/034568 PCT/IB2021/059266 chromatography (eluted with PE: EtOAc = 50: 1 to 10: 1) to give the title compound (3 g, 90% yield) as light yellow oil. LC/MS (ESI) m/z: 150 (M+H)+. Step 2: 2-methoxy-5-propylpyridine [0193]To a solution of 5-allyl-2-methoxypyridine (3 g, 20.1 mmol) in MeOH (30 mL) was added Pd(OH)2/C (0.28 g, 10% wt) under N2 atmosphere. After addition, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 25 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (2.74 g, 90.1% yield) as colorless oil, which was used in next step directly. LC/MS (ESI) m/z: 152 (M+H)+. Step 3: 5-propylpyridin-2(lH)-one (4) id="p-194" id="p-194" id="p-194" id="p-194" id="p-194" id="p-194" id="p-194" id="p-194" id="p-194"

[0194]To a solution of 2-methoxy-5-propylpyridine (2.74 g, 18.12 mmol) in EtOH (27 mL) was added aq.HBr (27 mL, 40% wt) and the mixture was stirred at 85 °C for 16 hrs. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc =10: 1 to 1: 1) to give the title compound (723 mg, 29.1% yield) as white solid. 1H NMR (400 MHz, CDC13) 13.21 (s, 1H), 7.35 (dd,J= 9.2, 2.5 Hz, 1H), 7.14 (d, J= 2.2 Hz, 1H), 6.55 (d, J= 9.2 Hz, 1H), 2.35 (t, J= 7.6Hz, 1H), 1.60-1.48 (m, 1H), 0.92 (t, J= 7.2 Hz, 2H). LC/MS (ESI) m/z: 138(M+H)+. Intermediate 16: 5-(cyclopropylmethyl)pyridin-2(lH)-one intermediate 16 Step 1: N*-[(lE)-cyclopropylmethylidene]-4-methylbenzene-l-sulfonohydrazide [0195]To a solution of 4-methylbenzene-l-sulfonohydrazide (1 g, 5.4 mmol) in MeOH (10 mL) was added cyclopropanecarbaldehyde (0.40 mL, 5.4 mmol) drop-wisely at 0 °C and the mixture was stirred at 70 °C for 10 mins. The mixture was concentrated to dryness and the residue was purified by flash chromatography (0 ~ 40% EtOAc in PE) to give the title compound (1.1 g, 86.0% yield) as white solid. LC-MS (ESI) m/z 239 (M+H)+. Step 2: 5-(cyclopropylmethyl)-2-methoxypyridine WO 2022/034568 PCT/IB2021/059266 id="p-196" id="p-196" id="p-196" id="p-196" id="p-196" id="p-196" id="p-196" id="p-196" id="p-196"

[0196]To mixture of N'-[(lE)-cyclopropylmethylidene]-4-methylbenzene-l-sulfonohydrazide (g, 4.2 mmol) and (6-methoxypyridin-3-yl)boronic acid (0.64 g, 4.2 mmol) in 1,4-dioxane (10 mL) was added K2CO3 (580 mg, 4.2 mmol) and the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (15 mL), washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 5% EtOAc in PE) to give 5- (cyclopropylmethyl)-2-methoxypyridine (210 mg, 30.7% yield) as colorless oil. LC-MS (ESI) m/z 164 (M+H)+. 1HNMR (400 MHz, CDCI3) 5 8.03 (d, J = 1.9 Hz, 1H), 7.48 (dd, J= 8.4, 1.9 Hz, 1H), 6.68 (d, J= 8.4 Hz, 1H), 3.92 (s, 3H), 2.46 (d, J= 6.9 Hz, 2H), 1.01 - 0.84 (m, 1H), 0.57 - 0.46 (m, 2H), 0.20 -0.17 (m, 2H). Step 3: 5-(cyclopropylmethyl)pyridin-2(lH)-one [0197]To a mixture of 5-(cyclopropylmethyl)-2-methoxypyridine (200 mg, 1.2 mmol) in MeCN (5 mL) was added Nai (367 mg, 2.5 mmol) and TMSC1 (0.31 mL, 2.5 mmol) and the reaction mixture was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and was concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give 5-(cyclopropylmethyl)pyridin- 2(lH)-one (50 mg, 27.4% yield) as colorless oil. LC-MS (ESI) m/z 150 (M+H)+. Intermediate 17: 5-(cyclobutylmethyl)pyridin-2(lH)-one ^x^o intermediate 17 [0198]The title compound was prepared from cyclobutanecarbaldehyde using the same sequence as the synthesis of intermediate 16.LC-MS (ESI) m/z 164 (M+H)+. Intermediate 18: 5-(cyclobutylmethyl)pyridin-2(lH)-one intermediate 18 [0199]The title compound was prepared from isobutyraldehyde using the same sequence as the synthesis of intermediate 16.LC-MS (ESI) m/z 152 (M+H)+. Intermediate 19: 5-isopropylpyridin-2(lH)-one H2, Pd(0H)2 aq HBrK2C03, Pd(PPh 3)1,4-dioxane/H 2O 100 °C MeOH, rt EtOH, 85°C Step 1 Step 2 Step 3 Intermediate 19 Step 1: 2-methoxy-5-(prop-l-en-2-yl)pyridine WO 2022/034568 PCT/IB2021/059266 id="p-200" id="p-200" id="p-200" id="p-200" id="p-200" id="p-200" id="p-200" id="p-200" id="p-200"

[0200]To a solution of 5-bromo-2-methoxypyridine (1.0 g, 5.32 mmol) and 4,4,5,5-tetramethyl- 2-(prop-l-en-2-yl)-l,3,2-dioxaborolane (1.34 g, 7.98 mmol) in 1,4-dioxane (10 ml) and water (mL) were added K2CO3 (1.47 g, 10.64 mmol), Pd(PPh3)4 (0.61 g, 0.53 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 200: 1 to 20: 1) to give the title compound (600 mg, 75.6% yield) as colorless oil. LC/MS (ESI) m/z: 150 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.25 (d, J= 2.4 Hz, 1H), 7.69 (dd,J= 8.6, 2.Hz, 1H), 6.71 (dd,J= 8.6, 0.6 Hz, 1H), 5.29 (s, 1H), 5.05-5.01 (m, 1H), 3.94 (s, 1H), 2.13 (d, J = 0.5 Hz, 1H). Step 2: 5-isopropyl-2-methoxypyridine id="p-201" id="p-201" id="p-201" id="p-201" id="p-201" id="p-201" id="p-201" id="p-201" id="p-201"

[0201] To a solution of 2-methoxy-5-(prop-l-en-2-yl)pyridine (600 mg, 4.02 mmol ) in MeOH (mL) was added Pd(OH)2 (50 mg, 10% wt) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 25 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (290 mg, 47.7% yield) as colorless oil, which was used in next step directly. 1H NMR (400 MHz, CD3OD) 5 7.95 (d,J=2.4 Hz, 1H), 7.59 (dd, J= 8.6, 2.5 Hz, 1H), 6.74 (d, J= 8.6 Hz, 1H), 3.(s, 3H), 2.93 - 2.85 (m, 1H), 1.24 (d, J= 6.9 Hz, 6H). LC/MS (ESI) m/z: 152 (M+H)+. Step 3: 5-isopropylpyridin-2(lH)-one id="p-202" id="p-202" id="p-202" id="p-202" id="p-202" id="p-202" id="p-202" id="p-202" id="p-202"

[0202]To a solution of 5-isopropyl-2-methoxypyridine (150 mg, 0.99 mmol) in EtOH (1.5 mL) was added aq.HBr (1.5 mL, 40% wt) under N2 atmosphere and the mixture was stirred at 85 °C for hrs. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with DCM (x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (115 mg, 84.5% yield) as white solid. LC/MS (ESI) m/z: 138 (M+H)+. Intermediate 20: 5-cyclobutylpyridin-2(lH)-one 1 Step1 2 Step 2 3 Step3 intermediate 20 Step 1: l-(6-methoxypyridin-3-yl)cyclobutan-l-ol WO 2022/034568 PCT/IB2021/059266 id="p-203" id="p-203" id="p-203" id="p-203" id="p-203" id="p-203" id="p-203" id="p-203" id="p-203"

[0203]To a stirred solution of 5-bromo-2-methoxypyridine (1.38 mL, 10.6 mmol) in dry THF (mL) was added n-BuLi (5.5 mL, 13.8 mmol) drop-wisely at -78 °C. After stirring at this temperature for 30 mins, cyclobutanone (1.2 mL, 15.9 mmol) was added and the resulting mixture was stirred at -78 °C for 30 mins and r.t. for 30 mins. The mixture was quenched with ice-water and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness, the residue was purified by flash chromatography (PE: EtOAc= 10: 1) to give the title compound (1.5 g, 78.6% yield). LC/MS (ESI) m/z: 180 (M+H)+. 1HNMR (400 MHz, CDCI3) 5 8.29 (d, J= 2.2 Hz, 1H), 7.72 (dd,J= 8.6, 2.6 Hz, 1H), 6.76 (dd, J= 8.6, 0.6 Hz, 1H), 3.94 (s, 3H), 2.62 - 2.46 (m, 2H), 2.41 - 2.32 (m, 2H), 2.08 - 1.94 (m, 2H), 1.69 - 1.59 (m, 2H). Step 2: 5-cyclobutyl-2-methoxypyridine [0204]To a solution of l-(6-methoxypyridin-3-yl)cyclobutan-l-ol (1 g, 5.5 mmol) in MeOH (mL) was added conc.H2SO4 (1 mL) followed by Pd/C (80 mg, 10% wt) at 0 °C, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at r.t. for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 10: 1 to 5: 1) to give the title compound (300 mg, 32.9% yield) as light yellow oil. LC/MS (ESI) (m/z): 164 (M+H)+. 1H NMR (400 MHz, CDCI3) 5 7.98 (t,J=4.Hz, 1H), 7.47 (dd, J= 8.5, 2.5 Hz, 1H), 6.69 (d, J= 8.5 Hz, 1H), 3.91 (s, 3H), 3.46 (dd, J= 17.4, 8.7 Hz, 1H), 2.40-2.28 (m, 2H), 2.16 - 2.02 (m, 3H), 1.91-1.82 (m, 1H). Step 3: 5-cyclobutylpyridin-2-ol id="p-205" id="p-205" id="p-205" id="p-205" id="p-205" id="p-205" id="p-205" id="p-205" id="p-205"

[0205]To a solution of 5-cyclobutyl-2-methoxypyridine (100 mg, 0.6 mmol ) in EtOH (5 mL) was added aq.HBr (2 mL, 48% wt) and the mixture stirred at 70 °C under N2 atmosphere for 16 hrs. The mixture was poured into ice-cooled saturated aq.NaHCO3 solution and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness to give the title compound (70 mg, 76.5% yield). LC/MS (ESI) (m/z): 150 (M+H)+. 1HNMR (400 MHz, CDC13) 5 12.76 (s, 1H), 7.(dd, 9.3, 2.4 Hz, 1H), 7.14 (d, J = 1.8 Hz, 1H), 6.56 (d, J= 9.3 Hz, 1H), 3.34 - 3.23 (dt,J= 17.2, 8.7 Hz, 1H), 2.27 - 2.23 (m , 2H), 2.06 - 1.92 (m, 3H), 1.89 - 1.76 (m, 1H). Intermediate 21: 5-cyclopropyl-4-methylpyridin-2(lH)-one WO 2022/034568 PCT/IB2021/059266 Step 1: 5-cyclopropyl-2-methoxy-4-methylpyridine [0206]To a solution of 5-bromo-2-methoxy-4-methylpyridine (2 g, 9.mmol) and cyclopropylboronic acid (1.11 g, 12.87 mmol) in toluene (30 mL) and water (3 mL) were added K3PO4 (6.30 g, 29.67 mmol), tricyclohexyl phosphine (0.28 g, 0.99 mmol), Pd(OAc)(0.11 g, 0.50 mmol) under N2 atmosphere, after addition, the mixture was degassed under Natmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was diluted with water (20 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 200: 1 to 10: 1) to give the title compound (1.42 g, 88.1% yield) as yellow oil. LC/MS (ESI) m/z: 164 (M+H)+. Step 2: 5-cyclopropyl-4-methylpyridin-2(lH)-one (3) [0207]To a solution of 5-cyclopropyl-2-methoxy-4-methylpyridine (1 g, 6.12 mmol) in CH3CN (10 mL) were added Nai (1.84 g, 12.25 mmol), TMSC1 (1.33 g, 12.25 mmol). The mixture was stirred at 70 °C overnight. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 1: 1) to give the title compound (525 mg, 57.4% yield) as brown solid. 1H-NMR (400 MHz, DMSO-d6) 5 10.96 (s, 1H), 6.67 (s, 1H), 5.(s, 1H), 1.97 (d,J=0.6Hz, 1H), 1.38-1.27 (m, 1H), 0.56-0.46 (m, 1H), 0.24-0.16 (m, 1H). LC/MS (ESI) m/z: 150(M+H)+. Intermediate 22: 4-cyclopropyl-5-methylpyridin-2(lH)-one Step 1: 2-chloro-4-cyclopropyl-5-methylpyridine [0208]To a mixture of 4-bromo-2-chloro-5-methylpyridine (700 mg, 3.39 mmol), K3PO4 (2.15 g, 10.17 mmol) and cyclopropylboronic acid (349 mg, 4.07 mmol) in 1,4-dioxane (25 mL) was added Pd(OAc)2 (38 mg, 0.17 mmol) and Tricyclohexyl phosphine (95 mg, 0.34 mmol) under Natmosphere and the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and filtered. The filtrate was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0-100% EtOAc in PE) to the title compoud (420 mg, 73.9% yield) as colorless oil. LC/MS (ESI) m/z: 168(M+H)+.

WO 2022/034568 PCT/IB2021/059266 Step 2: 4-cyclopropyl-5-methyl-2-[2-(trimethylsilyl)ethoxy] pyridine [0209]To a solution of 2-chloro-4-cyclopropyl-5-methylpyridine (250 mg, 1.49 mmol) in toluene (5 mL) was added 2-(trimethylsilyl)ethan-l-01 (2.1 mL, 14.91 mmol), Cs2CO3 (1.46 g, 4.47 mmol), Pd(OAc)2 (33 mg, 0.15 mmol), t-BuPhos (89 mg, 0.15 mmol), the mixture was degassed under Nfor three times and stirred at 110 °C for 16 hrs. The reaction mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0-30% EtOAc in PE) to give the title compound (201 mg, 54.0% yield) as light yellow oil. LC/MS (ESI) m/z: 250(M+H)+. Step 3: 4-cyclopropyl-5-methylpyridin-2-ol [0210]To a solution of 4-cyclopropyl-5-methyl-2-[2-(trimethylsilyl)ethoxy]pyridine (200 mg, 0.80 mmol) in THE (3 mL) was added TBAF (418 mg, 1.60 mmol) and the mixture was stirred at °C for 3 hrs. The reaction mixture was diluted with EtOAc (10 mL) and washed with saturated water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-20% MeOH in DCM) to give the title compound (56 mg, 46.8% yield) as white solid. LC/MS (ESI) m/z: 150 (M+H)+1H NMR (4MHz, DMSO-d) 5 11.12 (s, 1H), 7.08 (s, 1H), 5.83 (s, 1H), 2.08 (d, J =0.8 Hz, 3H), 1.80-1.(m, 1H), 0.97 - 0.91 (m, 2H), 0.68 - 0.62 (m, 2H). Intermediate 23: 5-(cyclopropylethynyl)pyridin-2(lH)-one Step 1: 5-(2-cyclopropylethynyl)-2-methoxypyridine [0211]To a solution of 5-iodo-2-methoxypyridine (1 g, 4.26 mmol) in CH3CN (20 mL) was added TEA (1.8 mL, 12.77 mmol) followed by the addition of Bis(triphenylphosphine)palladium(II) chloride (0.17 g, 0.21 mmol) , Cui (0.16 g, 0.85 mmol) and ethynylcyclopropane (0.43 mL, 5.11 mmol) under N2 with stirring. And the mixture was stirred at r.t. for 16 hrs. The reaction mixture was filtered through a Celite pad, and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 30 % EtOAc in PE) to give the title compound (700 mg, 95.0 % yield) as white solid. LC/MS (ESI) m/z: 174 (M+H)+. Step 2: 5-(2-cyclopropylethynyl)-l,2-dihydropyridin-2-one id="p-212" id="p-212" id="p-212" id="p-212" id="p-212" id="p-212" id="p-212" id="p-212" id="p-212"

[0212]To solution of 5-(2-cyclopropylethynyl)-2-methoxypyridine (500 mg, 2.89 mmol) in CH3CN (10 mL) was added Nai (865 mg, 5.78 mmol) and TMSC1 (0.74 mL, 5.773 mmol) and the reaction was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed WO 2022/034568 PCT/IB2021/059266 with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 - 5% MeOH in DCM) to give 5-(2- cyclopropylethynyl)-l,2-dihydropyridin-2-one (300 mg, 65.3 % yield) as yellow solid. LC/MS (ESI) m/z: 160 (M+H)+. Intermediate 24: 4-(cyclopropylethynyl)pyridin-2(lH)-one r^NH intermediate 24 [0213]Intermediate 24was prepared from 4-iodo-2-methoxypyridine using the same sequence that was used to synthesize intermediate 23. LC/MS (ESI) m/z: 160 (M+H)+. Intermediate 25: 5-cyclopropoxypyridin-2(lH)-one Intermediate 25 Step 1: 2-(benzyloxy)-5-cyclopropoxypyridine [0214]To a mixture of 6-(benzyloxy)pyridin-3 -01 (300 mg, 1.5mmol) and bromocyclopropane (1.2 mL, 14.9 mmol) in NMP (5 mL) was added CS2CO3 (1.4 g, 4.4 mmol) and the resulting solution was stirred in an autoclave at 150 °C for 8 hrs. The mixture was cooled to r.t. and diluted with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-50% of EtOAc in PE) to give the title compound (180 mg, 50% yield) as light yellow oil. LC/MS (ESI) m/z 242 [M+l] +. Step 2: 5-cyclopropoxypyridin-2(lH)-one [0215]To a solution of 2-(benzyloxy)-5-cyclopropoxypyridine (180 mg, 0.7 mmol) in MeOH (mL) was added Pd/C (20 mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (40 mg, 35.4% yield) as white foam-like solid. LC/MS (ESI) (m/z): 152(M+H)+. Intermediate 26: 5-propoxypyridin-2(lH)-one Intermediate 26 WO 2022/034568 PCT/IB2021/059266 id="p-216" id="p-216" id="p-216" id="p-216" id="p-216" id="p-216" id="p-216" id="p-216" id="p-216"

[0216] Intermediate 26 was synthesized according the same sequence as was used for the synthesis of intermediate 25. LC/MS (ESI) (m/z): 154 (M+H)+. Intermediate 27: 5-propoxypyridin-2(lH)-one Intermediate 27 id="p-217" id="p-217" id="p-217" id="p-217" id="p-217" id="p-217" id="p-217" id="p-217" id="p-217"

[0217]Intermediate 27was synthesized according the same sequence as was used for the synthesis of intermediate 25. LC/MS (ESI) (m/z): 140 (M+H)+. Intermediate 28: 5-(azetidin-l-yl)pyridin-2(lH)-one RuPhos, Pd2(dba) Cs2CO3,1,4-dioxane 120 °C, m.w.

H2, Pd/CMeOH Step 1Step 2 Step 1: 5-(azetidin-l-yl)-2-(benzyloxy)pyridine id="p-218" id="p-218" id="p-218" id="p-218" id="p-218" id="p-218" id="p-218" id="p-218" id="p-218"

[0218]To solution of 2-(benzyloxy)-5-bromopyridine (850 mg, 3.2 mmol ) in 1,4-dioxane (5 mL) was added azetidine (0.65 mL, 9.6 mmol) followed by CS2CO3 (2.1 g, 6.4 mmol), RuPhos (3mg, 0.64 mmol) and Pd2(dba)3 (260 mg, 0.3 mmol), the mixture was degassed under Natmosphere for three times and stirred in CEM reactor at 100 °C for 2 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (650 mg, 84.3% yield) as yellow oil. LC-MS (ESI) m/z 2(M+H)+. Step 2: 5-(azetidin-l-yl)pyridin-2-01 [0219]To solution of 5-(azetidin-l-yl)-2-(benzyloxy)pyridine (400 mg, 1.7 mmol) in MeOH (mL) was added Pd/C (50 mg, 10% wt). The mixture was degassed under N2 atmosphere and stirred under a H2 balloon at r.t. for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (230 mg, 90% yield) as yellow solid. LC-MS (ESI) m/z 1(M+H)+.

WO 2022/034568 PCT/IB2021/059266 Intermediate 29: 5-propylpyrazin-2-ol conc.H 2SO4 Intermediate 29 Step 3 Step 1: 5-allylpyrazin-2-amine [0220]To a mixture of 5-bromopyrazin-2-amine (500 mg, 2.87 mmol) and 4,4,5,5-tetramethyl-2- (prop-2-en-l-yl)-l,3,2-dioxaborolane (0.81 mb, 4.31 mmol) in DMF (10 mL) was added CsF (1.g, 8.6 mmol) and Pd(dppf)C12 (430 mg, 0.57 mmol). The mixture was degassed under Natmosphere for three times and stirred under N2 atmosphere at 100 °C for 9 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc = 4: 1) to give the title compound (250 mg, 64.1% yield) as yellow oil. LC/MS (ESI) (m/z): 135 (M+H)+. Step 2: 5-propylpyrazin-2-amine [0221]To a solution of 5-allylpyrazin-2-amine (240 mg, 1.78 mmol) in MeOH (10 mL) was added Pd/C (20 mg, 10% wt). The mixture was degassed under H2 atmosphere for three times and stirred under a H2 balloon at room temperature for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (200 mg, 82.1% yield) as yellow oil. LC/MS (ESI) (m/z): 138 (M+H)+. Step 3: 5-propylpyrazin-2-ol [0222]To a solution of NaNO2 (3 g, 43.74 mmol) in con.H2SO4 (10 mL) was added propylpyrazin- 2-amine (1 g, 7.3 mmol) in portions at 0 °C and the mixture was stirred at 100 °C for 2 hrs. The mixture was diluted with ice water, neutralized with IM aq.NaOH solution to pH=5 and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (eluted with DCM: MeOH= 15: 1) to give the title compound (320 mg, 31.8% yield). LC/MS (ESI) (m/z): 139 [M+H]+. Intermediate 30: 5-propylpyrimidin-2(lH)-one Intermediate 30 WO 2022/034568 PCT/IB2021/059266 id="p-223" id="p-223" id="p-223" id="p-223" id="p-223" id="p-223" id="p-223" id="p-223" id="p-223"

[0223]To a solution of 2-chloro-5-propylpyrimidine (500 mg, 3.19 mmol) in EtOH (5 mL) was added con.HCl (5 mL) at 0 °C and the mixture was stirred under N2 atmosphere at 100 °C for hrs. The mixture was diluted with ice water (10 mL), neutralized with saturated aq.NaHCOsolution to pH= 7 and extracted with DCM (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (eluted with DCM: MeOH= 15: 1) to give the title compound (200 mg, 45.3% yield) as yellow oil. LC/MS (ESI) m/z: 139 (M+H)+. Intermediate 31: 6-propylpyrimidin-4(3H)-one MeONa/MeOHh2n ^NH Intermediate 31 id="p-224" id="p-224" id="p-224" id="p-224" id="p-224" id="p-224" id="p-224" id="p-224" id="p-224"

[0224]To a mixture of ethyl 3-oxohexanoate (1.6 mL, 10 mmol) and formamidine acetate (1 g, mmol) in MeOH (10 mL) was added MeONa (7.5 mL, 1.5 M in MeOH) drop-wisely at 0 °C and the mixture was stirred at 60 °C overnight. The reaction mixture was diluted with DCM (mL), washed with water, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-100% of EtOAc in PE) to give the title compound (410 mg, 29.0% yield) as white solid. LC/MS (ESI) m/z: 139 (M+H)+. Intermediate 32: 4-propylpyridazin-3(2H)-one Step 1: 6-chloro-4-propylpyridazin-3(2H)-one id="p-225" id="p-225" id="p-225" id="p-225" id="p-225" id="p-225" id="p-225" id="p-225" id="p-225"

[0225]A solution of 3,6-dichloro-4-propylpyridazine (1.00 g, 5.23 mmol) in AcOH (10 mL) was stirred at 120 °C under N2 atmosphere for 5 hrs. The mixture was concentrated to dryness and the residue was neutralized with saturated aq.NaHCO3 solution. The mixture was extracted with EtOAc (2 x 20 mL) and the combined organic layers were washed with brie, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 8: 1 to 5: 1) to give the title compound (550 mg, 60.9% yield) as yellow oil. LC/MS (ESI) m/z: 173 (M+H)+. Step 2: 4-propylpyridazin-3(2H)-one WO 2022/034568 PCT/IB2021/059266 id="p-226" id="p-226" id="p-226" id="p-226" id="p-226" id="p-226" id="p-226" id="p-226" id="p-226"

[0226]To a solution of 6-chloro-4-propylpyridazin-3(2H)-one (500 mg, 2.90 mmol) in EtOAc (mL) was added TEA (0.05 mL, 0.360 mmol) and Pd/C (60 mg, 10% wt) and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 0 °C for 3 hrs. The reaction was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography (PE: EtOAc = 5: 1 to 1: 1) to give the title compound (75 mg, 18.7% yield) as off-white solid. LC/MS (ESI) m/z: 139 (M+H)+. Intermediate 33: 6-propylpyridazin-3-ol A_______ > (5 AcQH, 120°C A T N k 2co31 Pd(dp Pf)ci 2 T T1,4 ן-dioxane/H 20,75 °C ןןStep 1 2 Step 2 3 OHH2, Pd/C Q Y MeOH, rt ]Step 3 | Intermediate 33 Step 1: 3-allyl-6-chloropyridazine [0227]To a mixture of 2-allyl-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (705 mg, 4.2 mmol) and 3-chloro-6-iodopyridazine (1 g, 4.2 mmol) in 1,4-dioxane (10 mL) and water (2 mL) were added K2CO3 (1.74 g, 12.582 mmol) and Pd(dppf)C12 (153.44 mg, 0.210 mmol) under Natmosphere. Then the mixture reaction was stirred at 75 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 5: 1) to give the title compound (130 mg, 20.3% yield) as yellow oil. LC/MS (ESI) (m/z): 155 (M+H)+. Step 2: 6-allylpyridazin-3-01 [0228]A solution of 3-allyl-6-chloropyridazin (130 mg, 0.85 mmol) in AcOH (6 mL) was stirred at 120 °C for 2 hrs. The mixture reaction was concentrated to dryness and the residue was purified by chromatography on silica gel (PE: EtOAc= 3: 1) to give the title compound (70 mg, 61.3% yield) as yellow solid. LC/MS (ESI) (m/z): 137 (M+H)+. Step 3: 6-propylpyridazin-3-ol WO 2022/034568 PCT/IB2021/059266 id="p-229" id="p-229" id="p-229" id="p-229" id="p-229" id="p-229" id="p-229" id="p-229" id="p-229"

[0229]To a solution of 6-allylpyridazin-3-01 (70 mg, 0.459 mmol) in MeOH (3 mL) was added Pd/C (20 mg, 10% wt) at 0 °C, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (32 mg, 51.2% yield) as yellow solid. LC/MS (ESI) (m/z): 139 (M+H)+. Intermediate 34: 6-(cyclopropylmethyl)pyridazin-3-ol Intermediate 34 Step 1: dimethyl (3-cyclopropyl-2-oxopropyl)phosphonate [0230]To a solution of dimethyl methylphosphonate (652 mg, 5.25 mmol) in THF (5 mL) was added n-BuLi (2.62 mL, 5.25 mmol, 2M in THF) drop-wisely at -70 °C and the mixture was stirred at this temperature for 15 mins. A solution of methyl 2-cyclopropylacetate (300 mg, 2.62 mmol) in THF (3 mL) was added to the above mixture at -70 °C and the resulting mixture was stirred at - °C for 1 hr. The reaction mixture was quenched with saturated aq.NH4Cl solution at 0 °C and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (460 mg, 84.9% yield) as yellow solid. LC/MS (ESI) m/z: 207 (M+H)+. Step 2: ethyl (2Z)-5-cyclopropyl-4-oxopent-2-enoate [0231]To a solution of dimethyl (3-cyclopropyl-2-oxopropyl)phosphonate (460 mg, 2.23 mmol) in t-BuOH (5 mL) was added t-BuOK (250 mg, 2.23 mmol), ethyl 2-oxoacetate (0.22 mL, 2.mmol), and then the mixture was stirred at 25 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL) and washed with saturated aq.NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-5% EtOAc in PE) to give the title compound (81 mg, 19.9% yield) as yellow oil. LC/MS (ESI) m/z: 183 (M+H)+. 1HNMR (400 MHz, CDC13) 5 6.55 (d, J = 12.1 Hz, 1H), 6.02 (d, J= 12.1 Hz, 1H), 4.21 (q,J=7.2Hz, 2H), 2.52 (d, =7.0 Hz, 2H), 1.29 (dd,J=9.4, 4.8 Hz, 3H), 1.01 (dd, J= 13.9, 6.1Hz, 1H), 0.59 (q, J= 5.3 Hz, 2H), 0.17 (q, J= 5.0 Hz, 2H). Step 3: 6-(cyclopropylmethyl)pyridazin-3-ol [0232]To a solution of methyl (2Z)-5-cyclopropyl-4-oxopent-2-enoate (80 mg, 0.47 mmol) in EtOH (6 mL) and H2O (2 mL) was added hydrazine hydrate (0.1 mL), AcOH (2 mL), and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture was diluted with EtOAc (5 mL) and WO 2022/034568 PCT/IB2021/059266 washed with saturated aq.NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-10% MeOH in DCM) to give the title compound (32 mg, 44.8% yield) as white solid. LC/MS (ESI) m/z: 151 (M+H)+. 1HNMR (400 MHz, DMSO-6L) 5 12.55 (s, 1H), 7.22 (d, J= 9.7 Hz, 1H), 6.(d, J= 9.7 Hz, 1H), 2.22 (d, J= 7.0 Hz, 2H), 0.80 - 0.70 (m, 1H), 0.27 (dt, J= 1.1, 4.9 Hz, 2H), - 0.01 (q, J =4.9 Hz, 2H). Intermediate 35: 5-(lH-pyrazol-l-yl)pyridin-2(lH)-one HNB־־/ NCui, L-Proline K2CO3, DMSOStep 1 Pd/C, H2MeOH Step 2 Intermediate 35 Step 1: 2-(benzyloxy)-5-(lH-pyrazol-l-yl)pyridine id="p-233" id="p-233" id="p-233" id="p-233" id="p-233" id="p-233" id="p-233" id="p-233" id="p-233"

[0233]To a mixture of 2-(benzyloxy)-5-bromopyridine (1 g, 3.79 mmol) and IH-pyrazole (3mg, 5.68 mmol) in DMSO (10 mL) were added Cui (145 mg, 0.76 mmol), L-Proline (87 mg, 0.7mmol) and K2CO3 (1047 mg, 7.57 mmol) under N2 atmosphere and the mixture was stirred under N2 atmosphere at 120 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (350 mg, 36.8% yield) as white solid. LC/MS (ESI) (m/z): 252 (M+H)+. Step 2: 5-(lH-pyrazol-l-yl)pyridin-2-ol id="p-234" id="p-234" id="p-234" id="p-234" id="p-234" id="p-234" id="p-234" id="p-234" id="p-234"

[0234]To a solution of 2-(benzyloxy)-5-(lH-pyrazol-l-yl)pyridine(450 mg, 1.791 mmol) in MeOH (10 mL) was added Pd/C (45 mg, 10% wt) and the mixture was degassed udner Natmosphere for three times and stirred under H2 balloon at r.t. for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give he title compound (290 mg, 100.5% yield) as a colorless oil. LC/MS (ESI) m/z: 162 (M+H)+. Intermediate 36: (R)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one WO 2022/034568 PCT/IB2021/059266 Boc2O, NaHCO 3THF/ H2O, rtStep 1 BHa.THFTHF, rtStep 2 MsCI, Et 3NDCM, rtStep 3 NaN 3DMSO, 100°CStep 4 Mel, NaHDMF, rtStep 5 H2, Pd/CMeOH, rt Step 6 TFADCM, rt Step 7 Et 3N, GDIDCM, rt Step 8 intermediate 36 Step 1: (R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid id="p-235" id="p-235" id="p-235" id="p-235" id="p-235" id="p-235" id="p-235" id="p-235" id="p-235"

[0235]To a solution of (2R)-2-amino-3-cyclopropylpropanoic acid (6 g, 46.4 mmol) in THF (mL) and water (60 mL) were added NaHCO3 (11.1 g, 139.2 mmol) and di-tert-butyl decarbonate (12.9 mL, 60.4 mmol) at 0 °C and the mixture was stirred at room temperature for hrs. The reaction mixture was diluted with water and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (DCM: MeOH = 10: 1) to give the title compound (10 g, 93.9% yield) as yellow oil. 1H NMR (400 MHz, CDC13) 5 6.04 (s, 1H), 5.30 (d, J= 7.7 Hz, 1H), 4.35 (d, J= 6.0 Hz, 1H), 1.68- 1.65 (m, 2H), 1.43-1.42 (m, 9H), 0.73-0.74 (m, 1H), 0.47-0.46 (m, 2H), 0.10-0.12 (m, 2H). LC/MS (ESI) (m/z): 174 (M+H-56)+. Step 2: (R)-tert-butyl (l-cyclopropyl-3-hydroxypropan-2-yl)carbamate id="p-236" id="p-236" id="p-236" id="p-236" id="p-236" id="p-236" id="p-236" id="p-236" id="p-236"

[0236]To a solution of(R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid (6 g, 17.4 mmol) in THF (50 mL) was added BH3-THF complex (52.3 mL, 52.3 mmol, IM in THF) drop-wisely at 0 °C and the mixture was stirred at room temperature for 16 hrs. The reaction was quenched with MeOH at 0 °C and concentrated to dryness. The residue was purified by chromatography on silica gel (DCM: MeOH = 10: 1) to give the title compound (2 g, 35.5% yield) as yellow oil. LC/MS (ESI) (m/z): 160 (M+H-56)+. Step 3: (R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropyl methanesulfonate [0237]To a solution of (R)-tert-butyl (l-cyclopropyl-3-hydroxypropan-2-yl)carbamate (2.0 g, 9.mmol) in DCM (30 mL) were added TEA (3.9 mL, 27.9 mmol) followed by drop-wise addition of WO 2022/034568 PCT/IB2021/059266 MsCl (1.44 mL, 18.6 mmol) at 0 °C and the mixture was stirred at room temperature for 16 hrs. The mixture was diluted with water (10 mL) and extracted with DCM (2x15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (2.0 g, 73.4% yield) as yellow oil. LC/MS (ESI) (m/z): 238 (M+H-56)+. Step 4: (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)carbamate id="p-238" id="p-238" id="p-238" id="p-238" id="p-238" id="p-238" id="p-238" id="p-238" id="p-238"

[0238]To a solution of (R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropyl methanesulfonate (1.5 g, 5.1 mmol) in DMSO (20 mL) was added NaN3 (1.0 g, 15.3 mmol) and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2x15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (525 mg, 42.7% yield) as yellow oil. 1H NMR (400 MHz, CDC13) 5 4.64 (d, J= 5.2 Hz, 1H), 3.(s, 1H), 3.54-3.45 (m, 2H), 1.63 (s, 1H), 1.45 (s, 10H), 0.71-0.64 (m, 1H), 0.52-0.47 (m, 2H), 0.11- 0.08 (m, 2H). Step 5: (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)(methyl)carbamate id="p-239" id="p-239" id="p-239" id="p-239" id="p-239" id="p-239" id="p-239" id="p-239" id="p-239"

[0239]To a solution of (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)carbamate (525 mg, 2.mmol) in DMF (10 mL) was added NaH (114 mg, 2.84 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred at 0 °C for 1 hr. Then Mel (0.33 mL, 4.37 mmol) was added and the mixture was stirred at room temperature for 16 hrs. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE : EtOAc= 5: 1) to give the title compound (480 mg, yield 86.4%) as white solid. 1H NMR (400 MHz, CDC13) 4.21 (s, 1H), 3.52-3.22 (m, 2H), 2.78 (s, 3H), 1.62-1.54 (m, 1H), 1.48 (s, 9H), 1.33-1.26 (m, 1H), 0.68-0.58 (m, 1H), 0.48-0.46 (m, 2H), 0.1-0.03 (m, 2H). LC/MS (ESI) (m/z): 199 (M+H-56)+. Step 6: (R)-tert-butyl (l-amino-3-cyclopropylpropan-2-yl)(methyl)carbamate [0240]To a solution of (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)(methyl)carbamate (4mg, 1.89 mmol) in MeOH (6 mL) was added Pd/C (80 mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (230 mg, 53.4% yield) as yellow solid. LC/MS (ESI) (m/z): 229 (M+H)+.

WO 2022/034568 PCT/IB2021/059266 Sytep 7: (R)-3-cyclopropyl-N2-methylpropane-l,2-diamine id="p-241" id="p-241" id="p-241" id="p-241" id="p-241" id="p-241" id="p-241" id="p-241" id="p-241"

[0241]To a solution of (R)-tert-butyl (l-amino-3-cyclopropylpropan-2-yl)(methyl)carbamate (230 mg, 1.0 mmol) in DCM (4 mL) was added TFA (4 mL) at 0 °C and the reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was concentrated under reduced pressure to dryness to give the title compound (120 mg, 92.9% yield) as yellow oil. LC/MS (ESI) (m/z): 129 (M+H)+. Step 8: (S)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one id="p-242" id="p-242" id="p-242" id="p-242" id="p-242" id="p-242" id="p-242" id="p-242" id="p-242"

[0242]To a solution of (R)-3-cyclopropyl-N2-methylpropane-l,2-diamine (120 mg, 0.mmol) in DCM (5 mL) were added TEA (0.39 mL, 2.8 mmol) and CD I (152 mg, 0.94 mmol) and the mixture was stirred at room temperature for 16 hrs. The reaction mixture was diluted with water (5 mL) and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 1: 2) to give the title compound (120 mg, 82.7% yield) as white solid. LC/MS (ESI) (m/z): 155 (M+H)+. 1H-NMR (400 MHz, CDCI3) 5 4.57 (s, 1H), 3.64 - 3.53 (m, 2H), 3.22 - 3.18 (m, 1H), 2.75 (s, 3H), 1.65 - 1.50 (m, 2H), 0.69 - 0.59 (m, 1H), 0.52 - 0.50 (m, 2H), 0.12 - 0.07 (m, 2H). Intermediate 37: (S)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one o intermediate 37 [0243]Intermediate 37was prepared from (S)-2-amino-3-cyclopropylpropanoic acid using the same synthetic sequence that was used to synthesize intermediate36. LC/MS (ESI) (m/z): 1(M+H)+. Intermediate 38: l-(cyclopropylmethyl)-l,3-dihydro-2H-imidazol-2-one intermediate 38 id="p-244" id="p-244" id="p-244" id="p-244" id="p-244" id="p-244" id="p-244" id="p-244" id="p-244"

[0244]To a solution of l-methyl-2,3-dihydro-lH-imidazol-2-one (1 g, 10.2 mmol) in DMF (mL) was added NaH (410 mg, 10.2 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred at this temperature for 30 min. (Bromomethyl)cyclopropane (1.2 mL, 12.mmol) was added to the mixture and the resulting mixture was stirred at r.t. for 16 hrs. The mixture was diluted with EtOAc (20 mL), washed with saturated aq.NH4Cl solution and brine, dried over WO 2022/034568 PCT/IB2021/059266 anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 6: 1) to give the title compound (450 mg, 31.9% yield) as colorless oil. LC/MS (ESI) (m/z): 139 (M+H)+. 1H NMR (400 MHz, CDCI3) 5 10.34 (s, 1H), 6.35 - 6.22 (m, 2H), 3.52 - 3.45 (m, 2H), 1.11 (s, 1H), 0.62 - 0.53 (m, 2H), 0.33 (t, J= 5.3 Hz, 2H). Intermediate 39: l-isobutyl-l,3-dihydro-2H-imidazol-2-one o HN^ )— intermediate 39 [0245]Intermediate 39was prepared from l-methyl-2,3-dihydro-lH-imidazol-2-one and 1- bromo-2-methylpropane according to the synthesis of intermediate 38.LC/MS (ESI) (m/z): 1(M+H)+. Intermediate 40: l-(sec-butyl)-l,3-dihydro-2H-imidazol-2-one HN^ /— ،N intermediate 40 [0246]Intermediate 40was prepared from l-methyl-2,3-dihydro-lH-imidazol-2-one and 2- bromobutane according to the synthesis of intermediate 38.LC/MS (ESI) (m/z): 141 (M+H)+. Intermediate 41: 4-chloro-6-(lH-pyrazol-l-yl)pyrimidine Nz N 1 DMF intermediate 41 id="p-247" id="p-247" id="p-247" id="p-247" id="p-247" id="p-247" id="p-247" id="p-247" id="p-247"

[0247]To the mixture of 4,6-dichloropyrimidine (1 g, 6.71 mmol) and IH-pyrazole (457 mg, 6.mmol) in DMF (20 mL) was added Cs2CO3 (4.37 g, 13.4 mmol) and the mixture was stirred at r.t. for 18 hrs. The mixture was diluted with EtOAc (40 mL) and the mixture was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated with EtOAc (10 mL) and filtered. The filter cake was dried under vacuum to give the title compound (660 mg, 54.4% yield) as white solid. LC/MS (ESI) m/z: 181 (M+H)+. 1HNMR (400 MHz, CDC13) 8.79-8.79 (d, J = 0.8 Hz, 1H), 8.55-8.57 (dd, J = 2.7, 0.5 Hz, 1H), 7.97-7.98 (d, J = 1.0 Hz, 1H), 7.81 (d, J = 1.0 Hz, 1H), 6.53-6.54 (dd, J = 2.7, 1.6 Hz, 1H). Intermediate 42 : 2-chloro-4-cyclobutylpyrimidine 100 WO 2022/034568 PCT/IB2021/059266 id="p-248" id="p-248" id="p-248" id="p-248" id="p-248" id="p-248" id="p-248" id="p-248" id="p-248"

[0248]To a mixture of 2-chloropyrimidine (3 g, 26.2 mmol) and cyclobutanecarboxylic acid (2.mb, 23.6 mmol) in DCM (15 mL) and water (15 mL) was added AgNO3 (890 mg, 5.2 mmol), followed by in portions addition of (NH4)2S2O8 (6.0 g, 26.2 mmol) at room temperature and the mixture was stirred at 25 °C for 16 hrs. The mixture was diluted with DCM (50 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 5: 1 to 1: 1) to give the title compound (2.2 g, 49.8% yield) as colorless oil. LC/MS (ESI) m/z: 169 (M+H)+. 1H-NMR (400 MHz, CDCI3) 5 8.(d,J = 5.2 Hz, 1H), 7.11 (d, J= 5.2 Hz, 1H), 3.70-3.53 (m, 1H), 2.41-2.30 (m, 4H), 2.15-2.03 (m, 1H), 1.99-1.92(m, 1H). Intermediate 43: 2-chloro-4-isopropylpyrimidine intermediate 43 id="p-249" id="p-249" id="p-249" id="p-249" id="p-249" id="p-249" id="p-249" id="p-249" id="p-249"

[0249]Intermediate 43was prepared from 2-chloropyrimidine and isobutyric acid using the same synthetic method as intermediate 42.LC/MS (ESI) m/z: 157 (M+H)+1HNMR (400 MHz, CD3OD) 8.52 (d, =5.1 Hz, 1H), 7.17 (d, J= 5.1 Hz, 1H), 3.06 - 2.99 (m, 1H), 1.32 (d, J = 7.0 Hz, 6H). Intermediate 44: 2-chloro-4-cyclopropylpyrimidine intermediate 44 id="p-250" id="p-250" id="p-250" id="p-250" id="p-250" id="p-250" id="p-250" id="p-250" id="p-250"

[0250]Intermediate 44was prepared from 2-chloropyrimidine and cyclopropanecarboxylic acid using the same synthetic method as intermediate 42.LC/MS (ESI) m/z: 155 (M+H)+. Intermediate 45: 4-chloro-6-cyclobutylpyrimidine h2n ^nhMeOH, MeONaPOCla Step 1Step 2 intermediate 45 Step 1: 6-propyl-3,4-dihydropyrimidin-4-one 101 WO 2022/034568 PCT/IB2021/059266 id="p-251" id="p-251" id="p-251" id="p-251" id="p-251" id="p-251" id="p-251" id="p-251" id="p-251"

[0251]To a solution of methyl 3-cyclobutyl-3-oxopropanoate (2 g, 12.81 mmol) and formamidine acetate salt (1.33 g, 19.98 mmol) in MeOH (30 mL) was added 5N MeONa/MeOH solution (7.mL, 38.5 mmol) drop-wisely at 0 °C. After the addition, the mixture was stirred at 70 °C for 4 hrs. After cooling to 0 °C, the reaction was filtered and was treated with DCM (100 mL) and water (100 mL), the organic layer was separated and the aqueous layer was extracted with DCM (50 mL). The combined organic was concentrated to dryness and the residue was purified by flash chromatography (0-80% of EtOAc in PE) to give the title compound (400 mg, 29.0% yield) as white solid. LC/MS (ESI) m/z: 151 (M+H)+. Step 2: 4-chloro-6-cyclobutylpyrimidine id="p-252" id="p-252" id="p-252" id="p-252" id="p-252" id="p-252" id="p-252" id="p-252" id="p-252"

[0252] A stirred solution of 6-cyclobutyl-3,4-dihydropyrimidin-4-one (100 mg, 0.666 mmol ) in POC13 (2 mL) was stirred at 120 °C for 2 hrs. The solution was concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0-10% of EtOAc in PE) to give the title compound (70 mg, 62.3% yield) as light yellow oil. LC/MS (ESI) m/z: 169 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.91 (s, 1H), 7.20 (s, 1H), 3.63 - 3.59 (m, 1H), 2.40-2.30 (m, 4H), 2.12-2.(m, 1H), 1.96-1.93 (m, 1H). Intermediate 46: 3-chloro-5-cyclopropyl-l,2,4-oxadiazole __ '°؛ NH2OH.HCI_ N ؟ NaNHCNTHF, rt ,XZ^H EtOH, pyridine h2N/^n 1 Step 1 2 Step 2 3 NaNQ 2 N'°^__con.HCI, 0 °C ci^NStep intermediate 46 Step 1: N-cyanocyclopropanecarboxamide [0253]To a solution of sodium hydrogen cyanamide (1.25 g, 19.51 mmol) in THF (10 mL) was added cyclopropanecarbonyl chloride (1.02 g, 9.76 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in H2O (10 mL). The mixture was washed with EtOAc (2x3 mL), acidified with IN aq.HCl to pH~2 and extracted with DCM (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (564 mg, 52.5% yield) as colorless oil, which was used in next step directly. Step 2: 5-cyclopropyl-l,2,4-oxadiazol-3-amine 102 WO 2022/034568 PCT/IB2021/059266 id="p-254" id="p-254" id="p-254" id="p-254" id="p-254" id="p-254" id="p-254" id="p-254" id="p-254"

[0254]To a mixture of N-cyanocyclopropanecarboxamide (525 mg, 4.77 mmol) and hydroxylamine hydrochloride (497.0 mg, 7.15 mmol) in EtOH (6 mL) was added pyridine (1.g, 19.07 mmol) under N2 atmosphere and the mixture was stirred at 25 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with DCM (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness give the title compound (429 mg, 71.9% yield) as white solid, which was used in next step directly. LC/MS (ESI) m/z: 126 (M+H)+1H NMR (400 MHz, CDC13) 5 4.28 (s, 1H), 2.05 (tt, J= 7.0, 6.Hz, 1H), 1.19-1.12 (m, 2H). Step 3: 3-chloro-5-cyclopropyl-l,2,4-oxadiazole id="p-255" id="p-255" id="p-255" id="p-255" id="p-255" id="p-255" id="p-255" id="p-255" id="p-255"

[0255]To a solution of 5-cyclopropyl-l,2,4-oxadiazol-3-amine (200 mg, 1.60 mmol) in aq.HCl (mL, 36% wt) was added dropwise a solution of NaNO2 (276 mg, 4.00 mmol) in water (2 mL) and the mixture was stirred at 0 °C for 2 hrs. The mixture was diluted with water and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 200: 1 to 20: 1) to give the title compound (78 mg, 33.8% yield) as yellow oil. 1H NMR (400 MHz, CDC13) 5 2.24-2.15 (m, 1H), 1.34-1.25 (m, 5H). Intermediate 47: 3-chloro-5-(cyclopropylmethyl)-l,2,4-oxadiazole intermediate 47 id="p-256" id="p-256" id="p-256" id="p-256" id="p-256" id="p-256" id="p-256" id="p-256" id="p-256"

[0256]The title compound was prepared from 2-cyclopropylacetyl chloride using the same procedure as intermediate 46.LC/MS (ESI) m/z: 159 (M+H)+. Intermediate 48: 3-chloro-5-cyclobutyl-l,2,4-oxadiazole intermediate 48 id="p-257" id="p-257" id="p-257" id="p-257" id="p-257" id="p-257" id="p-257" id="p-257" id="p-257"

[0257]The title compound was prepared from cyclobutanecarbonyl chloride using the same procedure as intermediate 46.LC/MS (ESI) m/z: 159 (M+H)+. Intermediate 49: 5-bromo-l-propyl-lH-l,2,4-triazole KOH, cat.TBAF Tol, H2O, 60 °C intermediate 49 103 WO 2022/034568 PCT/IB2021/059266 id="p-258" id="p-258" id="p-258" id="p-258" id="p-258" id="p-258" id="p-258" id="p-258" id="p-258"

[0258]To a mixture of 3-bromo-4H-l,2,4-triazole (1 g, 6.76 mmol), 1-iodopropane (1.0 mL, 10.mmol) and TBAF (10 mg, cat.) in toluene (10 mL) was added a solution of KOH (750 mg, 13.mmol) in water (2 mL) and the mixture was stirred at 60 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (eluted with PE: EtOAc= 6: 1) to give the title compound (400 mg, 31.3% yield) as yellow oil. LC/MS (ESI) m/z: 190/192 (M+H)+1H-NMR(4MHz, CDC13)5 7.89 (s, 1H), 4.14 (t, J= 2.4 Hz, 2H),1.91 (m, 2H),0.95 (t, J= 2.4 Hz, 2H). Intermediate 50: 5-bromo-l-(cyclopropylmethyl)-lH-l,2,4-triazole Ct^ N Br intermediate 50 id="p-259" id="p-259" id="p-259" id="p-259" id="p-259" id="p-259" id="p-259" id="p-259" id="p-259"

[0259]The title compound was prepare from 3-bromo-4H-l,2,4-triazole and (bromomethyl)cyclopropane using the same procedure as intermediate 49.LC/MS (ESI) m/z: 202/204 (M+H)+. Intermediate 51: 5-bromo-l-isobutyl-lH-l,2,4-triazole intermediate 51 id="p-260" id="p-260" id="p-260" id="p-260" id="p-260" id="p-260" id="p-260" id="p-260" id="p-260"

[0260]The title compound was prepare from 3-bromo-4H-l,2,4-triazole and l-iodo-2- methylpropane using the same procedure as intermediate 49.LC/MS (ESI) m/z: 204/206 (M+H)+. 1H-NMR (400 MHz, CDC13)5 7.89 (s, 1H), 3.97 (d, J= 7.2 Hz, 2H), 2.35-2.86 (m, 1H), 0.95 (d, J=6.8Hz, 6H). 104 WO 2022/034568 PCT/IB2021/059266 Example 1: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid Step 1: methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate [0261]To a solution of methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyri din-3-yl)piperi din-3-yl)acetate (40 mg, 0.1 mmol) in DCM (1 mL) was added TEA (20 mg, 0.2 mmol) followed by MsCl (17 mg, 0.15 mmol) at 0 °C and the miture was stirred at this temperature for 2 hrs. The mixture was diuted with DCM (2 mL), washed with saturated aq.NaHCO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (43 mg, 91% yield) as light yellow solid, which was directly used in the next reaction without purification. LC/MS (ESI) (m/z): 474 (M+H)+. Step 2: methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo-5- propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-262" id="p-262" id="p-262" id="p-262" id="p-262" id="p-262" id="p-262" id="p-262" id="p-262"

[0262]To a mixture of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5- (((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (43 mg, 0.091 mmol) and 3-methyl-5-propyl-l,2-dihydropyridin-2-one (16.5 mg, 0.11 mmol) in toluene (mL) and water (1 mL) were added K2CO3 (25 mg, 0.182 mmol) and TBAF (3 mg, cat. ammount) and the reaction mixture was stirred at 100 °C for 16 hrs. The reaction mixture was diluted with water (3 mL) and extracted with EtOAc (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (35 mg, 72.9% yield) as light yellow solid. LC/MS (ESI) (m/z): 529 (M+H)+. 105 WO 2022/034568 PCT/IB2021/059266 Step 3: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid id="p-263" id="p-263" id="p-263" id="p-263" id="p-263" id="p-263" id="p-263" id="p-263" id="p-263"

[0263]To a solution of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo- 5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate(35 mg, 0.066 mmol) in THF (1 mL) and methanol (2 mL) was added a solution of LiOH (15.mg, 0.66 mmol) in water (1 mL) at 0 °C. After stirring at room temperature for 2 hrs, the reaction mixture was concentrated to dryness and the residue was dissolved in water (3 mL). The mixture was washed with MTBE twice and the aqueous layer was acidified with IN aq.HCl to pH~2 and extracted with EtOAc (2x2 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (22 mg, 64.6% yield) as white solid. LC/MS (ESI) (m/z): 515 (M+H)+. 1HNMR (400 MHz, DMSO-d6) 5 7.82 (d, J=8.3Hz, 1H), 7.62 (d,J=1.7Hz, 1H),7.55(d,J=8.4Hz, 1H), 7.17-7.16 (m, 1H), 5.56 (s, 2H), 4.23 (s, 3H), 3.20-3.04 (m, 4H), 2.60-2.55 (m, 4H), 2.39-2.27 (m, 4H), 2.15 (t,J=7.4 Hz, 2H), 1.95 (s, 3H), 1.84-1.68 (m, 1H), 1.35-1.26 (m, 2H), 0.71 (t, J= 3.ר Hz, 3H). Example 2: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin-l(2H)-yl)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid Step 1: 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridine id="p-264" id="p-264" id="p-264" id="p-264" id="p-264" id="p-264" id="p-264" id="p-264" id="p-264"

[0264]To a solution of (4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methanol (500 mg, 1.76 mmol) in DCM (10 mL) was added PBr3 (717 mg, 2.65 mmol) drop- wisely at 0 °C and the mixture was stirred at 0 °C to r.t. for 3 hrs. The mixture was diluted with 106 WO 2022/034568 PCT/IB2021/059266 DCM (10 mL), washed with ice-cooled saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by flash chromatography (silica gel, 0-30% EtOAc in PE) to give the title compound (510 mg, 83.7% yield) as white solid. LC/MS (ESI) m/z: 347 (M+H)+. Step 2: l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-4- (cyclopropylmethyl)-3-methylpyridin-2(lH)-one [0265]To a mixture of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridine (200 mg, 0.58 mmol) and 4-(cyclopropylmethyl)-3-methyl-1,2-dihydropyridin-2- one (136 mg, 0.83 mmol) in toluene (5 mL) and H2O (1 mL) was added K2CO3 (230 mg, 1.mmol) and TBAF (10mg, cat.) and the mixture was stirred at 100 °C for 3 hrs. The reaction mixture was diluted with EtOAc (5 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-56% EtOAc in PE) to give the title compound (220 mg, 88.9% yield) as white solid. LC/MS (ESI) m/z: 428/430 (M+H)+. Step 3: methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin-l(2H)- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate [0266]To a mixture of l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one (78 mg, 0.18 mmol), methyl 2- [(3S)-5,5-difluoropiperidin-3-yl]acetate (35 mg, 0.18 mmol), Cs2CO3 (177 mg, 0.mmol) and Ru-phos (17 mg, 0.036 mmol) in 1,4-dioxane (2 mL) was added Ru-phos-Pd-G3 (mg, 0.036 mmol). Then the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C under N2 atmosphere for 16 hrs. The reaction mixture was poured into ice-water and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-50% EtOAc in PE) to give the title compound (35 mg, 35.5% yield) as yellow solid. LC/MS (ESI) m/z: 541 (M+H)+. Step 4: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin-l(2H)-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid [0267]To a solution of methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin- l(2H)-yl)methyl)-l-methyl-1H- 1,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate (35 mg, 0.065 mmol) in MeOH (1 mL), H2O (1 mL), THE (4 mL) was added LiOH (mg, 2.1 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IN aq.HCl to pH~3 and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue 107 WO 2022/034568 PCT/IB2021/059266 was purified by prep.HPLC (C18, 10-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (15 mg, 43.8% yield) as white solid. LC/MS (ESI) m/z: 527 (M+H)+. 1H NMR (4MHz, CD3OD) 5 7.83 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 7.1 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.73 (s, 2H), 4.21 (s, 3H), 3.28 -3.23 (m, 2H), 3.15 -3.00 (m, 1H), 2.62 - 2.(m, 1H), 2.59 (s, 3H), 2.54 - 2.48 (m, 1H), 2.43 - 2.39 (m, 4H), 2.36 - 2.26 (m, 1H), 2.04 (s, 3H), 1.81-1.64 (m, 1H), 0.90 - 0.87 (m, 1H), 0.52 - 0.46 (m, 2H), 0.18-0.14 (m, 2H). The examples in the following table were prepared by the indicated method using analogous reactants. Ex# Structure & name Analytical & biological data MethodFAW°H °lijO N־ (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- methylpyridin-3-yl)-5,5-difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 527 (M+H)+.1H NMR (400 MHz, DMSO-d6) 7.73 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.41 (d, J =8.4 Hz, 1H), 6.04 (d, J = 7.2 Hz, 1H), 5.43 (s, 2H), 4.02 (s, 3H), 3.16 - 2.86 (m, 3H), 2.54 - 2.36 (m, 3H), 2.31 - 2.09 (m, 7H), 1.80 (s, 3H), 1.69-1.56 (m, 1H), 0.75 - 0.67 (m, 1H), 0.30 - 0.25 (m, 2H), 0.02 - 0.00 (m, 2H).

Example 2 4V ° A3 N־ O (S)-2-(5,5-difluoro-l-(2-methyl- 6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- 1H-1,2,3-tri azol-4-yl)pyri din-3- yl)piperidin-3-yl)acetic acid LC/MS (ESI) m/z: 501 (M+H)+.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 4.5 Hz, 1H), 7.81 (d, J = 9.2, 2.5 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.36 (dd, J = 9.2, 2.5 Hz, 1H), 6.(d, J = 9.2 Hz, 1H), 5.74 (s, 2H), 4.(s, 3H), 3.31 -3.28 (m, 2H), 3.13 - 3.03 (m, 1H), 2.63 (s, 3H), 2.61 - 2.57 (m, 1H), 2.56 - 2.49 (m, 1H), 2.43-2.38 (m, 2H), 2.36 - 2.30 (m, 1H), 2.25 (d, J = 7.6, 2H), 1.83 - 1.66 (m, 1H), 1.43-1.33 (m, 2H), 0.78 (t, J = 7.6 Hz, 3H).

Example 1 108 WO 2022/034568 PCT/IB2021/059266 5F^x..yH xj ° 'לוך° / NA VT (S)-2-(5,5-difluoro-l-(2-methyl- 6-( 1 -methyl-5 -((2-0X0-3 -propylpyridin-l(2H)-yl)methyl)- 1H-1,2,3-tri azol-4-yl)pyri din-3- yl)piperi din-3-yl)acetic acid LC/MS (ESI) m/z: 501 (M+H)+.1H NMR (400 MHz, CD3OD) 5 7.(dd, J = 6.8, 2.0 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.28 (dd, J = 6.8, 1.9 Hz, 1H), 6.(t, J = 6.9 Hz, 1H), 5.77 (s, 2H), 4.(s, 3H), 3.31-3.28 (m, 2H), 3.13 - 2.96 (m, 1H), 2.63-2.56 (m, 1H), 2.58 (s, 3H), 2.55-2.48 (m, 1H), 2.- 2.36 (m, 4H), 2.36 - 2.25 (m, 1H), 1.80-1.64 (m, 1H), 1.61 - 1.49 (m, 2H), 0.92 (d, J = 9.6, 3H).

Example 1 6 XV ‘n" ° ^־לוךI 0At^N^x N־ o (S)-2-( 1 -(2-ethyl-6-( 1 -methyl-5- ((2-oxo-5-propylpyridin-l(2H)- yl)methyl)- 1H-1,2,3 -tri azol-4- yl)pyridin-3-yl)-5,5-difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 515 (M+H)+.1H NMR (400 MHz, CD3OD) 5 7.(d, J= 8.4 Hz, 1H), 7.66 (d, J= 2.Hz, 1H), 7.61 (d, J= 8.4 Hz, 1H), 7.38 (dd, J= 9.2, 2.5 Hz, 1H), 6.(d,J = 9.4Hz, 1H), 5.86 (s, 2H),3.(dd, J= 8.4, 6.0 Hz, 2H), 3.14-3.(m, 2H), 2.99 (q, J = 7.5 Hz, 2H), 2.65-2.58 (m, 1H), 2.53 (dd, J = 10.8, 4.5 Hz, 1H), 2.40 (d, J= 6.Hz, 2H), 2.35-2.26 (m, 1H), 2.22 (t, J= 7.6 Hz, 2H), 1.82-1.62 (m, 1H), 1.41-1.26 (m, 5H), 0.76 (t, J = 7.Hz, 3H).

Example 1 7 pA/'-x^'x/OH - ° ^־לוךoN״ nX.N־ o (R)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-5-propylpyridin-l(2H)- yl)methyl)- 1H-1,2,3 -tri azol-4- yl)pyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.3 Hz, 1H), 7.66 (d, J = 2.Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 9.3, 2.5 Hz, 1H), 6.(d, J = 9.2 Hz, 1H), 5.86 (s, 2H), 4.17 (s, 3H), 3.26 - 3.23 (m, 2H), 3.14-3.05 (m, 1H), 2.99 (q, 1 = 7.Hz, 2H), 2.66 - 2.59 (m, 1H), 2.- 2.49 (m, 1H), 2.39-2.30 (m, 3H), 2.22 (t, J = 7.5 Hz, 2H), 1.85 - 1.(m, 1H), 1.40- 1.34 (m, 2H), 1.(t, J = 7.5 Hz, 3H), 0.76 (t, J = 7.Hz, 3H).

Example 2 109 WO 2022/034568 PCT/IB2021/059266 8° N.n ־ o (S)-2-( 1 -(2-ethyl-6-( 1 -methyl-5 - ((2-oxo-4-propylpyridin-l(2H)- yl)methyl)- 1H-1,2,3 -tri azol-4- yl)pyridin-3-yl)-5,5-difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 515 (M+H)+.1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.3 Hz, 1H), 7.77 (d, J = 7.Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 6.36 (s, 1H), 6.19 (dd, J = 7.1, 1.Hz, 1H), 5.84 (s, 2H), 4.14 (s, 3H), 3.29-3.21 (m, 2H), 3.13 - 3.04 (m, 1H), 2.96 (q, J = 7.5 Hz, 2H), 2.65 - 2.57 (m, 1H), 2.54 - 2.48 (m, 1H), 2.45 - 2.40 (m, 4H), 2.35 - 2.25 (m, 1H), 1.82-1.66 (m, 1H), 1.64-1.(m, 2H), 1.28 (t, J = 7.5 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H).

Example 1 9^"^°H I 0N־ a (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 527 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.3 Hz, 1H), 7.78 (d, J = 7.Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 6.49 (s, 1H), 6.26 (dd, J = 7.1, 1.Hz, 1H), 5.86 (s, 2H), 4.15 (s, 3H), 3.28 - 3.20 (m, 2H), 3.15 - 3.03 (m, 1H), 2.96 (q, J = 7.5 Hz, 2H), 2.- 2.58 (m, 1H), 2.56-2.50 (m, 1H), 2.44 - 2.34 (m, 4H), 2.31-2.20 (m, 1H), 1.82 - 1.66 (m, 1H), 1.29 (t, J = 7.5 Hz, 3H), 0.98 - 0.84 (m, 1H), 0.58 - 0.48 (m, 2H), 0.20 - 0.12 (m, 2H).

Example 1 10V 0 1 o N־ (S)-2-(l-(6-(5-((4- (cyclopropylmethyl)-3-methyl-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 541 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.89 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.87 (s, 2H),4.(s, 3H), 3.29-3.21 (m, 2H), 3.13 - 3.03 (m,lH), 2.96 (q, J = 7.4 Hz, 2H), 2.63-2.57 (m, 1H), 2.55 - 2.(m, 1H), 2.44 (d, J = 6.9 Hz, 2H), 2.38-2.35 (m, 2H), 2.34 - 2.25 (m, 1H), 2.09 (s, 3H), 1.81 - 1.62 (m, 1H), 1.27 (t, J = 7.5 Hz, 3H), 0.94 - 0.85 (m, 1H), 0.53 - 0.46 (m, 2H), 0.19-0.15 (m, 2H).

Example 2 110 WO 2022/034568 PCT/IB2021/059266 11pY'W™-n- ° 1 O n־ (R)-2-(l-(6-(5-((4- (cyclopropylmethyl)-3-methyl-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid LC/MS (ESI) m/z: 541 (M+H)+.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 6.29 (d, J = 7.2 Hz, 1H), 5.87 (s, 2H), 4.14 (s, 3H), 3.29-3.21 (m, 2H), 3.13-3.03 (m, 1H), 2.95 (q, J = 7.Hz, 2H), 2.63-2.57 (m, 1H), 2.56- 2.48 (m, 1H), 2.44 (d, J = 6.8 Hz, 2H), 2.38-2.35 (m, 2H), 2.33-2.(m, 1H), 2.09 (s, 3H), 1.79-1.64 (m, 1H), 1.27 (t, J = 7.6 Hz, 3H), 0.99- 0.83 (m, 1H), 0.54-0.44 (m, 2H), 0.19-0.14 (m, 2H).

Example 2 12V '"''VYI O N־ (S)-2-(l-(2-ethyl-6-(5-((5- isobutyl-2-oxopyridin-1 (2H)- yl)m ethyl)- 1-methyl-1H- 1,2,3- triazol-4-yl)pyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid LC/MS (ESI) m/z: 529 (M+H)+.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.61 (d, J = 8.Hz, 1H), 7.60 (d, J = 2.4 Hz, 1H), 7.36 (dd, J = 7.2, 2.4 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.87 (s, 2H),4.(s, 3H), 3.29-3.22 (m, 2H), 3.16-3.(m, 1H), 2.96 (q, J = 7.6 Hz, 2H), 2.70-2.61 (m, 1H), 2.56-2.48 (m, 1H), 2.40-2.27 (m, 3H), 2.09 (d, J = 6.8 Hz, 1H), 1.80-1.66 (m, 1H), 1.62-1.53 (m, 2H), 1.32(t, J = 7.6 Hz, 3H), 0.72 (d, J = 6.4 Hz, 6H).

Example 1 13f־YY Yr 011־ ~לו؛ו / 'oN־ O (S)-2-(l-(6-(5-((5-(cyclopropylmethyl)-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid LC/MS (ESI) m/z: 527 (M+H)+.1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.74 (d, J = 2.Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.49 (dd, J = 7.2, 2.4 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.99 (s, 2H), 4.(s, 3H), 3.30-3.26 (m, 2H), 3.21-3.(m, 1H), 3.03 (q, J = 7.6 Hz, 2H), 2.70-2.62 (m, 1H), 2.60-2.49 (m, 1H), 2.48-2.43 (m, 2H), 2.41-2.(m, 1H), 2.22 (d, J = 6.8 Hz, 1H), 1.88-1.72 (m, 1H), 1.36 (t, J = 7.Hz, 3H), 0.72-0.64 (m, 1H), 0.36- 0.28 (m, 2H), 0.03-0.00 (m, 2H).

Example 1 111 WO 2022/034568 PCT/IB2021/059266 14^VyVH V ° N.J 0 na o (S)-2-(l-(6-(5-((5-(cyclobutylmethyl)-2-oxopyridin- (2H)-yl)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2-ethylpyridin- 3-yl)-5,5-difluoropiperidin-3- yl)acetic acid LC/MS (ESI) m/z: 541 (M+H)+.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.Hz, 1H), 7.55 (d, J = 2.4 Hz, 1H), 7.34 (dd, J = 7.2, 2.4 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.89 (s, 2H),4.(s, 3H), 3.29 - 3.24 (m, 2H), 3.16 - 3.06 (m, 1H), 2.99 (q, J = 7.6 Hz, 2H), 2.65 - 2.59 (m, 1H), 2.56 - 2.(m, 1H), 2.41 - 2.37 (m, 2H), 2.34 - 2.20 (m, 4H), 1.83 - 1.65 (m, 5H), 1.48 - 1.39 (m, 2H), 1.32 (t, J = 7.Hz, 3H).

Example 1 ^¥yV H ‘n" ° JI o N״ nX.N־ o (S)-2-(l-(6-(5-((5-cyclopropyl-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 513 (M+H)+.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.68 (d, J = 2.Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.28 (dd, J = 7.2, 2.8 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.84 (s, 2H),4.(s, 3H), 3.28-3.21 (m, 2H), 3.16-3.(m, 1H), 2.99 (q, J = 7.6 Hz, 2H), 2.65-2.59 (m, 1H), 2.56-2.48 (m, 1H), 2.41-2.37 (m, 2H), 2.37-2.(m, 1H), 1.81-1.65 (m, 1H), 1.61- 1.53 (m, 1H), 1.33 (t, J = 7.6 Hz, 3H), 0.78-0.72 (m, 2H), 0.31-0.(m, 2H).

Example 1 16^TH N 1 onX.n־ o (S)-2-(l-(2-ethyl-6-(5-((5- isopropyl-2-oxopyridin-1 (2H)- yl)m ethyl)- 1-methyl-1H- 1,2,3- triazol-4-yl)pyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 515 (M+H)+.1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.64 (d, J = 2.Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.45 (dd, J = 7.2, 2.4 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.89 (s, 2H),4.(s, 3H), 3.26 - 3.22 (m, 2H), 3.14 - 3.08 (m, 1H), 2.99 (q, J = 7.6 Hz, 2H), 2.64 - 2.47 (m, 3H), 2.40 - 2.(m, 2H), 2.35 - 2.26 (m, 1H), 1.81 - 1.65 (m, 1H), 1.33 (t, J = 7.6 Hz, 3H), 0.97 (d, J = 6.8 Hz, 6H).

Example 1 112 WO 2022/034568 PCT/IB2021/059266 17fV..^oh ° 1 oN־ O (S)-2-(l-(6-(5-((5-cyclobutyl-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 527 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.64 (d, J = 2.Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.44 (dd, J = 9.6, 2.4 Hz, 1H), 6.(d, J = 9.6 Hz, 1H), 5.89 (s, 2H), 4.17 (s, 3H), 3.29 - 3.24 (m, 2H), 3.20 - 3.04 (m, 2H), 2.99 (q, J = 7.Hz, 2H), 2.65 - 2.58 (m, 1H), 2.55 - 2.49 (m, 1H), 2.42 - 2.40 (m, 2H), 2.35 -2.26 (m, 1H), 2.14 - 2.06 (m, 2H), 1.95 - 1.85 (m, 1H), 1.82 -1.(m, 4H), 1.32 (t, J = 7.6 Hz, 3H).

Example 1 18F،OH °"'''Ai'iJI n ־ o (S)-2-(l-(6-(5-((5-cyclopropyl-4- methyl-2-oxopyridin-1 (2H)- yl)m ethyl)- 1-methyl-1H- 1,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)- 5,5 -difluoropiperi din-3 -yl)acetic acid LC/MS (ESI) m/z: 527 (M+H)+.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.Hz, 1H), 7.52 (s, 1H), 6.37 (s, 1H), 5.82 (s, 2H), 4.17 (s, 3H), 3.29-3.(m, 2H), 3.13-3.05 (m, 1H),3.OO (q, J = 7.6 Hz, 2H), 2.65-2.60 (m, 1H), 2.56 - 2.50 (m, 1H), 2.41 - 2.28 (m, 3H), 2.27 (s, 3H), 1.80 - 1.70 (m, 1H), 1.55-1.49 (m, 1H), 1.32 (t, J = 7.6 Hz, 3H) , 0.73-0.68 (m, 2H), 0.12-0.08 (m, 2H).

Example 1 19f،°h ‘n" ° T 0 N־ (S)-2-(l-(6-(5-((4-cyclopropyl-5- methyl-2-oxopyridin-1 (2H)- yl)m ethyl)- 1-methyl-1H- 1,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)- 5,5 -difluoropiperi din-3 -yl)acetic acid LC/MS (ESI) m/z: 527 (M+H)+1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.63 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.52 (s, 1H), 6.06 (s, 1H), 5.79 (s, 2H), 4.(s, 3H), 3.29 - 3.20 (m, 2H), 3.15- 3.05 (m, 1H), 2.99 (q, J = 7.6 Hz, 2H), 2.65 -2.58 (m, 1H), 2.56 - 2.55 (m, 1H), 2.40-2.38 (m, 2H), 2.36 - 2.27 (m, 1H), 2.04 (s, 3H), 1.83 - 1.65 (m, 2H), 1.31 (t, J = 7.Hz, 3H) , 1.05 - 1.00 (m, 2H), 0.73- 0.66 (m, 2H).

Example 1 113 WO 2022/034568 PCT/IB2021/059266 20V ° n ־ o (S)-2-(l-(6-(5-((4-(cyclopropylethynyl)-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid LC/MS (ESI) m/z: 537 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.79 (d, J = 7.Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 6.46 (d, J =1.6 Hz, 1H), 6.16 (dd, J = 7.2, 1.6 Hz, 1H), 5.82 (s, 2H), 4.13 (s, 3H), 3.29-3.21 (m, 2H), 3.13-3.03 (m, 1H), 2.95 (q, J = 7.Hz, 2H), 2.66 - 2.58 (m, 1H), 2.55 - 2.48 (m, 1H), 2.40 - 2.26 (m, 3H), 1.80 - 1.65 (m, 1H), 1.52 - 1.44 (m, 1H), 1.28 (t, J = 7.6 Hz, 3H) , 0.96 - 0.87 (m, 2H), 0.79 - 0.75 (m, 2H).

Example 1 21V ° I 0AV^nAN־ o / (S)-2-(l-(6-(5-((5- (cyclopropylethynyl)-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid LC/MS (ESI) m/z: 537 (M+H)+1H NMR (400 MHz, CD3OD) 5 8.(d, J = 2.4 Hz, 1H), 7.86 (d, J = 8.Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.35 (dd, J = 7.2, 2.4 Hz, 1H), 6.(d, J = 7.2 Hz, 1H), 5.71 (s, 2H), 4.22 (s, 3H), 3.29-3.21 (m, 2H), 3.13-2.98 (m, 3H), 2.70-2.63 (m, 1H), 2.56-2.49 (m, 1H), 2.44-2.(m, 3H), 1.83-1.66 (m, 1H), 1.42- 1.28(m, 1H), 1.35 (t, J = 7.6 Hz, 3H) , 0.86-0.77 (m, 2H), 0.66- 0.61(m, 2H).

Example 1 22rvV H ‘n" ° AmI n>^AnA N־ O (R)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-5-propylpyridin- 1 (2H)- yl)methyl)-lH-l,2,3-triazol-4- yl)pyri din-3 -yl)piperidin-3 - yl)acetic acid LC/MS (ESI) m/z: 479 (M+H)+.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.66 (d, J = 2.Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 131 (dd, J = 9.2, 2.4 Hz, 1H), 6.(d, J = 9.2 Hz, 1H), 5.87 (s, 2H),4.(s, 3H), 3.20-3.17 (m, 1H), 3.08-3.(m, 1H), 2.95 (q, J = 7.6 Hz, 2H), 2.78-2.71 (m, 1H), 2.49-2.43 (m, 1H), 2.33-2.18 (m, 5H), 1.93-1.(m, 3H), 1.40-1.29 (m, 5H), 1.28- 1.17 (m, 1H), 0.75 (t, J = 7.6 Hz, 3H).

Example 2 114 WO 2022/034568 PCT/IB2021/059266 23u ° ^וך / ■I oN־ o (S)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-5-propylpyridin- 1 (2H)- yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3 -yl)piperi din-3 - yl)acetic acid LC/MS (ESI) m/z: 479 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.66 (d, J = 2.Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 131 (dd, J = 9.2, 2.4 Hz, 1H), 6.(d, J = 9.2 Hz, 1H), 5.87 (s, 2H), 4.16 (s, 3H), 3.24-3.03 (m, 2H), 2.95 (q, J = 7.6 Hz, 2H), 2.78-2.(m, 1H), 2.49-2.41 (m, 1H), 2.33- 2.18 (m, 5H), 1.92-1.73 (m, 3H), 1.42-1.29 (m, 5H), 1.27-1.17 (m, 1H), 0.75 (t, J = 7.6 Hz, 3H).

Example 2 24 WH " nX. n ־ o (S)-2-(l-(6-(5-((5-cyclopropoxy- 2-oxopyridin- 1 (2H)-yl)methyl)- -methyl- 1H-1,2,3 -triazol-4-yl)- 2-ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 529 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.96 (d, J = 8.3 Hz, 1H), 7.61 (dd, J = 14.4, 5.8 Hz, 2H), 7.30 (dd, J = 9.8, 3.Hz, 1H), 6.55 (d, J = 9.8 Hz, 1H), 6.00 (s, 2H), 4.16 (s, 3H), 3.28-3.(m, 2H), 3.14-3.04 (m, 2H), 3.04 - 2.91 (m, 2H), 2.63 - 2.47 (m, 2H), 2.42 - 2.23 (m, 3H), 1.77 - 1.63 (m, 1H), 1.33 (t, J = 7.5 Hz, 3H), 0.48 - 0.39 (m, 2H), 0.36 - 0.20 (m, 2H).

Example 1 1 ON־ o (S)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-5-propoxypyridin- 1 (2H)- yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 531 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.93-7.91 (d, J = 8.4 Hz, 1H), 7.64- 7.62 (d, J = 8.4 Hz, 1H), 7.-7.47 (d, J = 3.1 Hz, 1H), 7.34- 7.30 (dd, J = 9.8, 3.2 Hz, 1H), 6.- 6.53 (d, J = 9.8 Hz, 1H), 5.90 (s, 2H), 4.17 (s, 3H), 3.46 - 3.44 (m, 2H), 3.30 -3.26 (m, 2H), 3.14- 3.05 (m, 1H), 3.02 - 2.97 (q, J = 7.Hz, 2H), 2.69 - 2.47 (m, 2H), 2.34 - 2.27 (m, 3H), 1.80 - 1.65 (m, 1H) 1.62- 1.53 (m, 2H), 1.34 (t, 1 = 7.Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H).

Example 1 115 WO 2022/034568 PCT/IB2021/059266 26FW ,2, nA N־ o (S)-2-(l-(6-(5-((5-ethoxy-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 517 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.91 (d, J = 8.3 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 3.1 Hz, 1H), 7.34 - 7.29 (m, 1H), 6.54 (d, J = 9.8 Hz, 1H), 5.89 (s, 2H), 4.17 (s, 3H), 3.55 (q, J = 7.0 Hz, 2H), 3.-3.21 (m, 2H), 3.17-3.08 (m, 1H), 2.99 (q, J = 7.5 Hz, 2H), 2.- 2.58 (m, 1H), 2.56 - 2.48 (m, 1H), 2.43 - 2.38 (m, 2H), 2.36 - 2.26 (m, 1H), 1.82- 1.66 (m, 1H), 1.33 (t, J = 7.5 Hz, 3H), 1.18 (t, J = 7.0 Hz, 3H).

Example 1 27FVyvH V ° (S)-2-( 1 -(6-(5-((5-(azetidin- 1 -yl)- 2-oxopyridin- 1 (2H)-yl)methyl)- -methyl- 1H-1,2,3 -triazol-4-yl)- 2-ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC-MS (ESI) m/z 528 (M+H)+. 1H NMR (400 MHz, CD3OD) 57.80 - 7.79 (d, J = 8.3 Hz, 1H), 7.53 - 7.(d, J = 8.4 Hz, 1H), 7.01 - 6.98 (dd, J = 9.6, 3.0 Hz, 1H), 6.82 (d, J = 3.Hz, 1H), 6.44 - 6.41 (d, J = 9.6 Hz, 1H), 5.81 (s, 2H), 4.07 (s, 3H), 3.- 3.34 (m, 4H), 3.7 - 3.11 (m, 2H), 3.05 - 2.98 (m, 1H), 2.93 - 2.87 (m, 2H), 2.54 - 2.48 (m, 1H), 2.4 - 2.(m, 1H), 2.30 (d, J = 6.9 Hz, 2H), 2.26 - 2.20 (m, 1H), 2.14 - 2.06 (m, 2H), 1.71 - 1.59 (m, 1H), 1.26- 1.22 (t, J = 7.5 Hz, 3H).

Example 1 28V ° I 0N. t^nA NAN׳ nV (S)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-S-( IH-pyrazol- 1 -yl)pyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)- 5,5 -difluoropiperi din- 3 -yl)acetic acid LC/MS (ESI) m/z: 539 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.41 (d, J = 2.8 Hz, 1H), 7.85 - 7.76 (m, 3H), 7.64 (s, 1H), 7.54 (d, J = 1.7 Hz, 1H), 6.57 (d, J = 9.7 Hz, 1H), 6.41 - 6.(m, 1H), 5.70 (s, 2H), 4.17 (s, 3H), 3.13 (d, J = 9.7 Hz, 2H), 3.04 - 2.(m, 1H), 2.85 (q, J = 7.5 Hz, 2H), 2.57 - 2.48 (m, 1H), 2.45 - 2.35 (m, 1H), 2.31 (d, J = 7.0 Hz, 2H), 2.26 - 2.14 (m, 1H), 1.74 - 1.56 (m, 1H), 1.16 (t, 1 = 7.5 Hz, 3H).

Example 1 116 WO 2022/034568 PCT/IB2021/059266 29H ؟ FVy° n-n / n (S)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-S -propylpyrazin- 1 (2H)- yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 516 (M+H)+1H NMR (400 MHz, CD3OD) 5 8.05 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.(d, J = 8.4 Hz, lH),7.57(s, 1H), 5.(s, 2H), 4.19 (s, 3H), 3.30 - 3.22 (s, 2H), 3.15-3.05 (m, 1H), 2.97 (d, J = 7.6 Hz, 1H), 2.64 - 2.27 (m, 7H), 1.81 - 1.66 (m, 1H), 1.52 - 1.42 (m, 2H), 1.29 (t, J = 7.6 Hz, 3H), 0.78 (t, J = 7.6 Hz, 3H).

Example 1 30n" °"^וזרoN" M-M (S)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-5-propylpyrimidin- (2H)-yl)methyl)- 1H-1,2,3- tri azol-4-yl)pyri din-3 -yl)-5 ,5 - difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.(d, J = 3.2 Hz, 1H), 8.14 (d, 1 = 3.Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 5.74 (s, 2H), 4.24 (s, 3H), 3.25 - 3.22 (m, 2H), 3.13 - 3.05 (m, 1H), 2.97 (q, J = 7.2 Hz, 2H), 2.64 - 2.28 (m, 7H), 1.82 - 1.65 (m, 1H), 1.44-1.31 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H), 0.(t, J = 7.6 Hz, 3H).

Example 1 31V 0 '^וך /0 N־ o (S)-2-(l-(2-ethyl-6-(l-methyl-5- ((6-oxo-4-propylpyrimidin-(6H)-yl)methyl)- 1H-1,2,3- tri azol-4-yl)pyri din-3 -yl)-5 ,5 - difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 516 [M+l] +. 1H NMR (400 MHz, CD3OD) 5 8.(s, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 6.25 (s, 1H), 5.67 (s, 2H), 4.25 (s, 3H), 3.-3.19 (m, 2H), 3.13-3.05 (m, 1H), 2.99 (t, J = 7.5 Hz, 2H), 2.66 - 2.58 (m, 1H), 2.57 - 2.48 (m, 1H), 2.46 - 2.37 (m, 4H), 2.35 - 2.25 (m, 1H), 1.86 - 1.67 (m, 1H), 1.62 (dd, J= 14.9, 7.4 Hz, 2H), 1.31 (t, J = 7.5 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H).

Example 1 32V °"T! 0 N־(S)-2-(5,5 -difluoro- 1 -(2-methyl- LC/MS (ESI) m/z: 502 (M+H)+.1H NMR (400 MHz, DMSO-d6) 7.76 (d, J= 8.3 Hz, 1H), 7.61 (d, J = 4.0 Hz, 1H), 7.43 (d, J= 8.4 Hz, 1H), 7.11 (d, =4.0 Hz, 1H), 5.83-5.(m, 2H), 3.96 (s, 3H), 3.10 - 2.(m, 3H), 2.41 - 2.39 (m, 2H), 2.29 Example 1 117 WO 2022/034568 PCT/IB2021/059266 6-(l-methyl-5-((6-oxo-5- propylpyridazin- 1 (6H)- yl)methyl)- 1H-1,2,3 -tri azol-4- yl)pyridin-3 -yl)piperidin-3 - yl)acetic acid (s, 3H), 2.31 - 2.29 (m, 7H), 1.96 - 1.90 (m, 1H), 1.69 -1.60 (m, 1H), 1.56 - 1.44 (m, 2H), 0.83 (t, J= 7.Hz, 3H).^-"VH M ° T O1mA N־ (S)-2-(5,5-difluoro-l -(2-methyl- 6-(l-methyl-5-((6-oxo-4- propylpyridazin- 1 (6H)- yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3 -yl)piperidin-3 - yl)acetic acid LC/MS (ESI) m/z: 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.77 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.48 (d, J = 8.2 Hz, 1H), 6.(d, J = 2.0Hz, 1H), 5.88 (s, 2H),4.(s, 3H), 3.27-3.20 (m, 2H), 3.09-2.(m, 1H), 2.60-2.50 (m, 2H), 2.49- 2.45 (m, 6H), 2.42-2.36 (m, 2H), 2.32-2.25 (m, 1H), 1.80-1.65 (m, 1H), 1.60 (dd, J = 15.2, 7.5 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H).

Example 1 34M ° T 0N־N N J (S)-2-(5,5-difluoro-l -(2-methyl- 6-(l-methyl-5-((6-oxo-3- propylpyridazin- 1 (6H)- yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3 -yl)piperidin-3 - yl)acetic acid LC/MS (ESI) (m/z): 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J= 8.3 Hz, 1H), 7.49 (d, J= 8.Hz, 1H), 7.28 (d, J= 9.5 Hz, 1H), 6.91 (d, J= 9.5 Hz, 1H), 5.88 (s, 2H), 4.18 (s, 3H), 3.25 (d, J= 10.3 Hz, 2H), 3.08 - 2.99 (m, 1H), 2.60-2.(m, 1H), 2.49 (s, 3H), 2.41-2.38 (m, 3H), 1.79 - 1.59 (m, 2H), 1.45-1.(m, 4H), 0.75 (t, J= 7.4 Hz, 3H).

Example 1 ^■""Y0h V ° H u (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-6- oxopyridazin-l(6H)-yl)methyl)- -methyl- 1H-1,2,3 -triazol-4-yl)- LC/MS (ESI) m/z: 528 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.80 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.38 (d, J = 9.5 Hz, 1H), 6.(d, J = 9.4 Hz, 1H), 5.97 (s, 2H),4.(s, 3H), 3.22-3.16 (m, 2H), 3.11 - 3.00 (m, 1H), 2.87 (d, J = 7.5 Hz, 2H), 2.62 - 2.54 (m, 1H), 2.53 - 2.(m, 1H), 2.39 - 2.35 (m, 2H), 2.(d, J = 7.1 Hz, 3H), 1.78 - 1.64 (m, 1H), 1.21 (t, J = 7.4 Hz, 3H), 0.78 - 0.70 (m, 1H), 0.37 (d, J = 7.0 Hz, 2H), 0.03-0.01 (m, 2H).

Example 1 118 WO 2022/034568 PCT/IB2021/059266 2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3-yl)acetic acidM ° |וך /JI 0 N־ nJ (S)-2-(l-(6-(5-((3-cyclopropyl-6- oxopyridazin-l(6H)-yl)methyl)- -methyl- 1H-1,2,3 -triazol-4-yl)- 2-ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 514 [M+l] +.1HNMR (400 MHz, CD3OD) 5 7.(d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.Hz, 1H), 7.27 (d, J = 9.5 Hz, 1H), 6.88 (d, J = 9.4 Hz, 1H), 5.95(s, 2H), 4.13 (s, 3H), 3.21 (d, J = 10.5 Hz, 2H), 3.09 (d, J = 28.7 Hz, 1H), 2.(t, J = 7.4 Hz, 2H), 2.59 (d, J = 10.Hz, 1H), 2.50 (dd, J= 8.5, 4.8 Hz, 1H), 2.41 - 2.36 (m, 2H), 2.34 - 2.(m, 1H), 1.82-1.67 (m, 2H), 1.21 (t, J = 7.5 Hz, 3H), 0.78 (dd, J = 8.2, 2.Hz, 2H),0.41 (d, J = 4.9 Hz, 2H).

Example 1 37V ° N^N oI1Y N־ o (S)-2-(l-(4-ethyl-2-(l-methyl-5- ((2-oxo-5-propylpyridin- 1 (2H)- yl)methyl)-lH-pyrazol-4- yl)pyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) (m/z): 515 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.(s, 1H), 8.13 (s, 1H), 7.47 (d,J=2.Hz, 1H), 7.40 (dd, J= 9.2, 2.5 Hz, 1H), 6.56 (d, J= 9.2 Hz, 1H), 5.(s, 2H), 3.91 (s, 3H), 3.66 (d, J = 11.2 Hz, 2H), 3.61 (s, 2H), 3.58 (s, 2H), 3.23-3.17 (m, 2H), 2.92-2.(m, 2H), 2.73-2.68 (m, 1H), 2.52- 2.46 (m, 1H), 2.41 (d, J = 7.4 Hz, 2H), 2.24 (t, J= 7.5 Hz, 2H), 1.43- 1.36 (m, 3H), 0.77 (t, J = 7.3 Hz, 3H).

Example 1 38 F¥yvH ‘n" °״״Yr'SN^N I o ؟ ־ N (S)-2-(l-(4-ethyl-2-(l-methyl-5- ((2-oxo-5-propylpyrimidin- l(2H)-yl)methyl)-lH-pyrazol-4- yl)pyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC-MS: m/z 516 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.46 (d, J = 2.2 Hz, 1H), 8.42 (s, 1H), 8.14 (s, 1H), 8.01 (d, 1 = 3.1 Hz, 1H), 5.(s, 2H), 4.02 (s, 3H), 3.30 - 3.(m, 1H), 3.26 - 3.13 (m, 2H), 2.- 2.84 (m, 2H), 2.73 - 2.66 (m, 1H), 2.54 - 2.45 (m, 1H), 2.36 - 2.41 (d, 2H), 2.38 - 2.28 (m, 3H), 1.84- 1.66 (m, 1H), 1.48 - 1.40 (m, 2H), 1.27 - 1.23 (t, J = 7.5 Hz, 3H), 0.83 - 0.79 (t, J = 7.3 Hz, 3H).

Example 1 119 WO 2022/034568 PCT/IB2021/059266 39‘n" 0/y/S N^N JI o nYN־ o (S)-2-( 1 -(2-(5-((5-cyclopropyl-2- oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl-lH-pyrazol-4-yl)-4- ethylpyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) (m/z): 513 (M+H)+. 1H-NMR (400 MHz, CD3OD) 5 8.(s, 1H), 8.13 (s, 1H), 7.55 (d, J= 2.Hz, 1H), 7.29 (dd, J = 9.3, 2.6 Hz, 1H), 6.52 (d, J= 9.3 Hz, 1H) 5.83 (s, 2H), 3.92 (s, 3H), 3.38-3.35 (m, 2H), 3.24-3.13 (m, 1H), 2.95-2.89 (m, 2H), 2.70 (t, J= 10.9 Hz, 1H), 2.55- 2.47(m, 1H), 2.40-2.38 (m, 2H), 2.34-2.27 (m, 1H), 1.82-1.67 (m, 1H), 1.63-1.56 (m, 1H), 1.29 (t, J = 7.5 Hz, 3H), 0.79-0.74 (m, 2H), 0.36-0.32 (m, 2H).

Example 1 40 YyyH V ° N^NT 0، / n^N־ o (S)-2-(l-(4-ethyl-2-(5-((5- isobutyl-2-oxopyridin-l(2H)- yl)methyl)-l-methyl-lH-pyrazol- 4-yl)pyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 529 (M+H)+.1H NMR (400 MHz, CD3OD) 5 8.(s, 1H), 8.14 (s, 1H), 7.40 - 131 (m, 2H), 6.56 (d, J = 9.3 Hz, 1H), 5.(s, 2H), 3.92 (s, 3H), 3.23 - 3.13 (m, 1H), 2.89 (q, J= 1A Hz, 2H), 2.72 - 2.67 (m, 1H), 2.55 - 2.45 (m, 1H), 2.37 (d, J= 7.2 Hz, 2H), 2.35 - 2.(m, 1H), 2.12 (d, J = 7.1 Hz, 2H), 1.80 - 1.65 (m, 1H), 1.60 (dt, J = 13.4, 6.7 Hz, 1H), 1.27 (t, J= 7.5 Hz, 3H), 0.73 (d, J =6.6 Hz, 6H).

Example 1 41YtVhV 0 N^N I o n־ (S)-2-( 1 -(2-ethyl-6-( 1 -methyl-5 - ((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-pyrazol-4- yl)pyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid LC-MS: m/z 514 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 7.80 (s, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.42 (d, J = 1.9 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.29 (dd, J = 9.2, 2.5 Hz, 1H), 6.45 (d, J = 9.2 Hz, 1H), 5.73 (s, 2H), 3.80 (s, 3H), 3.14 - 3.07 (m, 2H), 3.02 - 2.92 (m, 1H), 2.84 - 2.78 (m, 2H), 2.53 - 2.46 (m, 1H), 2.44 - 2.36 (m, 1H), 2.31 - 2.29 (d, J = 7.1 Hz, 2H), 2.23 - 2.16 (m, 1H), 2.12 - 2.08 (t, J = 7.4 Hz, 2H), 1.70 - 1.56 (m, 1H), 1.31 - 1.22 (m, 2H), 1.15-1.11 (t, J = 7.5 Hz, 3H), 0.68 - 0.64 (t, J = 7.3 Hz, 3H).

Example 1 120 WO 2022/034568 PCT/IB2021/059266 42u ° I 0(/',nA N־Nx O (R)-2-(l-(2-ethyl-6-(l-methyl-5- ((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-pyrazol-4- yl)pyridin-3 -yl)piperidin-3 - yl)acetic acid LC/MS (ESI) (m/z): 478 (M+H)+. 1H-NMR (400 MHz, CD3OD) 5 7.(s, 1H), 7.51-7.53 (d, J = 2.0 Hz, 1H), 7.43-7.49 (m, 2H), 7.37-7.(dd, J= 9.2, 2.5 Hz, 1H), 6.53-6.(d,J = 9.2Hz, 1H), 5.82 (s, 2H),3.(s, 3H), 3.12-3.15 (d, J = 9.9 Hz, 1H), 3.00-3.02 (d, J = 11.2 Hz, 1H), 2.85-2.91 (m, 2H), 2.67-2.73 (m, 1H), 2.41-2.46 (m, 1H), 2.29-2.(d, J = 6.8 Hz, 2H), 2.17-2.21 (m, 3H), 2.00 - 2.05 (m, 1H), 1.73 - 1.(m, 3H), 1.20 - 1.24 (m, 4H), 0.89 - 0.92 (m, 1H), 0.74 - 0.77 (t, J= 3.ר Hz, 3H).

Example 1 Example 43: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3-propylpyridin-l(4H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid LiOHTHF/MeOH/H2O Step 5 Example 43 Step 1: 4-(benzyloxy)-3-bromopyridine id="p-268" id="p-268" id="p-268" id="p-268" id="p-268" id="p-268" id="p-268" id="p-268" id="p-268"

[0268]To a solution of 3-brom opyri din-4-01 (0.13 mL, 1.16 mmol) in DMF (2 mL) was added NaH (92 mg, 2.30 mmol, 60% dispersion in mineral oil) in portions at 0 °C under N2 atmosphere and the reaction was stirred at 0 °C for 20 min. BnBr (0.21 mL, 1.76 mmol) was added to the above mixture and the resulting mixture was stirred at 25 °C for 16 hrs. The reaction was quenched with water (20 mL) at 0 °C and the mixture was extracted with EtOAc (3x15 mL). The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and concentrated to 121 WO 2022/034568 PCT/IB2021/059266 dryness. The residue was purified by column chromatography (PE: EtOAc= 50: 1 to 20: 1) to give the title compound (300 mg, 98.6% yield) as light yellow solid. LC/MS (ESI) m/z: 264 (M+H)+. Step 2: 3-allyl-4-(benzyloxy) pyridine id="p-269" id="p-269" id="p-269" id="p-269" id="p-269" id="p-269" id="p-269" id="p-269" id="p-269"

[0269]To a mixture of 4-(benzyloxy)-3-bromopyridine (300 mg, 1.14 mmol), Tibutyl(vinyl)tin (0.53 mL, 1.71 mmol) and LiCl (121 mg, 2.85 mmol) was added Pd(PPh3)4 (132 mg, 0.114 mmol) under N2 atmosphere. After addition, the mixture was degassed under N2 atmosphere at 100 °C for hrs. The mixture was diluted with EtOAc (10 mL), washed with saturated aq.KF solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography (DCM: MeOH = 50: 1 to 20: 1) to give the title compound 3(205 mg, 80.2% yield) as yellow oil. LC/MS (ESI) m/z: 226 (M+H)+. Step 3: 3-propylpyridin-4-ol id="p-270" id="p-270" id="p-270" id="p-270" id="p-270" id="p-270" id="p-270" id="p-270" id="p-270"

[0270]To a solution of 3-allyl-4-(benzyloxy)pyridine (150 mg, 0.67 mmol) in MeOH (3 mL) was added Pd(OH)2/C (20 mg, 10% wt) at 25 °C under N2 atmosphere and the mixture was degassed under N2 atmosphere for three times, stirred under a H2 balloon at 25 °C for 5 hrs. The mixture was filtered and the filter cake was washed with MeOH (2x5 mL). The filtrate was concentrated to dryness and the residue was purified by column chromatography (DCM: MeOH = 20: 1 to 10: 1) to give compound 4(50 mg, 54.7% yield) as colorless oil. LC/MS (ESI) m/z: 138 (M+H)+. Step 4: methyl (R)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3-propylpyridin- l(4H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-271" id="p-271" id="p-271" id="p-271" id="p-271" id="p-271" id="p-271" id="p-271" id="p-271"

[0271]To a mixture of 3-propylpyridin-4-01 (15.7 mg, 0.114 mmol) and methyl (S)-2-(5,5- difluoro-l-(2-methyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l, 2,3-tri azol -4-yl)pyridin-3-yl)piperidin-3-yl)acetate (36 mg, 0.076 mmol) in toluene (2 mL) and H2O (1 mL) was added K2CO3 (31.5 mg, 0.23 mmol) followed by TBAF (2 mg, 0.008 mmol) and the reaction mixture was heated to 80 °C for 16 hrs. The mixture was diluted with EtOAc (3 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (50 mg, 100% yield) as yellow solid, which was used in next reaction directly. LC/MS (ESI) m/z: 515 (M+H)+. Step 5: (R)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3-propylpyridin-l(4H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid id="p-272" id="p-272" id="p-272" id="p-272" id="p-272" id="p-272" id="p-272" id="p-272" id="p-272"

[0272]To a solution of methyl (R)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3- propylpyridin-l(4H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (50 mg, 0.097 mmol) in THE (2 mL), MeOH (0.50 mL) and water (0.5 mL) was added LiOH.H2O (42 mg, 1.00 mmol) at 25 °C and the mixture was stirred at 25 °C for 16 hrs. The reaction was concentrated 122 WO 2022/034568 PCT/IB2021/059266 to dryness and the residue was diluted with water (5 mL). The mixture was basified with IN aq.NaOH to pH~14 and washed with EtOAc (2 x 2mL). The aqueous layer was acidified with IN aq.HCl to pH~3 and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (5.2 mg, 10.7%) as white solid. LC/MS (ESI) m/z: 501 (M+H)+. 1H NMR (400 MHz, DMSO) 5 7.90 (d, J= 8.3 Hz, 1H), 7.84 - 7.75 (m, 2H), 7.59 (d, J= 8.4 Hz, 1H), 6.03 (d, J= 3.ר Hz, 1H), 5.69 (s, 2H), 4.10 (s, 3H), 3.21 - 3.07 (m, 3H), 2.59 - 2.56 (m, 1H), 2.52 (s, 3H), 2.40 - 2.25 (m, 4H), 2.22 - 2.15 (m, 2H), 2.03 - 1.95 (m, 1H), 1.80- 1.73 (m, 1H), 1.40-1.31 (m, 2H), 0.78 (t, J =7.4 Hz, 3H). Example 44: 2-[5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5-propyl-l,6- dihydropyridazin-l-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetic acid Step 1: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]acetonitrile id="p-273" id="p-273" id="p-273" id="p-273" id="p-273" id="p-273" id="p-273" id="p-273" id="p-273"

[0273]To a solution of 3-bromo-6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2- methylpyridine (1.1 g, 3.18 mmol) in CH3CN (10 mL) was added NaCN (260 mg, 5.31 mmol) in DMSO (10 mL) and the reaction mixture was stirred at r.t. for 30 min, then was partitioned between EtOAc and water. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic extracts were concentrated washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0% to 100% EtOAc in PE) to give the title compound (680 mg, 73.2 % yield) as white solid. 1H NMR (400 MHz, CDC13) 5 7.92 (q, J= 8.4 Hz, 2H), 4.64 (s, 2H), 4.19 (s, 3H), 2.69 (s, 3H), 1.66 (s, 2H). 123 WO 2022/034568 PCT/IB2021/059266 Step 2: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]acetic acid id="p-274" id="p-274" id="p-274" id="p-274" id="p-274" id="p-274" id="p-274" id="p-274" id="p-274"

[0274]To a solution of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]acetonitrile (630 mg, 2.16 mmol) in ethanol (10 mL) and H2O (10 mL) was added KOH (4mg, 8.63 mmol) and the resulting mixture was refluxed for 16 hrs. The ethanol was removed under reduced pressure, and then the solution was cooled to below 10° C and acidified with concentrated aq.HCl to pH~l. The mixture was extracted with EtOAc (2 x 10 mL) and the combined organic extracts were concentrated washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (680 mg , 101.4% yield) as white solid. LC/MS (ESI) m/z: 312/314 (M+H) +. Step 3: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]ethan-l-ol id="p-275" id="p-275" id="p-275" id="p-275" id="p-275" id="p-275" id="p-275" id="p-275" id="p-275"

[0275]To a mixture of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]acetic acid (450 mg, 1.45 mmol) in THE was added BH3.THF complex (4.3 mL, 1 M in THF) drop-wisely at 0 °C and the mixture was stirred at r.t. for 6 hrs. The reaction mixture was quenched by drop-wise addition of MeOH (5 mL) at 0 °C and the resulting mixture was concentrated to dryness to give the title compound (250 mg, 58.2 % yield) as white solid. LC/MS (ESI) m/z: 298/300 (M+H)+. Step 4: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]ethyl methanesulfonate id="p-276" id="p-276" id="p-276" id="p-276" id="p-276" id="p-276" id="p-276" id="p-276" id="p-276"

[0276]To a stirred solution of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]ethan-l-01 (250 mg, 0.84 mmol) in DCM (10 mL) was added MsCl (0.1 mL, 1.26 mmol) and TEA (0.35 mL, 2.52 mmol) at 0 °C under N2 atmosphere. After stirring at r.t. for 3 hrs, the reaction mixture was quenched with H2O (10 mL), extracted with DCM (2x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 9: 1 to 4: 1) to give the title compound (270 mg, 85.5 % yield) as yellow solid. LC/MS (ESI) m/z: 376/378 (M+H)+. Step 5: 2-{2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]ethyl}-4- propyl-2,3-dihydropyridazin-3-one [0277]To a solution of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]ethyl methanesulfonate (120 mg, 0.32 mmol) and 4-propyl-2,3-dihydropyridazin-3-one (66 mg, 0.48 mmol) in toluene (2 mL) was added K2CO3 (132 mg, 0.96 mmol) in H2O (2 mL) followed by TBAF (8 mg, 0.03 mmol) and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~25 % EtOAc 124 WO 2022/034568 PCT/IB2021/059266 in PE) to give the title compound (40 mg, 30.0 % yield) as brown solid. LC/MS (ESI) m/z: 418/4(M+H)+. Step 6: methyl 2-[(3R)-5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5-propyl-l,6- dihydropyridazin-l-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetate [0278]To mixture of 2-{2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]ethyl}-4-propyl-2,3-dihydropyridazin-3-one (40 mg, 0.10 mmol) and methyl 2-[(3R)-5,5- difluoropiperidin-3-yl]acetate (22 mg, 0.12 mmol) in toluene (2 mL) were added Cs2CO3 (62 mg, 0.19 mmol) followed by the addition of BINAP (6 mg, 0.01 mmol ) and Pd(OAc)2 (2 mg, 0.mmol) under N2 atmosphere. The reaction was degassed under N2 atmosphere for three times and stirred at 110 °C in a CEM microwave reactor for 2 hrs. The mixture was diluted with EtOAc (mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 55% EtOAc in PE) to give the title compound (10 mg, 19.7 % yield) as yellow solid. LC/MS (ESI) m/z: 531 (M+H)+. Step 7: 2-[5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5-propyl-l,6-dihydropyridazin- l-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetic acid id="p-279" id="p-279" id="p-279" id="p-279" id="p-279" id="p-279" id="p-279" id="p-279" id="p-279"

[0279] To a solution of methyl 2-[5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5-propyl- l,6-dihydropyridazin-l-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetate (mg, 0.02 mmol) in THE (5 mL) and MeOH (1 mL) was added a solution of LiOH (8 mg, 0.2 mmol) in H2O (1 mL). The mixture was stirred at r.t. for 2 hrs. The mixture was acidified with IN aq.HCl to pH~3 and extracted with DCM (2x2 mL). The combined organic layers were washd with brine and concentrated to dryness. The residue was purified by prep.HPLC (C18, 0 ~ 90 % acetonitrile in H2O with 0.1% formic acid) to give 2-[5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5- propyl- 1,6-dihydropyridazin- 1 -yl)ethyl]- 1H-1,2,3 -tri azol-4-yl }pyri din-3 -yl)piperi din-3 -yl]acetic acid (2.2 mg, 22.6 % yield) as white solid. LC/MS (ESI) m/z: 517 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.65 (d, J= 8.3 Hz, 1H), 7.57 (d, J= 4.2 Hz, 1H), 7.44 (d, J= 8.3 Hz, 1H), 6.99 (d, J = 4.2 Hz, 1H), 4.61 (s, 3H), 4.50 (t,J=7.3 Hz, 2H), 4.06 (s, 3H), 3.78 (t, J= 6.6 Hz, 2H), 3.14 - 2.99 (m, 1H), 2.56 (s, 3H), 2.54 - 2.47 (m, 1H), 2.42 - 2.35 (m, 4H), 2.34 - 2.25 (m, 1H), 1.83 - 1.64 (m, 1H), 1.57- 1.45 (m, 2H), 0.92 (t, J= 7.4 Hz, 3H). Example 45 and 46: 2-((3R,5R) or (3S,5S)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid and 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid 125 WO 2022/034568 PCT/IB2021/059266 HO, CbzEtOAcH2, Pd/C HO,,.

Step 1k 2coDMFStep 2 BnBr H0"DAST, DOMBn 3 cis-mixture Bn trgns- mixture 0..AQ H2, Pd/C FCbzCI H2, Pd/C trans-mixture cis-mixtureLiOH, THEMeOH, H2Or H 2 cis-mixture OH1) Oxalyl chloride p DCM, DMF cat.2) TMSCHN2. THF Step 3O -78°-rt, 16hStep 4 CF3COOAg MeOH CbzQ Step 9 y trans-mixture Step 5 EtOAc TEA,THF trans-mixture Step 7 Step 6 Step 8BrCbz 6 trans-mixture Cbz 7 trans-mixture Cbz 8 trans-mixture TEA, MeOH MsCI, TEA, DCM PPTS, MeOH 12 50°C,16hStep 10 Step 11 trans-mixture Ru-phos, Pd2(dba) 3Cs2CO3, dioxane 14-P1 and 14-P2 Stereochemisry not assigned 13 trans-mixture OTHP N-N Step 12 Step 1: Cis-methyl 5-hydroxypiperidine-3-carboxylate [0280]To a solution of cis-l-benzyl 3-methyl 5-hydroxypiperidine-l,3-dicarboxylate (8 g, 27.mmol) in EtOAc (100 mL) was added Pd/C (1 g, 10% wt) and the mixture was degassed under Natmosphere for three times, stirred under a H2 balloon at room temperature for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (4.3 g, 99% yield) as colorless oil. LC/MS (ESI) m/z: 160 (M+l) +. Step 2: Cis-methyl l-benzyl-5-hydroxypiperidine-3-carboxylate [0281]To a mixture of cis-methyl 5-hydroxypiperidine-3-carboxylate (4.3 g, 27.0 mmol) and K2CO3 (7.5 g, 54.1 mmol) in DMF (50 mL) was added BnBr (7.4 g, 40.5 mmol) and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (100 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0- 100%, EtOAc in PE) to give the title compound (3.85 g, 57.2% yield) as yellow oil. LC/MS (ESI) m/z: 250 (M+l) +. Step 3: Trans-methyl l-benzyl-5-fluoropiperidine-3-carboxylate [0282]To a mixture of cis-methyl l-benzyl-5-hydroxypiperidine-3-carboxylate (3.85 g, 15.mmol) in DCM (50 mL) was added DAST (4.1 mL, 30.9 mmol) drop-wisely at -78 °C and the mixture was stirred at -78 °C to r.t. for 16 hrs. The mixture was quenched with saturated 126 WO 2022/034568 PCT/IB2021/059266 aq.NaHCO3 solution at 0 °C and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-100%, EtOAc in PE) to give the title compound (3.2 g, 82.5% yield) as yellow oil. LC/MS (ESI) m/z: 252 (M+l) +. Step 4: Trans-methyl 5-fluoropiperidine-3-carboxylate [0283]To a mixture of trans-methyl l-benzyl-5-fluoropiperidine-3-carboxylate (3.2 g, 12.7 mmol) in MeOH (50 mL) was added Pd(OH)2 (400 mg, 10% wt) and AcOH (3 drops) and the mixture was degassed under N2 for three times and stirred under a H2 balloon at r.t. for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (2.5 g, 100% yield) as colorless oil. LC/MS (ESI) m/z: 162 (M+l) +. Step 5: Trans-l-benzyl 3-methyl 5-fluoropiperidine-l,3-dicarboxylate id="p-284" id="p-284" id="p-284" id="p-284" id="p-284" id="p-284" id="p-284" id="p-284" id="p-284"

[0284]To a mixture of trans-methyl 5-fluoropiperidine-3-carboxylate (2.5 g, 15.5 mmol) in THE (30 mL) and saturated aq.NaHCO3 solution (15 mL) was added CbzCl (5.27 g, 31.0 mmol) drop- wisely at 0 °C and the mixture was stirred at r.t. for 16 hrs. The mixture was extracted with EtOAc (2 x 20 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-50%, EtOAc in PE) to give the title compound (3.7 g, 80.8% yield) as yellow oil. LC/MS (ESI) m/z: 296 (M+l) +. Step 6: Trans-l-((benzyloxy)carbonyl)-5-fluoropiperidine-3-carboxylic acid id="p-285" id="p-285" id="p-285" id="p-285" id="p-285" id="p-285" id="p-285" id="p-285" id="p-285"

[0285]To a solution of trans-l-benzyl 3-methyl 5-fluoropiperidine-l,3-dicarboxylate (3.7 g, 12.mmol) in MeOH (40 mL), THF (20 mL) and H2O (20 mL) was added LiOHH2O (2.63 g, 62.mmol) and the mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (50 mL), washed with EtOAc (2x10 mL). The aqueous layer was acidified with IN aq.HCl to pH~4 and extracted with DCM (3 x 30mL). The combined organic layers were washed brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (3.1 g, 88% yield) as white solid. LC/MS (ESI) m/z: 282 (M+l) +. Step 7: Trans-benzyl 3-(chlorocarbonyl)-5-fluoropiperidine-l-carboxylate [0286]To a solution of l-[(benzyloxy)carbonyl]-5-fluoropiperidine-3-carboxylic acid (3.1 g, 11.mmol) andDMF (0.085 mL, 1.10 mmol) in DCM (31 mL) was added Oxalyl chloride (2.80 g, 22.mmol) drop-wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (40 mL). A solution of TMSCHN(16.5 mL, 2M in toluene) was added to the above mixture and the mixture was stirred at r.t. for hrs. The reaction mixture was quenched with AcOH (6 mL) and concentrated to dryness to give a yellow residue. The residue was dissolved in MeOH (50 mL) and F3CCOOAg (0.48 g, 2.16 mmol) 127 WO 2022/034568 PCT/IB2021/059266 and TEA (6 mL) were added. The reaction mixture was sonicated with ultrasound at room temperature for 1 hr. The mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel (40g), 0-100%, EtOAc in PE) to give the title compound (2.0 g, 60% yield) as yellow oil. LC/MS (ESI) m/z: 310 (M+l) +. Step 8: Trans-methyl 2-(5-fluoropiperidin-3-yl)acetate [0287]To a mixture of trans-benzyl 3-fluoro-5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (2 g, 6.46 mmol) in EtOAc (50 mL) was added Pd/C (200 mg, 10% wt), the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at r.t. for 2 hrs. The reaction mixture was filtered and the filtrate was concentrated to dryness to give the title compound (1.1 g, yield 97%) as off-white solid. LC/MS (ESI) m/z: 176 (M+l) +. Step 9: Trans-methyl 2-(l-(2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate [0288]To a mixture of 3-bromo-2-ethyl-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine(600 mg, 1.57 mmol ), trans-methyl 2-(5-fluoropiperidin-3-yl)acetate (276 mg, 1.mmol ), Ru-phos (147 mg, 0.315 mmol) and Cs2CO3 (1.0 mg, 3.14 mmol) in 1,4-dioxane (15 mL) was added Pd2(dba)3 (216 mg, 0.236 mmol) under N2 atmosphere, the mixture was degassed under N2 for three times and stirred at 120 °C for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0- 40% EtOAc in PE) to give the title compound (430 mg, 57.5% yield) as yellow solid. LC/MS (ESI) m/z: 476 (M+l) +. Step 10: Methyl 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate (14-P1) & methyl 2-((3R,5R) or (3S,5S)-l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate (14-P2) [0289]To a mixture of methyl 2-[l-(2-ethyl-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3- triazol-4-yl}pyridin-3-yl)-5-fluoropiperidin-3-yl]acetate (430 mg, 0.904 mmol) in MeOH (10 mL) was added PPTS (454 mg, 1.81 mmol). After stirred at 50 °C for 16 hrs, the mixture was poured into saturated aq.NH4Cl solution and extracted with EtOAc (3x10 mL). The combined organic phase was washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the racemic product, which was purified by chiral SECto give compoiund 14-P1(peak 1, retention time: 5.min) (64 mg, yield 18%) and 14-P2(peak 2, retention time: 5.83 min) (92 mg, yield 26%) as white solid. LC/MS (ESI) m/z: 392.5 (M+l) +. SFC condition: Column: ChiralPak OJ, 250x21.2 mm I.D., pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 40%; Flow rate: mL /min; Column temperature: 35 °C. 128 WO 2022/034568 PCT/IB2021/059266 Step 11: methyl 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy) methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate [0290]To a mixture of compound 14-P1(64 mg, 0.16 mmol) and TEA (0.07 mL, 0.510 mmol) in DCM (3 mL) was added MsCl (0.025 mL, 0.33 mmol) at 0 °C. After stirring at 0 °C for 1 hr, the reaction mixture was diluted with DCM (5 mL), washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (76 mg, 99% yield) as yellow solid. LC/MS (ESI) m/z: 470 (M+l) +. Step 12: methyl 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate [0291]To a mixture of compound 15(35 mg, 0.075 mmol) and K2CO3 (21 mg, 0.151 mmol) in toluene (2 mL) and H2O (0.4 mL) was added 5-propyl-l,2-dihydropyridin-2-one (12 mg, 0.0mmol). After stirring at 100 °C for 2 hrs, the reaction mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to give the title compound (38 mg, 99.8% yield) as yellow solid. LC/MS (ESI) m/z: 511 (M+l) +. Step 13: 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid [0292]To a solution of compound 16(38 mg, 0.074 mmol) in THE (2 mL), H2O (0.5 mL) and MeOH (0.5 mL) was added LiOHH2O (31 mg, 0.740 mmol). After stirring at r.t. for 16 hrs, the reaction mixture was acidified with IN aq.HCl to pH~6 and extracted with DCM (3x5 mL). The combined organic layers were washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (8.5 mg, 23% yield) as white solid. LC/MS (ESI) m/z: 4(M+1)+1HNMR (400 MHz, CD3OD) 5 7.88 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 9.3, 2.4 Hz, 1H), 6.52 (d, J = 9.2 Hz, 1H), 5.87 (s, 2H), 4.82 - 4.(m, 1H), 4.16 (s, 3H), 3.21 - 3.12 (m, 1H), 3.02 - 2.90 (m, 2H), 2.89 - 2.79 (m, 1H), 2.54 - 2.(m, 3H), 2.39 - 2.27 (m, 2H), 2.21 (t, J = 7.5 Hz, 2H), 1.48 - 1.28 (m, 7H), 0.76 (t, J = 7.3 Hz, 3H). Example 46: 2-((3R,5R) or (33,5S)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid id="p-293" id="p-293" id="p-293" id="p-293" id="p-293" id="p-293" id="p-293" id="p-293" id="p-293"

[0293]The title compound was prepared from compound 14-P2as the same sequence for the synthesis of example 45LC/MS (ESI) m/z: 497 (M+l) +. 1HNMR (400 MHz,CD3OD) 5 7.88 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 9.3, 2.5 Hz, 1H), 6.52 (d, J = 9.2 Hz, 1H), 5.87 (s, 2H), 4.73 (d, J = 4.6 Hz, 1H), 4.16 (s, 3H), 3.33 (s, 1H), 3.20 - 3.14 (m, 1H), 3.01 - 2.90 (m, 2H), 2.88 - 2.81 (m, 1H), 2.54 - 2.40 (m, 3H), 2.39 - 2.26 (m, 2H), 129 WO 2022/034568 PCT/IB2021/059266 2.21 (t, J = 7.6 Hz, 2H), 1.50 - 1.40 (m, 1H), 1.39 - 1.33 (m, 2H), 1.31 (t, J = 7.5 Hz, 3H), 0.76 (t, J = 7.3 Hz, 3H). Example 47: 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid Step 1: 6-bromo-3-fluoro-2-methylpyridine 1-oxide id="p-294" id="p-294" id="p-294" id="p-294" id="p-294" id="p-294" id="p-294" id="p-294" id="p-294"

[0294]To solution of 6-bromo-3-fluoro-2-methylpyridine (10 g, 52.6 mmol) in TFA (100 mL) was added H202 (40 mL, 353 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at °C for 20 hrs. The reaction was cooled to 0 °C and quenched with saturated aq.Na2S2O3 solution. The mixture was extracted with EtOAc (3 x 100 mL) and the combined organic layers were washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 10: to 0: 1) to give the title compound (8.2 g, 75.6% yield) as yellow solid. Step 2: 6-bromo-3-fluoro-2-methyl-4-nitropyridine 1-oxide id="p-295" id="p-295" id="p-295" id="p-295" id="p-295" id="p-295" id="p-295" id="p-295" id="p-295"

[0295]To a solution of 6-bromo-3-fluoro-2-methylpyridine 1-oxide (7 g, 34.0 mmol) in conc.H2SO4 (70 mL, 731 mmol) was added KNO3 (1.96 g, 19.4 mmol) in portions at 0 °C and the mixture was stirred at 120 °C for 6 hrs. The reaction mixture was poured into ice-water and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with saturated aq.NaHCO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The 130 WO 2022/034568 PCT/IB2021/059266 residue was recrystallized in EtOAc to give the title compound (2.57 g, 30.1% yield) as yellow solid. LC/MS (ESI) m/z: 251 (M+H)+. Step 3: 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-methyl-4-nitropyridine 1-oxide [0296]To a solution of 6-bromo-3-fluoro-2-methyl-4-nitropyridine 1-oxide (1.2 g, 4.78 mmol) in THE (5 mL) was added TEA (0.7 mL, 5.04 mmol) and a solution of ethyl 2-(piperidin-3-yl)acetate (0.9 g, 5.26 mmol) in THF (5 mL) at 0 °C and the reaction was stirred at 25 °C for 24 hrs. The mixture was diluted with EtOAc (20 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 10: 1 to 3: 1) to give the title compound (1.55 g, 82.8% yield) as red solid. LC/MS (ESI) m/z: 4(M+H)+. Step 4: ethyl 2-(l-(6-bromo-2-methyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate id="p-297" id="p-297" id="p-297" id="p-297" id="p-297" id="p-297" id="p-297" id="p-297" id="p-297"

[0297]To a solution of 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-methyl-4- nitropyridine 1-oxide (1.55 g, 4.13 mmol ) in DCM (15 mL) was added a solution of PBr3 (0.mL, 9.63 mmol) in DCM (2 mL) at 0 °C under N2 atmosphere and the mixture was stirred at 16 °C for 3 hrs. The reaction was poured into ice-cooled saturated aq.NaHCO3 solution and extracted with DCM (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 30: 1 to 10: 1) to give the title compound (1.52 g, 93.9% yield) as red oil. LC/MS (ESI) m/z: 386 (M+H)+. Step 5: ethyl 2-(l-(6-bromo-4-fluoro-2-methylpyridin-3-yl)piperidin-3-yl)acetate id="p-298" id="p-298" id="p-298" id="p-298" id="p-298" id="p-298" id="p-298" id="p-298" id="p-298"

[0298]To solution of ethyl 2-(l-(6-bromo-2-methyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate (1.5 g, 3.88 mmol) in DMSO (15 mL) was added KF (1.13 g, 19.4 mmol) and the reaction mixture was stirred at 140 °C under N2 atmosphere for 3 hrs. The mixture was poured into ice-water and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 20: 1 to 10: 1) to give the title compound (700 mg, 50.2% yield) as yellow solid. LC/MS (ESI) m/z: 359 (M+H)+. Step 6: ethyl 2-(l-(4-fluoro-6-(3-hydroxyprop-l-yn-l-yl)-2-methylpyridin-3-yl)piperidin-3- yl)acetate id="p-299" id="p-299" id="p-299" id="p-299" id="p-299" id="p-299" id="p-299" id="p-299" id="p-299"

[0299]To a mixture of ethyl 2-( l-(6-bromo-4-fluoro-2-methylpyridin-3-yl)piperidin-3-yl)acetate (830 mg, 2.31 mmol) and TEA (0.96 mL, 6.93 mmol) in MeCN (8 mL) were added Cui (10 mg, 0.046 mmol) and Pd(PPh3)2C12 (32.4 mg, 0.046 mmol) at 16 °C under N2 atmosphere. Then prop- 2-yn-l-ol (0.27 mL, 4.62 mmol) was added and the resulting mixture was degassed under N 131 WO 2022/034568 PCT/IB2021/059266 atmosphere for three times and stirred at 25 °C for 22 hrs. The mixture was diluted with EtOAc (20 mL) and filtered. The filtrate was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc= 10: 1 to 1: 1) to give the title compound (430 mg, 55.7% yield) as yellow oil. LC/MS (ESI) m/z: 335 (M+H)+. Step 7: ethyl 2-(l-(4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)piperidin-3-yl)acetate id="p-300" id="p-300" id="p-300" id="p-300" id="p-300" id="p-300" id="p-300" id="p-300" id="p-300"

[0300]To a solution of ethyl 2-(l-(4-fluoro-6-(3-hydroxyprop-l-yn-l-yl)-2-methylpyridin-3- yl)piperi din-3-yl)acetate (430 mg, 1.29 mmol) in 1,4-dioxane (10 mL) were added TMSCH2N(332mg, 2.57 mmol), Cp*RuCl(PPh3)2 (51 mg, 0.064 mmol) and cuprous iodide (12.25 mg, 0.0mmol) under N2 atmosphere. The mixture reaction was degassed under N2 atmosphere for three times and stirred at 50 °C under N2 atmosphere for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THE (10 mL) and TBAF (336 mg, 1.29 mmol) was added. The mixture was stirred at room temperature for 1 hr. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (DCM: EtOAc= 6: 1) to give the title compound (2mg, 39.7% yield) as yellow solid. LC/MS (ESI) (m/z): 392 (M+H)+. Step 8: ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-301" id="p-301" id="p-301" id="p-301" id="p-301" id="p-301" id="p-301" id="p-301" id="p-301"

[0301]To a solution of ethyl 2-(l-(4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (200 mg, 0.511 mmol) in DCM (10 mL) were added TEA (0.213 mL, 1.53mmol) and MsCl (0.079 mL, 1.02 mmol) at 0 °C and the mixture was stirred at room temperature for 1 hr. The mixture was diluted with water and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the title compound (210 mg, 87.5% yield) as yellow solid. LC/MS (ESI) (m/z): 470 (M+H)+. Step 9: ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-302" id="p-302" id="p-302" id="p-302" id="p-302" id="p-302" id="p-302" id="p-302" id="p-302"

[0302]To a mixture of ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5- (((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (135 mg, 0.29 mmol) and 5-propyl-l,2-dihydropyridin-2-one (59 mg, 0.43 mmol) in toluene (4 mL) and H2O (1 mL) were added K2CO3 (80 mg, 0.57 mmol) and TBAF (7.5 mg, 0.03 mmol) under Natmosphere and the mixture was stirred at 70 °C for 3 hrs. The reaction mixture was diluted with water and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was 132 WO 2022/034568 PCT/IB2021/059266 purified by silica gel chromatography (PE: EtOAc= 5: 1 to 2: 1) to give the title compound (70 mg, 47.7% yield) as yellow oil. LC/MS (ESI) (m/z): 511 (M+H)+. Step 10: 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid [0303]To a solution of ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (50 mg, 0.098 mmol) in THE (2 mL) and MeOH (3 mL) was added a solution of Li OH (23.5 mg, 0.98 mmol) in water (1 mL) at 0 °C and the mixture was stirred at room temperature for 1 hr. The mixture was concentrated to 1/5 volume, diluted with water and washed with ethyl acetate twice. The aqueous layer was acidified with IN aq.HCl to pH~3 and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (10 mg, 21.2% yield) as white solid. LC/MS (ESI) m/z: 483 (M+H)+. 1H NMR (400 MHz, CD3OD)57.83 (d,J=2.1 Hz, 1H), 7.60 (d, J= 13.Hz, 1H), 7.38 (dd, J= 9.2, 2.5 Hz, 1H), 6.47 (d, J= 9.2 Hz, 1H), 5.72 (s, 2H), 4.23 (s, 3H), 3.(t, 11.7 Hz, 2H), 3.06-3.03 (m, 2H), 2.63 (s, 3H), 2.31-2.26 (m, 4H), 1.96-1.90 (m, 1H), 1.(d, J= 12.9 Hz, 2H), 1.51-1.36 (m, 4H), 0.80 (t, J= 3.ר Hz, 3H). Example 48: 2-(l-(2-ethyl-4-fluoro-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid F F FH2O2, TFA^^y^ KNO3, H2SO؟/NyJ THF NyJ o'' NVBr Step 1 Br Step 2 Br Step 3 1 2 3 ? no tbaf/xS1]/X^N02 ----------------F --------------------------- *־II T THF Y1 Pd(PPh 3)2CI2, TEACui, MeCNBr ste P6 Br ste P7 7 8 N X F/nA/ °^1_MsCI,TEA, II ך OOM K2CO3, TBAF I 9H2O N, AXA !סי-י A ״ ״ NCV^OMs Step 10 N־ A xA/NO: 0^ , N °I! J -- -- ^ ־־*־-- ־ ׳־TEA, THF |l 1 DCMRr n''VBr Step 4 u T Step 5 4 Br 6 QY QQץ y 1) tmsch2n3_ ך ף aq.LiOH nJTHF, MeOH T OnA ؛ 4Step 11 N־NXExample 48 X 133 WO 2022/034568 PCT/IB2021/059266 Step 1: 6-bromo-2-ethyl-3-fluoropyridine id="p-304" id="p-304" id="p-304" id="p-304" id="p-304" id="p-304" id="p-304" id="p-304" id="p-304"

[0304]To a mixture of 6-bromo-3-fluoro-2-methylpyridine (7.9 g, 41.6 mmol) and DMPU (6.mL, 54.1 mmol) in THF (80 mL) was added LDA (27 mL, 54.1 mmol, 2M in THF) drop-wisely at -70 °C under N2 atmosphere and the mixture was stirred at -70 °C for 1 hr. Mel (3.37 mL, 54.mmol) was added to the above mixture and the resulting mixture was stirred at -70 °C for 3 hrs and r.t. for 16 hrs. The reaction was quenched with saturated aq.NH4Cl solution and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with PE) to give the title compound (2 g, 21.2% yield) as colorless oil. LC/MS (ESI) m/z: 204/206 (M+H)+. Step 2: 6-bromo-2-ethyl-3-fluoropyridine 1-oxide [0305]To a solution of 6-bromo-2-ethyl-3-fluoropyridine (2 g, 10.5 mmol) in TEA (20 mL) was added H202 (8 mL, 70.6 mmol) and the mixture was stirred at 70 °C under N2 atmosphere for hrs. The reaction was cooled to 0 °C and quenched with saturated aq.Na2S2O3 solution. The mixture was extracted with EtOAc (3 x 50 mL) and the combined organic layers were washed saturated aq.NaHCO3 solution and brine (50 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography (PE: EtOAc =10: 1 to 5: 1) to give the title compound (1.5 g, 65.0% yield) as yellow solid. LC/MS (ESI) m/z: 220/222 (M+H)+. Step 3: 6-bromo-2-ethyl-3-fluoro-4-nitropyridine 1-oxide [0306]To a solution of 6-bromo-2-ethyl-3-fluoropyridine 1-oxide (5.0 g, 22.7 mmol) in conc.H2SO4 (50 mL) was added KNO3 (9.19 g, 90.9 mmol) in portions at 0 °C and the mixture was stirred at 120 °C for 4 hrs. The mixture was poured into ice-water and extracted with EtOAc (3 x mL). The combined organic layers were washed with saturated aq.NaHCO3 solution and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 5: 1 to 3: 1) to give the title compound (3mg, 6.31% yield) as yellow solid. LC/MS (ESI) m/z: 265/267 (M+H)+. Step 4: 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-ethyl-4-nitropyridine 1-oxide id="p-307" id="p-307" id="p-307" id="p-307" id="p-307" id="p-307" id="p-307" id="p-307" id="p-307"

[0307]To a solution of 6-bromo-2-ethyl-3-fluoro-4-nitropyridine 1-oxide (380 mg, 1.43 mmol) and ethyl 2-(piperidin-3-yl)acetate (318 mg, 1.86 mmol) in THF ( 5 mL) was added TEA (0.mL, 4.30 mmol) and the mixture was stirred at 25 °C for 4 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc =10: 1 to 3: 1) to give the title compound (480 mg, 80.4% yield) as yellow oil. LC/MS (ESI) m/z: 416/418 (M+H)+. Step 5: ethyl 2-(l-(6-bromo-2-ethyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate 134 WO 2022/034568 PCT/IB2021/059266 id="p-308" id="p-308" id="p-308" id="p-308" id="p-308" id="p-308" id="p-308" id="p-308" id="p-308"

[0308]To a solution of 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-ethyl-4- nitropyridine 1-oxide (480 mg, 1.15 mmol) in DCM (5 mL) was added a solution of PBr3 (0.mL, 1.15 mmol) in DCM (1 mL) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 5 hrs. The reaction mixture was poured into ice-cooled saturated aq.NaHCO3 solution and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 30: 1 to 20: 1) to give the title compound (435 mg, 94.3% yield) as yellow solid. LC/MS (ESI) m/z: 400/402 (M+H)+. Step 6: ethyl 2-(l-(6-bromo-2-ethyl-4-fluoropyridin-3-yl)piperidin-3-yl)acetate id="p-309" id="p-309" id="p-309" id="p-309" id="p-309" id="p-309" id="p-309" id="p-309" id="p-309"

[0309]To a solution of ethyl 2-(l-(6-bromo-2-ethyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate (435 mg, 1.09 mmol) in DMF (5 mL) was added TBAF (5.43 mL, 5.43 mmol, IM in THE) and the reaction was stirred at 50 °C for 1 hr. The mixture was poured into ice-water and extracted with EtOAc (2x10 mL). The combined organic layers were washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 30: 1 to 20: 1) to give the title compound (220 mg, 54.2% yield) as yellow solid. LC/MS (ESI) m/z: 373/375 (M+H)+. Step 7: ethyl 2-(l-(2-ethyl-4-fluoro-6-(3-hydroxyprop-l-yn-l-yl)pyridin-3-yl)piperidin-3- yl)acetate id="p-310" id="p-310" id="p-310" id="p-310" id="p-310" id="p-310" id="p-310" id="p-310" id="p-310"

[0310]To a mixture of ethyl 2-(l-(6-bromo-2-ethyl-4-fluoropyridin-3-yl)piperidin-3-yl)acetate (220 mg, 0.59 mmol) and prop-2-yn-l-ol (0.10 mL, 1.77 mmol) in CH3CN (5 mL) was added TEA (0.25 mL, 1.77 mmol), Pd(PPh3)2C12 (41.4 mg, 0.059 mmol) and Cui (11.2 mg, 0.059 mmol) at °C under N2 atmosphere and the mixture was stirred under N2 atmosphere at 25 °C for 16 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc = 10: 1 to 2: 1) to give the title compound (167 mg, 81.3% yield) as yellow solid. LC/MS (ESI) m/z: 349 (M+H)+. Step 8: ethyl 2-(l-(2-ethyl-4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-311" id="p-311" id="p-311" id="p-311" id="p-311" id="p-311" id="p-311" id="p-311" id="p-311"

[0311]To a mixture of ethyl 2-(l-(2-ethyl-4-fluoro-6-(3-hydroxyprop-l-yn-l-yl)pyridin-3- yl)piperidin-3-yl)acetate (167 mg, 0.48 mmol) and TMSCH2N3 (0.14 mL, 0.96 mmol) in 1,4- dioxane (3 mL) were added Cp*RuCl(PPh3)2 (38 mg, 0.05 mmol) and Cui (9.1 mg, 0.05 mmol) under N2 atmosphere. The reaction mixture was degassed and stirred under N2 atmosphere at °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (mL) followed by the addition of TBAF (1.5 mL, 3 mmol, 2M in THF). The mixture was diluted 135 WO 2022/034568 PCT/IB2021/059266 with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (DCM: EtOAc = 100: 0 to 1: 1) to give the title compound (100 mg, 51.4% yield) as yellow oil. LC/MS (ESI) m/z: 406 (M+H)+. Step 9: ethyl 2-(l-(2-ethyl-4-fluoro-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-312" id="p-312" id="p-312" id="p-312" id="p-312" id="p-312" id="p-312" id="p-312" id="p-312"

[0312]To a solution of ethyl 2-(l-(2-ethyl-4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (40 mg, 0.099 mmol) in DCM (2 mL) was added TEA (0.10 mL, 0.719 mmol) and MsCl (0.05 mL, 0.646 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 30 min. The mixture was diluted with DCM (5 mL) and washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (50 mg, 100% yield), which was directly used to next step directly. LC/MS (ESI) m/z: 484 (M+H)+. Step 10: 2-(l-(2-ethyl-4-fluoro-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- 1,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid [0313]The title compound was prepared as the procedure described for the synthesis of Example 47.LC/MS (ESI) m/z: 497 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.69 - 7.62 (m, 2H), 7.48 - 7.30 (m, 1H), 6.53 - 6.49 (d, J = 9.2 Hz, 1H), 5.84 (s, 2H), 4.16 (s, 3H), 3.21 - 3.13 (m, 2H), 3.-2.98 (m, 4H), 2.31-2.28 (d, J = 7.0 Hz, 2H), 2.21 - 2.26 (m, 2H), 1.98- 1.88 (m, 1H), 1.80-1.(m, 2H)1.51-1.36 ״ (m, 4H), 1.32 - 1.26 (m, 3H), 0.80 - 0.75 (m, 3H). Example 49: (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid NH4OHDCM, 0°CStep 2 TFAA, PyDCM, 0°C^x^OTHPPd(PPh 3)2CI2, Cui, CH3CN, RTStep 4 SOCl285°CStep 1 Step 3 TMSCH2N392361-49-4, Cui,1,4-dioxane, RTStep 5 136 WO 2022/034568 PCT/IB2021/059266 Step 1: 3,6-dibromopicolinoyl chloride id="p-314" id="p-314" id="p-314" id="p-314" id="p-314" id="p-314" id="p-314" id="p-314" id="p-314"

[0314]A solution of 3,6-dibromopicolinic acid (1 g, 3.56 mmol) in SOC12(10 mL) was stirred at °C for 3 hrs. The reaction mixture was concentrated to dryness to give the title compound (1.g, 95.0% yield) as yellow oil, which was directly used in the next step. Step 2: 3,6-dibromopicolinamide [0315]To a solution of 3,6-dibromopyridine-2-carbonyl chloride (1 g, 3.34 mmol) in DCM (mL) was added drop-wisely NH4OH (10 mL) at 0 °C and the mixture was stirred at 0 °C for 1 hr. The mixture was poured into ice water and extracted with DCM (2x10 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (900 mg, 90% yield). 1HNMR (400 MHz, CDC13) 8 7.88 (d, J= 8.4Hz, 1H), 7.45 (d, J= 8.4Hz, 1H), 5.59 (s, 2H). LC/MS (ESI) m/z: 281 (M+H)+. Step 3: 3,6-dibromopicolinonitrile [0316]To a solution of 3,6-dibromopicolinamide (900 mg, 3.21 mmol) in DCM (10 mL) was added pyridine (1.3 mL, 16 mmol), followed by TFAA (1.25 mL, 9 mmol) at 0 °C and the mixture was stirred at this temperature for 1 hr. The mixture was poured into ice water and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (eluted with PE: EtOAc = 30: 1 to 5: 1) to give the title compound (650 mg, 77.2% yield) as white solid. 1HNMR (400 MHz, CDC13) 5 7.85 (d, J= 8.4 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H). Step 3: 3-bromo-6-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-l-yn-l-yl)picolinonitrile [0317]To a mixture of 3,6-dibromopicolinonitrile (2.3 g, 8.7 mmol ) and 2-(prop-2-yn-l- yloxy)oxane (1.5 g, 10.54 mmol) in MeCN (20 mL) was added TEA (3.7 mL, 26.34 mmol), Cui (84 mg, 0.44 mmol) and Pd(PPh3)2C12 (310 mg, 0.44 mmol ). The mixture was degassed under Natmosphere for three times and stirred under N2 atmosphere at room temperature for 16 hrs. The mixture was diluted with ice water and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 2: 1) to give the title compound (2.2 g, 54.4% yield) as yellow solid. 1H NMR (400 MHz, CDC13) 5 7.97 (d, J= 8.4 Hz, 1H), 7.48 (d, J= 8.4 Hz, 1H), 4.86 (t,J=3.2 Hz, 1H), 4.50 (q, J= 16.4 Hz, 2H), 3.93-3.81 (m, 1H), 3.62-3.51 (m, 1H), 1.91-1.72 (m, 2H), 1.75- 1.60 (m, 3H). LC (ESI) m/z: 238 (M+H-84)+. Step 4: 3-bromo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4- yl)picolinonitrile [0318]To a solution of 3-bromo-6-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-l-yn-l- yl)picolinonitrile (2.2 g, 6.85 mmol) in 1,4-dioxane (5 mL) were added 137 WO 2022/034568 PCT/IB2021/059266 (azidomethyl)trimethylsilane (1.1 g, 8.22 mmol), Cui (65 mg, 0.34 mmol), Cp*RuCl(PPh3)2 (2mg, 0.34 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (10 mL). TBAF (1.8 g, 13.7 mmol) was added to the above mixture and the resulting mixture was stirred at 0 °C for 10 min. The mixture was diluted with EtOAc (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by flash chromatography (PE: EtOAc = 4: 1) to give the title compound (1.6 g, 51.8% yield) as white solid. LC/MS (ESI) (m/z): 294 (M+H-84)+. Step 6: methyl 2-((3S)-l-(2-cyano-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0319]To a mixture of 3-bromo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH- l,2,3-triazol-4-yl)picolinonitrile (80 mg, 0.21 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3- yl)acetate (40.9 mg, 0.21 mmol) in 1,4-dioxane (7.5 mL) were added Cs2CO3 (137.8 mg, 0.mmol) , Ru-Phos Pd G3 (35 mg, 0.04 mmol), Ru-phos (20 mg, 0.04 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 110 °C overnight. The mixture was diluted with EtOAc (5 mL) and washed with water, brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 2: 1) to give the title compound (70 mg, 67.5% yield) as yellow solid. LC/MS (ESI) m/z: 491 (M+H)+. Step 7: methyl (S)-2-(l-(2-cyano-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0320]To a solution of methyl 2-((3S)-l-(2-cyano-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (70 mg, 0.14 mmol) in MeOH (5 mL) was added PPTS (72 mg, 0.28 mmol) and the mixture was stirred at °C for 16 hrs. The mixture was concentrated to dryness and the residue was purified by chromatography on silica gel (eluted with PE: EtOAc= 1: 1) to give the title compound (55 mg, 94.8% yield) as yellow solid. LC/MS (ESI) m/z: 407 (M+H)+. Step 8: methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0321]To a solution of methyl (S)-2-(l-(2-cyano-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (60 mg, 0.15 mmol ) in DCM (2 mL) was added TEA (0.06 mL, 0.44 mmol), followed by MsCl (25 mg, 0.22 mmol ) at 0 °C and the reaction mixture was stirred at 0 °C for 1 hr. The mixture was diluted with ice water and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous 138 WO 2022/034568 PCT/IB2021/059266 Na2SO4, filtered and concentrated to dryness give the title compound (65 mg, 90.8% yield) as yellow solid. LC/MS (ESI) m/z: 485 (M+H)+. Step 9: methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0322]To a mixture of methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (70 mg, 0.14 mmol) and 5- propylpyridin-2(lH)-one (20 mg, 0.14 mmol) in toluene (5 mL) and water (1 mL) was added K2CO3 (40 mg, 0.29 mmol) and TBAF (3.4 mg, cat.) and the mixture was stirred at 110 °C for 1.hrs. The reaction mixture was diluted with EtOAc (5 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (65 mg, 88.4% yield) as yellow solid. LC/MS (ESI) m/z: 526 (M+H)+. Step 10: (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid (12) [0323]To a solution of methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (35 mg, 0.0mmol) in MeOH (1 mL), water (1 mL) and THE (4 mL) was added LiOH (28 mg, 0.67 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl and extracted with EtOAc (3x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (20 mg, 58.7% yield) as white solid. 1H NMR (400 MHz, CD3OD) 5 8.21 (d, J = 9.2 Hz, 1H), 7.91 (d, J= 2.0 Hz, 1H), 7.80 (d, J= 9.2 Hz, 1H), 7.39 (dd, J= 9.2, 2.0 Hz, 1H), 6.(d, J=9.2Hz, 1H), 5.55 (s, 2H), 4.31 (s, 3H), 3.98-3.74 (m, 2H), 3.57-3.32 (m, 4H), 3.03-2.91 (m, 1H), 2.59-2.32 (m, 6H), 1.90-1.74 (m, 6H), 1.55-1.45 (m, 1H), 0.88 (t, J= 12, 3H). LC/MS (ESI) m/z: 512 (M+H)+. Example 50: (R)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- 1,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid Example 50 139 WO 2022/034568 PCT/IB2021/059266 id="p-324" id="p-324" id="p-324" id="p-324" id="p-324" id="p-324" id="p-324" id="p-324" id="p-324"

[0324]The title compound was prepared as the procedure described for the synthesis of example 49LC/MS (ESI) m/z: 476 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.17 - 8.14 (d, J = 8.9 Hz, 1H), 7.91 (s, 1H), 7.71 - 7.68 (d, J = 9.0 Hz, 1H), 7.41 - 7.37 (m, 1H), 6.42 - 6.39 (d, J = 9.2 Hz, 1H), 5.54 (s, 2H), 4.30 (s, 3H), 3.77 - 3.65 (m, 2H), 3.02 - 2.96 (m, 1H), 2.81 - 2.74 (m, 1H), 2.- 2.39 (m, 3H), 2.27 - 2.24 (m, 2H), 1.99 - 1.81 (m, 3H), 1.59 - 1.46 (m, 3H), 0.89 - 0.85 (m, 3H). Example 51: (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- 1,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid id="p-325" id="p-325" id="p-325" id="p-325" id="p-325" id="p-325" id="p-325" id="p-325" id="p-325"

[0325]The title compound was prepared as the procedure described for the synthesis of example 49LC/MS (ESI) m/z: 476 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.21 (d, J= 9.2 Hz, 1H), 7.(d, J= 2.0 Hz, 1H), 7.80 (d, J = 9.2 Hz, 1H), 7.39 (dd,J= 9.2, 2.0 Hz, 1H), 6.41 (d, J = 9.2 Hz, 1H), 5.55 (s, 2H), 4.31 (s, 3H), 3.98 - 3.74 (m, 2H), 3.57 - 3.32 (m, 4H), 3.03 - 2.91 (m, 1H), 2.- 2.32 (m, 6H), 1.90 - 1.74 (m, 6H), 1.55 - 1.45 (m, 1H), 0.88 (t, J= 12, 3H). Example 52 and 53: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic aci and (S) or (R)-2- (l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic acid Step 3Cs2CO3, Cui dioxane,110 °C =xample 52 ana 50 Stereochemisry not assigned 140 WO 2022/034568 PCT/IB2021/059266 Step 1: (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate [0326]To a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol (1 g, 2.91 mmol) in DCM (10 mL) were added TEA (590 mg, 5.8 mmol) followed by drop-wise addition of MsCl (0.40 g, 3.49 mmol) at 0 °C, and the mixture was stirred at 0 °C for 2 hrs. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (1.27 g, 103.5% yield) as yellow oil, which was used in next step directly. LC/MS (ESI) m/z: 423 (M+H)+. Step 2: l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- propylpyridin-2(lH)-one [0327]To a mixture of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate (1.27 g, 3.01 mmol) and 5-propylpyridin-2(lH)-one (0.54 g, 3.91 mmol) in toluene (15 mL) and water (3 mL) were added K2CO3 (1.25 g, 9.02 mmol), TBAF (80 mg, 0.mmol) and the mixture was stirred at 100 °C for 16 hrs. The mixture was diluted EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 1: 1) to give the title compound (1.06 g, 76.1% yield) as yellow solid. LC/MS (ESI) m/z: 464 (M+H)+. Step 3: ethyl (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetate and ethyl (S)-2-(l-(2-ethyl-6-(l- methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2- oxopiperidin-3-yl)acetate [0328]To a mixture of l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-5-propylpyridin-2(lH)-one (120 mg, 0.26 mmol) and ethyl 2-(2-oxopiperidin-3- yl)acetate (48 mg, 0.26 mmol) in 1,4-dioxane (3 mL) was added Cs2CO3 (253 mg, 0.78 mmol), N1,N2-dimethylethane-l,2-diamine (2.3 mg, 0.026 mmol), Cui (9.9 mg, 0.052 mmol) under Natmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chiral SEC to give arbitrarily assigned: ethyl (R)-2-(l-(2-ethyl-6-(l- methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2- oxopiperi din-3-yl)acetate (Peak 1, retention time: 6.782 min) (37 mg, yield 27.4%) and ethyl (S)- 2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyri din-l(2H)-yl)methyl)-lH- 1,2,3-tri azol-4- yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetate (Peak 2, retention time: 7.367 min) (37 mg, yield 27.4%) as white solid. LC/MS (ESI) m/z: 521 (M+H)+. SFC Instrument: Waters Thar preparative SFC, Column: ChiralPak IA, 250x21. 2mm I.D., 5pm, Mobile phase: A for CO2 and B 141 WO 2022/034568 PCT/IB2021/059266 for MEOH+0.1%NH3H2O, Gradient: B 35%, Flow rate: 50mL /min, Column temperature: 35 °C, Wavelength: 220nm. Step 4: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic acid [0329]To a solution of ethyl (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetate (37 mg, 0.071 mmol) in THF (2 mL), MeOH (0.5 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (30 mg, 0.71 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water. The mixture was washed with EtOAc (2x3 mL) and the aqueous layer was acidified with IN aq.HCl to pH = 3 and extracted with EtOAc (3x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (14.7 mg, 42.0% yield) as white solid. LC/MS (ESI) m/z: 493 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.03 (dd, J = 8.2, 1.9 Hz, 1H), 7.76-7.65 (m, 1H), 7.41 (dd, J = 9.3, 2.5 Hz, 1H), 6.55 (d, =9.2 Hz, 1H), 5.(s, 1H), 4.14 (s, 1H), 3.82-3.46 (m, 1H), 2.88-2.68 (m, 2H), 2.27-2.22 (m, 1H), 2.15-1.96 (m, 1H), 1.47-1.36 (m, 1H), 1.31-1.25 (m, 1H), 0.79 (t, J = 7.2 Hz, 1H). Example 53: (S) or (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic acid [0330]The title compound was prepared according to the procedure described for the synthesis of example 53. LC/MS (ESI) m/z: 493 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.03 (dd, J= 8.3, 1.Hz, 1H), 7.77 - 7.64 (m, 2H), 7.41 (dd, J= 9.2, 2.5 Hz, 1H), 6.55 (d, J= 9.2 Hz, 1H), 5.91 (s, 2H), 4.14 (s, 3H), 3.81 - 3.46 (m, 2H), 2.89-2.70 (m, 5H), 2.25 (t, J= 7.6 Hz, 2H), 2.16-1.93 (m, 4H), 1.47 - 1.37 (m, 2H), 1.31-1.25 (m, 3H), 0.79 (t, J =7.2 Hz, 3H). Example 54 and 55: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid and (S) or (R)- 2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid 142 WO 2022/034568 PCT/IB2021/059266 ^oc NalO4, RuO2EtOAc/H 2OStep 2 (Boc)2OTEA, DCMStep 1 Example 54 and 55 Stereochemisry not assigned Step 1: tert-butyl 3-(2-ethoxy-2-oxoethyl)piperidine-l-carboxylate [0331]To a mixture of ethyl 2-(piperidin-3-yl)acetate (1 g, 5.8 mmol) in DCM (25 mL) and di- tert-butyl dicarbonate (1.9 mL, 8.8 mmol) was added TEA (1.6 mL, 11.7 mmol) at 0 °C and the mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness and the residue was purified by flash chromatography (0 ~ 20% EtOAc in PE) to give the title compound (1.3 g, 82.3% yield) as yellow oil. LC-MS (ESI) m/z 272 (M+H)+. Step 2: tert-butyl 5-(2-ethoxy-2-oxoethyl)-2-oxopiperidine-l-carboxylate [0332]To solution of tert-butyl 3-(2-ethoxy-2-oxoethyl)piperidine-l-carboxylate (1.3 g, 4.mmol) in EtOAc (10 mL) was added a solution of NaIO4 (5.1 g, 24.0 mmol) in H2O (mL) followed by Ruthenium(IV) oxide hydrate (70 mg, 0.45 mmol) at 0 °C and the reaction mixture was stirred at r.t. for 2 hrs. The reaction mixture was filtered through a celite pad and the filter cake was washed with EtOAc (2x5 mL). The filtrate was washed with saturated aq.Na2SO3 solution and brine, dried over anhydrous Na2SO4, filtered andwas concentrated to dryness. The residue was purified by flash chromatography (0 ~ 30% EtOAc in PE) to give the title compound (1.1 g, 80.1% yield) as yellow oil. LC-MS (ESI) m/z 2(M+H)+. Step 3: ethyl 2-(6-oxopiperidin-3-yl)acetate [0333]To a solution of tert-butyl 5-(2-ethoxy-2-oxoethyl)-2-oxopiperidine-l-carboxylate (1.1 g, 3.9 mmol) in 1,4-dioxane (5 mL) was added HCl/l,4-dioxane (4.8 mL, 4M) at 0 °C and the reaction mixture was stirred at r.t. for 1 hr. The mixture was concentrated to dryness and the residue was basified with saturated aq.NaHCO3 solution. The mixture was extracted with EtOAc (2x10 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (640 mg, 89.6% yield) as yellow syrup. LC-MS (ESI) m/z 186 (M+H)+. 143 WO 2022/034568 PCT/IB2021/059266 Step 4: ethyl (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetate and ethyl (S)-2-(l-(2-ethyl-6-(l- methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-6- oxopiperidin-3-yl)acetate id="p-334" id="p-334" id="p-334" id="p-334" id="p-334" id="p-334" id="p-334" id="p-334" id="p-334"

[0334]To a solution of l-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-5-propyl-l,2-dihydropyridin-2-one (250 mg, 0.5 mmol) in 1,4-dioxane (10 mL) were added ethyl 2-(6-oxopiperidin-3-yl)acetate (150 mg, 0.8 mmol) followed by the addition of Cs2CO3 (527 mg, 1.6 mmol), Cui (21 mg, 0.11 mmol) and N1,N2-dimethylethane-l,2-diamine (15 mg, 0.11 mmol) and the reaction mixture was stirred at 120 °C forl6 hrs. The mixture was filtered through a Celite pad and the filter cake was washed with EtOAc (10 mL). The filtrate was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) and further separated by chiral SEC to give arbitrarily assigned: ethyl 2-[(3R)-l-(2-ethyl-6-{l-methyl-5-[(2-oxo-5-propyl- l,2-dihydropyridin-l-yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)-6-oxopiperidin-3-yl]acetate (peak 1 retention time: 4.123 min) (35 mg, 9.2% yield) and ethyl 2-[(3S)-l-(2-ethyl-6-{l-methyl- 5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)-6- oxopiperi din-3-yl]acetate (peak 2, retention time:4.669 min) (40 mg, 10.3% yield) as white solid. LC-MS (ESI) m/z 521 (M+H)+. SFC condition: Column: ChiralPak IA, 250x21. 2mm I.D., 5pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 30%; Flow rate: mL /min; Column temperature: 35 °C. Step 5: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid [0335]To solution of ethyl 2-[(3R)-l-(2-ethyl-6-{l-methyl-5-[(2-oxo-5-propyl-l,2- dihydropyridin-l-yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)-6-oxopiperidin-3-yl]acetate (mg, 0.06 mmol) in THE (4 mL) and MeOH (1 mL) was added LiOH (28 mg, 0.7 mmol) in H2O (1 mL) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was concentrated to dryness and the residue was diluted with water (5 mL) and washed with EtOAc (2x3 mL) twice. The aqueous layer was acidified with IN aq.HCl to pH ~3 and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (C18, 0 ~ 90 % acetonitrile in H2O with 0.1 % formic acid) to give the title compound (7 mg, 21.2% yield) as white solid. LC- MS (ESI) m/z 493 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.06 - 8.03 (m, 1H), 7.78 - 7.71 (m, 1H), 7.66 - 7.65 (t, J= 2.6 Hz, 1H), 7.442 - 7.29 (dd, J= 9.3, 2.5 Hz, 1H), 6.55 (d, J= 9.3 Hz, 1H), 5.91 (d, J= 1.8 Hz, 2H), 4.15 (s, 3H), 3.87 - 3.41 (m, 2H), 2.81 - 2.67 (m, 3H), 2.62 - 2. 144 WO 2022/034568 PCT/IB2021/059266 (m, 1H), 2.45 - 2.43 (m, 2H), 2.35 - 2.32 (m, 1H), 2.26 - 2.22 (t, J= 7.5 Hz, 2H), 2.20 - 2.09 (m, 1H), 1.89 - 1.78 (m, 1H), 1.47 - 1.36 (m, 2H), 1.32 - 1.26 (q, J= 7.6 Hz, 3H), 0.80 - 0.77 (t, J= Hz, 3H). Example 55: (S) or (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid [0336]The title compound was prepared according to the procedure described for the synthesis of Example 54.1HNMR (400 MHz, CD3OD) 5 7.98 - 7.91 (m, 1H), 7.67 - 7.60 (m, 1H), 7.56 (t, J= 2.6 Hz, 1H), 7.34 -7.27 (m, 1H), 6.45 (d, J= 9.3 Hz, 1H), 5.81 (d, J= 1.7 Hz, 2H), 4.05 (s, 3H), 3.76 - 3.34 (m, 2H), 2.72 - 2.58 (m, 3H), 2.53 - 2.39 (m, 1H), 2.39 - 2.32 (m, 2H), 2.28 - 2.18 (m, 1H), 2.15 (t,J=7.5Hz, 2H), 2.06 (d, J= 13.6 Hz, 1H), 1.82- 1.65 (m, 1H), 1.38 - 1.(m, 2H), 1.19 (q, J= 7.6 Hz, 3H), 0.69 (t, J= 13 Hz, 3H). LC/MS (ESI) m/z: 493 (M+H)+. Example 56: (R)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetic acid Step 1: 3-(5-bromopyrazin-2-yl)prop-2-yn-l-ol [0337]To a solution of 2,5-dibromopyrazine (1.6 g, 6.73 mmol) and prop-2-yn-l-ol (0.38 g, 6.mmol) in MeCN (16 mL) were added TEA (2.0 g, 20.18 mmol), Cui (30 mg, 0.14 mmol), Pd(PPh3)2C12 (90 mg, 0.14 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 25 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2x15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (453 mg, 31.6% yield) as yellow solid. LC/MS (ESI) m/z: 213/ 215 (M+H)+. Step 2: (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol id="p-338" id="p-338" id="p-338" id="p-338" id="p-338" id="p-338" id="p-338" id="p-338" id="p-338"

[0338]To a solution of 3-(5-bromopyrazin-2-yl)prop-2-yn-l-ol (453 mg, 2.13 mmol) and TMSCH2N3 (493.76 mg, 3.83 mmol) in 1,4-dioxane (5 mL) were added Cui (20.3 mg, 0. 145 WO 2022/034568 PCT/IB2021/059266 mmol), chloro(pentamethylcyclopentadienyl)bis(triphenylphosphine)ruthenium(II) (84.7 mg, 0.11 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (5 mL). TBAF (1 M in THF, 4.3 mL) was added and the resulting mixture was stirred at 25 °C for 1 hr. The mixture was diluted with water (10 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (205 mg, 35.7% yield) as yellow solid. LC/MS (ESI) m/z: 270/ 272 (M+H)+. Step 3: (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate id="p-339" id="p-339" id="p-339" id="p-339" id="p-339" id="p-339" id="p-339" id="p-339" id="p-339"

[0339]To a solution of (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol (2mg, 0.76 mmol) in DCM (2 mL) were added TEA (230.4 mg, 2.28 mmol) and MsCl (104.3 mg, 0.91 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 0 °C for 2 hrs. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (295 mg, 111.6% yield) as yellow solid, which was used in next step directly. LC/MS (ESI) m/z: 348/ 350 (M+H)+. Step 4: l-((4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- propylpyridin-2(lH)-one [0340]To a solution of (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate (295 mg, 0.85 mmol) and 5-propylpyridin-2(lH)-one (174.3 mg, 1.27 mmol ) in toluene (5 mL) and H2O (1 mL) were added K2CO3 (351 mg, 2.54 mmol), TBAF (22 mg, 0.085 mmol) at r.t. under N2 atmosphere and the mixture was stirred at 100 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 2: 1) to give the title compound 6 (130 mg, 39.4% yield) as yellow solid. LC/MS (ESI) m/z: 389/ 391 (M+H)+. Step 5: methyl (S)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetate [0341]To a solution of l-((4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- propylpyridin-2(lH)-one (30 mg, 0.077 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3- yl)acetate (14.9 mg, 0.077 mmol) in 1,4-dioxane (2 mL) were added Cs2CO3 (49 mg, 0.mmol), Ru-Phos Pd G3 (13 mg, 0.015 mmol), Ru-Phos (7.2 mg, 0.015 mmol) under N 146 WO 2022/034568 PCT/IB2021/059266 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (30 mg, 77.6% yield) as white solid, which was used in next step directly. LC/MS (ESI) m/z: 502 (M+H)+. Step 6: (S)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- 1,2,3-tr iazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetic acid [0342]To a solution of methyl (S)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetate (30 mg, 0.06 mmol) in THE (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (25 mg, 0.60 mmol) at °C. The reaction was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc (2x3 mL) and the aqueous layer was acidified with IN aq.HCl to pH = 4 and extracted with EtOAc (3x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (CIS, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (3.6 mg, 12.3% yield) as white solid. LC/MS (ESI) m/z: 488 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.68 (s, 1H), 8.41 (s, 1H), 7.71 (d, J= 2.4 Hz, 1H), 131 (dd, J= 12.0, 2.6 Hz, 1H), 6.43 (d, J= 9.6 Hz, 1H), 5.60 (s, 2H), 4.25 (s, 4H), 3.29 - 3.19 (m, 3H), 3.02- 2.91 (m, 1H), 2.40 - 2.27 (m, 7H), 1.91 - 1.75 (m, 1H), 1.49 - 1.40 (m, 2H), 0.86 - 0.78 (m, 3H). Example 57: 2-(l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol- 4-yl)pyrazin-2-yl)piperidin-3-yl)acetic acid Example 57 id="p-343" id="p-343" id="p-343" id="p-343" id="p-343" id="p-343" id="p-343" id="p-343" id="p-343"

[0343]The title compound was prepared according to the procedure described for the synthesis of example 56LC/MS (ESI) m/z: 452 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.63 (d, J= 1.Hz, 1H), 8.30 (s, 1H), 7.70 (d, J= 2.0 Hz, 1H), 7.35 (dd, J= 9.2 Hz, d, J= 2.8 Hz, 1H), 6.44 (d, J = 9.2 Hz, 1H), 5.59 (s, 2H), 4.47 - 4.41 (m, 2H), 4.24 (s, 3H), 3.02 - 2.95 (m, 2H), 2.34 - 2.24 (m, 147 WO 2022/034568 PCT/IB2021/059266 4H), 2.11 -2.02 (m, 1H), 1.93 - 1.84 (m, 2H), 1.51-1.40 (m, 2H), 1.36 - 1.24 (m, 2H), 0.83 (d, J = 7.2 Hz, 3H). Example 58: 2-[(3R)-l-(6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]- lH-l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetic acid Step 1: 3,6-dibromo-2-(trifluoromethyl)pyridine id="p-344" id="p-344" id="p-344" id="p-344" id="p-344" id="p-344" id="p-344" id="p-344" id="p-344"

[0344]To a solution of 5-bromo-6-(trifluoromethyl)pyridin-2-amine (1.01 g, 4.14 mmol) in aq.HBr (1.34 g, 16.59 mmol, 40% wt) was added Br2 (0.59 mL, 11.61 mmol), NaNO2 (0.72 g, 10.37 mmol) in water (10 mL) at 0 °C, and the mixture was stirred at 0 °C for 1 hr. The reaction mixture was diluted with EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-10% EtOAc in PE) to give the title compound (720 mg, 56.9% yield) as white solid. 1HNMR (400 MHz, DMSO) 5 8.34 (d, J= 8.4 Hz, 1H), 7.95 (d, J= 8.4 Hz, 1H). Step 2: 3-bromo-6-[3-(oxan-2-yloxy)prop-l-yn-l-yl]-2-(trifluoromethyl)pyridine id="p-345" id="p-345" id="p-345" id="p-345" id="p-345" id="p-345" id="p-345" id="p-345" id="p-345"

[0345]To a solution of 3,6-dibromo-2-(trifluoromethyl)pyridine (720 mg, 2.36 mmol) in acetonitrile (10 mL) was added 2-(prop-2-yn-l-yloxy)oxane (397 mg, 2.83 mmol), Cui (22 mg, 0.11 mmol), triethylamine (0.98 mL, 7.08 mmol), Pd(PPh3)2C12 (83 mg, 0.11 mmol), and the mixture was degassed under N2 for 3 times and stirred at 25 °C for 16 hrs. The reaction mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0- 20% EtOAc in PE) to give the title compound (696 mg, 80.9% yield) as yellow oil. LC/MS (ESI) 148 WO 2022/034568 PCT/IB2021/059266 m/z: 364 (M+H)+. 1H NMR (400 MHz, DMSO-A) 5 8.42 (d, J= 8.4 Hz, 1H), 7.78 (d, J= 8.3 Hz, 1H), 4.82 (d, J= 3.2 Hz, 1H), 4.59 - 4.43 (m, 2H), 3.81-3.72 (m, 1H), 3.53 - 3.46 (m, 1H), 1.74 - 1.63 (m, 2H), 1.56 - 1.47 (m, 4H). Step 3: 3-bromo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4- yl)-2-(trifluoromethyl)pyridine id="p-346" id="p-346" id="p-346" id="p-346" id="p-346" id="p-346" id="p-346" id="p-346" id="p-346"

[0346]To a solution of 3-bromo-6-[3-(oxan-2-yloxy)prop-l-yn-l-yl]-2-(trifluoromethyl)pyridine (696 mg, 1.91 mmol) in 1,4-dioxane (7 mL) was added TMSCH2N3 (246 mg, 1.91 mmol), Cui (18 mg, 0.096 mmol), pentamethylcyclopentadienylbis(triphenylphosphine)ruthenium(II) chloride (76 mg, 0.096 mmol), and the mixture was degassed under N2 for three times and stirred at 50 °C for 16 hrs. Then the reaction mixture was concentrated to dryness and the residue was dissolved in THF (7 mL). TBAF (1.49 g, 5.73 mmol) was added to the mixture and the resulting mixture was stirred at r.t. for 1 hr. The mixture was diluted with EtOAc (10 mL), washed with saturated aq.NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-60% EtOAc in PE) to give the title compound (306 mg, 38.0% yield) as white solid. 1H NMR (400 MHz, DMSO-da) 8.52 (d, J= 8.5 Hz, 1H), 8.30 (d, J= 8.5 Hz, 1H), 5.36 (d, J= 12.5 Hz, 1H), 5.19 (d, J= 12.5 Hz, 1H), 4.77-4.72 (m, 1H), 4.18 (s, 3H), 3.77 - 3.68 (m, 1H), 3.46 - 3.41 (m, 1H), 1.73-1.61 (m, 2H), 1.57- 1.44 (m, 4H). Step 4: ethyl 2-((3R)-l-(6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate id="p-347" id="p-347" id="p-347" id="p-347" id="p-347" id="p-347" id="p-347" id="p-347" id="p-347"

[0347]To a solution of 3-bromo-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol-4-yl}- 2-(trifluoromethyl)pyridine (180 mg, 0.42 mmol) in 1,4-dioxane (5 mL) was added Cs2CO3 (4mg, 1.28 mmol), ethyl 2-[(3R)-piperidin-3-yl]acetate (73 mg, 0.42 mmol), RuPhos Pd G3 (mg, 0.085 mmol), RuPhos (40 mg, 0.085 mmol) and the mixture was degassed under N2 for times and stirred at 120 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-60% EtOAc in PE) to give the title compound (125 mg, 57.2% yield) as yellow solid. LC/MS (ESI) m/z: 512 (M+H)+. Step 5: ethyl (R)-2-(l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- (trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate [0348]To a solution of ethyl 2-[(3S)-l-(6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate (125 mg, 0.24 mmol) in MeOH (mL) was added PPTS (184 mg, 0.73 mmol) and the mixture was stirred at 60 °C for 2 hrs. The reaction mixture was concentrated to dryness and the residue was diluted with DCM (10 mL), 149 WO 2022/034568 PCT/IB2021/059266 washed with saturated aq. NH4C1 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-80% EtOAc in PE) to give the title compound (102 mg, 97.7% yield) as yellow solid. LC/MS (ESI) m/z: 428 (M+H)+. Step 6: ethyl (R)-2-(l-(6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)-2- (trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate [0349]To a solution of ethyl 2-[(3R)-l-{6-[5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl]- 2-(trifluoromethyl)pyridin-3-yl}piperidin-3-yl]acetate (50 mg, 0.11 mmol) in DCM (3 mL) was added TEA (0.081 mL, 0.58 mmol), MsCl (0.011 mL, 0.14 mmol), and then the mixture was stirred at 0 °C for 30 mins. The reaction mixture was diluted with DCM (5 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to the title compound (62 mg, 94.4% yield) as yellow oil. LC/MS (ESI) m/z: 506 (M+H)+. Step 7: ethyl 2-[(3R)-l-(6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]- lH-l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate id="p-350" id="p-350" id="p-350" id="p-350" id="p-350" id="p-350" id="p-350" id="p-350" id="p-350"

[0350]To a solution of ethyl 2-[(3S)-l-(6-{5-[(methanesulfonyloxy)methyl]-l-methyl-lH-l,2,3- triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate (62 mg, 0.12 mmol) in toluene (5 mL) and water (1 mL) was added 5-propyl-l,2-dihydropyridin-2-one (34 mg, 0.mmol), K2CO3 (51 mg, 0.36 mmol), and then the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (71 mg, 95.1% yield) as yellow solid. LC/MS (ESI) m/z: 547 (M+H)+. Step 8: 2-[(3R)-l-(6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]-lH- l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetic acid id="p-351" id="p-351" id="p-351" id="p-351" id="p-351" id="p-351" id="p-351" id="p-351" id="p-351"

[0351]To a solution of ethyl 2-[(3R)-l-(6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l- yl)methyl]-lH-l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate (69 mg, 0.12 mmol) in THE (2 mL) was added MeOH (0.5 mL), water (0.5 mL), LiOH (30 mg, 1.mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was acidified with IN aq.HCl and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (28 mg, 42.8% yield) as white solid. LC/MS (ESI) m/z: 519 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.27 (d, J= 8.6 Hz, 1H), 8.01 (d, J= 8.6 Hz, 1H), 7.73 (d, J= 2.1 Hz, 1H), 7.40 - 7.35 (m, 1H), 6.49 (d, J= 9.2 Hz, 1H), 5.76 (s, 2H), 4.22 (s, 3H), 3.23-3.18 (m, 1H), 3.11 - 3.05 (m, 1H), 2.88 - 2.80 (m, 1H), 2.66 - 2.59 (m, 1H), 2.35 - 2.28 150 WO 2022/034568 PCT/IB2021/059266 (m, 2H), 2.27 - 2.19 (m, 3H), 1.94- 1.72 (m, 3H), 1.43 - 1.33 (m, 2H), 1.31-1.20 (m, 1H), 0.(t,J = 7.3Hz, 3H). Example 59: (R)-2-(l-(6-(5-((5-cyclopropyl-2-oxopyridin-l(2H)-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid Example 59 The title compound was prepared according to the procedure described for the synthesis of example 58.LC/MS (ESI) m/z: 519 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.29 (d, J= 8.5 Hz, 1H), 8.04 (d, J= 8.7 Hz, 1H), 7.74 - 7.71 (m, 1H), 7.31 - 7.26 (m, 1H), 6.49 (d, J= 9.3 Hz, 1H), 5.79 (s, 2H), 4.22 (s, 3H), 3.26 - 3.22 (m, 1H), 3.16 - 3.10 (m, 1H), 2.90 - 2.84 (m, 1H), 2.68 - 2.62 (m, 1H), 2.35 - 2.30 (m, 2H), 2.28 - 2.21 (m, 1H), 1.96 - 1.89 (m, 1H), 1.85 - 1.76 (m, 2H), 1.64 - 1.56 (m, 1H), 1.33 - 1.24 (m, 1H), 0.80 - 0.74 (m, 2H), 0.37 - 0.31 (m, 2H).

Example 60: (R)-2-(l-(2-(difluoromethyl)-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid 1,4-dioxane, waterStep 1 THPOPAST PCM Step 2Step 3Pd(PPh 3)2CITEA, Gul CH3CN Step 1: 3,6-dibromopicolinaldehyde [0352]To a solution of 3,6-dibromo-2-methylpyridine (2 g, 7.9 mmol) in 1,4-dioxane (20 mL)was added SeO2 (3.54 g, 31.9 mmol) and H2O (0.5 mL) the mixture was stirred at 120 °C for 151 WO 2022/034568 PCT/IB2021/059266 hrs. The mixture was diluted with ice water (10 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 10: 1) to give the title compound (1.2 g, 56.8% yield) as white solid. LC/MS (ESI) (m/z): 2(M+H)+. 1HNMR (400 MHz, CDCI3) 5 10.09 (s, 1H), 7.87 (d, J= 8.4 Hz, 1H), 7.54 (d, J= 8.Hz, 1H). Step 2: 3,6-dibromo-2-(difluoromethyl)pyridine [0353]To a solution of 3,6-dibromopyridine-2-carbaldehyde (500 mg, 1.8 mmol) in DCM (mL) was added DAST (0.6 mL, 4.7 mmol) at 0 °C and the mixture was stirred at 25 °C for 1 hr. The mixture was diluted with DCM (10 mL) and washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 10: 1) to give the title compound (4mg, 73.8% yield) as white solid. LC/MS (ESI) (m/z): 288 (M+H)+1HNMR (400 MHz, CDC13) 7.81 (d, J= 8.4 Hz, 1H), 7.49 (d, J= 8.4 Hz, 1H), 6.80 (t, J = 53.6 Hz, 1H) Step 3: 3-bromo-2-(difluoromethyl)-6-[3-(oxan-2 yloxy)prop-l-yn-l-yl]pyridine [0354]To a mixture of 3,6-dibromo-2-(difluoromethyl)pyridine (400 mg, 1.3 mmol) and (prop- 2-yn-l-yloxy)tetrahydro-2H-pyran (195 mg, 1.3 mmol) in MeCN (10 mL) was added TEA (4mg, 4.1 mmol), Cui (13.2 mg, 0.07 mmol) and Pd(PPh3)2C12 (49 mg, 0.07 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at r.t. overnight. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 2: 1) to give the title compound (400 mg, 82.9% yield) as yellow solid. 1H NMR (400 MHz, CDC13) 5 7.92 (s, 1H), 7.40 (t, J= 7.8 Hz, 1H), 6.(s, 1H), 4.87 (t,J= 3.3 Hz, 1H),4.50(d,J= 11.6 Hz, 2H), 3.89 - 3.80 (m, 1H), 3.59 - 3.52 (m, 1H), 1.88 - 1.58 (m, 6H). Step 4: 3-bromo-2-(difluoromethyl)-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine [0355]To a solution of 3-bromo-2-(difluoromethyl)-6-[3-(oxan-2-yloxy)prop-l-yn-l-yl]pyridine (1.5 g, 4.3 mmol) in 1,4-dioxane (10 mL) were added (azidomethyl)trimethylsilane (0.56 g, 4.mmol), Cui (0.007 mL, 0.2 mmol) , Cp*RuCl(PPh3)2 (0.17 g, 0.2 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 50 °C for hrs. The mixture was concentrated to dryness and the residue was dissolved in THE (10 mL).TBAF (1.8 g, 13.7 mmol) was added to the above mixture and the resulting mixture was stirred at °C for 10 mins. The mixture was diluted with EtOAc (10 mL) and washed with water, brine, 152 WO 2022/034568 PCT/IB2021/059266 dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 4: 1) to give the title compound (1.25 g, 71.5% yield) as white solid. LC/MS (ESI) (m/z): 403 (M+H)+1H NMR (400 MHz, CDC13) 5 8.21 (d, J= 8.5 Hz, 1H), 8.00 (t, J= 10.1 Hz, 1H), 7.06 - 6.79 (m, 1H), 5.38 - 5.25 (m, 2H), 4.76 (t, J = 3.4 Hz, 1H), 4.17 (s, 3H), 3.88 - 3.75 (m, 1H), 3.51 (dd, J= 10.9, 4.9 Hz, 1H), 1.83 - 1.68 (m, 3H), 1.51 (d, J = 4.9 Hz, 2H). Step 5: ethyl 2-[(3R)-l-[2-(difluoromethyl)-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3- triazol-4-yl}pyridin-3-yl] piperidin-3-yl] acetate [0356]To a mixture of 3-bromo-2-(difluoromethyl)-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH- l,2,3-triazol-4-yl}pyridine(100 mg, 0.24 mmol) and ethyl 2-[(3R)-piperidin-3-yl]acetate (42 mg, 0.248 mmol) in 1,4-dioxane (7.5 mL) were added Cs:CO3 (242 mg, 0.74 mmol) , Ru-Phos Pd G(42 mg, 0.04 mmol), Ru-phos (23 mg, 0.04 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 4: 1) to give the title compound (100 mg, 81.6% yield). LC/MS (ESI) m/z: 494 (M+H)+. Step 6: ethyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate [0357]To a solution of ethyl give ethyl 2-[(3R)-l-[2-(difluoromethyl)-6-{l-methyl-5-[(oxan-2- yloxy)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl]piperidin-3-yl]acetate (80 mg, 0.162 mmol) in MeOH (10 mL) was added PPTS (203 mg, 0.810 mmol) and the mixture was stirred at 50 °C for hrs. The mixture was concentrated to dryness and the residue was purified by chromatography on silica gel (eluted with PE: EtOAc= 1: 1) to give the title compound (65 mg, 97% yield). LC/MS (ESI) m/z: 410 (M+H)+. Step 7: ethyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate [0358]To a solution of ethyl 2-[(3R)-l-[2-(difluoromethyl)-6-[5-(hydroxymethyl)-l-methyl-1H- l,2,3-triazol-4-yl]pyridin-3-yl]piperidin-3-yl]acetate (65 mg, 0.159 mmol) in DCM (10 mL) was added TEA (0.1 mL, 0.4 mmol) followed by MsCl (0.1 mL, 0.2 mmol) at 0 °C and the reaction mixture was stirred at 0 °C for 1 hr. The mixture was diluted with ice water and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness give the title compound (70 mg, 90% yield) as yellow solid. LC/MS (ESI) m/z: 488 (M+H)+. Step 8: [(3R)-l-[2-(difluoromethyl)-6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l- yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl]piperidin-3-yl]acetate 153 WO 2022/034568 PCT/IB2021/059266 id="p-359" id="p-359" id="p-359" id="p-359" id="p-359" id="p-359" id="p-359" id="p-359" id="p-359"

[0359]To a mixture of 2-{4-[6-(difluoromethyl)-5-[(3R)-3-(2-ethoxy-2-oxoethyl)piperidin-l- yl]pyridin-2-yl]-l-methyl-lH-l,2,3-triazol-5-yl}ethane-l-sulfonic acid (60 mg, 0.1 mmol) and 5- propylpyridin-2-ol (17 mg, 0.1 mmol) in toluene (5 mL) and water (1 mL) was added K2CO3 (mg, 0.3 mmol) and TBAF (0.6 mg, 0.002 mmol) and the mixture was stirred at 110 °C for 1.hrs. The reaction mixture was diluted with EtOAc (5 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (60 mg, 92.2% yield) as yellow solid. LC/MS (ESI) m/z: 529 (M+H)+. Step 9: 2-[(3R)-l-[2-(difluoromethyl)-6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l- yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl]piperidin-3-yl]acetic acid [0360]To a solution of 2-{4-[6-(difluoromethyl)-5-[(3R)-3-(2-ethoxy-2-oxoethyl)piperidin-l- yl]pyridin-2-yl]-l-methyl-lH-l,2,3-triazol-5-yl}ethane-l-sulfonic acid (65 mg, 0.13 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (5.5 mg, 0.13 mmol) and the mixture was stirred at 25 °C for 1.5 hrs. The reaction mixture was acidified with IM aq.HCl to pH=4 and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep- HPLC to give the title compound (30 mg, 44.9% yield) as white solid. LC/MS (ESI) m/z: 5(M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.15 (d, J = 8.7 Hz, 1H), 8.00 (d, J= 2.0 Hz, 1H), 7.(d, J= 8.6 Hz, 1H), 131 (dd, J= 9.2, 2.4 Hz, 1H), 7.20 (t, J= 54.4 Hz, 1H), 6.48 (d, J= 9.2 Hz, 1H), 5.78 (s, 2H), 4.26 (s, 3H), 3.23 (d, J= 11.5 Hz, 1H), 3.12 (d, J= 10.8 Hz, 1H), 2.89-2.(m, 1H), 2.65 -2.57 (m, 1H), 2.25 (dd, J=20.7, 13.4 Hz, 5H), 1.96- 1.80 (m, 3H), 1.37 (dd, J= 14.9, 7.4 Hz, 2H), 1.31-1.22 (m, 1H), 0.75 (t, J= 13 Hz, 3H). Example 61: 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-3-methyl-2-oxoimidazolidin-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetic acid 154 WO 2022/034568 PCT/IB2021/059266 Example 61 Step 1: (4S)-l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-4- (cyclopropylmethyl)-3-methylimidazolidin-2-one [0361]To a mixture of 3-bromo-6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2- ethylpyridine (140 mg, 0.39 mmol) and (5S)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one (90 mg, 0.58 mmol) in DMF (10 mL) was added NaH (47 mg, 1.17 mmol, 60% dispersion in mineral oil) at 0 °C and the mixture was stirred at r.t for 16 hrs. The reaction mixture was quenched with ice-water and the mixture was extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 35 % EtOAc in PE) to give the title compound (90 mg, 53.4% yield) as white solid. LC/MS (ESI) m/z: 434/436 (M+H)+. Step 2: methyl 2-[(3S)-l-[6-(5-{[(4S)-4-(cyclopropylmethyl)-3-methyl-2-oxoimidazolidin-l- yl]methyl}-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3- yl] acetate [0362]To a mixture of (4S)-l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-4-(cyclopropylmethyl)-3-methylimidazolidin-2-one (45 mg, 0.10 mmol) and methyl 2-[(3S)-5,5-difluoropiperidin-3-yl]acetate (30 mg, 0.16 mmol) in 1,4-dioxane (5 mL) was added Cs:CO: (104 mg 0.32 mmol) and Pd2(dba)3 (9 mg, 0.01 mmol) and RuPhos (5 mg, 0.01 mmol) under N2 atmosphere and the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (22 mg, 40.3% yield) as yellow solid. LC/MS (ESI) m/z: 546 (M+H)+. 155 WO 2022/034568 PCT/IB2021/059266 Step 3: 2-[(3S)-l-[6-(5-{[(4S)-4-(cyclopropylmethyl)-3-methyl-2-oxoimidazolidin-l- yl]methyl}-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3- yl] acetic acid id="p-363" id="p-363" id="p-363" id="p-363" id="p-363" id="p-363" id="p-363" id="p-363" id="p-363"

[0363]To a solution of methyl 2-[(3R)-l-[6-(5-{[(4S)-4-(cyclopropylmethyl)-3-methyl-2- oxoimidazolidin- 1 -yl]methyl } -1 -methyl- 1H-1,2,3 -tri azol-4-yl)-2-ethylpyri din-3 -yl]-5,5- difluoropiperi din-3-yl]acetate (22 mg, 0.04 mmol) in THF (5 mL) and MeOH (1 mL) was added a solution of LiOH (4 mg 0.18 mmol) in H2O (1 mL) and the mixture was stirred at r.t. for 3 hrs. The mixture was acidified with IN aq.HCl to pH~4 and extracted with DCM (3x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (C18, 0 ~ 90 % acetonitrile in H2O with 0.1% HCOOH) to give the title compound (11 mg, 50.9% yield) as white solid. 1H NMR (400 MHz, CD3OD) 5 7.87 (d, J= 8.3 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 5.13 (s, 2H), 4.11 (s, 3H), 3.54 - 3.47 (m, 1H), 3.41 (t, J = 8.8 Hz, 1H), 3.22 (d, J= 10.1 Hz, 2H), 3.10 - 2.93 (m, 4H), 2.76 (s, 3H), 2.63 - 2.48 (m, 2H), 2.38 - 2.23 (m, 3H), 1.95 (s, 3H), 1.77 - 1.62 (m, 1H), 1.46 - 1.30 (m, 6H), 0.54 - 0.42 (m, 1H), 0.40 - 0.29 (m, 2H). LC/MS (ESI) m/z: 532 (M+H)+. The examples in the following table were prepared by using method analogous to the examples as indicated in the method column in the table. Ex# Structure & name Analytical & biological data MethodF/ .>'X/OH FN 1 Y V ° Y! JI 0N-N^ L^N— 2-((S)-l-(6-(5-(((R)-4- (cy cl opropylmethyl)-3-methyl- 2-oxoimidazolidin- 1 - yl)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-methylpyri din- -yl)-5, 5-difluoropiperidin-3 - yl)acetic acid LC/MS (ESI) m/z: 519 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.86 (d, J= 8.3 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 5.05 (d, J = 1.1 Hz, 2H), 4.(s, 3H), 3.57 - 3.43 (m, 2H), 3.29 - 3.18 (m, 2H), 3.16 - 3.04 (m, 2H), 2.76 (s, 3H), 2.63 - 2.57 (m, 1H), 2.59 (s, 3H), 2.52 - 2.49 (m, 1H), 2.46 - 2.38 (m, 2H), 2.38 - 2.26 (m, 1H), 1.87-1.64 (m, 1H), 1.55-1.(m, 1H), 1.44 - 1.33 (m, 1H), 0.56 - 0.43 (m, 1H), 0.42 - 0.31 (m, 2H), 0.01 --0.03 (m, 2H).

Example 156 WO 2022/034568 PCT/IB2021/059266 63FVyVH °''Y! N-N^ 2-((S)-l-(6-(5-(((S)-4- (cy cl opropylmethyl)-3-methyl- 2-oxoimidazolidin- 1 - yl)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-methylpyri din- -yl)-5, 5-difluoropiperidin-3 - yl)acetic acid LC/MS (ESI) m/z: 518 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.84 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 5.03 (s, 2H), 4.12 (s, 3H), 3.45 - 3.47 (m, 2H), 3.29 - 3.18 (m, 1H), 3.13 - 3.02 (m, 2H), 2.75 (s, 3H), 2.60 - 2.63 (m, 1H), 2.59 (s, 3H), 2.48 - 2.54 ( m, 1H), 2.45 -2.36 (m, 2H), 2.30 - 2.(m,lH), 1.81 - 1.65 (m, 1H), 1.53 - 1.44 (m, 1H), 1.34 - 1.40 (m, 1H), 0.53 - 0.44 (m, 1H), 0.40 - 0.29 (m, 2H), 0.02 - 0.03 (m, 2H).

Example 64v 1 T V ° 111 N-N^ 2-((R)-l-(6-(5-(((S)-4- (cy cl opropylmethyl)-3-methyl- 2-oxoimidazolidin- 1 - yl)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-methylpyri din- -yl)-5, 5-difluoropiperidin-3 - yl)acetic acid LC/MS (ESI) m/z: 519 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.86 (d, J= 8.3 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 5.05 (d, J = 1.1 Hz, 2H), 4.(s, 3H), 3.57 - 3.43 (m, 2H), 3.29 - 3.18 (m, 2H), 3.16 - 3.04 (m, 2H), 2.76 (s, 3H), 2.63 - 2.57 (m, 1H), 2.59 (s, 3H), 2.52 - 2.49 (m, 1H), 2.47 - 2.38 (m, 2H), 2.38 - 2.26 (m, 1H), 1.87-1.64 (m, 1H), 1.55-1.(m, 1H), 1.44 - 1.33 (m, 1H), 0.56 - 0.43 (m, 1H), 0.42 - 0.31 (m, 2H), 0.01 --0.03 (m, 2H).

Example Example 65: 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 157 WO 2022/034568 PCT/IB2021/059266 H H2, Pd/CMeOH, rtStep 1 Step 1: tert-butyl (S)-(l-amino-3-cyclopropylpropan-2-yl)carbamate [0364]To a solution of tert-butyl (S)-(l-azido-3-cyclopropylpropan-2-yl)carbamate (580 mg, 2.mmol) in MeOH (8 mL) was added Pd/C (100 mg, 5% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (500 mg, 96.6% yield) as yellow solid. LC/MS (ESI) (m/z): 215 (M+H)+. Step 2: 4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazole-5-carbaldehyde [0365]To a solution of oxalyl chloride (0.15 mL, 1.74 mmol) in DCM (10 mL) was added a solution of DMSO (0.19 mL, 2.6 mmol) in DCM (2 mL) at -78 °C. After stirring for 20 minutes, a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol (300 mg, 0.87 mmol) in DCM (5 mL) was added and the mixture was stirred at -78 °C for 2 hrs. TEA (0.47 mL, 3.4 mmol) was added drop-wisely at -78 °C and the resulting mixture was stirred from -78 °C to r.t. for 2 hrs. The mixture was diluted with DCM (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 3: 1) to give the title compound (170 mg, 57.0% yield) as white solid. LC/MS (ESI) (m/z): 343 (M+H)+. Step 3: tert-butyl (S)-(l-cyclopropyl-3-(((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3- triazol-5-yl)methyl)amino)propan-2-yl)carbamate [0366]To a mixture of 4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazole-5- carbaldehyde (173 mg, 0.51 mmol) and tert-butyl (S)-(l-amino-3-cyclopropylpropan-2- yl)carbamate (108 mg, 0.5 mmol) in DCE (5 mL) was added sodium triacetoxyborohydride (1 158 WO 2022/034568 PCT/IB2021/059266 mg, 0.76 mmol) and the reaction was stirred at room temperature under N2 atmosphere for hrs. The reaction mixture was quenched with saturated aq.NaHCO3 solution (5 mL) and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 2: 1) to give the title compound (160 mg, 58.6% yield) as white solid. LC/MS (ESI) (m/z): 541 (M+H)+. Step 4: (S)-3-cyclopropyl-Nl-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)propane-l,2-diamine TEA salt [0367]To a solution of tert-butyl (S)-(l-cyclopropyl-3-(((4-(6-ethyl-5-iodopyridin-2-yl)-l- methyl-lH-l,2,3-triazol-5-yl)methyl)amino)propan-2-yl)carbamate (160 mg, 0.3 mmol) in DCM (5 mL) was added TEA (5 mL, 67.3 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was concentrated under reduced pressure to give the title compound (160 mg, yield 100%) as yellow oil, which was directly used in the next step. LC/MS (ESI) (m/z): 441 (M+H)+. Step 5: (S)-4-(cyclopropylmethyl)-l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3- triazol-5-yl)methyl)imidazolidin-2-one [0368]To a solution of (S)-3-cyclopropyl-Nl-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH- l,2,3-triazol-5-yl)methyl)propane-l,2-diamine TFA salt (160 mg, 0.34 mmol) in DCM (6 mL) were added TEA (0.13 mL, 0.91 mmol) and CDI (49.3 mg, 0.3 mmol) and the mixture was stirred at room temperature for 16 hrs. The reaction mixture was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 3: 1) to give the title compound (110 mg, 77.5% yield) as white solid. LC/MS (ESI) (m/z): 467 (M+H)+. Step 6: methyl 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate id="p-369" id="p-369" id="p-369" id="p-369" id="p-369" id="p-369" id="p-369" id="p-369" id="p-369"

[0369]To a mixture of (S)-4-(cyclopropylmethyl)-l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl- lH-l,2,3-triazol-5-yl)methyl)imidazolidin-2-one (30 mg, 0.064 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (12.4 mg, 0.064 mmol) in 1,4-dioxane (2 mL) were added Cs2CO(42 mg, 0.128 mmol), RuPhos (15 mg, 0.032 mmol) and RuPhos Pd G3 (15 mg, 0.0mmol) under N2 atmosphere and the mixture reaction was stirred at 100 °C under N2 atmosphere for 16 hrs. The reaction mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (15 mg, 43.9% yield) as yellow solid. LC/MS (ESI) (m/z): 532 (M+H)+. 159 WO 2022/034568 PCT/IB2021/059266 Step 7: 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-370" id="p-370" id="p-370" id="p-370" id="p-370" id="p-370" id="p-370" id="p-370" id="p-370"

[0370]To a solution of methyl 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l- yl)methyl)-l-methyl-lH- 1,2,3-tri azol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (15 mg, 0.028 mmol) in THF (1 mL) and MeOH (2 mL) was added a solution of LiOH (6.7 mg, 0.28 mmol) in water (1 mL) at 0 °C. After stirring at room temperature for 2 hrs, the reaction mixture was concentrated to dryness and the residue was dissolved in water (3 mL). The mixture was washed with EtOAc twice and the aqueous layer was acidified with IN aq.HCl to pH~2 and extracted with EtOAc (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (4.3 mg, 29.6% yield) as white solid. LC/MS (ESI) (m/z): 518 (M+H)+. 1HNMR (4MHz, CD3OD) 5 7.88 (d, J= 8.4 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 5.12 (s, 2H), 4.12 (s, 3H), 3.72-3.65 (m, 1H), 3.44 (t, J= 8.9 Hz, 1H), 3.26-3.21 (m, 2H), 3.13-3.07 (m, 1H), 3.06-3.02 (m, 1H), 3.0-2.94 (m, 2H), 2.61 (t, J= 10.3 Hz, 1H), 2.55-2.46 (m, 1H), 2.41-2.39 (m, 2H), 2.33-2.(m, 1H), 1.81-1.67 (m, 1H), 1.42-1.22 (m, 8H), 0.61-0.55 (m, 1H), 0.38-0.36 (m, 2H). Example 66: 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)-2-oxo-2,3- dihydro-lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin- 3-yl] acetic acid Step 8Pd(Pt-Bu 3)2, Cs2CO31,4-dioxane 160 WO 2022/034568 PCT/IB2021/059266 Step 1: methyl (2S)-2-amino-4-methylpentanoate hydrochloride [0371]To a solution of L-leucine (5 g, 38.12 mmol) in MeOH (50 mL) was added sulfuroyl di chloride (6.2 mL, 76.24 mmol) and the reaction mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness to give the title compound (5 g, 90.3 % yield) as white solid. Step 2: (5R)-5-(2-methylpropyl)imidazolidine-2,4-dione [0372]To a solution of methyl (2S)-2-amino-4-methylpentanoate (4 g, 27.6 mmol) in water (mL) was added KOCN (2.35 g, 28.9 mmol) and the mixture was stirred at r.t. for 1 hr. The mixture was extracted with EtOAc (2 x 20 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was dissolved in 2N aq.HCl (20 mL) and the mixture was stirred at reflux for 1 hr. The mixture was extracted with EtOAc (3x10 mL) and the combined organic phases were dried over Na2SO4, filtered and concentrated to dryness to give the title compound (2.3 g, 53.5 % yield). LC/MS (ESI) m/z: 1(M+H)+. Step 3: 3-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-5-(2- methylpropyl)imidazolidine-2,4-dione [0373]To a stirred mixture of 3-bromo-6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2- ethylpyridine (500 mg, 1.39 mmol) and 5-(2-methylpropyl)imidazolidine-2,4-dione (434 mg, 2.78 mmol) in DMF (10 mL) was added Na2CO3 (442 mg, 4.17 mmol) in portions at r.t., and the mixture was stirred at 50 °C for 16 hrs. The reaction mixture was quenched with H2O (10 mL) and extracted with EtOAc (3x5 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography flash chromatography (silica gel, EtOAc: PE= 1: 2) to give the title compound (200 mg, 33.1% yield) as white solid. LC/MS (ESI) m/z: 436/438 (M+H)+. Step 4: l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-5- hydroxy-4-(2-methylpropyl)imidazolidin-2-one [0374]To a stirred solution of 3-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-5-(2-methylpropyl)imidazolidine-2,4-dione (50 mg, 0.12 mmol) in THE (5 mL) was added LiAlH4 (9 mg, 0.23 mmol) at 0 °C and the mixture was stirred at this temperature for mins. The reaction mixture was quenched with Na2SO4.9H2O and stirred at r.t. for 10 mins. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (mg, 79.6% yield) as white solid. LC/MS (ESI) m/z: 438/440 (M+H)+. Step 5: (S)-2-(N-methyl-4-nitrophenylsulfonamido)hex-5-enoic acid id="p-375" id="p-375" id="p-375" id="p-375" id="p-375" id="p-375" id="p-375" id="p-375" id="p-375"

[0375]To a stirred solution of l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-5-hydroxy-4-(2-methylpropyl)imidazolidin-2-one (50 mg, 0.11 mmol) in DCM ( 161 WO 2022/034568 PCT/IB2021/059266 mL) was added TFA (0.5 mL) at r.t.. After stirring at r.t. for 3 hrs, the reaction mixture was concentrated to dryness under reduced pressure to give the title compound (50 mg, 104.3% yield) as yellow oil, which was used directly without further purification. LC/MS (ESI) m/z: 420/4(M+H)+. Step 6: l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-3- methyl-4-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one [0376]To a stirred solution of l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-4-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one (50 mg, 0.12 mmol) in DMF (mL) was added NaH (14 mg 0.36 mmol, 60% dispersion in mineral oil) in portions at 0 °C, and the mixture was stirred at this temperature for 30 mins. Mel (0.015 mL, 0.24 mmol) was added to the mixture and the resulting mixture was stirred at r.t. for 3 hrs. The reaction mixture was quenched with sat.NH4Cl solution and extracted with EtOAc (3x5 mL). The combined organic phase was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (silica gel, EtOAc: PE= 1: 3) to give the title compound (50 mg, 96.8 % yield) as white solid. LC/MS (ESI) m/z: 434/436 (M+H)+. Step 7: methyl 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)-2-oxo-2,3- dihydro-lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin- 3-yl] acetate id="p-377" id="p-377" id="p-377" id="p-377" id="p-377" id="p-377" id="p-377" id="p-377" id="p-377"

[0377]To a solution of l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-3-methyl-4-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one (50 mg, 0.12 mmol ) in 1,4-dioxane (5 mL) was added methyl 2-[(3R)-5,5-difluoropiperidin-3-yl]acetate (27 mg, 0.mmol) followed by the addition of CS2CO3 (114 mg, 0.35 mmol) and Bis(tri-tert- butylphosphine)palladium (6 mg, 0.012 mmol) under N2 atmosphere with stirring and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture was filtered through a Celite pad and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50 % EtOAc in PE) to give the title compound (28 mg, 44.4% yield) as yellow solid. LC/MS (ESI) m/z: 546 (M+H)+. Step 8: 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)-2-oxo-2,3-dihydro- lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin-3- yl] acetic acid [0378]To a solution of methyl 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)- 2-oxo-2,3-dihydro-lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5- difluoropiperi din-3-yl]acetate (28 mg, 0.051 mmol) in THE (5 mL) and MeOH (1 mL) was added LiOH (8 mg, 0.33 mmol) in H2O (1 mL) and the reaction was stirred at r.t. for 3 hrs. The mixture 162 WO 2022/034568 PCT/IB2021/059266 was concentrated to dryness and the residue was dissolved in H2O (3 mL). The mixture was acidified with 1 N aq.HCl to pH~4 and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was was purified by perp-HPLC (C18, 0 ~ 90 % acetonitrile in H2O with 0.1 % formic acid) to give the title compound (6 mg, 22% yield) as white solid. LC/MS (ESI) m/z: 5(M+H)+. 1HNMR (400 MHz, CD3OD) 5 7.90 (d, J= 8.3 Hz, 1H), 7.60 (d, J= 8.4 Hz, 1H), 6.(s, 1H), 5.50 (s, 2H), 4.12 (s, 3H), 3.28 - 3.21 (m, 2H), 3.19 (s, 3H), 3.17 - 3.04 (m, 1H), 2.98 (q, J= 7.5 Hz, 2H), 2.61 (t, J= 10.6 Hz, 1H), 2.57 - 2.46 (m, 1H), 2.40 (d, J= 6.9 Hz, 2H), 2.36 - 2.26 (m, 1H), 2.23-2.16 (m, 2H), 1.83 - 1.64 (m, 2H), 1.33 (t, J= 15 Hz, 3H), 0.86 (d, J= 6.Hz, 6H). Example 67: Preparation of (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxo-2,3- dihydro-lH-imidazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)- 5,5-difluoropiperidin-3-yl)acetic acid Example 67 id="p-379" id="p-379" id="p-379" id="p-379" id="p-379" id="p-379" id="p-379" id="p-379" id="p-379"

[0379]The title compound was prepared from (S)-2-amino-3-cyclopropylpropanoic acid using the same synthetic sequence that was used to synthesize example 66.LC/MS (ESI) m/z: 5(M+H)+. 1HNMR (400 MHz, DMSO-d6) 5 7.88 (d, J= 8.3 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 6.50 (s, 1H), 5.26 (s, 2H), 4.14 (s, 3H), 3.22 - 3.07 (m, 2H), 3.05 (s, 3H), 2.60 (d, J= 10.0 Hz, 1H), 2.55 (s, 3H), 2.39 - 2.25 (m, 4H), 2.21 (d, J= 5.9 Hz, 2H), 1.81 - 1.74 (m, 1H), 0.79 - 0.(m, 1H), 0.46 - 0.33 (m, 2H), 0.09 - 0.01 (m, 2H). Example 68: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH-l,2,4- triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid 163 WO 2022/034568 PCT/IB2021/059266 Example 68 Step 1: 2-cyclopropyl-N-[(methylcarbamoyl)amino] acetamide id="p-380" id="p-380" id="p-380" id="p-380" id="p-380" id="p-380" id="p-380" id="p-380" id="p-380"

[0380]To a solution of 2-cyclopropylacetic acid (500 mg, 5.0 mmol) and l-amino-3-methylurea (370 mg, 4.2 mmol) in MeCN (10 mL) was added DCC (1.03 g, 5.0 mmol) at 0 °C under Natmosphere. After the addition, the resulting solution was stirred at r.t. for 3 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (560 mg, 78.6% yield) as white solid. LC/MS (ESI) m/z: 172 (M+l) +. Step 2: 3-(cyclopropylmethyl)-4-methyl-4,5-dihydro-lH-l,2,4-triazol-5-one id="p-381" id="p-381" id="p-381" id="p-381" id="p-381" id="p-381" id="p-381" id="p-381" id="p-381"

[0381]A solution of 2-cyclopropyl-N-[(methylcarbamoyl)amino]acetamide (514 mg, 3.0 mmol) in aq.NaOH solution (12 mL, 24.0 mmol, 2 M in water) was stirred at 100 °C for 16 hrs. The mixture was washed with EtOAc (30 mL) and the aqueous layer was treated with IN aq.HCl to adjust pH=l. The aqueous layer was concentrated under vacuum to dryness and the residue was purified by flash chromatography (eluent: 0-50% of MeOH in H2O) to give the title compound (220 mg, 47.8% yield) as white solid. LC/MS (ESI) m/z: 154 (M+l) +. Step 3: 3-(cyclopropylmethyl)-l-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol- 5-yl]methyl}-4-methyl-4,5-dihydro-lH-l,2,4-triazol-5-one id="p-382" id="p-382" id="p-382" id="p-382" id="p-382" id="p-382" id="p-382" id="p-382" id="p-382"

[0382]To a mixture of 6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2-ethyl-3- iodopyridine(50 mg, 0.12 mmol) and K2CO3 (51 mg, 0.37 mmol) in DMF (5 mL) was added 3- (cyclopropylmethyl)-4-methyl-4,5-dihydro-lH-l,2,4-triazol-5-one (28 mg, 0.18 mmol) under Natmosphere. After the addition, the resulting solution was stirred at 60 °C for 3 hrs. The mixture was diluted with EtOAc (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluent: 0-100% of EtOAc in PE) to give the title compound (36 mg, 61.1% yield) as white solid. LC/MS (ESI) m/z: 480 (M+l) +. 164 WO 2022/034568 PCT/IB2021/059266 Step 4: methyl (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH-l,2,4- triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetate [0383]To a mixture of 5-(cyclopropylmethyl)-2-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH- l,2,3-triazol-5-yl)methyl)-4-methyl-2,4-dihydro-3H-l,2,4-triazol-3-one (36 mg, 0.075 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate (14.5 mg, 0.075 mmol) in 1,4-dioxane (8 mL) were added Cs:CO: (49 mg, 0.15 mmol) , Ru-Phos Pd G3 (14 mg, 0.015 mmol), Ru-phos (7 mg, 0.017 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 110 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL) and washed with water, brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluent: 0~ 50% of EtOAc in PE) to give the title compound (26 mg, 61.1% yield) as yellow solid. LC/MS (ESI) m/z: 545 (M+H)+. Step 5: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH-l,2,4-triazol- l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetic acid id="p-384" id="p-384" id="p-384" id="p-384" id="p-384" id="p-384" id="p-384" id="p-384" id="p-384"

[0384]To a solution of (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH- l,2,4-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetate (26 mg, 0.05 mmol) in MeOH (1 mL), water (1 mL) and THE (mL) was added LiOH (14 mg, 0.34 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (8.9 mg, 41.6% yield) as white solid. LC/MS (ESI) m/z: 531 [M+l] +. 1H NMR (400 MHz, CD3OD) 5 7.83 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 8.2 Hz, 1H), 5.72 (s, 2H), 4.13 (s, 3H), 3.52 - 3.45 (m, 1H), 3.25 - 3.(m, 1H), 3.23 (s, 3H), 3.22 - 3.19 (m, 1H), 3.13 (d, J = 1.6 Hz, 2H), 2.95 (q, J = 7.6 Hz, 2H), 2.64 - 2.54 (m, 1H), 2.53 - 2.45 (m, 1H), 2.42 (d, J = 6.9 Hz, 2H), 2.38 (dd, J = 6.7, 2.8 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H), 0.96 (m, 1H), 0.52 - 0.47 (m, 2H), 0.15 - 0.12 (m, 2H). Example 69: 2-((R)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 165 WO 2022/034568 PCT/IB2021/059266 Step 1: (S)-3-cyclopropyl-2-hydroxypropanoic acid id="p-385" id="p-385" id="p-385" id="p-385" id="p-385" id="p-385" id="p-385" id="p-385" id="p-385"

[0385]To suspension of (S)-2-amino-3-cyclopropylpropanoic acid (5 g, 38.7 mmol) in H2O (mL) was added 2N H2SO4 (22 mL, 44 mmol) and the mixture was cooled to 0 °C. To the above mixture, 2N aq.NaNO2 solution (19.5 mL, 39.0 mmol) were added drop-wisely while maintaining the internal temperature below than 5 °C. The reaction was stirred at 0 °C for 3 hrs and r.t. for hrs. The reaction mixture was saturated with NaCl and extracted with EtOAc (5 x 30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness to give the title compound (2.14 g, 42.5% yield) as yellow oil. Step 2: (S)-N-benzyl-3-cyclopropyl-2-hydroxypropanamide id="p-386" id="p-386" id="p-386" id="p-386" id="p-386" id="p-386" id="p-386" id="p-386" id="p-386"

[0386]To a mixture of (S)-3-cyclopropyl-2-hydroxypropanoic acid (2.14 g, 16.4 mmol), phenylmethanamine (2.16 mL, 19.7 mmol), TEA (6.86 mL, 49.3 mmol) and HOBt (3.33 g, 24.mmol) in DMF (20 mL) was added EDCI (4.37 mL, 24.7 mmol) at 0 °C under N2 atmosphere and the reaction was stirred at 25 °C for 2 hrs. Water (50 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography on silica (DCM: MeOH = 100: 1 to 30: 1) to give the title compound (2.6 g, 72.1% yield) as yellow oil. LC/MS (ESI) m/z: 220 (M+H)+. Step 3: (S)-l-(benzylamino)-3-cyclopropylpropan-2-ol id="p-387" id="p-387" id="p-387" id="p-387" id="p-387" id="p-387" id="p-387" id="p-387" id="p-387"

[0387]To suspension of LiAlH4 (1.35 g, 35.6 mmol) in THE (10 mL) was added solution of (S)- N-benzyl-3-cyclopropyl-2-hydroxypropanamide (2.6 g, 11.8 mmol) in THF (10 mL) drop-wisely 166 WO 2022/034568 PCT/IB2021/059266 at 0 °C under N2 atmosphere and the mixture was stirred at 70 °C for 16 hrs. The reaction was cooled to 0 °C and quenched with 1.5 mL water, 1.5 mL 15% NaOH solution and 4.5 mL water. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica (DCM: MeOH =100: 1 to 20: 1) to give the title compound (1.g, 62.8% yield) as yellow solid. LC/MS (ESI) m/z: 206 (M+H)+. Step 4: (S)-3-benzyl-5-(cyclopropylmethyl)oxazolidin-2-one id="p-388" id="p-388" id="p-388" id="p-388" id="p-388" id="p-388" id="p-388" id="p-388" id="p-388"

[0388]To a solution of (S)-l-(benzylamino)-3-cyclopropylpropan-2-ol (1.5 g, 7.31 mmol) in CH3CN (15 mL) were added TEA (1.05 mL, 7.55 mmol) and N,N’-disuccinimidyl carbonate (1.g, 7.30 mmol) at 0 °C and the mixture was stirred at 25 °C for 16 hrs. The reaction mixture concentrated to dryness and the residue was purified by column chromatography on silica (DCM: MeOH= 100: 1 to 50: 1) to give the title compound (1.3 g, 76.9% yield) as yellow oil. LC/MS (ESI) m/z: 232 (M+H)+. Step 5: (S)-l-amino-3-cyclopropylpropan-2-ol id="p-389" id="p-389" id="p-389" id="p-389" id="p-389" id="p-389" id="p-389" id="p-389" id="p-389"

[0389]To a solution of (S)-3-benzyl-5-(cyclopropylmethyl)oxazolidin-2-one (900 mg, 3.mmol) in MeOH (7 mL) was added Pd/C (100 mg, 10% wt) at 25 °C under N2 atmosphere and the mixture was stirred under a H2 balloon at 25 °C for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (450 mg, 100% yield) as yellow oil. LC/MS (ESI) m/z: 116(M+H)+. Step 6: (S)-5-(cyclopropylmethyl)oxazolidin-2-one id="p-390" id="p-390" id="p-390" id="p-390" id="p-390" id="p-390" id="p-390" id="p-390" id="p-390"

[0390]To a mixture of (S)-l-amino-3-cyclopropylpropan-2-ol (450 mg, 3.9 mmol) and TEA (1.mL, 8.7 mmol) in CH3CN (10 mL) was added DSC (1.2 g, 4.69 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 16 hrs. The reaction was concentrated to dryness and the residue was purified by column chromatography on silica (DCM: MeOH= 100: 1 to 20: 1) to give the title compound (460 mg, 83.5% yield) as white solid. LC/MS (ESI) m/z: 142 (M+H)+. Step 7: (S)-3-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- (cyclopropylmethyl)oxazolidin-2-one id="p-391" id="p-391" id="p-391" id="p-391" id="p-391" id="p-391" id="p-391" id="p-391" id="p-391"

[0391]To a solution of (S)-5-(cyclopropylmethyl)oxazolidin-2-one (102 mg, 0.722 mmol) in DMF (2 mL) was added NaH (44.4 mg, 1.11 mmol, 60% dispersion in mineral oil) at 0 °C under N2 atmosphere and the mixture was stirred at 0 °C for 0.5 hr. A solution of 3-bromo-6-(5- (bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine (200 mg, 0.555 mmol) in DMF (mL) was added to the mixture and the resulting mixture was stirred at r.t. for 2 hrs. The mixture was quenched with saturated aq.NH4Cl solution and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to 167 WO 2022/034568 PCT/IB2021/059266 dryness. The residue was purified by column chromatography on silica gel (PE: EtOAc= 3: 1 to 1: 1) to give the title compound (175 mg, 75.0% yield) as white solid. LC/MS (ESI) m/z: 420 (M+H)+. Step 8: methyl 2-((S)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate id="p-392" id="p-392" id="p-392" id="p-392" id="p-392" id="p-392" id="p-392" id="p-392" id="p-392"

[0392]To a mixture of (S)-3-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-5-(cyclopropylmethyl)oxazolidin-2-one (130 mg, 0.309 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (59.8 mg, 0.309 mmol) and Cs2CO3 (101 mg, 0.309 mmol) in 1,4- dioxane (4 mL) was added Ru PHOS (65 mg, 0.139 mmol) and RuPhos Pd G3 (65 mg, 0.0mmol), the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica gel (PE: EtOAc= 3: 1 to 1: 1) to give the title compound (1mg, 60.8% yield) as yellow solid. LC/MS (ESI) m/z: 543 (M+H)+. Step 9: 2-((S)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-393" id="p-393" id="p-393" id="p-393" id="p-393" id="p-393" id="p-393" id="p-393" id="p-393"

[0393]To a solution of methyl 2-((S)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3- yl)methyl)-l-methyl-lH- 1,2,3-tri azol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (100 mg, 0.188 mmol) in THE (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOHH2O (150 mg, 3.58 mmol) and the mixture was stirred at 25 °C for 2 hrs. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc (2x3 mL), acidified with IN aq.HCl to pH~4 and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (11.mg, 11.7% yield) as white solid. LC/MS (ESI) m/z: 519 (M+H)+1H NMR (400 MHz, CD3OD) 7.89 (d, J= 8.3 Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 5.27-5.11 (m, 2H), 4.58 (dt,J= 13.6, 6.6 Hz, 1H), 4.14 (s, 3H), 3.60 (t, J= 8.8 Hz, 1H), 3.26 -3.20 (m, 3H), 3.15 - 3.01 (m, 1H), 2.97 (q, J = 7.5 Hz, 2H), 2.65 - 2.55 (m, 1H), 2.52 - 2.50 (m,lH), 2.43 - 2.36 (m, 2H), 2.31 -2.29 (m, 1H), 1.81-1.66 (m, 1H), 1.65 -1.58 (m, 1H), 1.42- 1.33 (m, 4H), 0.70 - 0.59 (m, 1H), 0.45 - 0.33 (m, 2H), 0.09 - 0.04 (m, 2H). Example 70: (R)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 168 WO 2022/034568 PCT/IB2021/059266 Example 70 Step 1: l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-3- (cyclopropylmethyl)imidazolidin-2-one [0394]To a solution of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridine (100 mg, 0.29 mmol) and l-(cyclopropylmethyl)imidazolidin-2-one (48.6 mg, 0.mmol) in DMF (2 mL) was added t-BuOK (1 M in THF, 0.58 mL, 0.58 mmol) at 0 °C under Nand the mixture was stirred at 0 °C for 1 hr. The mixture was quenched with water and extracted with EtOAc (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 30: 1 to 3: 1) to give the title compound (90 mg, 76.8% yield) as white solid. LC/MS (ESI) m/z: 405/407 (M+H)+. Step 2: methyl (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0395]To a mixture of l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-3-(cyclopropylmethyl)imidazolidin-2-one (90 mg, 0.22 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (64.4 mg, 0.33 mmol) in toluene (2 mL) were added Cs2CO3 (144.mg, 0.44 mmol), BINAP (27.7 mg, 0.044 mmol), Pd(OAc)2 (5.0 mg, 0.022 mmol) under Natmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 10: 1 to 1: 1) to give the title compound (95 mg, 82.7% yield) as white solid. LC/MS (ESI) m/z: 518 (M+H)+. Step 3: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid [0396]To a solution of methyl (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate (95 mg, 0.18 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (77 mg, 1.84 mmol) at 25 °C. The reaction was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc twice and the aqueous layer was acidified with IN aq.HCl to pH = 2 and 169 WO 2022/034568 PCT/IB2021/059266 extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (14 mg, 15.1% yield) as white solid. LC/MS (ESI) m/z: 504 (M+H)+1HNMR (400 MHz, CD3OD) 5 7.85 (d, J= 8.2 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 5.06 (s, 2H), 4.12 (s, 3H), 3.46-3.38 (m, 3H), 3.37-3.34 (m, 1H), 3.28-3.22 (m, 2H), 3.11-2.96 (m, 3H), 2.58 (s, 4H), 2.54-2.44 (m, 1H), 2.42-2.33 (m, 2H), 2.33- 2.25 (m, 1H), 0.94-0.87 (m, 1H), 0.55-0.48 (m, 2H), 0.23-0.18 (m, 2H). Example 71: (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH-imidazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid Step 1: l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-3- isobutyl-l,3-dihydro-2H-imidazol-2-one [0397]To a mixture of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridine (100 mg, 0.29 mmol) and l-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one (mg, 0.43 mmol) in DMF (2 mL) was added t-BuOK (0.58 mL, 0.58 mmol, IM in THF) drop- wisely at 0 °C and the mixture was stirred at 0 °C for 2 hrs. The mixture was quenched with saturated aq.NH4Cl solution and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column silica chromatography on silica (PE: EtOAc =5: 1 to 3: 1) to give the title compound (90 mg, 76.8% yield) as yellow solid. LC/MS (ESI) m/z: 406 (M+H)+. Step 2: methyl (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH-imidazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate [0398]To the mixture of l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-3-isobutyl-l,3-dihydro-2H-imidazol-2-one (40 mg, 0.10 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (17 mg, 0.10 mmol) in toluene (2 mL) was added Cs2CO3 (96 mg, 0.30 mmol), BINAP (24 mg, 0.04 mmol) and Pd(OAc)2 (9 mg, 0.04 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography on silica (PE: EtOAc= 3: 1) to give the title compound (40 mg, 78.3% yield). LC/MS (ESI) m/z: 5(M+H)+. 170 WO 2022/034568 PCT/IB2021/059266 Step 3: (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH-imidazol-l-yl)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid id="p-399" id="p-399" id="p-399" id="p-399" id="p-399" id="p-399" id="p-399" id="p-399" id="p-399"

[0399]To a solution of methyl (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH- imidazol- 1 -yl)methyl)- 1 -methyl- 1H-1,2,3 -tri azol-4-yl)-2-methylpyri din-3 -yl)piperidin-3 - yl)acetate (40 mg, 0.08mmol) in THF (2mL) and MeOH (1 mL) was added a solution of Li OH (mg, 0.29 mmol) in H2O (1 mL) and the mixture was stirred at r.t. for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc (2x3 mL), acidified with IN aq.HCl to pH~4 and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (C18, 0 ~ 90 % acetonitrile in H2O with 0.1 % formic acid) to give the title compound (20 mg, 51.4% yield) as white solid. LC/MS (ESI) m/z: 504 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.88 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 3.0 Hz, 1H), 6.40 (d, J = 3.0 Hz, 1H), 5.47 (s, 2H), 4.15 (s, 3H), 3.42 (d, J = 7.3 Hz, 2H), 3.00-3.20 (m, 2H), 2.62-2.67 (m, 1H), 2.61 (s, 3H), 2.42-2.58 (m, 2H), 2.36-2.41 (m, 2H), 2.28-2.35 (m, 1H), 1.90-2.10 (m, 1H), 1.66-1.79 (m, 1H), 0.89 (d, J = 6.7 Hz, 6H). Example 72: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-lH-imidazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetic acid id="p-400" id="p-400" id="p-400" id="p-400" id="p-400" id="p-400" id="p-400" id="p-400" id="p-400"

[0400]The title compound was prepared from l-(cyclopropylmethyl)-l,3-dihydro-2H-imidazol- 2-one using the same synthetic sequence that was used to synthesize example 71. LC/MS (ESI) (m/z): 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.89 (d, J= 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 6.67 (d, =3.0 Hz, 1H), 6.51 (d,J=3.0Hz, 1H), 5.47 (s, 2H), 4.16 (s, 3H), 3.47 (d, J=7.Hz, 2H), 3.37-3.31 (m, 2H), 3.14-3.01 (m, 1H), 2.63 -2.55 (m, 4H), 2.53 -2.45 (m, 1H), 2.- 2.36 (m, 2H), 2.35 - 2.25 (m, 1H), 1.82 - 1.63 (m, 1H), 1.14-1.04 (m, 1H), 0.57 - 0.50 (m, 2H), 0.32 (q, J =4.7 Hz, 2H). Example 73: 2-((3S)-l-(6-(5-((3-(sec-butyl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 171 WO 2022/034568 PCT/IB2021/059266 Example 73 id="p-401" id="p-401" id="p-401" id="p-401" id="p-401" id="p-401" id="p-401" id="p-401" id="p-401"

[0401]The title compound was prepared from 1-(sec-butyl)- 1,3-dihydro-2H-imidazol-2-one using the same synthetic sequence that was used to synthesize example 71.LC/MS (ESI) m/z: 5(M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.90 - 7.86 (d, J = 8.4 Hz, 1H), 7.57 - 7.53 (d, J = 8.Hz, 1H), 6.73 - 6.66 (d, J = 3.0 Hz, 1H), 6.49 - 6.42 (d, J = 3.0 Hz, 1H), 5.54 - 5.43 (m, 2H), 4.(s, 3H), 4.11 - 4.04 (m, 1H), 3.31 (s, 2H), 3.13 - 3.00 (m, 1H), 2.61 (s, 3H), 2.59 - 2.50 (d, J = 11.0 Hz, 2H), 2.35 - 2.26 (d, 1 = 6.8 Hz, 3H), 1.74 - 1.60 (m, 3H), 1.29 - 1.26 (d, 1 = 6.8 Hz, 3H), 0.83 -0.79 (m, 3H). Example 74: (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid Example 74 Step 1: ethyl (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate id="p-402" id="p-402" id="p-402" id="p-402" id="p-402" id="p-402" id="p-402" id="p-402" id="p-402"

[0402]To a mixture of ethyl 2-[(3R)-l-{2-ethyl-6-[5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl]pyridin-3-yl}piperidin-3-yl]acetate (60 mg, 0.16 mmol ) and 2-chloro-4- cyclobutylpyrimidine (34 mg, 0.2 mmol ) in THF (5 mL) was t-BuOK (0.20 mL, IM in THF) drop- wisely at 0 °C. After the addition, the mixture was stirred at r.t. for 16 hrs. The reaction mixture was diluted with EtOAc (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-50% of EtOAc in PE) to give the title compound (62 mg, 77% yield) as white solid. LC-MS (ESI) m/z: 520 [M+l] +. Step 2: (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid [0403]To a solution of ethyl (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (62 mg, 0.12 mmol) in MeOH ( 172 WO 2022/034568 PCT/IB2021/059266 mL), water (1 mL) and THF (4 mL) was added LiOH (34 mg, 1 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl to pH=3 and extracted with DCM (3x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (31 mg, 55.2% yield) as white solid. LC/MS (ESI) m/z: 492 [M+l] +. 1H NMR (400 MHz, CD3OD) 8.41 (d, J= 5.1 Hz, 1H), 7.84 (d, J= 8.0 Hz, 1H), 7.51 (d, J= 8.4 Hz, 1H), 6.98 (d, J= 5.1 Hz, 1H), 6.21 (t, J= 7.8 Hz, 2H), 4.23 (s, 3H), 3.54 - 3.47 (m, 1H), 3.17 - 3.10 (m, 1H), 3.07 - 2.(m, 1H), 2.84 (q, J= 7.4 Hz, 2H), 2.71 (td, J= 10.9, 2.9 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.30 (d, J = 6.7 Hz, 2H), 2.25 -2.18 (m, 5H), 2.02 (dd,J= 10.5, 7.5 Hz, 1H), 1.92 - 1.74 (m, 4H), 1.24-1.(t, J = 72, 6.8 Hz, 3H). The examples in the following table were prepared by using method analogous to the examples as indicated in the method column in the table. Ex# Structure & name Analytical & biological data Method^•""Y0h V ° 'לול N" N־N (S)-2-(l-(6-(5-(((4- cyclopropylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- triazol-4-yl)-2-methylpyridin-3-yl)- 5,5 -difluoropiperi din-3 -yl)acetic acid LC/MS (ESI) m/z: 500 (M+H)+. 1H-NMR (400 MHz, CD3OD) 8.27 (d, J= 4.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.54 (d, J= 8.4 Hz, 1H), 6.98 (d, J= 4.2 Hz, 1H), 6.(q, 7= 10.4 Hz 2H), 4.21 (s, 3H), 3.31-3.29 (m, 2H), 3.09 - 3.02 (m, 1H), 2.55 - 2.52 (m, 1H), 2.51 - 2.49 (m, 1H), 2.50 (s, 3H), 2.39 - 2.26 (m, 3H), 1.98-1.91 (m, 1H), 1.78 - 1.67 (m, 1H), 0.99 - 0.(m, 2H), 0.90 - 0.83 (m, 2H).

Example 76^•""Y0h °'לולN*N v—// N-N^ N^X (S)-2-(l-(6-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- triazol-4-yl)-2-methylpyridin-3-yl)- 5,5 -difluoropiperi din-3 -yl)acetic acid LC/MS (ESI) m/z: 514 (M+H)+. 1H-NMR (400 MHz, CD3OD) 8.40 (d, J = 4.8 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 6.98 (d, J= 5.2 Hz, 1H), 6.(s, 2H), 4.23 (s, 3H), 3.54-3.45 (m, 1H), 3.37-3.25 (m, 2H), 3.14-3.(m, 1H), 2.62 - 2.57 (m, 1H), 2.(s, 3H), 2.49 - 2.44 (m, 1H), 2.40- 2.28 (m, 3H), 2.26 - 2.14 (m, 4H), 2.06 - 1.97 (m, 1H), 1.82 - 1.67 (m, 2H).

Example 173 WO 2022/034568 PCT/IB2021/059266 77V ° 'ל؛וN* N-N N (S)-2-(5,5-difluoro-l-(6-(5-(((4- isopropylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-methylpyri din-3- yl)piperidin-3-yl)acetic acid LC/MS (ESI) m/z: 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.42 (d, J= 5.1 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.54 (d, J= 8.4 Hz, 1H), 7.01 (d, J = 5.1 Hz, 1H), 6.- 6.07 (m, 2H), 4.23 (s, 3H), 3.26 - 3.22 (m, 2H), 3.16 - 3.00 (m, 1H), 2.89 - 2.73 (m, 1H), 2.70 - 2.(m, 1H), 2.49-2.47 (m, 1H), 2.(s, 3H), 2.44 - 2.36 (m, 2H), 2.- 2.23 (m, 1H), 1.82 - 1.63 (m, 1H), 1.16 (d, 6.9 Hz, 6H).

Example 78V ° Yd J. //^ n-n^ Xn-T^ (S)-2-(l-(6-(5-(((6-(lH-pyrazol-l- yl)pyrimidin-4-yl)oxy)methyl)- 1 - methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 526 (M+H)+. 1H-NMR (400 MHz, CD3OD) 5: 8.64-8.59 (m, 2H), 7.84 (d, J= 8.Hz, 1H), 7.77 (s, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.29 (s, 1H), 6.(t,J= 1.6 Hz, 1H), 6.16 (s,2H), 4.22 (s, 3H), 3.31 -3.25 (m, 2H), 3.14 - 3.00 (m, 1H), 2.62 - 2.55 (m, 1H), 2.52 -2.49 (m, 1H), 2.48 (s, 3H), 2.36 -2.48 (m, 3H), 1.80-1.64 (m, 1H).

Example 79f¥)״"Vh V ° 'לוך / 'I N^x N-N NA—1 (S)-2-(l-(6-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)- 5,5 -difluoropiperi din-3 -yl)acetic acid LC/MS (ESI) m/z: 528 (M+H)+1H NMR (400 MHz, CD3OD) 5 8.(d, J= 5.2 Hz, 1H), 7.88 (d, J= 8.Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 6.99 (d, J= 5.0 Hz, 1H), 6.20 (s, 2H), 4.23 (s, 3H), 3.54-3.49 (m, 1H), 3.25-3.17 (m, 2H), 3.11-3.(m, 1H), 2.87 (q, J= 7.6 Hz, 2H), 2.62-2.56 (m, 1H), 2.53-2.44 (m, 1H), 2.40-2.34 (m, 2H), 2.33-2.(m, 1H), 2.26-2.18 (m, 4H), 2.08- 1.98 (m, 1H), 1.84-1.74 (m, 1H), 1.73-1.65 (m, 1H), 1.23 (t, J= 7.Hz, 3H).

Example 80° J. /^NN» YoAAN-N N—, LC/MS (ESI) m/z: 492 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.66 (d, J= 0.9 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.54 (d, J= 8.4 Hz, 1H), 6.79 (s, 1H), 6.12 (s, 2H), 4.20 (s, 3H), 3.61 - 3.51 (m, 1H), 3.16 (d, J= 11.0 Hz, 1H), 3.03 (d, Example 174 WO 2022/034568 PCT/IB2021/059266 (R)-2-(l-(6-(5-(((6-cyclobutylpyrimidin-4- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-ethylpyri din-3- yl)piperidin-3-yl)acetic acid J = 11.2 Hz, 1H), 2.82 (t, J = 7.Hz, 2H), 2.76 - 2.66 (m, 1H), 2.- 2.39 (m, 1H), 2.33 - 2.19 (m, 7H), 2.11 - 2.02 (m, 1H), 1.91 - 1.72 (m, 4H), 1.21 (t, J = 15 Hz, 4H).V ° 'litN^N־N (S)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-ethylpyri din-3- yl)piperidin-3-yl)acetic acid LC/MS (ESI) (m/z): 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.60-8.61 (m, 2H), 7.84 (s, 1H), 7.77-7.78 (d, J = 1.1 Hz, 1H), 7.41- 7.44 (m, 2H), 7.25-7.26 (m, 1H), 6.54-6.55 (m, 1H), 5.98 (s, 2H), 4.01 (s, 3H), 3.20-3.24 (m, 2H), 2.97-3.07 (m, 1H), 2.54-2.59 (m, 1H), 2.46 (s, 3H), 2.37-2.39 (m, 2H), 2.24-2.30 (m, 1H), 1.59-1.(m, 2H).

Example 82 QI xL (R)-2-( 1 -(6-(5 -(((6-( 1 H-pyrazol- 1 - yl)pyrimidin-4-yl)oxy)methyl)- 1 - methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyri din-3-yl)piperi din-3- yl)acetic acid LC/MS (ESI) m/z: 504 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.62-8.64 (d, J= 0.9 Hz, 1H), 8.59- 8.61 (dd, J = 2.7, 0.5 Hz, 1H), 7.82-7.84 (d, J= 8.3 Hz, 1H), 7.76- 7.78 (d, J= 1.1 Hz, 1H), 7.48-7.(d, J= 8.4 Hz, 1H), 7.28-7.30 (d, J = 0.9 Hz, 1H), 6.53-6.55 (dd, J = 2.7, 1.6 Hz, 1H), 6.20 (s, 2H), 4.(s, 3H), 3.12-3.18 (m, 1H), 3.00- 3.06 (m, 1H), 2.80-2.86 (q, J= Hz, 2H), 2.66-2.74 (m, 1H), 2.39- 2.47 (m, 1H), 2.27-2.33 (m, 2H), 2.15-2.26 (m, 1H), 2.03 (s, 1H), 1.73-1.91 (m, 3H), 1.27-1.19 (m, 1H), 1.24-1.20 (t, J= 15 Hz, 3H).

Example 83n"V H v ° (R)-2-(l-(2-ethyl-6-(l-methyl-5- (((4-(pyrrolidin- 1 -yl)pyrimidin-2- yl)oxy)methyl)- 1H-1,2,3-tri azol-4- LC/MS (ESI) m/z: 507 [M+l^H NMR (400 MHz,CD3OD) 5 7.(d, J=6.1 Hz, 1H), 7.82 (d, J= 8.3 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 6.12 (dt, J= 15.4, 13.3 Hz, 3H), 4.20 (s, 3H), 3.32 (s, 2H), 3.17 (d,J= 11.8 Hz, 3H), 3.03 (d, 11.3 Hz, 1H), 2.87 (q, J=15Hz, 2H), 2.77 - 2.68 (m, 1H), 2.50-2.41 (m, 1H), 2.36-2.(m, 3H), 2.06 - 1.93 (m, 2H), 1.92 Example 175 WO 2022/034568 PCT/IB2021/059266 yl)pyridin-3 -yl)piperidin-3 - yl)acetic acid-1.74(m, 5H), 1.28 (t,J= 7.Hz, 3H), 1.25- 1.17 (m, 1H). 84 ryV H ° I n 0N-N^ N^—1 (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-methylpyri din-3- yl)piperidin-3-yl)acetic acid LC/MS (ESI) m/z: 504 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.41 (d,J=5.1 Hz, 1H), 8.12 (s, 2H), 7.03 (d, J= 5.2 Hz, 1H), 5.86 (s, 2H), 4.33 (s, 3H), 3.56 - 3.54 (m, 1H), 3.52 - 3.50 (m, 1H), 3.28 -3.25 (m, 1H), 2.93 - 2.(m, 1H), 2.78 (s, 3H), 2.64 - 2.(m, 1H), 2.34-2.27 (m, 7H), 1.-1.84(m, 4H), 1.33 - 1.29 (m, 2H).

Example 85 n'V H V ° HIX/x N-N^ 1X (R)-2-( 1 -(6-(5 -(((6-( 1 H-pyrazol- 1 - yl)pyrimidin-4-yl)oxy)methyl)- 1 - methyl-lH-l,2,3-triazol-4-yl)-2- m ethylpyri din-3-yl)piperi din-3- yl)acetic acid LC/MS (ESI) m/z: 481 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.64 - 8.56 (m, 2H), 7.99 - 7.(m, 1H), 7.82 - 7.75 (m, 2H), 7.(s, 1H), 6.57 - 6.52 (m, 1H), 6.(s, 2H), 4.27 (s, 3H), 3.29 - 3.(m, 1H), 3.20-3.14 (m, 1H), 2.- 2.75 (m, 1H), 2.60 (s, 3H), 2.- 2.47 (m, 1H), 2.35 - 2.30 (m, 2H), 2.29 -2.18 (m, 1H), 1.94 - 1.76 (m, 3H), 1.30-1.19 (m, 1H).

Example 86V ° x 1mT n־nN1i / xN-N p (S)-2-(5,5-difluoro-l-(6-(5-(((4-i sobutylpyridazin-3 - yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-methylpyri din-3- yl)piperidin-3-yl)acetic acid 1H NMR (400 MHz, CD3OD) 8.71 (d, J= 4.7 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.51 (d, J= 8.3 Hz, 1H), 7.39 (d, J= 4.7 Hz, 1H), 6.(s, 2H), 4.28 (s, 3H), 3.25 (d, J = 11.2 Hz, 2H), 3.15 - 3.00 (m, 1H), 2.63 - 2.45 (m, 2H), 2.43 - 2.(m, 8H), 1.78 - 1.62 (m, 2H), 0.(d, J = 6.6 Hz, 6H). LC/MS (ESI) m/z: 516 (M+H)+.

Example 176 WO 2022/034568 PCT/IB2021/059266 87F¥yVh ‘n‘ 0 N^N TN-N^ ° । (S)-2-(l-(2-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H- pyrazol-4-yl)-4-ethylpyrimi din-5- yl)-5,5-difluoropiperidin-3- yl)acetic acid LC/MS (ESI) m/z: 528 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.42 (d, J = 5.1 Hz, 1H), 8.38 (s, 1H), 8.08 (s, 1H), 6.99 (d, J = 5.Hz, 1H), 6.16 (s, 2H), 4.02 (s, 3H), 3.58 - 3.51 (m, 1H), 3.28 - 3.(m, 3H), 2.79-2.86 (m, 2H), 2.70 - 2.64 (m, 1H), 2.42-2.5l(m, 1H), 2.37-2.41(d, J = 6.9 Hz, 2H), 2.22- 2.30 (m, 5H), 2.00-2.08 (m, 8.Hz, 1H), 1.68- 1.86 (m, 2H), 1.20- 1.24 (m, 3H).

Example 88u ° 'llYTN YNJx flN-N^ A—. 2-(l-(6-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- triazol-4-yl)-2-ethyl-4- fluoropyri din-3-yl)piperi din-3- yl)acetic acid LC/MS (ESI) m/z: 510 (M+H)+. 1H-NMR (400 MHz, CD3OD) 8.41 (d, J= 5.1 Hz, 1H), 7.63 (d, J = 13.1 Hz, 1H), 6.99 (d,J=5.1Hz, 1H), 6.19 (s, 2H), 4.23 (s, 3H), 3.57 - 3.48 (m, 1H), 3.15 (t, J = 11.7 Hz, 2H), 3.01 - 2.98 (m, 2H), 2.89 (q, J= 7.5 Hz, 2H), 2.29 (d, J = 7.0 Hz, 2H), 2.26 -2.19 (m, 4H), 2.06 -1.99 (m, 1H), 1.94 - 1.87 (m, 1H), 1.84-1.76 (m, 3H), 1.48-1.(m, 2H), 1.19 (t, J = 7.5 Hz, 3H).

Example N-N^ (S)-2-(l-(6-(5-(((6-(lH-pyrazol-l- yl)pyrimidin-4-yl)oxy)methyl)- 1 - methyl-lH-pyrazol-4-yl)-2- methylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) (m/z): 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.60-8.61 (m, 2H), 7.84 (s, 1H), 7.77-7.78 (d, J= 1.1 Hz, 1H), 7.- 7.44 (m, 2H), 7.25 -7.26 (m, 1H), 6.54 - 6.55 (m, 1H), 5.98 (s, 2H), 4.01 (s, 3H), 3.20 - 3.24 (m, 2H), 2.97 - 3.07 (m, 1H), 2.54 - 2.59 (m, 1H), 2.46 (s, 3H), 2.37 - 2.39 (m, 2H), 2.24-2.30 (m, 1H), 1.59 -1.(m, 2H).

Example 90zx ,..'yOHu ° (zYAJ(N־Nx XN^ (R)-2-( 1 -(6-(5 -(((6-( 1 H-pyrazol- 1 - LC/MS (ESI) (m/z): 503 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.60 (s, 2H), 7.85 (s, 1H), 7.77 (s, 1H), 7.39-7.45 (m, 2H), 7.27 (s, 1H), 6.55 (s, 1H), 6.05 (s, 2H), 4.01 (s, 3H), 3.09-3.11 (d, J= 11.Hz, 1H), 2.97-2.99 (d, J= 10.9 Hz, 1H), 2.78-2.83 (m, 2H), 2.65 - 2.70 Example 177 WO 2022/034568 PCT/IB2021/059266 yl)pyrimidin-4-yl)oxy)methyl)- 1 - methyl-lH-pyrazol-4-yl)-2- ethylpyri din-3-yl)piperi din-3- yl)acetic acid (t, J= 9.5 Hz, 1H), 2.39 - 2.44 (t, J = 10.3 Hz, 1H), 2.28 -2.30 (m, 2H), 2.17-2.20 (m, 1H), 1.73 - 1.89 (m, 3H), 1.18 - 1.21 (m, 4H).

I N^XRo arbitrarily assigned enantiomer A:(R) or (S)-2-(l-(6-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-ethylpyridin-3-yl)-6- oxopiperi din-3-yl)acetic acid LC-MS (ESI) m/z 506 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.42-8.41(d, 1H), 8.03-8.(M, 1H), 7.72 - 7.67 (m, 1H), 7.00 (d,J=5.1 Hz, 1H), 6.28- 6.27 (m, 1H), 6.17-6.14 (d,J = 13.0 Hz, 1H), 4.24 (s, 3H), 3.79 - 3.53 (m, 3H), 2.69 - 2.62 (m, 3H), 2.52 - 2.41(m, 3H), 2.32 - 2.(m, 5H), 2.14 (d, J= 13.0 Hz, 1H), 2.08- 1.97 (m, 1H), 1.8- 1.81 (m, 2H), 1.24- 1.18 (m 3H).

Example 92X J CT N׳nI N*X/ O M'**XN־N N N—, arbitrarily assigned enantiomer B:(S) or (R)-2-(l-(6-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-ethylpyridin-3-yl)-6- oxopiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 507 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.32 (d, J = 5.1 Hz, 1H), 7.91 (dd, J= 8.2, 5.3 Hz, 1H), 7.59 (dd, J = 12.5, 8.2 Hz, 1H), 6.90 (d, J = 5.Hz, 1H), 6.20 - 6.12 (m, 1H), 6.(d, J = 13.0 Hz, 1H), 4.14 (s, 3H), 3.71 - 3.30 (m, 3H), 2.66 - 2.(m, 3H), 2.47 - 2.36 (m, 1H), 2.- 2.29 (m, 2H), 2.24 - 2.12 (m, 5H), 2.07 - 1.99 (m, 1H), 1.99 - 1.90 (m, 1H), 1.79 - 1.62 (m, 2H), 1.11 (q, J =7.4 Hz, 3H).

Example 93k /، N^O'litT N-N.^T^oY JiN-N^ NA—I arbitrarily assigned enantiomer A:(R) or (S)-2-(l-(6-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol -4-yl)-2-ethylpyri din-3-yl)-2- LC/MS (ESI) m/z: 506 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.42 (d, J = 5.1 Hz, 1H), 8.00 (dd, J= 8.3, 2.9 Hz, 1H), 7.68 (dd, J = 14.4, 8.2 Hz, 1H), 7.00 (d, J = 5.Hz, 1H), 6.28 (dd, J= 13.0, 3.9 Hz, 1H), 6.13 (d, J = 13.0 Hz, 1H), 4.24 (s, 3H), 3.80 - 3.71 (m, 1H), 3.64 - 3.52 (m, 2H), 3.43 (d, J = 12.1 Hz, 1H), 2.89 - 2.79 (m, 1H), 2.76 - 2.65 (m, 4H), 2.31 - 2.(m, 4H), 2.14 - 2.00 (m, 4H), 1.98 Example 178 WO 2022/034568 PCT/IB2021/059266 oxopiperi din-3-yl)acetic acid - 1.89 (m, 1H), 1.88 - 1.79 (m, 1H), 1.20 (td, J= 7.5, 2.8 Hz, 3H). 941XN o"YmT N-N>V I ONI '"*XN־N N ,arbitrarily assigned enantiomer B:(S) or (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H-1,2,3- tri azol-4-yl)-2-ethylpyridin-3-yl)-2- oxopiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 506 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.(d, 5.1 Hz, 1H), 7.99 (dd, J =8.2, 3.3 Hz, 1H), 7.69 (dd, J=20.3, 8.2 Hz, 1H), 7.00 (d, J = 5.1 Hz, 1H), 6.28 (dd, J = 13.0, 3.3 Hz, 1H), 6.13 (d, J = 13.0 Hz, 1H), 4.24 (s, 3H), 3.80 - 3.72 (m, 1H), 3.65 - 3.53 (m, 2H), 3.44 - 3.(m, 1H), 2.86 - 2.65 (m, 4H), 2.- 2.48 (m, 1H), 2.31 - 2.23 (m, 4H), 2.16 - 2.09 (m, 1H), 2.09 - 1.98 (m, 3H), 1.93 - 1.79 (m, 2H), 1.20 (td, J = 7.5, 2.4 Hz, 3H).

Example Example 95: (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid Example 95 Step 1: ethyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate id="p-404" id="p-404" id="p-404" id="p-404" id="p-404" id="p-404" id="p-404" id="p-404" id="p-404"

[0404]To a solution of ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)pyri din-3-yl)piperi din-3-yl)acetate (60 mg, 0.155 mmol) in THF (3 mL) was added NaH (12.4 mg, 0.31 mmol, 60% dispersion in mineral oil) under N2 atmosphere at 0 °C and the mixture was stirred at 0 °C for 30 mins. Then 2,4-dichloro-6-cyclobutyl-l,3,5-triazine (38 mg, 0.1 179 WO 2022/034568 PCT/IB2021/059266 mmol) was added and the resulting mixture was stirred at 0 °C for 2 hrs. The mixture was diluted with saturated aq.NH4Cl solution and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 3: 1) to give the title compound (60 mg, 69.8% yield) as white solid. LC/MS (ESI) (m/z): 555 (M+H)+. Step 2: ethyl (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate id="p-405" id="p-405" id="p-405" id="p-405" id="p-405" id="p-405" id="p-405" id="p-405" id="p-405"

[0405]To a solution of ethyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2- yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate(60 mg, 0.108 mmol) in EtOAc (3 mL) were added TEA (0.075 mL, 0.540 mmol) and Pd/C (mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give title compound (52 mg, 92.4% yield) as yellow oil. LC/MS (ESI) (m/z): 521 (M+H)+. Step 3: (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid id="p-406" id="p-406" id="p-406" id="p-406" id="p-406" id="p-406" id="p-406" id="p-406" id="p-406"

[0406]To a solution of ethyl (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (20 mg, 0.038 mmol) in 1,2-dichloroethane (2 mL) was added trimethyltin hydroxide (69 mg, 0.38 mmol) at room temperature. After stirring at 80 °C for 16 hrs, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (5.5 mg, 29% yield) as white solid. LC/MS (ESI) (m/z): 493 (M+H)+1H-NMR (400 MHz, CD3OD) 5 8.82 (s, 1H), 7.84-7.86 (d, J= 8.3 Hz, 1H), 7.50-7.52 (d, J= 8.4 Hz, 1H), 6.23-6.30 (m, 2H), 4.22 (s, 3H), 3.54-3.58 (m, 1H), 3.14-3.17 (d, J = 10.8 Hz, 1H), 3.02-3.05 (d, J= 11.5 Hz, 1H), 2.81-2.87 (m, 2H), 2.69-2.74 (m, 1H), 2.41-2.(m, 1H), 2.17-2.37 (m, 8H), 2.01-2.09 (m, 2H), 1.74-1.91 (m, 4H), 1.20-1.24 (m, 4H). Example 96: (R)-2-(l-(6-(5-(((4-cyclobutyl-6-morpholino-l,3,5-triazin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid 180 WO 2022/034568 PCT/IB2021/059266 Step 1: (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)pyridin-3- yl)piperidin-3-yl)acetic acid id="p-407" id="p-407" id="p-407" id="p-407" id="p-407" id="p-407" id="p-407" id="p-407" id="p-407"

[0407]To a solution of ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)pyridin-3-yl)piperidin-3-yl)acetate (200 mg, 0.516 mmol) in THF (2 mL) and MeOH (6 mL) was added a solution of LiOH (16.6 mg, 0.51 mmol) in water (2 mL) at 0 °C. After stirring at room temperature for 2 hrs, the reaction mixture was concentrated to dryness and the residue was dissolved in water. The mixture was washed with EtOAc (2x3 mL) and the aqueous layer was acidified with IN aq.HCl to pH~2 and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness give the title compound (180 mg, 97% yield) as white solid. LC/MS (ESI) (m/z): 360 (M+H)+. Step 2: allyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)pyridin- 3-yl)piperidin-3-yl)acetate id="p-408" id="p-408" id="p-408" id="p-408" id="p-408" id="p-408" id="p-408" id="p-408" id="p-408"

[0408]To a mixture of (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)piperidin-3-yl)acetic acid (180 mg, 0.501 mmol) and 3-bromoprop-l-ene (0.0mL, 0.751 mmol) in DMF (6 mL) was added K2CO3 (138 mg, 1.002 mmol) at room temperature and the reaction mixture was stirred at 30 °C for 4 hrs. The mixture was diluted with water and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 1: 1) to give the title compound (1mg, 65% yield) as yellow solid. LC/MS (ESI) (m/z): 400 (M+H)+. Step 3: allyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate id="p-409" id="p-409" id="p-409" id="p-409" id="p-409" id="p-409" id="p-409" id="p-409" id="p-409"

[0409]To a mixture of allyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)piperidin-3-yl)acetate (130 mg, 0.325 mmol) and 2,4-dichloro-6-cyclobutyl-l,3,5- 181 WO 2022/034568 PCT/IB2021/059266 triazine (80 mg, 0.39 mmol) in THF (6 mL) was added t-BuOK (0.65 mL, 0.65 mmol, IM in THF) under N2 atmosphere at 0 °C and the mixture was stirred at 0 °C for 2 hrs. The mixture was poured into ice-cooled saturated aq.NH4Cl solution and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (150 mg, 81.4% yield) as yellow oil. LC/MS (ESI) (m/z): 568 (M+H)+. Step 4: (R)-2-(l-(6-(5-(((4-cyclobutyl-6-morpholino-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid id="p-410" id="p-410" id="p-410" id="p-410" id="p-410" id="p-410" id="p-410" id="p-410" id="p-410"

[0410]To a solution of allyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2- yl)oxy )methyl)- 1-methyl-1H- 1,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (1mg, 0.21 mmol) inDCM (5 mL) were added morpholine (0.037 mL, 0.423 mmol) and tetrakis(triphenylphosphine)palladium (122 mg, 0.106 mmol) under N2 atmosphere and the reaction mixture was stirred at r.t. for 2 hrs. The reaction mixture was diluted with DCM (5 mL), washed with water and brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 45-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (50 mg, 40.9% yield) as white solid. LC/MS (ESI) (m/z): 578 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.84-7.86 (d, J= 8.3 Hz, 1H), 7.50-7.52 (d, J= 8.4 Hz, 1H), 6.13- 6.20 (m, 2H), 4.19 (s, 3H), 3.88 (s, 2H), 3.67 (s, 2H), 3.52 (m, 4H), 3.33-3.42 (m, 1H), 3.16-3.(d, 11.1 Hz, 1H), 3.02-3.04 (d, J= 11.5 Hz, 1H), 2.84-2.89 (m, 2H), 2.70-2.76 (m, 1H), 2.42-4.47 (m, 1H), 2.28-2.36 (m, 4H), 2.17-2.25 (m, 3H), 1.97-2.05 (m, 1H), 1.80-1.92 (m, 3H), 1.25- 1.29 (m, 4H). Example 97: 2-[(3R)-l-{2-ethyl-6-[l-methyl-5-({[6-(lH-l,2,3-triazol-l-yl)pyrimidin-4- yl]oxy}methyl)- 1H-1,2,3-triazol-4-yl]pyridin-3-yl}piperidin-3-yl]acetic acid Pd(PPh 3)4, ch2ci2Step 3 Step 1: prop-2-en-l-yl 2-[(3R)-l-[6-(5-{[(6-chloropyrimidin-4-yl)oxy]methyl}-l-methyl-lH- 1,2,3-tr iazol-4-yl)-2-ethylpyridin-3-yl] piperidin-3-yl] acetate 182 WO 2022/034568 PCT/IB2021/059266 id="p-411" id="p-411" id="p-411" id="p-411" id="p-411" id="p-411" id="p-411" id="p-411" id="p-411"

[0411]To a solution of prop-2-en-l-yl 2-[(3R)-l-{2-ethyl-6-[5-(hydroxymethyl)-l-methyl-1H- l,2,3-triazol-4-yl]pyridin-3-yl}piperidin-3-yl]acetate (135 mg, 0.34 mmol) in THF (10 mL) was added t-BuOK (114 mg, 1.01 mmol) and 4,6-dichloropyrimidine (101 mg, 0.68 mmol) at °C under N2 atmosphere and the mixture was stirred at r.t. for 1 hr. The reaction mixture was quenched with ice-water (10 mL), extracted with EtOAc (2x10 mL). The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 35 % EtOAc in PE) to give the title compound (140 mg, 80.9% yield) as white solid. LC/MS (ESI) m/z: 513 (M+H)+. Step 2: allyl (R)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-l-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate id="p-412" id="p-412" id="p-412" id="p-412" id="p-412" id="p-412" id="p-412" id="p-412" id="p-412"

[0412]To a solution of prop-2-en-l-yl 2-[(3R)-l-[6-(5-{[(6-chloropyrimidin-4-yl)oxy]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]piperidin-3-yl]acetate (140 mg, 0.27 mmol) in CH3CN (3 mL) was added DBU (125 mg, 0.82 mmol) and 2H-l,2,3-triazole (94 mg, 1.37 mmol) and the mixture was stirred in a CEM microwave reactor at 105 °C for 3 hrs. The reaction mixture was evaporated to dryness and the residue was purified by prep-TLC (EtOAc: PE= 1: 2) to give allyl (R)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-l-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (50 mg, 33.6% yield) (45 mg, 29% yield) as white solid. LC/MS (ESI) m/z: 545 (M+H)+. Step 3: 2-[(3R)-l-{2-ethyl-6-[l-methyl-5-({[6-(lH-l,2,3-triazol-l-yl)pyrimidin-4- yl]oxy} methyl)- 1H-1,2,3-triazol-4-yl]pyridin-3-yl} piperidin-3-yl]acetic acid id="p-413" id="p-413" id="p-413" id="p-413" id="p-413" id="p-413" id="p-413" id="p-413" id="p-413"

[0413]To a solution of prop-2-en-l-yl 2-[(3R)-l-{2-ethyl-6-[l-methyl-5-({[6-(lH-l,2,3-triazol- l-yl)pyrimidin-4-yl]oxy}methyl)-lH-l,2,3-triazol-4-yl]pyridin-3-yl}piperidin-3-yl]acetate (mg, 0.10 mmol) in DCM (3 mL) was added Pd(PPh3)4 (5 mg, 0.005 mmol) and morpholine (mg, 0.2 mmol) and the mixture was degassed under N2 atmosphere for three times and stirred at r.t. for 4 hrs. The reaction mixture was evaporated to dryness and the residue was purified by perp- HPLC (C18, 0 ~ 90 % acetonitrile in H2O with 0.1% HCOOH) to give the title compound (12 mg, 25.9% yield) as white solid. 1H NMR (400 MHz, CD3OD) 5 8.80 (d, J= 1.3 Hz, 1H), 8.79 (d, J = 0.9 Hz, 1H), 7.91 (d, J= 1.3 Hz, 1H), 7.84 (d, J= 8.3 Hz, 1H), 7.59 (d, J= 0.9 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 6.27 (s, 2H), 4.24 (s, 3H), 3.18 - 3.12 (m, 1H), 3.07 - 2.99 (m, 1H), 2.83 (q, J= Hz, 2H), 2.76 - 2.65 (m, 1H), 2.46 - 2.38 (m, 1H), 2.30 (d, J= 6.4 Hz, 2H), 2.24 - 2.14 (m, 1H), 1.92 - 1.72 (m, 3H), 1.23 (t, J= 15 Hz, 4H). LC/MS (ESI) m/z: 505 (M+H)+. Example 98: (R)-2-(l-(6-(5-(((6-(2H-l,2,3-triazol-2-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid 183 WO 2022/034568 PCT/IB2021/059266 Example 98 id="p-414" id="p-414" id="p-414" id="p-414" id="p-414" id="p-414" id="p-414" id="p-414" id="p-414"

[0414]The title compound was prepared using the same procedure as example 97.LC/MS (ESI) m/z: 505 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.76 (d, J= 0.8 Hz, 1H), 8.07 (s, 2H), 7.84 (d, J= 8.3 Hz, 1H), 7.50 (dd,J= 4.6, 3.8 Hz, 2H), 6.26 (s, 2H), 4.24 (s, 3H), 3.17 - 3.11 (m, 1H), 3.- 2.98 (m, 1H), 2.83 (q, J= 7.5 Hz, 2H), 2.74 - 2.66 (m, 1H), 2.48 - 2.39 (m, 1H), 2.29 (d, J= 6.Hz, 2H), 2.25-2.15 (m, 1H), 1.91 - 1.70 (m, 3H), 1.22 (t, J= 7.5 Hz, 3H).

Example 99: (S)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-l-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-415" id="p-415" id="p-415" id="p-415" id="p-415" id="p-415" id="p-415" id="p-415" id="p-415"

[0415]The title compound was prepared from methyl (S)-2-(5,5-difluoro-l-(6-(5- (hydroxymethyl)-l-m ethyl-1H- 1,2,3-tri azol-4-yl)-2-methylpyri din-3-yl)piperi din-3-yl)acetate using the same sequence that was synthesized example 97.1HNMR (400 MHz, CD3OD) 5 8.79 (t, J= 1.1 Hz, 2H), 7.91 (d, J= 1.3 Hz, 1H), 7.85 (d, J= 8.3 Hz, 1H), 7.59 (d, J= 0.9 Hz, 1H), 7.(d, 8.4 Hz, 1H), 6.26 - 6.18 (m, 2H), 4.24 (s, 3H), 3.27 (d, J= 13.2 Hz, 2H), 3.11 - 2.96 (m,1H), 2.64 - 2.54 (m, 1H), 2.53 - 2.44 (m, 4H), 2.43 - 2.23 (m, 3H), 1.80 - 1.61 (m, 1H). LC/MS (ESI) m/z: 527 (M+H)+. Example 100: (S)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-2-yl)pyrimidin-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 184 WO 2022/034568 PCT/IB2021/059266 id="p-416" id="p-416" id="p-416" id="p-416" id="p-416" id="p-416" id="p-416" id="p-416" id="p-416"

[0416]The title compound was prepared from methyl (S)-2-(5,5-difluoro-l-(6-(5- (hydroxymethyl)-l-m ethyl-1H- 1,2,3-tri azol-4-yl)-2-methylpyri din-3-yl)piperi din-3-yl)acetate using the same sequence that was synthesized example 97.LC/MS (ESI) m/z: 527 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.74 (s, 1H), 8.09 (s, 2H), 7.99 (d, J= 8.4 Hz, 1H), 7.80 (d, J= 8.Hz, 1H), 7.51 (s, 1H), 6.12 (s, 2H), 4.28 (s, 3H), 3.37 (s, 2H), 3.17-3.09 (m, 1H), 2.70-2.64 (m, 1H), 2.60 (s, 3H), 2.55 - 2.47 (m, 1H), 2.42 (d, J= 7.1 Hz, 2H), 2.35 - 2.27 (m, 1H), 1.82 - 1.(m, 1H).

Example 101: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid Step 1: 2-chloro-4-(lH-pyrazol-l-yl)pyrimidine id="p-417" id="p-417" id="p-417" id="p-417" id="p-417" id="p-417" id="p-417" id="p-417" id="p-417"

[0417]To a solution of 2,4-dichloropyrimidine (5.0 g, 33.6 mmol) in DMF (50 mL) was added IH-pyrazole (2.28 g, 33.6 mmol) followed by K2CO3 (9.28 g, 67.1 mmol) and the reaction was stirred at r.t. for 16 hrs. The mixture was diluted with EtOAc (50 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 5% EtOAc in PE) to give the title compound (1.2 g, 19.8% yield) as yellow solid. LC/MS (ESI) (m/z): 181 (M+H)+. 1H NMR (400 MHz, CDC13) 185 WO 2022/034568 PCT/IB2021/059266 8.63 (d, J= 5.5 Hz, 1H), 8.58 (d, J= 2.4 Hz, 1H), 7.86 (d, J= 5.5 Hz, 1H), 7.82 (d, J= 0.8 Hz, 1H), 6.54 (dd, J= 2.7, 1.6 Hz, 1H). Step 2: ethyl (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate id="p-418" id="p-418" id="p-418" id="p-418" id="p-418" id="p-418" id="p-418" id="p-418" id="p-418"

[0418]To a mixture of ethyl ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (40 mg, 0.11 mmol) and 2-chloro-4-(lH-pyrazol- l-yl)pyrimidine (30 mg, 0.16 mmol) in THF (5 mL) was added t-BuOK (0.22 mL, 0.22 mmol, 1.M in THF) drop-wisely at 0 °C and the reaction was stirred at 0 °C for 1 hr. The mixture was quenched with saturated aq.NH4Cl solution at 0 0C and extracted with EtOAc (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 60% EtOAc in PE) to give the title compound (35 mg, 59.5% yield) as yellow oil. LC/MS (ESI) (m/z): 5(M+H)+. Step 3: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid [0419]To a solution of ethyl (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (36 mg, 0.065 mmol) in THF (4 mL)/H20 (4 mL)/MeOH (4 mL) was added LiOH.H2O (28 mg, 0.66 mmol), and the reaction was stirred at r.t. for 2 hrs. Volatiles were removed under vacuum and the residue was diluted with H2O (5 mL). The mixture was adjusted with IN aq.HCl to pH~4. The mixture was extracted with EtOAc (3x5 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep- HPLC (C18, 5-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (15 mg, 45.2% yield) as white solid. LC/MS (ESI) (m/z): 504 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.57 (d, J = 5.5 Hz, 1H), 8.34 (d, J= 2.6 Hz, 1H), 7.96 (d, J= 8.5 Hz, 1H), 7.81 - 7.74 (m, 2H), 7.61 (d, J = 5.5 Hz, 1H), 6.51 - 6.50 (m, 1H), 6.16-6.09 (m, 2H), 4.27 (s, 3H), 3.25 (d, J= 13.1 Hz, 3H), 3.(d,J = 11.0 Hz, 1H), 2.98 -2.92 (m, 2H), 2.84 - 2.78 m, 1H), 2.56-2.51 (m, 1H), 2.33 -2.31 (m, 2H), 2.27 - 2.21 (m, 1 H), 1.93 - 1.76 (m, 3H), 1.30 - 1.26 (m, 4H). Example 102: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid 186 WO 2022/034568 PCT/IB2021/059266 id="p-420" id="p-420" id="p-420" id="p-420" id="p-420" id="p-420" id="p-420" id="p-420" id="p-420"

[0420]The title compound was synthesized from Intermediate 2Aof example 101according to the same sequence as was used for the synthesis of example 101.LC/MS (ESI) m/z: 490 (M+H)+. 1HNMR (400 MHz, DMSO-d6) 5 8.72 (d, J= 5.5 Hz, 1H), 8.42 (d, J= 2.2 Hz, 1H), 7.93 (d, J = 1.0 Hz, 1H), 7.88 (d, J= 8.3 Hz, 1H), 7.59 (d, J= 5.5 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 6.57 (dd, J= 2.7, 1.6 Hz, 1H), 6.14 (s, 2H), 4.16 (s, 3H), 3.10 (d, J= 10.4 Hz, 1H), 3.02 (d, J= 11.5 Hz, 1H), 2.67 - 2.61 (m, 1H), 2.43 - 2.37 (m, 1H), 2.32 (s, 3H), 2.27 - 2.19 (m, 2H), 2.10 - 2.03 (m, 1H), 1.82 - 1.71 (m, 2H), 1.67 - 1.59 (m, 1H), 1.16 -1.08 (m, 1H). Example 103: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid Step 1 NaHDMF Step 2K2CO3,CulDMSO LiOHTHF/MeOH/H2OStep 3 Example 103 Step 1: ethyl (R)-2-(l-(6-(5-(((4-iodopyridin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4- yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate id="p-421" id="p-421" id="p-421" id="p-421" id="p-421" id="p-421" id="p-421" id="p-421" id="p-421"

[0421]To a solution of ethyl (R)-2-(l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)piperidin-3-yl)acetate (200 mg, 0.53 mmol) in DMF (10 mL) was added NaH (43 mg, 1.07 mmol, 60% dispersion in mineral oil) at 0 °C and the mixture was stirred at 0 °C for min. A solution of 2-fluoro-4-iodopyridine(240 mg, 1.07 mmol) in DMF (2 mL) was added drop-wisely to the above mixture and the resulting mixture was stirred at r.t. for 30 min. The mixture was quenched with saturated aq.NH4Cl solution at 0 °C and was extracted with EtOAc (x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, ~ 45% EtOAc in PE) to give the title compound (120 mg, 38.9% yield) as yellow solid. LC/MS (ESI) (m/z): 577 (M+H)+. Step 2: ethyl (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate id="p-422" id="p-422" id="p-422" id="p-422" id="p-422" id="p-422" id="p-422" id="p-422" id="p-422"

[0422]To a solution of ethyl (R)-2-(l-(6-(5-(((4-iodopyridin-2-yl)oxy)methyl)-l-methyl-lH- 187 WO 2022/034568 PCT/IB2021/059266 l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (120 mg, 0.21 mmol) in DMSO (mL) was added IH-pyrazole (28 mg, 0.42 mmol) followed by K2CO3 (58 mg, 0.42 mmol), Cui (mg, 0.04 mmol) and N,N'-Dimethyl- 1,2-ethanediamine (4 mg, 0.04 mmol). The reaction was stirred at 120 °C for 16 hrs. The mixture was diluted with EtOAc (15 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 40% EtOAc in PE) to give the title compound (50 mg, 46.5% yield) as yellow solid. LC/MS (ESI) m/z: 517 (M+H)+. Step 3: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid [0423]The title compounds was synthesized from compound 3 according to the same sequence as was used for the synthesis of example 101.LC/MS (ESI) m/z: 489 (M+H)+. 1H NMR (400 MHz, CD3OD)5 8.31 (d, =2.6 Hz, 1H), 8.18 (d,J=5.8Hz, 1H), 7.79 (d, =8.4 Hz, 1H), 7.74 (d, J = 1.6 Hz, 1H), 7.51 -7.42 (m, 2H), 7.24 (d, J= 1.7 Hz, 1H), 6.57-6.44 (m, 1H), 6.03 (d,J=2.1 Hz, 2H), 4.22 (s, 3H), 3.20 (d,J=11.0 Hz, 1H), 3.08 (d, J =11.3 Hz, 1H), 2.75 - 2.65 (m, 1H), 2.(s, 3H), 2.42 (d, J =11.2 Hz, 1H), 2.33 - 2.27 (m, 2H), 2.25 - 2.17 (m, 1H), 1.93 - 1.86 (m, 1H), 1.85 - 1.72 (m, 2H), 1.22 - 1.15 (m, 1H). Example 104: (R)-2-(l-(6-(5-(((4-(2H-l,2,3-triazol-2-yl)pyridin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid K2CO3,CulDMSOStep 1 LiOHTHF/MeOH/H2O Step 2 Example 104 Step 1: ethyl (R)-2-(l-(6-(5-(((4-(2H-l,2,3-triazol-2-yl)pyridin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate id="p-424" id="p-424" id="p-424" id="p-424" id="p-424" id="p-424" id="p-424" id="p-424" id="p-424"

[0424]To a solution of ethyl (R)-2-(l-(6-(5-(((4-iodopyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (120 mg, 0.21 mmol) in DMSO (mL) was added 1,2,3-1H-Triazole (29 mg, 0.42 mmol) followed by K2CO3 (58 mg, 0.42 mmol), Cui (8 mg, 0.04 mmol) and N,N'-Dimethyl- 1,2-ethanediamine (4 mg, 0.04 mmol). The reaction was stirred at 120 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (65 mg, 69.8% yield) as yellow solid. LC/MS (ESI) m/z: 518 (M+H)+. 1H NMR (400 MHz, CDC13) 5 8.20 (d, J= 5.6 Hz, 1H), 7.87 (d, J= 8.3 Hz, 1H), 7.77 (s, 2H), 7. 188 WO 2022/034568 PCT/IB2021/059266 (dd, J= 5.6, 1.8 Hz, 1H), 7.40 (d, J= 1.8 Hz, 1H), 7.26 (d, J= 8.3 Hz, 1H), 6.04 (s, 2H), 4.10 (s, 3H), 4.05 - 4.03 (m, 2H), 3.02 - 2.95 (m, 1H), 2.97 (d, J= 11.4 Hz, 1H), 2.64 - 2.54 (m, 1H), 2.-2.38 (m, 3H), 2.37-2.30 (m, 1H), 2.21 -2.16(m, 1H), 1.84 7 1.75 (m, 1H), 1.18 (dd, J=4.7, 2.Hz, 3H), 1.13-1.05 (m, 1H). Step 2: (R)-2-(l-(6-(5-(((4-(2H-l,2,3-triazol-2-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid The title compounds was synthesized according to the same sequence as was used for the synthesis of example 103LC/MS (ESI) m/z:490 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.(d, J= 5.7 Hz, 1H), 7.97 (s, 2H), 7.78 (d, J= 8.3 Hz, 1H), 7.70 (dd, J= 5.7, 1.8 Hz, 1H), 7.48 (d, J= 8.3 Hz, 1H), 7.47 (d, J= 1.8 Hz, 1H), 6.06 (s, 2H), 4.22 (s, 3H), 3.22 - 3.19 (m, 1H), 3.10 - 3.05 (m, 1H), 2.73 - 2.66 (m, 1H), 2.46 (s, 3H), 2.44 - 2.40 (m, 1H), 2.32 - 2.28 (m, 2H), 2.25 - 2.18 (m, 1H), 1.93 - 1.87 (m, 1H), 1.84 - 1.72 (m, 2H), 1.26 - 1.18 (m, 1H). Example 105: (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)-3- methylisoxazol-5-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid Step 1: tert-butyl (Z)-3-(methylamino)but-2-enoate id="p-425" id="p-425" id="p-425" id="p-425" id="p-425" id="p-425" id="p-425" id="p-425" id="p-425"

[0425]To aq.MeNH2 solution (40% wt in water) (5.9 g, 190 mmol) was added tert-butyl 3- oxobutanoate (10 g, 63.2 mmol) drop-wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with DCM (50 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (10.8 g, 99.8% 189 WO 2022/034568 PCT/IB2021/059266 yield) as yellow oil. LC/MS (ESI) m/z: 172 (M+H)+. Step 2: tert-butyl (E)-2-(5-bromo-6-methylpicolinoyl)-3-(methylimino)butanoate id="p-426" id="p-426" id="p-426" id="p-426" id="p-426" id="p-426" id="p-426" id="p-426" id="p-426"

[0426]To a mixture of 5-bromo-6-methylpicolinoyl chloride (1 g, 4.27 mmol) and tert-butyl (Z)- 3-(methylamino)but-2-enoate (0.80 g, 4.69 mmol) in THE (10 mL) was added pyridine (1.69 g, 21.3 mmol) drop-wisely at 0 °C and the mixture was stirred at r.t. for 16 hrs. The mixture was diluted EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give title compound (964 mg, 61.2% yield) as yellow solid. LC/MS (ESI) m/z: 369/371 (M+H)+. Step 3: 5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazole-4-carboxylic acid id="p-427" id="p-427" id="p-427" id="p-427" id="p-427" id="p-427" id="p-427" id="p-427" id="p-427"

[0427]To a solution of tert-butyl (E)-2-(5-bromo-6-methylpicolinoyl)-3-(methylimino)butanoate (964 mg, 2.61 mmol) in EtOH (10 mL) was added hydroxylamine hydrochloride (272 mg, 3.mmol) and the mixture was stirred at 60 °C for 3 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with DCM: MeOH = 200: 1 to 20: 1) to give the title compound (3mg, 45.5% yield) as white solid. LC/MS (ESI) m/z: 297/299 (M+H)+. Step 4: (5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazol-4-yl)methanol id="p-428" id="p-428" id="p-428" id="p-428" id="p-428" id="p-428" id="p-428" id="p-428" id="p-428"

[0428]To a solution of 5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazole-4-carboxylic acid (353 mg, 1.19 mmol) in THE (5 mL) was added BH3-THF (3 mL, 3 mmol, 1 M in THE) drop- wisely at 0 °C and the mixture was stirred at 60 °C for 2 hrs. The mixture was quenched with MeOH at 0 °C and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 30: 1 to 3: 1) to give the title compound (163 mg, 48.5% yield) as white solid. LC/MS (ESI) m/z: 283/285 (M+H)+. Step 5: 5-(5-bromo-6-methylpyridin-2-yl)-3-methyl-4-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)isoxazole [0429]To a solution of (5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazol-4-yl)methanol (1mg, 0.58 mmol) in DCM (3 mL) were added DHP (121 mg, 1.44 mmol), PPTS (7.2 mg, 0.0mmol) and the mixture was stirred at r.t. for 16 hrs. The mixture was quenched with saturated aq.NaHCO3 and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with DCM: MeOH= 200: 1 to 20: 1) to give the title compound (200 mg, 94.6% yield) as yellow oil. LC/MS (ESI) m/z: 367/369 (M+H)+. 190 WO 2022/034568 PCT/IB2021/059266 Step 6: methyl 2-((3S)-5,5-difluoro-l-(2-methyl-6-(3-methyl-4-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)isoxazol-5-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-430" id="p-430" id="p-430" id="p-430" id="p-430" id="p-430" id="p-430" id="p-430" id="p-430"

[0430]To a mixture of 5-(5-bromo-6-methylpyridin-2-yl)-3-methyl-4-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)isoxazole (95 mg, 0.26 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate (50.0 mg, 0.26 mmol) in 1,4-dioxane (2 mL) were added Cs2CO3 (253 mg, 0.78 mmol), Pd2(dba)(24 mg, 0.026 mmol), Ru-Phos (12 mg, 0.026 mmol ) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 1: 1) to give the title compound (45 mg, 36.2% yield) as yellow solid. LC/MS (ESI) m/z: 480 (M+H)+. Step 7: methyl (S)-2-(5,5-difluoro-l-(6-(4-(hydroxymethyl)-3-methylisoxazol-5-yl)-2- methylpyridin-3-yl)piperidin-3-yl)acetate id="p-431" id="p-431" id="p-431" id="p-431" id="p-431" id="p-431" id="p-431" id="p-431" id="p-431"

[0431]To a solution of methyl 2-((3S)-5,5-difluoro-l-(2-methyl-6-(3-methyl-4-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)isoxazol-5-yl)pyridin-3-yl)piperidin-3-yl)acetate (45 mg, 0.094 mmol) in MeOH (2 mL) was added PPTS (47 mg, 0.19 mmol) and the mixture was stirred at 60 °C for 2 hrs. The mixture was diluted with EtOAc (5 mL) and washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 1: 1) to give the title compound (mg, 80.9% yield) as yellow oil. LC/MS (ESI) m/z: 396 (M+H)+. Step 8: methyl (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)-3- methylisoxazol-5-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate id="p-432" id="p-432" id="p-432" id="p-432" id="p-432" id="p-432" id="p-432" id="p-432" id="p-432"

[0432]To a solution of methyl (S)-2-(5,5-difluoro-l-(6-(4-(hydroxymethyl)-3-methylisoxazol-5- yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (30 mg, 0.076 mmol) and 4-chloro-6-(lH-pyrazol- l-yl)pyrimidine (20.6 mg, 0.11 mmol) in THE (2 mL) was added t-BuOK (0.15 mL, 0.15 mmol, M in THF) drop-wisely at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 2 hrs. The mixture was quenched with water and extracted with EtOAc (3x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (30 mg, yield 73.3%) as yellow oil, which was used in next step directly. LC/MS (ESI) m/z: 540 (M+H)+. Step 9: (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)-3-methylisoxazol-5- yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-433" id="p-433" id="p-433" id="p-433" id="p-433" id="p-433" id="p-433" id="p-433" id="p-433"

[0433]To a solution of methyl (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)- 3-methylisoxazol-5-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.0 191 WO 2022/034568 PCT/IB2021/059266 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (23.3 mg, 0.mmol) at 25 °C and the mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc (2 x mL) and the aqueous layer was acidified with IN aq.HCl to pH = 4 and extracted with DCM (x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (5 mg, 17.1% yield) as white solid. 1HNMR (400 MHz, CD3OD) 5 8.63 (s, 1H), 8.59 (d, J= 2.6 Hz, 1H), 7.76 (d, J= 1.0 Hz, 1H), 7.73 (d,J = 8.2Hz, 1H), 7.53 (d,J = 8.4Hz, 1H), 7.27 (s, 1H), 6.54 (dd, J = 2.6, 1.7 Hz, 1H), 5.(s, 2H), 3.40-3.33 (m, 2H), 3.15-3.03 (m, 1H), 2.64-2.57 (m, 1H), 2.55-2.50 (m, 1H), 2.48 (s, 3H), 2.41 (s, 3H), 2.41-2.38 (m, 2H), 2.36-2.27 (m, 1H), 1.80-1.66 (m, 1H). LC/MS (ESI) m/z: 5(M+H)+. Example 106: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl-3,4-dihydropyrazin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid Step 1: methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl-3,4-dihydropyrazin- 2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-434" id="p-434" id="p-434" id="p-434" id="p-434" id="p-434" id="p-434" id="p-434" id="p-434"

[0434]To a mixture of methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (55 mg, 0.14 mmol) and 3-chloro-l- propylpyrazin-2(lH)-one (27 mg, 0.15 mmol) in DMF (5 mL) was added t-BuOK (0.42 mL, 0.mmol, 1 M in THF) at 0 °C and the mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with saturated aq.NH4Cl solution and brine, dried over anhydrous Na2SO4 filtered and concentrated to dryness to give the title compound (70 mg, 94.2% yield). LC/MS (ESI) (m/z): 532 (M+H)+. Step 2: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl-3,4-dihydropyrazin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid id="p-435" id="p-435" id="p-435" id="p-435" id="p-435" id="p-435" id="p-435" id="p-435" id="p-435"

[0435]To a solution of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl- 3,4-dihydropyrazin-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (74 mg, 0.14 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (29 mg, 0.7 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to 192 WO 2022/034568 PCT/IB2021/059266 dryness. The residue was diluted with water (5 mL) and washed with EtOAc (2x3 mL). The aqueous layer was acidified with IN aq.HCl to pH- 3 and extracted with DCM (3x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (15 mg, 20.8% yield) as white solid. LC/MS (ESI) m/z: 518 (M+H)+. 1H-NMR (400 MHz, CD3OD) 5 7.83 (d, J= 8.Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.16 (d, J= 4.4 Hz, 1H), 6.92 (d, J= 4.4 Hz, 1H), 5.99 (s, 2H), 4.21 (s, 3H),3.90(t,J=8.4Hz, 2H), 3.30-3.24 (m, 2H), 3.14 - 3.00 (m, 1H), 2.64 - 2.51 (m, 1H), 2.47 - 2.26 (m, 7H), 1.81 - 1.62 (m, 3H), 0.94 (t, J = 7.2 Hz, 3H).

Example 107: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid BnCIJone's reagentAcetone MeOHStep 4 5 1 Step 1aq.NaOH MeOH Example 107 Step 1: 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one [0436]To a solution of 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one (5 g, 35.2 mmol) in MeOH (100 mL) was added a solution of NaOH (1.41 g, 35.2 mmol) in H2O (10 mL) and the reaction was stirred at 80 °C for 30 min. (Chioromethy!)benzene (4.05 mL, 35.2 mmol) was added drop-wisely to the above mixture and the resulting mixture was stirred at 80 °C for 16 hrs. The mixture was diluted with H2O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (800 mg, 9.8% yield) as brown yellow solid, which was directly used in the next step. LC/MS (ESI) m/z: 233 (M+H)+. Step 2: 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid [0437]To a solution of 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (800 mg, 3.44 mmol) in acetone (50 mL) was added newly prepared Jone ’s-reagent (2.6 mL, 5.2 mmol) at 0 °C and the mixture was stirred at r.t. for 1 hr. The mixture was poured into ice-water and extracted with EtOAc (3x10 mL). The combined organic layers were washed with saturated aq.Na2SO3 solution and 193 WO 2022/034568 PCT/IB2021/059266 brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (850 mg, 100% yield) as yellow oil, which was directly used in the next reaction without purification. LC/MS (ESI) m/z: 247 (M+H)+. Step 3: 5-(benzyloxy)-4-oxo-l-propyl-l,4-dihydropyridine-2-carboxylic acid [0438]A mixture of 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid (850 mg, 3.44 mmol) and propan- 1-amine (816 mg, 13.8 mmol) in MeOH (10 mL) was stirred at r.t. for 16 hrs. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (10 mL). The mixture was acidified with 3N aq.HCl to pH~2 and filtered. The filter cake was washed with water, dried under vacuum to give the title compound (390 mg, 39.3% yield) as light yellow solid. LC/MS (ESI) m/z: 288 (M+H)+. Step 4: 3-(benzyloxy)-l-propyl-l,4-dihydropyridin-4-one [0439]The solution of 5-(benzyloxy)-4-oxo-l-propyl-l,4-dihydropyridine-2-carboxylic acid (2mg, 0.87mmol) in DMF (5 mL) was stirred at 130 °C for 1 hr. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (150 mg, 70.9% yield) as yellow solid. LC/MS (ESI) m/z: 244 (M+H)+. Step 5: 3-hydroxy-l-propylpyridin-4(lH)-one [0440]To a solution of 3-(benzyloxy)- 1-propyl-l,4-dihydropyridin-4-one (150 mg, 0.62 mmol) in MeOH (3 mL) was added Pd(OH)2 (30 mg, 10% wt), the mixture was degassed under Natmosphere for three times and stirred under a H2 balloon at r.t. for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (90 mg, 95.3% yield) as white solid. LC/MS (ESI) (m/z): 154 (M+H)+. 1HNMR (400 MHz, CDC13) 5 7.18 - 7.24 (m, 2H), 6.43 (d, J= 6.9 Hz, 1H), 3.74 - 3.80 (m, 2H), 1.89 - 1.78 (m, 2H), 0.92 - 0.98 (m, 3H). Step 6: methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate id="p-441" id="p-441" id="p-441" id="p-441" id="p-441" id="p-441" id="p-441" id="p-441" id="p-441"

[0441]To a mixture of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.062 mmol) and 3- hydroxy-l-propylpyridin-4(lH)-one (14 mg, 0.092 mmol) in CH3CN (1 mL) was added K2CO(25 mg, 0.18 mmol) and TBAI (4 mg, 0.01 mmol) and the mixture was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (32 mg, 94.8% yield) as yellow solid. LC/MS (ESI) (m/z): 545 (M+H)+. Step 7: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-442" id="p-442" id="p-442" id="p-442" id="p-442" id="p-442" id="p-442" id="p-442" id="p-442"

[0442]To a solution of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl- 1,4- 194 WO 2022/034568 PCT/IB2021/059266 dihydropyri din-3-yl)oxy)methyl)-lH- 1,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (32 mg, 0.059 mmol) in MeOH (1 mL), water (1 mL) and THF (2 mL) was added LiOH.H2O (12 mg, 0.29 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness. The residue was diluted with water (3 mL) and washed with EtOAc (2x3 mL). The aqueous layer was acidified with IM aq.HCl to pH ~ 3 and extracted with DCM (3x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep HPLC to give the title compound (9 mg, 28.9% yield) as white solid. LC/MS (ESI) (m/z): 531 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.93 (d, J= 8.4 Hz, 1H), 7.77 (d, J= 2.1 Hz, 1H), 7.63 - 7.58 (m, 2H), 6.42 (d, J= 7.2 Hz, 1H), 6.01 - 5.82 (m, 2H), 4.22 (s, 3H), 3.71 - 3.68 (t, J= 7.2 Hz, 2H), 3.2 - 3.20 (m, 2H), 3.14-3.05 (m, 1H), 2.9 - 2.93 (m, 2H), 2.65 - 2.57 (m, 1H), 2.63 - 2.58 (m, 1H), 2.40 (d, J= 7.0 Hz, 2H), 2.34 - 2.25 (m, 1H), 1.80 - 1.64 (m, 1H), 1.5 - 1.49 (m, 2H), 1.33 - 1.29 (t, J= 15 Hz, 3H), 0.73 - 0.(t, J = 7.4 Hz, 3H). Example 108: 2-[(lS)-5-(6-{5-[(5-cyclobutyl-2-oxo-l,2-dihydropyridin-l-yl)methyl]-l- methyl-lH-l,2,3-triazol-4-yl}-2-ethylpyridin-3-yl)-3,3-difluorocyclohexyl]acetic acid Example 108 Step 1: 6-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)-2- propylpyridazin-3(2H)-one id="p-443" id="p-443" id="p-443" id="p-443" id="p-443" id="p-443" id="p-443" id="p-443" id="p-443"

[0443]To a solution of [4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol- 5yl]methanol (150 mg, 0.5 mmol) in DMF (4 mL) was added NaH (42 mg, 1.1 mmol, 60% dispersion in mineral oil) at 0 °C and the mixture was stirred at this temperature for 30 min. 3- Chioro-1-propyl-l,2-dihydropyrazin-2-one (101 mg, 0.6 mmol) was added to the above mixture and the resulting mixture was stirred at r.t. for 1.5 hrs. The reaction was quenched with saturated aq.NH4Cl solution and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 4: 1) to give the title compound (1 195 WO 2022/034568 PCT/IB2021/059266 mg, 54.0% yield) as off-white solid. LC/MS (ESI) (m/z): 420 (M+H)+. Step 2: methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((6-oxo-l-propyl-l,6- dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-444" id="p-444" id="p-444" id="p-444" id="p-444" id="p-444" id="p-444" id="p-444" id="p-444"

[0444]To a solution of 6-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-2-propylpyridazin-3(2H)-one (120 mg, 0.28 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (55 mg, 0.28 mmol) in toluene (3 mL) were added Cs2CO3 (234 mg, 0.71 mmol), BINAP (35.7 mg, 0.05 mmol), Pd(OAc)2 (6.4 mg, 0.028 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 10: 1 to 1: 1) to give the title compound (100 mg, 67.2% yield) as white solid. LC/MS (ESI) m/z: 534 (M+H)+. Step 3: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((6-oxo-l-propyl-l,6 dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid id="p-445" id="p-445" id="p-445" id="p-445" id="p-445" id="p-445" id="p-445" id="p-445" id="p-445"

[0445]To a solution of (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((6-oxo-l-propyl-l,6- dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (mg, 0.094 mmol ) in THE (2 mL), MeOH (1 mL) and water (1 mL) was added LiOH.H2O (40 mg, 0.1 mmol) and the mixture was stirred at 25 °C for 3 hrs. The reaction mixture was acidified with IM aq.HCl to pH~4 and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (15 mg, 30.8% yield) as white solid. LC/MS (ESI) m/z: 518 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 7.86 (d, J= 8.3 Hz, 1H), 7.55 (d, J= 8.Hz, 1H), 7.16 (d, J= 9.7 Hz, 1H), 6.94 (d, J= 9.7 Hz, 1H), 5.97 (s, 2H), 4.19 (s, 3H), 3.79 - 3.(m, 2H), 3.30 - 3.25 (m, 2H), 3.14 - 3.03 (m, 1H), 2.60 (t, J= 10.5 Hz, 1H), 2.52 (s, 3H), 2.51 - 2.42 (m, 1H),2.39(d,J=6.5Hz, 2H), 2.30 (s, 1H), 1.82- 1.66 (m, 1H), 1.65 - 1.55 (m, 2H), 0.(t, J =7.4 Hz, 3H). Example 109: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5-dihydropyridazin-4- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 196 WO 2022/034568 PCT/IB2021/059266 MeONaMeOH acetoneStep 2 H2, Pd(OH)2TEA, EtOAcStep 3 Step 4 MeONaMeOHStep 1 Step 1: 3,5-dichloro-4-methoxypyridazine [0446]To a solution of 3,4,5-trichloropyridazine (5 g, 27.26 mmol) in MeOH (50 mL) was added MeONa/MeOH solution (5.5 mL, 5 M) drop-wisely at -10 °C and the mixture was stirred at 0 °C for 1 hr. The mixture was concentrated to dryness and the residue was dissolved in H2O (50 mL). The mixture was extracted with DCM (2x30 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (PE: EtOAc= 20: 1) to give the title compound (1.5 g, 30.7% yield) as yellow solid. LC/MS (ESI) m/z: 179 (M+H)+. 1HNMR (400 MHz, CDC13) 5 9.01 (s, 1H), 4.15 (s, 3H). Step 2: 3-chloro-4,5-dimethoxypyridazine [0447]To a solution of 3,5-dichloro-4-methoxypyridazine (2.8 g, 15.64 mmol) in MeOH (30 mL) was MeONa/MeOH solution (3.2 mL, 16 mmol, 5 M) drop-wisely at r.t. and the mixture was stirred at 80 °C for 1 hr. The mixture was concentrated to dryness and the residue was dissolved in H2O (50 mL). The mixture was extracted with DCM (2 x 30 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (PE: EtOAc= 10: 1) to give the title compound (1.g, 58.6% yield) as yellow solid. LC/MS (ESI) m/z: 175 (M+H)+. Step 3: 4,5-dimethoxypyridazine id="p-448" id="p-448" id="p-448" id="p-448" id="p-448" id="p-448" id="p-448" id="p-448" id="p-448"

[0448]To a solution of 3-chloro-4,5-dimethoxypyridazine (600 mg, 3.44 mmol) in EtOAc (20 mL) were added TEA (695 mg, 6.87 mmol) and Pd(OH)2/C (48 mg, 0.03 mmol, 10% wt) and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 197 WO 2022/034568 PCT/IB2021/059266 °C for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (210 mg, 43.6% yield) as white solid. LC/MS (ESI) m/z: 141 (M+H)+. 1H NMR (4MHz, CDC13) 5 8.78 (s, 2H), 3.96 (s, 6H). Step 4: 5-methoxy-l-propyl-l,4-dihydropyridazin-4-one id="p-449" id="p-449" id="p-449" id="p-449" id="p-449" id="p-449" id="p-449" id="p-449" id="p-449"

[0449]To a solution of 4,5-dimethoxypyridazine (200 mg, 1.43 mmol) in acetone (5mL) was added 1-iodopropane (485 mg, 2.85 mmol) and the mixture was stirred at 50 °C for 18 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel column chromatography (PE: EtOAc= 3: 1) to give the title compound (80 mg, 33.3% yield). LC/MS (ESI) (m/z): 169 (M+H)+. 1H NMR (400 MHz, CDC13)5 7.86 (s, 1H), 7.42 (s, 1H), 3.93-3.98 (m, 2H), 3.80 (s, 3H), 1.81-1.89 (m, 2H), 0.87-0.93 (m, 3H). Step 5: 5-hydroxy-l-propyl-l,4-dihydropyridazin-4-one id="p-450" id="p-450" id="p-450" id="p-450" id="p-450" id="p-450" id="p-450" id="p-450" id="p-450"

[0450]To a solution of 5-methoxy-l-propyl-l,4-dihydropyridazin-4-one (80 mg, 0.48 mmol) in DCM (3mL) was BBr3 (0.18 mL, 1.90 mmol) drop-wisely at 0 °Cand the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with MeOH at 0 °C and poured into ice-cooled saturated aq.NaHCO3 solution. The mixture was extracted with DCM (2x5 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 1: 1) to give the title compound (30 mg, 40.9% yield) as yellow solid. LC/MS (ESI) m/z: 155 (M+H)+. Step 6: methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5-dihydropyridazin-4- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate id="p-451" id="p-451" id="p-451" id="p-451" id="p-451" id="p-451" id="p-451" id="p-451" id="p-451"

[0451]To the mixture of 5-hydroxy-l-propyl-l,4-dihydropyridazin-4-one (14 mg, 0.09 mmol) and methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.06 mmol) in MeCN (3 mL) was added K2CO3(25 mg, 0.18 mmol) and TBAI (5 mg, 0.01 mmol) and the mixture was stirred at °C for 1 6 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 5: 1 to 1: 1) to give the title compound (20 mg, 59.7% yield) as yellow solid. LC/MS (ESI) m/z: 546 (M+H)+. Step 7: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5-dihydropyridazin-4- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-452" id="p-452" id="p-452" id="p-452" id="p-452" id="p-452" id="p-452" id="p-452" id="p-452"

[0452]To a solution of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5- dihydropyridazin-4-yl)oxy)methyl)-lH- 1,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (20 mg, 0.037 mmol) in THE (1 mL) and MeOH (1 mL) was added a solution of LiOH 198 WO 2022/034568 PCT/IB2021/059266 (15 mg , 0.37 mmol) in H2O (0.5 mL), and the mixture was stirred at r.t. for 2 hrs. The mixture was acidified with IN aq.HCl to pH~4 and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (C18, 0 ~ 90% acetonitrile in H2O with 0.1% HCOOH) to give the title compound (9 mg, 46.2% yield) as white solid. LC/MS (ESI) m/z: 532 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.54 (s, 1H), 7.94 (d,J=9.5 Hz, 2H), 7.61 (d, J= 8.4 Hz, 1H), 6.04 - 5.(m, 2H), 4.22 (s, 3H), 3.91 - 3.96 (t, J= 7.1 Hz, 2H), 3.25 - 3.22 (m, 2H), 3.14 - 3.05 (m, 1H), 2.- 2.92 (q, J= ך.ך Hz, 2H), 2.63 - 2.58 (t, J= 10.8 Hz, 1H), 2.53 - 2.50 (m, 1H), 2.41 - 2.39 (m, 2H), 2.31 - 2.26 (m, 1H), 1.80 - 1.63 (m, 3H), 1.26 - 1.32 (t, J= 15 Hz, 3H), 0.72 - 0.78 (t, J = 1A Hz, 3H). Example 110: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-methyl-3-oxo-6-propyl-3,4-dihydropyrazin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid HCIAcOHStep 3 Example 110 Step 1: N-(l-hydroxypentan-2-yl)-N*-methylethanediamide id="p-453" id="p-453" id="p-453" id="p-453" id="p-453" id="p-453" id="p-453" id="p-453" id="p-453"

[0453]To a solution of 2-aminopentan-l-ol (1.21 g, 11.63 mmol) in toluene (15 mL) and EtOAc was added ethyl (methylcarbamoyl)formate (1.67 g, 12.79 mmol), and the mixture was stirred at °C for 16 hrs. The reaction mixture was concentrated to dryness and the solid was washed with PE, dried under vacuum to give the title compound (2.06 g, 94.1% yield) as white solid. LC/MS (ESI) m/z: 189(M+H)+. Step 2: N*-methyl-N-(l-oxopentan-2-yl)ethanediamide id="p-454" id="p-454" id="p-454" id="p-454" id="p-454" id="p-454" id="p-454" id="p-454" id="p-454"

[0454]To a solution of N-(l-hydroxypentan-2-yl)-N'-methylethanediamide (400 mg, 2.12 mmol) in DCM (15 mL) was added Dess-Martin periodinane (900 mg, 2.12 mmol) and the mixture was stirred at r.t. for 3 hrs. The mixture was washed with saturated aq.NaHCO3 solution and brine, dried 0verNa2S04, filtered and concentrated to dryness to give the title compound (405 mg, 81.9% yield) as white solid. LC/MS (ESI) m/z: 187 (M+H)+. Step 3: 3-hydroxy-l-methyl-5-propyl-l,2-dihydropyrazin-2-one 199 WO 2022/034568 PCT/IB2021/059266 id="p-455" id="p-455" id="p-455" id="p-455" id="p-455" id="p-455" id="p-455" id="p-455" id="p-455"

[0455]To a solution of N'-methyl-N-(l-oxopentan-2-yl)ethanediamide (405 mg, 2.14 mmol) in AcOH (5 mL) was added conc.HCl (0.5 mL) and the mixture was stirred at 100 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0-15% MeOH in DCM) to give the title compound (121 mg, 33.5% yield) as yellow solid. LC/MS (ESI) m/z: 169 (M+H)+. 1H NMR (400 MHz, DMSO-d6) 5 11.25 (s, 1H), 6.29 (s, 1H), 3.23 (s, 3H), 2.16 (t, J = 7.4 Hz, 2H), 1.49 (dt, J = 14.5, 7.3 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H). Step 4: 3-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methoxy}-l- methyl-5-propyl-l,2-dihydropyrazin-2-one id="p-456" id="p-456" id="p-456" id="p-456" id="p-456" id="p-456" id="p-456" id="p-456" id="p-456"

[0456]To a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate (207 mg, 0.49 mmol) in DMF (5 mL) was added 3-hydroxy-l-methyl-5-propyl- l,2-dihydropyrazin-2-one (115 mg, 0.68 mmol), K2CO3 (203 mg, 1.47 mmol) and the mixture was stirred at 60 °C for 2 hrs. The reaction mixture was diluted with EtOAc (10 mL), washed with saturated aq.NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-100% EtOAc in PE) to give the title compound (58 mg, 23.9% yield) as white solid. LC/MS (ESI) m/z: 495 (M+H)+. Step 5: methyl 2-[(3S)-l-[2-ethyl-6-(l-methyl-5-{[(4-methyl-3-oxo-6-propyl-3,4- dihydropyrazin-2-yl)oxy]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin- 3-yl] acetate id="p-457" id="p-457" id="p-457" id="p-457" id="p-457" id="p-457" id="p-457" id="p-457" id="p-457"

[0457]To a solution of 3-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methoxy}-l-methyl-5-propyl-l,2-dihydropyrazin-2-one (58 mg, 0.12 mmol) in 1,4-dioxane (mL) was added Cs2CO3 (118 mg, 0.36 mmol), methyl 2-[(3S)-5,5-difluoropiperidin-3-yl]acetate (23 mg, 0.12 mmol), Ruphos-Pd-G3 (30 mg, 0.036 mmol), RuPhos (11 mg, 0.024 mmol) and the mixture was degassed under N2 for 3 times and stirred at 110 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (75 mg, 88.3% yield) as yellow solid, which was directly used to the next reaction without purification. LC/MS (ESI) m/z: 5(M+H)+. Step 6: 2-[(3S)-l-[2-ethyl-6-(l-methyl-5-{[(4-methyl-3-oxo-6-propyl-3,4-dihydropyrazin-2- yl)oxy]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid id="p-458" id="p-458" id="p-458" id="p-458" id="p-458" id="p-458" id="p-458" id="p-458" id="p-458"

[0458]To a solution of methyl 2-[(3S)-l-[2-ethyl-6-(l-methyl-5-{[(4-methyl-3-oxo-6-propyl-3,4- dihydropyrazin-2-yl)oxy]methyl}-lH- 1,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperi din-3- yl]acetate (75 mg, 0.11 mmol) in THE (2 mL), MeOH (0.5 mL), H2O (1 mL) was added LiOH (mg, 1.07 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed 200 WO 2022/034568 PCT/IB2021/059266 with MTBE (3x5 mL), acidified with IN aq.HCl to pH~3 and extracted with DCM (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (mg, 30% yield) as white solid. LC/MS (ESI) m/z: 546 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.86 (d, J= 8.3 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 6.94 (s, 1H), 6.12 (s, 2H), 4.21 (s, 3H), 3.48 (s, 3H), 3.22 (d, J= 10.2 Hz, 2H), 3.07 (dd, J= 24.7, 9.4 Hz, 1H), 2.89 (q, J= 7.4 Hz, 2H), 2.59 (t, J = 10.5 Hz, 1H), 2.54 - 2.46 (m, 1H), 2.36 (d, J= 7.0 Hz, 2H), 2.34 - 2.27 (m, 1H), 2.26 - 2.22 (m, 2H), 1.71 (dt,J=24.4, 15.7 Hz, 1H), 1.46 (dt,J= 13.8, 6.9 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H), 0.(t, J = 7.4 Hz, 3H).

Example 111: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridazin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid Example 111 Step 1: 5-chloro-3,4-dimethoxypyridazine id="p-459" id="p-459" id="p-459" id="p-459" id="p-459" id="p-459" id="p-459" id="p-459" id="p-459"

[0459]To a solution of 3,5-dichloro-4-methoxypyridazine (3.2 g, 17.9 mmol) in MeOH (20 mL) was added sodium methoxide solution (30% in methanol) (3.22 g, 17.9 mmol) at room temperature under N2 atmosphere and the reaction was stirred at 90 °C for 3 hrs. The mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 10: 1) to give the title compound (0.74 g, 23.7% yield) as white solid. LCMS (ESI) m/z: 175 (M+H)+. Step 2: 3,4-dimethoxypyridazine id="p-460" id="p-460" id="p-460" id="p-460" id="p-460" id="p-460" id="p-460" id="p-460" id="p-460"

[0460]To a solution of 5-chloro-3,4-dimethoxypyridazine (740 mg, 4.24 mmol) in EtOAc (10 mL) was added TEA (1.18 mL, 8.4 mmol) and Pd(OH)2/C (120 mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room 201 WO 2022/034568 PCT/IB2021/059266 temperature for 4 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (500 mg, 84.2% yield) as white solid. LC/MS (ESI) (m/z): 141 (M+H)+. Step 3: 3-methoxy-l-propylpyridazin-4(lH)-one id="p-461" id="p-461" id="p-461" id="p-461" id="p-461" id="p-461" id="p-461" id="p-461" id="p-461"

[0461]To a solution of 3,4-dimethoxypyridazine (500 mg, 3.57 mmol) in acetone (10 mL) was added 1-iodopropane (0.52 mL, 5.35 mmol) at room temperature and the reaction mixture was stirred at 50 °C for 16 hrs. The mixture was diluted with water (5 mL) and extracted with DCM (x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 20: 1) to give the title compound (80 mg, 13.3% yield) as white solid. LC/MS (ESI) (m/z): 169 (M+H)+. Step 4: 3-hydroxy-l-propylpyridazin-4(lH)-one id="p-462" id="p-462" id="p-462" id="p-462" id="p-462" id="p-462" id="p-462" id="p-462" id="p-462"

[0462]To a solution of 3-methoxy-l-propylpyridazin-4(lH)-one (80 mg, 0.476 mmol) in DCM (mL) was added BBr3 (0.135 mL, 1.43 mmol) at 0 °C and the mixture was stirred at r.t. for 1 hr. The reaction was quenched with MeOH at 0 °C and the mixture was basified with saturated aq.NaHCO3 solution. The mixture was extracted with DCM (2x5 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (30 mg, 40.9% yield) as yellow solid. LC/MS (ESI) (m/z): 155 (M+H)+. Step 5: methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridazin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate id="p-463" id="p-463" id="p-463" id="p-463" id="p-463" id="p-463" id="p-463" id="p-463" id="p-463"

[0463]To a mixture of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.062 mmol) and 3- hydroxy-l-propylpyridazin-4(lH)-one (14.3 mg, 0.093 mmol) in CH3CN (2 mL) were added K2CO3 (17 mg, 0.124 mmol) and TBAI (2.3 mg, 0.006 mmol) and the mixture reaction was stirred at 70 °C under N2 atmosphere for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (15 mg, 44% yield) as yellow oil. LC/MS (ESI) (m/z): 546 (M+H)+. Step 6: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridazin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-464" id="p-464" id="p-464" id="p-464" id="p-464" id="p-464" id="p-464" id="p-464" id="p-464"

[0464]To a solution of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl- 1,4- dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate (10 mg, 0.018 mmol) in THE (0.5 mL) and MeOH (1 mL) was added a solution of LiOH (4.3 mg, 0.18 mmol) in water (0.5 mL) at 0 °C. After stirring at room temperature for 2 hrs, the 202 WO 2022/034568 PCT/IB2021/059266 reaction mixture was acidified with IN aq.HCl to pH~3 and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (1.4 mg, 14.4% yield) as white solid. LC/MS (ESI) (m/z): 532 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 8.19 (d, J= 7.1 Hz, 1H), 7.90 (d, J= 8.3 Hz, 1H), 7.58 (d, J= 8.3 Hz, 1H), 6.41 (d, J= 7.0 Hz, 1H), 6.12 (s, 2H), 4.21 (s, 3H), 3.83 (t, J= 7.Hz, 2H), 3.23 (d, J= 11.8 Hz, 2H), 3.13 - 3.03 (m, 1H), 2.94-2.89 (m, 2H), 2.60 (t, J= 10.7 Hz, 1H), 2.54 - 2.47 (m, 1H), 2.39 - 2.38 (m, 2H), 2.32 - 2.25 (m, 1H), 1.73 - 1.67 (m, 3H), 1.36 - 1.(m, 3H), 0.83 (t, J= 7.4 Hz, 3H).

Example 112: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid sMel, EtOH m-CPBADCMStep 3NaHCO3, EtOHStep 2 Step 1 Step 1: methyl (Z)-carbamohydrazonothioate hydroiodide id="p-465" id="p-465" id="p-465" id="p-465" id="p-465" id="p-465" id="p-465" id="p-465" id="p-465"

[0465]To a solution of aminothiourea (5 g, 54.9 mmol) in EtOH (30 mL) was added Mel (4.1 mL, 65.8 mmol). After stirring at 75 °C for 16 hrs, the reaction mixture was cooled to 0 °C and filtered. Then filter cake was concentrated to dryness to give the title compound (4.2 g, 72.8% yield) as white solid, which was directly used in the next reaction without purification. Step 2: 5-cyclopropyl-3-(methylthio)-l,2,4-triazine [0466]To a solution of methyl (Z)-carbamohydrazonothioate hydroiodide (4 g, 38.0 mmol) in EtOH (80 mL) was added 2-cyclopropyl-2-oxoacetaldehyde (5.6 g, 57.05 mmol). After stirring at °C for 16 hrs, the reaction mixture was poured into ice-water and extracted with DCM (3 x 203 WO 2022/034568 PCT/IB2021/059266 mL). The combined organic layers were washed brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-50% EtOAc in PE) to give the title compound (2.8 g, 44% yield) as yellow oil. LC/MS (ESI) m/z: 1(M+H)+. Step 3: 5-cyclopropyl-3-(methylsulfonyl)-l,2,4-triazine id="p-467" id="p-467" id="p-467" id="p-467" id="p-467" id="p-467" id="p-467" id="p-467" id="p-467"

[0467]To a solution of 5-cyclopropyl-3-(methylthio)-l,2,4-triazine (2.6 g, 15.5 mmol) in DCM (40 mL) was added m-CPBA (8.05 g, 46.6 mmol) at 0 °C. After stirring at r.t. for 1 hr, the reaction mixture was quenched with saturated aq.Na2S2O3 solution and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was triturated with EtOAc and the slurry was filtered. The filter cake was dried under vacuum to give the title compound (1.3 g, 42% yield) as yellow solid. LC/MS (ESI) m/z: 200 (M+H)+. Step 4: methyl (R)-2-(l-(6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin- 3-yl)-5,5-difluoropiperidin-3-yl)acetate [0468]To a solution of methyl 2-[(3R)-l-(2-ethyl-6-{5-[(methanesulfonyloxy)methyl]-l-methyl- lH-l,2,3-triazol-4-yl}pyridin-3-yl)-5,5-difluoropiperidin-3-yl]acetate (40 mg, 0.082 mmol) in DMF (3 mL) was added NaN3 (20 mg, 0.41 mmol). After stirring at 60 °C for 2 hrs, the reaction mixture was poured into water and extracted with EtOAc (3x5 mL). The combined organic phases were washed brine, dried over Na2SO4, filtered and concentrated to give the title compound (mg, 96.3% yield) as yellow oil, which was directly used in the next reaction without purification. Step 5: methyl (R)-2-(l-(6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin- 3-yl)-5,5-difluoropiperidin-3-yl)acetate [0469]To a solution of methyl (R)-2-(l-(6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (31 mg, 0.079 mmol) in THE (2 mL) and water (0.2 mL) was added PPh3 (103 mg, 0.4 mmol). After stirring at r.t. for 16 hrs, the reaction mixture was concentrated to dryness. The residue was purified by flash chromatography (silica gel, - 50%, MeOH in DCM) to give the title compound (31 mg, 96% yield) as yellow solid. LC/MS (ESI) m/z: 409 (M+l) +. Step 6: methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0470]To a solution of methyl (R)-2-(l-(6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (31 mg, 0.076 mmol) and DIPEA (29 mg, 0.23 mmol) in NMP (2 mL) was added 5-cyclopropyl-3-(methylsulfonyl)-l,2,4-triazine (30 mg, 0.15 mmol). After stirring at 100 °C for 2 hrs, the reaction mixture was poured into water and 204 WO 2022/034568 PCT/IB2021/059266 extracted with EtOAc (3x5 mL). The combined organic phases were washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-100% EtOAc in PE) to give the title compound (20 mg, 50% yield) as yellow solid. LC/MS (ESI) m/z: 528 (M+l) +. Step 8: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-471" id="p-471" id="p-471" id="p-471" id="p-471" id="p-471" id="p-471" id="p-471" id="p-471"

[0471]To a solution of methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (20 mg, 0.038 mmol) in THE (2 mL), water (0.5 mL) and MeOH (0.5 mL) was added LiOH (8 mg, 0.mmol). After stirring at r.t. for 2 hrs, the reaction mixture was poured into water and washed with MTBE (3x2 mL). The aqueous layer was acidified with IN aq.HCl to pH~4 and extracted with DCM (3x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10- 95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (3 mg, 15.4% yield) as white solid. LC/MS (ESI) m/z: 514 (M+l) +. 1H NMR (400 MHz, CD3OD) 5 8.50 (s, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.61 (d, J= 8.4 Hz, 1H), 5.10 (d, J= 2.2 Hz, 2H), 4.22 (s, 3H), 3.28 - 3.20 (m, 2H), 3.15 - 3.05 (m, 1H), 3.03 - 2.96 (m, 2H), 2.62 (dd, J= 12.1, 9.7 Hz, 1H), 2.57 - 2.46 (m, 1H), 2.- 2.37 (m, 2H), 2.36 - 2.27 (m, 1H), 1.96 - 1.89 (m, 1H), 1.79 - 1.68 (m, 1H), 1.35 (t, J= 15 Hz, 3H), 1.11-1.06 (m, 2H), 1.02 - 0.94 (m, 2H). Example 113: 2-(3,3-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-propylpyridin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-4-yl)acetic acid 205 WO 2022/034568 PCT/IB2021/059266 Step 1: 3-bromo-2-methyl-6-(l-methyl-5-(((3-propylpyridin-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridine [0472]To a solution of (4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methanol (500 mg, 1.76 mmol) in DMF (10 mL) was added NaH (106 mg, 2.65 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred this temperature for min. A solution of 2-chloro-3-propylpyridine (300 mg, 1.92 mmol) in DMF (3 mL) was added to the above mixture drop-wise at 0 °C and the resulting mixture was stirred at r.t. for 4 hrs. The mixture was quenched with saturated aq.NH4Cl solution and extracted with EtOAc (3x10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-30 EtOAc in PE) to give the title compound (620 mg, 86.1% yield) as white solid. LC/MS (ESI) m/z: 402 (M+H)+. Step 2: tert-butyl (E)-3,3-difluoro-4-(2-methoxy-2-oxoethylidene)piperidine-l-carboxylate [0473]To a solution of ethyl 2-(diethoxyphosphoryl)acetate (500 mg, 2.23 mmol) in THE (10 mL) was added NaH (116 mg, 2.9 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred this temperature for 30 min. A solution of tert-butyl 3,3-difluoro-4- oxopiperidine- 1-carboxylate (524 mg, 2.23 mmol) in THE (5 mL) was added drop-wise at 0 °C to the above mixture and the resulting mixture was stirred at r.t. for 2 hrs. The mixture was quenched with ice-cooled saturated aq.NH4Cl solution and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-40 EtOAc in PE) to give the title compound (260 mg, 40% yield) as light-yellow oil. LC/MS (ESI) m/z: 292 (M+H)+. Step 3: tert-butyl 3,3-difluoro-4-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate id="p-474" id="p-474" id="p-474" id="p-474" id="p-474" id="p-474" id="p-474" id="p-474" id="p-474"

[0474]To a solution of tert-butyl (E)-3,3-difluoro-4-(2-methoxy-2-oxoethylidene)piperidine-l- carboxylate (260 mg, 0.89 mmol) in MeOH (5 mL) was added Pd/C (30 mg, 10%wt) and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at r.t. for hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (240 mg, 92% yield) as light yellow oil. LC/MS (ESI) m/z: 294 (M+H)+. Step 4: methyl 2-(3,3-difluoropiperidin-4-yl)acetate hydrochloride [0475]To a solution of tert-butyl 3,3-difluoro-4-(2-methoxy-2-oxoethyl)piperidine- 1-carboxylate (240 mg, 0.82 mmol) in 1,4-dioxane (3 mL) was added 4N HCl/l,4-dioxane solution (2 mL) and the mixture was stirred at r.t. for 3 hrs. The mixture was concentrated to dryness and the residue was washed with MTBE, dried under vacuum to give the title compound (170 mg, 90% yield) as yellow solid. LC/MS (ESI) m/z: 194 (M+H)+. 206 WO 2022/034568 PCT/IB2021/059266 Step 5: 2-(3,3-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-propylpyridin-2-yl)oxy)methyl)-lH- 1,2,3-triazol-4-yl)pyridin-3-yl)piperidin-4-yl)acetic acid [0476]To a mixture of 3-bromo-2-methyl-6-(l-methyl-5-(((3-propylpyridin-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine (50 mg, 0.12 mmol) and methyl 2-(3,3-difluoropiperidin-4- yl)acetate hydrochloride (29 mg, 0.12 mmol) in 1,4-dioxane (10 mL) was added t-BuONa (36 mg, 0.37 mmol), the mixture was degassed under N2 for three times and Pd(OAc)2 (10 mg, 0.044 mmol) and XantPhos (26 mg, 0.044 mmol) were added under N2 atmosphere. The resulting mixture was stirred at 110 0C for 16 hrs. H2O (10 mL) was added and the mixture was stirred at r.t. for 1 hr. The mixture was washed with MTBE (2x5 mL) and the aqueous layer was acidified with 1 N aq.HCl to pH~4, extracted with DCM (3x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (11 mg, 17.7% yield) as white solid. LC/MS (ESI) m/z: 5(M+H)+. 1HNMR (400 MHz, CD3OD) 5 7.96-7.94 (dd,J= 5.2, 2 Hz, 1H), 7.81 -7.78 (d, J= 7.Hz, 1H), 7.54 - 7.52 (d, J= 8.0 Hz, 1H), 7.47 - 7.45 (dd, J= 12, 1.6 Hz, 1H), 6.91 - 6.88 (m, 1H), 5.95 (s, 2H), 4.22 (s, 3H), 3.35-3.33 (m, 1H), 3.19 - 3.01 (m, 3H), 2.86 - 2.75 (m, 2H), 2.44 - 2.(m, 1H), 2.42 (s, 3H), 2.31 - 2.27 (m, 1H), 2.06 - 2.00 (m, 1H), 1.75 - 1.69 (m, 2H), 1.46 - 1.40 (m, 2H), 0.80 - 0.76 (t, J= 7.6 Hz, 3H). Example 114: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 1 2 Example 114 Step 1: methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0477]To a mixture of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (40 mg, 0.098 mmol) and 3-chloro-5- cyclopropyl-l,2,4-oxadiazole (21.2 mg, 0.15 mmol) in THF (2 mL) was added t-BuOK (0.2 mL, 0.20 mmol, IM in THF) drop-wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with ice-water and extracted with EtOAc (2x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (50 mg, 98.9% yield) as yellow solid, which was used in next step directly. LC/MS (ESI) m/z: 518 (M+H)+. 207 WO 2022/034568 PCT/IB2021/059266 Step 2: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid [0478]To a solution of methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (50 mg, 0.097 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (40.5 mg, 0.97 mmol) and the mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc (2x3 mL), acidified with IN aq.HCl to pH = 4 and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (6.7 mg, 13.8% yield) as white solid. LC/MS (ESI) m/z: 504 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.88 (d, J= 8.2 Hz, 1H), 7.56 (d, J= 8.2 Hz, 1H), 6.05 (s, 2H), 4.20 (s, 3H), 3.23 (t, 10.2 Hz, 2H), 3.12-3.01 (m, 1H), 2.92 - 2.84 (m, 2H), 2.64 - 2.56 (m, 1H), 2.53 - 2.45(m, 1H), 2.43 - 2.36 (m, 2H), 2.34 - 2.24 (m, 1H), 2.17 - 2.09 (m, 1H), 1.79 - 1.65 (m, 1H), 1.29 - 1.20 (m, 5H), 1.11 - 1.04 (m, 2H). Example 115: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid Step 1: methyl (R)-2-(l-(2-ethyl-6-(5-formyl-l-methyl-lH-l,2,3-triazol-4-yl)pyridin-3-yl)- 5,5-difluoropiperidin-3-yl)acetate [0479]To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (80 mg, 0.20 mmol) in DCM (5 mL) was added DMP (331 mg, 0.78 mmol) and the mixture was stirred at 25 °C for 1 hr. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with DCM (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (50 mg, 62.8% yield) as yellow oil. LC/MS (ESI) m/z: 208 WO 2022/034568 PCT/IB2021/059266 408 (M+H)+. Step 2: methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0480]To a solution of methyl (R)-2-(l-(2-ethyl-6-(5-formyl-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (25 mg, 0.061 mmol) and 5-cyclopropyl-l,2,4- oxadiazol-3-amine (15.4 mg, 0.12 mmol) in MeOH (2 mL) was added AcOH (3 drops) under Natmosphere and the mixture was stirred at 65 °C for 16 hrs. NaBH3CN (38 mg, 0.61 mmol) was added to the above mixture at 25 °C and the resulting mixture was continued to stirr at 25 °C for hrs. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with DCM (2 x mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (35 mg, 110.4% yield) as yellow oil, which was used in the next step directly. LC/MS (ESI) m/z: 517 (M+H)+. Step 2: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)amino)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid [0481]To a solution of methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3- yl)amino)methyl)-l-methyl-1H- 1,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (35 mg, 0.068 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (28.4 mg, 0.68 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The aqueous solution was washed with EtOAc (2x3 mL), acidified with IN aq.HCl to pH~3 and extracted with DCM (3x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10- 95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (12.5 mg, 36.5% yield) as white solid. LC/MS (ESI) m/z: 503 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.90 (d, J= 8.2 Hz, 1H), 7.60 (d, J= 8.4 Hz, 1H), 4.78 (s, 2H), 4.21 (s, 3H), 3.27-3.20 (m, 2H), 3.14-3.06 (m, 1H), 3.02-2.96 (m, 2H), 2.65-2.58 (m, 1H), 2.55-2.46 (m, 1H), 2.43-2.37 (m, 2H), 2.34-2.25 (m, 1H), 2.09-2.01 (m, 1H), 1.81-1.65 (m, 1H), 1.38-1.31 (m, 4H), 1.18-1.10 (m, 2H), 1.07-1.02 (m, 2H).

The examples list in the table were prepared according to the same method as described for the synthesis of example 114 and 115. EX# Structure & name Analytical data Method 209 WO 2022/034568 PCT/IB2021/059266 116FVyV H ‘n" ° JI N-O N-N^ (S)-2-(l-(6-(5-(((5-(cyclopropylmethyl)- 1,2,4- oxadiazol-3-yl)oxy)methyl)- -methyl- 1H-1,2,3 -tri azol-4- yl)-2-ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 518 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.89 (d, J= 8.4 Hz, 1H), 7.56 (d, J = 8.3 Hz, 1H), 6.09 (s, 2H), 4.22 (s, 3H), 3.26 - 3.22 (m, 1H), 3.13 - 3.01 (m, 1H), 2.89 (q, J = 7.6 Hz, 2H), 2.73 (d, J= 7.1 Hz, 2H), 2.- 2.56 (m, 1H), 2.55 - 2.46 (m, 1H), 2.41 - 2.36 (m, 2H), 2.35 - 2.27 (m, 1H), 1.81-1.65 (m, 1H), 1.26 (t, J= 7.5 Hz, 3H), 1.14-1.(m, 1H), 0.60 (t, J = 6.3 Hz, 2H), 0.31-0.24 (m, 2H).

Example114 117V 0 I N-0 N-N H (S)-2-(l-(6-(5-(((5- (cyclopropylmethyl)- 1,2,4- oxadiazol-3-yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 517 (M+l) +. 1H-NMR (400 MHz, CD3OD) 7.91 (d, J= 8.3 Hz, 1H), 7.(d, J= 8.4 Hz, 1H), 4.81 (s, 2H), 4.24 (s, 3H), 3.25 (t, J = 10.3 Hz, 2H), 3.16 - 3.04 (m, 1H), 3.(q, J = 7.6 Hz, 2H), 2.67 - 2.39 (m, 6H), 2.36 - 2.24 (m, 1H), 1.84 - 1.65 (m, 1H), 1.36 (t, J = 7.5 Hz, 3H), 1.13 - 1.02 (m, 1H), 0.(q, J = 5.5 Hz, 2H), 0.24 (q, J = 4.Hz, 2H).

Example115 118FVyV H n" ° N^NI N-O /// aN-N^ ° N (S)-2-(l-(2-(5-(((5- (cyclopropylmethyl)- 1,2,4- oxadiazol-3-yl)oxy)methyl)--methyl- lH-pyrazol-4-yl)-4- ethylpyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 518 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.38 (s, 1H), 8.10 (s, 1H), 6.04 (s, 2H), 4.01 (s, 3H), 3.30 - 3.23 (m, 2H), 3.21-3.11 (m, 1H), 2.89- 2.83 (q, J = 7.5 Hz, 2H), 2.74 - 2.72 (d, 1 = 7.1 Hz, 2H), 2.69 - 2.66 (d, J = 10.7 Hz, 1H), 2.51 - 2.44 (m, 1H), 2.41 - 2.39 (dd, J = 6.9, 3.4 Hz, 2H), 2.36 - 2.27 (m, 1H), 1.81-1.66 (m, 1H), 1.29- 1.25 (t, J = 7.5 Hz, 3H), 1.14- 1.07 (m, 1H), 0.62 - 0.57 (m, 2H), 0.230 - 0.25(m, 2H).

Example114 210 WO 2022/034568 PCT/IB2021/059266 119F¥yVh n" 0 I N-0NT^'dY Y׳׳ N-N^(S)-2-(l-(6-(5-(((5-cyclobutyl-l,2,4-oxadiazol-3- yl)oxy)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 518 (M+H)+. 1H-NMR (400 MHz, CD3OD) 7.89 (d, J= 8.6 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 6.09 (s, 2H), 4.22 (s, 3H), 3.71 - 3.67 (m, 1H), 3.23 - 3.20 (m, 3H), 3.12 -3.02 (m, 2H), 2.91 - 2.86 (m, 2H), 2.63 - 2.58 (m, 1H), 2.44 - 2.26 (m, 6H), 2.18 - 2.09 (m, 1H), 2.05 - 1.96 (m, 1H), 1.81 -1.64 (m, 1H), 1.26 (t,J= 7.Hz, 3H).

Example114 120FVyVH‘n" ־lltN-0 N-N H N X/ (S)-2-(l-(6- X(5-(((5- cyclobutyl-l,2,4-oxadiazol-3- yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 517 (M+H)+. 1H-NMR (400 MHz, CD3OD) 7.91 (d, J= 8.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 4.81 (s, 2H),4.58(s, 1H), 4.24 (s, 3H), 3.66-3.57 (m, 1H), 3.24 (d, J = 10.2 Hz, 2H), 3.13-3.07 (m, 1H), 3.03-2.98 (m, 2H), 2.62 (t, J = 10.6 Hz, 1H), 2.55-2.49 (m, 1H), 2.41-2.23 (m, 7H), 2.14-2.06 (m, 1H), 2.04-1.(m, 1H), 1.81-1.67 (m, 1H), 1.(t, J =7.5 Hz, 3H).

Example115 Example 121: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((l-propyl-lH-l,2,4-triazol-5-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-482" id="p-482" id="p-482" id="p-482" id="p-482" id="p-482" id="p-482" id="p-482" id="p-482"

[0482]To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.073 mmol ) and 3-bromo-4- propyl-4H-l,2,4-triazole (21 mg, 0.11 mmol ) in DMF (1 mL) was added t-BuOK (0.15 mL, 0.mmol, 1 M in THF) at 0 °C and the mixture was stirred at r.t. for 16 hrs. The reaction was quenched 211 WO 2022/034568 PCT/IB2021/059266 with ice water (5 mL) and the mixture was stirred at r.t. for 1 hr. The mixture was washed MTBE (2x3 mL) and the aqueous layer was acidified with IN aq.HCl and extracted with DCM (2xmL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (mg, 27.2% yield) as white solid. LC/MS (ESI) m/z: 505 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.88 (d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 6.11 (s, 2H), 4.24 (s, 3H), 3.79 (t, J = 6.8 Hz, 2H), 3.25 - 3.18 (m, 2H), 3.13 - 2.99 (m, 1H), 2.84 (t, J = 7.2 Hz, 2H), 2.61-2.26 (m, 5H), 1.74 - 1.59 (m, 3H), 1.22 (t, J = 7.2 Hz, 3H), 0.73 (t, J = 7.6 Hz, 3H). The examples list in the below table were prepared according to the same method as described for the synthesis of example 121. Ex# Structure & name Analytical data Method122^¥yVH ‘n" 0 1 ׳n ~ N,fV%X?N"P (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)- 1H-1,2,4- triazol-5-yl)oxy)methyl)- 1 - methyl- 1H-1,2,3 -triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 517(M+H)+. 1H NMR (400 MHz, CD3OD) 7.89 (d, J = 8.3 Hz, 1H), 7.60 (s, 1H), 7.56 (d, J = 8.3 Hz, 1H), 6.10 (s, 2H), 4.24 (s, 3H), 3.69 (d, 7.1 Hz, 2H), 3.23 - 3.18 (m, 2H), 3.09 - 3.02 (m, 1H), 2.(dd, J= 14.9, 7.4 Hz, 2H), 2.62 - 2.56 (m, 1H), 2.50 - 2.44 (m, 1H), 2.39 (d, J = 6.8 Hz, 1H), 2.33 -2.25 (m, 1H), 1.84- 1.(m, 1H), 1.30 (s, 1H), 1.21 (t, J= 7.5 Hz, 3H), 1.04 (s, 1H), 0.36 (d, J =6.9 Hz, 2H), 0.14 (d, J = 5.Hz, 2H).

Example 121 123V ° N.rV^oXM-M (S)-2-(l-(2-ethyl-6-(5-(((l- isobutyl-1H-1, 2,4-tri azol-5- yl)oxy)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)pyridin-3-yl)- 5,5 -difluoropiperi din-3 -yl)acetic acid LC/MS (ESI) m/z: 519 (M+H)+. 1H-NMR (400 MHz, CD3OD) 7.88 (d, J= 8.4 Hz, 1H), 7.60 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 6.11 (s, 2H), 4.24 (s, 3H), 3.62 (d, J = 7.2 Hz, 2H), 3.30-3.19 (m, 2H), 3.13-3.02 (s, 1H), 2.86 (q, J = 7.6 Hz, 2H), 2.62-2.25 (m, 5H), 2.03-1.91 (m, 1H), 1.80- 1.64 (m, 1H), 1.23 (t, J= 7.6 Hz, 3H), 0.73 (d, J =6.8 Hz, 6H).

Example121 Example 124: (S)-2-(l-(2-ethyl-6-(5-(((2-isobutyl-2H-tetrazol-5-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid 212 WO 2022/034568 PCT/IB2021/059266 ^0H . S N PPh 3, DIAD ، ,N TEA, DCM NStep 1 KMnO4TBAB, aq.AcOHCHCl3Step 2 IS^Nn " וזm-nh Step 1: 2-(2-methylpropyl)-5-(methylsulfanyl)-2H-l,2,3,4-tetrazole [0483]To a mixture of 5-(Methylthio)-lH-tetrazole (1 g, 8.61 mmol), 2-methyl-l-propanol (1.28 g, 17.2 mmol) and PPh3 (4.06 g, 15.5 mmol) in DCM (50 mL) was added TEA (1.31g, 12.92 mmol) followed by drop-wise addition of DIAD (1.74 g, 8.61 mmol) at 0 °C under Natmosphere and the mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc= 2: 1) to give the title compound (810 mg, 54.6% yield) as white solid. LC/MS (ESI) m/z: 173 (M+H)+. 1HNMR (4MHz, CDCI3) 5 4.37 (d, J= 7.2 Hz, 2H), 2.68 (s, 3H), 2.31-2.43 (m, 1H), 0.97 (d, J= 6.7 Hz, 6H). Step 2: 5-methanesulfonyl-2-(2-methylpropyl)-2H-l,2,3,4-tetrazole [0484]To a solution of 2-(2-methylpropyl)-5-(methylsulfanyl)-2H-l,2,3,4-tetrazole (800 mg, 4.64 mmol) in chloroform (40 mL) was added TBAB (75 mg, 0.23 mmol), aq.AcOH (25 mL, 10% wt) followed by KMnO4 (1.47 g, 9.29 mmol) and the mixture was stirred at r.t. for 18 hrs. The mixture was diluted with DCM (20 mL) and washed with water (3x10 mL) and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (530 mg, 55.9% yield) as white solid. LC/MS (ESI) m/z: 205 (M+H)+. Step 3: (S)-2-(l-(2-ethyl-6-(5-(((2-isobutyl-2H-tetrazol-5-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-485" id="p-485" id="p-485" id="p-485" id="p-485" id="p-485" id="p-485" id="p-485" id="p-485"

[0485]To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.073 mmol) and 5- methanesulfonyl-2-(2-methylpropyl)-2H-l,2,3,4-tetrazole (29 mg, 0.15 mmol) in CH3CN (1 mL) was added NaOH (14 mg ,0.37 mmol) and the mixture was stirred at 80 °C for 3 hrs. The mixture was diluted with water (10 mL), washed with MTBE (2x3 mL), acidified with IN aq.HCl to pH~and extracted with DCM (3x5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (Cl 8, ~ 90 % acetonitrile in H2O with 0.1 % HCOOH) to give the title compound (11 mg, 29.0% yield) as white solid. LC/MS (ESI) m/z: 520 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.87 (d, J= 8. 213 WO 2022/034568 PCT/IB2021/059266 Hz, 1H), 7.56 (d, J= 8.0 Hz, 1H), 6.17 (s, 2H), 4.28 (d, J= 7.2 Hz, 2H), 4.23 (s, 3H), 3.25 - 3.(m, 2H), 3.12-3.02 (m, 1H), 2.90 - 2.84 (q, J= 7.7 Hz, 2H), 2.62 - 2.57 (t, J= 10.8 Hz, 1H), 2.-2.38 (m, 3H), 2.31-2.15 (m, 2H), 1.72- 1.68 (m, 1H), 1.25 - 1.21 (t, J= 15 Hz, 3H), 0.89 (d, J=7.2Hz, 6H). Example 125: (S)-2-(l-(6-(5-(((2-(cyclopropylmethyl)-2H-tetrazol-5-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-486" id="p-486" id="p-486" id="p-486" id="p-486" id="p-486" id="p-486" id="p-486" id="p-486"

[0486]The title compound was prepared from cyclopropylmethanol using the same sequence that was synthesized example 124LC/MS (ESI) m/z: 518 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.89 - 7.86 (d, J = 8.3 Hz, 1H), 7.57 - 7.54 (d, J = 8.3 Hz, 1H), 6.18 (s, 2H), 4.32 - 4.29 (d, J = 7.Hz, 2H), 4.23 (s, 3H), 3.27 - 3.19 (m, 2H), 3.15 - 3.07 (m, 1H), 2.91 - 2.84 (m, 2H), 2.63 - 2.(m, 1H), 2.54 - 2.46 (m, 1H), 2.39 - 2.26 (d, J = 6.0 Hz, 2H), 2.33 - 2.26 (m, 1H), 1.79 - 1.64 (m, 1H), 1.32 -1.28 (m, 1H), 1.25 - 1.21 (t, J= 7.2 Hz, 3H), 0.64 - 0.59 (m, 2H), 0.45 - 0.37 (m, 2H). Example 126: (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid Step 7RuPhos, Pd2(dba) 3Cs2CO3, 1,4-dioxane 110°C Step 1: ethyl 4-hydroxy-l-(4-methoxybenzyl)-lH-l,2,3-triazole-5-carboxylate 214 WO 2022/034568 PCT/IB2021/059266 id="p-487" id="p-487" id="p-487" id="p-487" id="p-487" id="p-487" id="p-487" id="p-487" id="p-487"

[0487]To a newly prepared EtONa/EtOH solution (22 mmol in 50 mL of EtOH) was added diethyl malonate (3.54 g, 22 mmol) under N2 atmosphere and the mixture was stirred at r.t. for 0.5 hr. To the above mixture, a solution of l-(azidomethyl)-4-methoxybenzene (2.4 g, 14.7 mmol) in ethanol (4 mL) was added drop-wisely and the resulting mixture was stirred at 85 °C for 5 hrs. The mixture was concentrated to dryrness and diluted with water, the aqueous solution was acidified with IN aq.HCl to pH = 2 and extracted with DCM (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 1: 1) to give the title compound (1.82 g, 50.1% yield) as red solid. LC/MS (ESI) m/z: 278 (M+H)+. Step 2: ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)-l- (4-methoxybenzyl)-lH-l,2,3-triazole-5-carboxylate [0488]To a solution of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridine (970 mg, 2.7 mmol) and ethyl 4-hydroxy-l-(4-methoxybenzyl)-lH-l,2,3-triazole-5- carboxylate (747 mg, 2.7 mmol) in DMF (10 mL) was added Cs2CO3 (2.63 g, 8.08 mmol) under N2 atmosphere and the mixture was stirred at r.t. for 1 hr. The mixture was diluted with water (mL) and extracted with EtOAc (2x15 mL). The combined organic layers were washed with saturated aq.NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 2: 1) to give the title compound (839 mg, 56% yield) as white solid. LC/MS (ESI) m/z: 556/558 (M+H)+. Step 3: ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)- lH-l,2,3-triazole-5-carboxylate [0489]To a solution of ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-l-(4-methoxybenzyl)-lH-l,2,3-triazole-5-carboxylate (800 mg, 1.44 mmol) in MeCN (20 mL) was added a solution of CAN (1.97 g, 3.59 mmol) in water (20 mL) drop-wisely at 0 °C and the mixture was stirred at r.t. for 16 hrs. The slurry was filtered and the filter cake was washed with water, dried under vacuum to give the title compound (600 mg, 76.5% yield) as white solid. LC/MS (ESI) m/z: 436/438 (M+H)+. Step 4: 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)-lH- l,2,3-triazole-5-carboxylic acid [0490]To a solution of ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-lH-l,2,3-triazole-5-carboxylate (600 mg, 1.17 mmol) in THE (10 mL), EtOH (mL) and H2O (5 mL) was added NaOH (468 mg, 11.69 mmol) and the mixture was stirred at °C for 5 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (mL). The aqueous layer was acidified with IN aq.HCl to pH = 3 and extracted with DCM (2xmL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered 215 WO 2022/034568 PCT/IB2021/059266 and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 1: 1) to give the title compound (500 mg, 83.8% yield) as white solid. LC/MS (ESI) m/z: 408/410 (M+H)+. Step 5: 6-(5-(((lH-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-3-bromo-2- ethylpyridine [0491]־A solution of 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-lH-l,2,3-triazole-5-carboxylic acid (500 mg, 0.98 mmol) in DMF (10 mL) was stirred at 120 °C for 16 hrs. The mixture was diluted with EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give title compound (290 mg, 77.2% yield) as white solid. LC/MS (ESI) m/z: 364/366 (M+H)+. Step 6: 3-bromo-6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridine (7A) & 3-bromo-6-(5-(((2-(cyclopropylmethyl)-2H- l,2,3-triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine (7B) id="p-492" id="p-492" id="p-492" id="p-492" id="p-492" id="p-492" id="p-492" id="p-492" id="p-492"

[0492]To a solution of 3-bromo-2-ethyl-6-{l-methyl-5-[(lH-l,2,3-triazol-4-yloxy)methyl]-lH- l,2,3-triazol-4-yl}pyridine (140 mg, 0.38 mmol) in DMF (5 mL) was added K2CO3 (159 mg, 1.mmol) followed by (bromomethyl)cyclopropane (0.18 mL, 1.92 mmol). After stirring at r.t. for hrs, the reaction mixture was diluted with ice-water and extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-100% EtOAc in PE) to give 3-bromo-6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine 7A(45 mg, yield 28.0%) and 3-bromo-6-(5-(((2- (cyclopropylmethyl)-2H-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridine 7B(85 mg, yield 52.9%) as white solid. 7A:1H NMR (400 MHz, DMSO-d6) 5 8.(d, J= 8.4 Hz, 1H), 7.87 (d, J= 8.4 Hz, 1H), 7.71 (s, 1H), 5.89 (s, 2H), 4.16 (s, 3H), 4.10 (d, J = 7.2 Hz, 2H), 2.87 (q, J= 7.6 Hz, 2H), 1.24-1.15 (m, 1H), 1.18 (t, J= 7.6 Hz, 3H), 0.53-0.48 (m, 2H), 0.37-0.32 (m, 2H). 7B: 1H-NMR (400 MHz, DMSO-d6) 5 8.11 (d, J= 8.4 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.31 (s, 1H), 5.90 (s, 2H), 4.16 (s, 3H), 4.06 (d, J= 7.2 Hz, 2H), 2.87 (q, J= 7.Hz, 2H), 1.20-1.14 (m, 1H), 1.16 (t, J = 7.6 Hz, 3H), 0.52 - 0.46 (m, 2H), 0.33 - 0.30 (m, 2H). LC/MS (ESI) m/z: 420/422 (M+H)+. Step 7: methyl (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0493]To a mixture of 3-bromo-6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4- yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine (45 mg, 0.11 mmol), methyl 2- [(3S)-5,5-difluoropiperidin-3-yl]acetate (21 mg, 0.11 mmol) and Cs2CO3 (105 mg, 0.32 mmol) in 216 WO 2022/034568 PCT/IB2021/059266 1,4-dioxane (2 mL) was added Ru-Phos (5 mg, 0.011 mmol ) followed by Ru-Phos Pd G3 (9 mg, 0.011 mmol). Then the mixture was degassed under N2 atmosphere for three times and stirred at 120 °C under N2 atmosphere for 16 hrs. The mixture was diluted with ice-water and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (35 mg, 61.3% yield) as yellow solid. LC/MS (ESI) m/z: 531(M+H)+. Step 8: (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-494" id="p-494" id="p-494" id="p-494" id="p-494" id="p-494" id="p-494" id="p-494" id="p-494"

[0494]To a solution of methyl (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4- yl)oxy )methyl)-!-methyl-lH- 1,2,3-tri azol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (35 mg, 0.066 mmol) in THE (1 mL) and MeOH (0.5 mL) was added a solution of LiOH (8 mg, 0.33 mmol) in water (0.5 mL) at 0 °C and the mixture was stirred at r.t. for 1 hr. The reaction mixture was acidified with IN aq.HCl to pH= 3 and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-10% MeOH in DCM) and further purified by prep-HPLC to give the title compound (10 mg, 27.9% yield) as white solid. LC/MS (ESI) m/z: 517 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 7.89 (d, J = 8.4 Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.56 (s, 1H), 5.98 (s, 2H), 4.21 (s, 3H), 4.10 (d, J= 7.6 Hz, 2H), 3.28 - 3.20 (m, 2H), 3.13 - 3.02 (m, 1H), 2.90 (q, J= 7.6 Hz, 2H), 2.63 - 2.26 (m, 5H), 1.80 - 1.65 (m, 1H), 1.25 (t, J= 7.6 Hz, 3H), 1.21-1.13 (m, 1H), 0.58 - 0.53 (m, 2H), 0.35 - 0.30 (m, 2H). Example 127: ((S)-2-(l-(6-(5-(((2-(cyclopropylmethyl)-2H-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid id="p-495" id="p-495" id="p-495" id="p-495" id="p-495" id="p-495" id="p-495" id="p-495" id="p-495"

[0495]The title compound was prepared from 3-bromo-6-(5-(((2-(cyclopropylmethyl)-2H-l,2,3- triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine using the same procedure as the synthesis of example 126.LC/MS (ESI) m/z: 517 (M+H)+. 1H-NMR (400 MHz, 217 WO 2022/034568 PCT/IB2021/059266 CD3OD) 5 7.86 (d,J= 8.4 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 7.14 (s, 1H), 5.99 (s, 2H), 4.20 (s, 3H), 4.01 (d, J= 7.2 Hz, 2H), 3.26-3.20 (m, 2H), 3.13-3.02 (m, 1H), 2.90 (q, J=1.6 Hz, 2H), 2.63- 2.28 (m, 5H), 1.80 - 1.65 (m, 1H), 1.27 (t, J= 7.6 Hz, 3H), 1.24-1.14 (m, 1H), 0.55 - 0.50 (m, 2H), 0.34 - 0.29 (m, 2H). Example 128: (S)-2-(l-(2-ethyl-6-(5-(((l-isobutyl-lH-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid Example 128 id="p-496" id="p-496" id="p-496" id="p-496" id="p-496" id="p-496" id="p-496" id="p-496" id="p-496"

[0496]The title compound was prepared according the same sequence for the synthesis of example 126LC/MS (ESI) m/z: 519 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.88 (d, J= 8.2 Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.49 (s, 1H), 5.97 (s, 2H), 4.21 (s, 3H), 4.07 (d, J= 7.2 Hz, 2H), 3.26 - 3.19 (m, 2H), 3.13-3.01 (m, 1H), 2.94 - 2.86 (m, 2H), 2.59 (t, J= 10.8 Hz, 1H), 2.55 - 2.46 (m, 1H), 2.40 - 2.24 (m, 3H), 2.11-2.00 (m, 1H), 1.80 - 1.64 (m, 1H), 1.25 (t, J= 7.6 Hz, 3H), 0.84 (d, J=6.8Hz, 6H).

Example 129: (S)-2-(l-(2-ethyl-6-(5-(((2-isobutyl-2H-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid Example 129 id="p-497" id="p-497" id="p-497" id="p-497" id="p-497" id="p-497" id="p-497" id="p-497" id="p-497"

[0497]The title compound was prepared according the same sequence for the synthesis of example 126LC/MS (ESI) m/z: 519 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.86 (d, J= 8.4 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 7.13 (s, 1H), 5.99 (s, 2H), 4.20 (s, 3H), 3.97 (d, J= 7.2 Hz, 2H), 3.26 - 3.18 (m, 2H), 3.11 - 3.00 (m, 1H), 2.94 - 2.87 (m, 2H), 2.59 (t, J= 10.6 Hz, 1H), 2.54 - 2.42 (m, 1H), 2.38 - 2.25 (m, 3H), 2.17 - 2.06 (m, 1H), 1.79 - 1.59 (m, 1H), 1.27 (t, J= 7.6 Hz, 3H), 0.(d, J=6.8Hz, 6H). 218 WO 2022/034568 PCT/IB2021/059266 Example 130: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid RuPhos-Pd-G 3, Ru-phos, Cs2CO3, 1,4-dioxane. 110°CStep 6 8 Example 130 Step 1: prop-2-yn-l-ylcyclopropane [0498]To a solution of ethynyltrimethylsilane (3 g, 30.5 mmol) in anhydrous THF (15 mL) was added n-BuLi (16 mL, 40 mmol, 2.5 M in THF) drop-wisely at -70 °C under N2 atmosphere and the mixture was stirred at 0 °C for 10 min. The mixture was re-cooled to -70 °C and HMPA (8.mL, 45.8 mmol) was added. Then the mixture was stirred at -70 °C for 30 min. (Bromomethyl)cyclopropane (3.0 mL, 30.54 mmol) was added to the above mixture and the resulting mixture was stirred at -70 °C to r.t. for 16 hrs. The mixture was quenched with water and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give (3-cyclopropylprop-l-yn-l- yl) trimethylsilane (3.2 g, 68.8% yield) as colorless oil. To a solution of (3-cyclopropylprop-l-yn- 1-yl) trimethyl silane (3.2 g, 21 mmol) in THF (9 mL) was added TBAF (15 mL, 30 mmol, 2M in THF) and the mixture was stirred at room temperature for 4 hrs. The mixture was washed with saturated aq.NH4Cl solution (10 mL) once and the solution was used to next step directly. Step 2: l-benzyl-4-(cyclopropylmethyl)-lH-l,2,3-triazole id="p-499" id="p-499" id="p-499" id="p-499" id="p-499" id="p-499" id="p-499" id="p-499" id="p-499"

[0499]To the above solution was added a solution of (azidomethyl)benzene (4 g, 29.8 mmol) in THF (10 mL) followed by a solution of sodium ascorbate (1.2 g, 6 mmol) in water (10 ml) and CuSO4 (0.5 g, 3 mmol) and the resulting mixture was stirred at 25 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 50: 1 to 1: 1) to give the title compound (2 g, 31.4% yield) as yellow oil. LC/MS (ESI) 219 WO 2022/034568 PCT/IB2021/059266 m/z: 214 (M+H)+. Step 3: 4-(cyclopropylmethyl)-lH-l,2,3-triazole id="p-500" id="p-500" id="p-500" id="p-500" id="p-500" id="p-500" id="p-500" id="p-500" id="p-500"

[0500]To a solution of l-benzyl-4-(cyclopropylmethyl)-lH-l,2,3-triazole (2 g, 9.38 mmol) in EtOH (20 mL) were added Pd(OH)2 (300 mg, 10% wt) and aq.HCl (0.5 mL, 36% wt). After addition, the mixture was degassed under N2 atmosphere for three times and stirred under a Hballoon at 50 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (1.52 g, 100% yield) as colorless oil, which was used to next step directly. LC/MS (ESI) m/z: 124 (M+H)+. Step 4: 6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3-iodopyridine [0501]To a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl) methanol (500 mg, 1.45 mmol) in DCM (5 mL) was added PBr3 (984 mg, 3.63 mmol) drop-wisely at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 2 hrs. The mixture was quenched with saturated aq.NaHCO3 solution and extracted with DCM (2x10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (529 mg, 89.5% yield) as white solid. LC/MS (ESI) m/z: 407/409 (M+H)+. Step 5: 6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethyl-3-iodopyridine (7A) & 6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3-iodopyridine (7B) & 6-(5-((4- (cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3- iodopyridine (7C) [0502]To a solution of 6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3- iodopyridine (300 mg, 0.74 mmol) and 4-(cyclopropylmethyl)-lH-l,2,3-triazole (136 mg, 1.mmol) in DMF (3 mL) was added K2CO3 (306 mg, 2.21 mmo 1) under N2 atmosphere and the mixture was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 2: 1) to give compound 7A(103 mg, yield 31.1%) and a mixture of 7B and 7C(190 mg, 57.1% yield) as white solid. The mixture of 7B&7Cwas isolated by prep.HPLC to give 7B (35 mg, 10.6% yield) and 7C (80 mg, 24.1% yield) as white solid. LC/MS (ESI) m/z: 450 (M+H)+. The absolute configurations were confirmed by NOE. 6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethyl-3-iodopyridine (7A): 1H NMR (400 MHz, CDC13) 5 7.76 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.26 (s, 1H), 6.19 (s, 2H), 3.88 (s, 3H), 2.83 (q, J = 7.6 Hz, 2H), 2.(d, J = 7.2 Hz, 2H), 1.16 (t, J = 7.6 Hz, 3H), 0.83-0.73 (m, 1H), 0.36 - 0.31 (m, 2H), 0.02-0.00 (m, 2H). 6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4- 220 WO 2022/034568 PCT/IB2021/059266 yl)-2-ethyl-3-iodopyridine (7B): 1H NMR (400 MHz, CD3OD) 5 8.29 (d, J= 8.4 Hz, 1H), 7.70 (d, J= 8.4 Hz, 1H), 7.64 (s, 1H), 6.34 (s, 2H), 4.07 (s, 3H), 3.00 (q, J= 7.6 Hz, 2H), 2.54 (d, J= 7.Hz, 2H), 1.25 (t, J= 7.6 Hz, 3H), 0.90-0.82 (m, 1H), 0.54 - 0.48 (m, 2H), 0.07 - 0.02 (m, 2H). 6-(5-((4-(cy cl opropylmethyl)-lH- 1,2,3-tri azol-l-yl)methyl)-l-methyl-1H- 1,2,3-tri azol-4-yl)-2- ethyl-3-iodopyridine (7C): 1H NMR (400 MHz, CD3OD) 5 8.29 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.64 (s, 1H), 6.34 (s, 2H), 4.07 (s, 3H), 3.06 (q, J = 7.6 Hz, 2H), 2.56 (d, J = 7.2 Hz, 2H), 1.27 (t, J = 7.6 Hz, 3H), 0.90 - 0.82 (m, 1H), 0.54 - 0.48 (m, 2H), 0.07 - 0.02 (m, 2H). Step 6: methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate [0503]To a solution of 6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethyl-3-iodopyridine (103 mg, 0.23 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3-yl)acetate (44 mg, 0.23 mmol) in 1,4-dioxane (3 mL) were added Cs2CO(149.4 mg, 0.46 mmol), RuPhos-Pd-G3 (11.2 mg, 0.013 mmol) andRuPhos (21.4 mg, 0.046 mmol ) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give title compound (120 mg, yield 100%) as yellow solid, which was used in next step directly. LC/MS (ESI) m/z: 515 (M+H)+. Step 8: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid [0504]To a solution of methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2- yl)methyl)-l-methyl-lH- 1,2,3-tri azol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (120 mg, 0.23 mmol) in THE (2 mL), MeOH (0.5 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (98 mg, 2.33 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water. The mixture was washed with EtOAc twice and the aqueous layer was acidified with IM aq.HCl to pH = 4 and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep- HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (19.2 mg, 13.2% yield) as white solid. LC/MS (ESI) m/z: 501 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J= 8.2 Hz, 1H), 7.39 (d, J= 8.4 Hz, 1H), 7.34 (s, 1H), 6.23 (s, 2H), 3.96 (s, 3H), 3.13-3.03 (m, 2H), 2.91 (m, 1H), 2.77 (q, J= 7.4 Hz, 2H), 2.47 - 2.41 (m, 1H), 2.37 (d, J= 7.0 Hz, 2H), 2.35 - 2.29 (m, 1H), 2.28 - 2.22 (m, 2H), 2.19 - 2.09 (m, 1H), 1.66 - 1.48 (m, 1H), 1.15 (t, J = 7.4 Hz, 3H), 0.85 - 0.76 (m, 1H), 0.35 - 0.29 (m, 2H), 0.02 - 0.00 (m, 2H). 221 WO 2022/034568 PCT/IB2021/059266 The examples in the following table were prepared by using method analogous to the examples as indicated in the method column in the table.

Ex# Structure & name Analytical data Method131‘n" ° Y (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-lH-l,2,3- triazol-l-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 501 (M+H)+.1H NMR (400 MHz, CD3OD) 7.80 (d, J = 8.2 Hz, 1H), 7.75 (s, 1H), 7.45 (d, =8.4 Hz, 1H), 6.(s, 2H), 4.03 (s, 3H), 3.28-3.10 (m, 2H), 3.01-2.88 (m, 1H), 2.84 (q, J = 7.6 Hz, 2H), 2.51-2.44 (m, 1H), 2.41 (d, =7.0Hz, 2H), 2.39-2.(m, 1H), 2.29-2.23 (m, 2H), 2.19- 2.11 (m, 1H), 1.67-1.51 (m, 1H), 1.16 (t, J = 7.6 Hz, 3H), 0.85-0.(m, 1H), 0.35-0.29 (m, 2H), 0.02- 0.00 (m, 2H).

Example 130 132‘n" 0 rO <3 N״ "A (S)-2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-l,2,3- triazol-l-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 501 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.92 (d, J = 8.4 Hz, 1H), 7.62 (s, 1H), 7.61 (d, J = 8.2 Hz, 1H), 6.(d, J = 4.4 Hz, 2H), 4.08 (s, 3H), 3.28-3.21 (m, 2H), 3.16-3.05 (m, 1H), 2.95 (q, J= 7.6 Hz, 2H), 2.65- 2.57 (m, 1H), 2.56-2.51 (m, 1H), 2.49 (d, J= 6.8 Hz, 2H), 2.44-2.(m, 2H), 2.36-2.27 (m, 1H), 1.81- 1.66 (m, 1H), 1.28 (t, J = 7.6 Hz, 3H), 0.88-0.79 (m, 1H), 0.52-0.(m, 2H), 0.02-0.00 (m, 2H).

Example 130 133FVyyH V ° N—N f >—/ א n"n(S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-lH-l,2,3- triazol-l-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic LC/MS (ESI) m/z: 487 (M+H)+.1H NMR (400 MHz, CD3OD) 8.04 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 6.(s, 2H), 4.22 (s, 3H), 3.28-3.23 (m, 2H), 3.13-3.03 (m, 1H), 2.63 (s, 3H), 2.62-2.58 (m, 1H), 2.56 (d, J = 6.8 Hz, 2H), 2.54-2.49 (m, 1H), 2.43-2.39 (m, 2H), 2.37-2.27 (m, 1H), 1.82-1.64 (m, 1H), 1.00-0.(m, 1H), 0.51-0.46 (m, 2H), 0.18- 0.13 (m, 2H).

Example130 222 WO 2022/034568 PCT/IB2021/059266 acid 134n" °-'״yA N^N N־ nV(S)-2-(l-(2-(5-((5-(cyclopropylmethyl)-lH-l,2,3- triazol-l-yl)methyl)-l-methyl- lH-pyrazol-4-yl)-4- ethylpyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 501 (M+H)+.1H NMR (400 MHz, CD3OD) 8.41 (s, 1H), 8.12 (s, 1H), 7.62 (s, 1H), 6.32 (s, 2H), 3.88 (s, 3H), 3.28-3.24 (m, 2H), 3.22-3.12 (m, 1H), 2.90 (q, J= 7.6 Hz, 2H), 2.73- 2.67 (m, 1H), 2.58 (d,J=6.8 Hz, 2H), 2.56-2.41 (m, 1H), 2.40-2.(m, 2H), 2.36-2.26 (m, 1H), 1.82- 1.66 (m, 1H), 1.30 (t, J = 7.6 Hz, 3H), 0.94-0.85 (m, 1H), 0.54-0.(m, 2H), 0.09-0.05 (m, 2H).

Example 130 135 FYyyH ‘n" ° N^N W N^XN-N ׳ .X N )x (S)-2-(l-(2-(5-((4-(cyclopropylmethyl)-lH-l,2,3- triazol-l-yl)methyl)-l-methyl- lH-pyrazol-4-yl)-4- ethylpyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 501 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.46 (s, 1H), 8.13 (s, 1H), 7.84 (s, 1H), 6.28 (s, 2H), 3.98 (s, 3H), 3.28-3.24 (m, 2H), 3.23-3.12 (m, 1H), 2.92 (q, J= 7.6 Hz, 2H), 2.74- 2.68 (m, 1H), 2.55 (d,J=6.8 Hz, 2H), 2.54-2.45 (m, 1H), 2.42-2.(m, 2H), 2.36-2.26 (m, 1H), 1.82- 1.66 (m, 1H), 1.31 (t, J = 7.6 Hz, 3H), 0.99-0.86 (m, 1H), 0.49-0.(m, 2H), 0.16-0.12 (m, 2H).

Example 130 136 ■Vr N^N VYn-n N־ A— (S)-2-(l-(2-(5-((4-(cyclopropylmethyl)-2H-l,2,3- triazol-2-yl)methyl)-l-methyl- lH-pyrazol-4-yl)-4- ethylpyrimidin-5-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 501 (M+H)+. 1H NMR: N/AExample 130 223 WO 2022/034568 PCT/IB2021/059266 Example 137: 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid & example 138 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid Step 1: 5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazole (2) id="p-505" id="p-505" id="p-505" id="p-505" id="p-505" id="p-505" id="p-505" id="p-505" id="p-505"

[0505]To a solution of 2-cyclopropylacetonitrile (1 g, 12.33 mmol) in 1-Butanol (20 mL) was added NaN3 (0.96 g, 14.80 mmol) and ZnC12 (1.7 g, 12.33 mmol). The reaction mixture was stirred under N2 atmosphere at 110 °C for 16 hrs. After cooling to room temperature, 1-Butanol was removed under reduced pressure. To the mixture was added 0.5M aq.NaOH (2.0 eq) and the resulting suspension was filtered. The filtrate was acidified with IM aq.HCl to pH = 4 and extracted with EtOAc (2 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (800 mg, 52.3% yield) as white solid. LC/MS (ESI) m/z: 125 (M+H)+. Step 2: methyl 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetate (3A) and methyl (S)-2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-tetrazol-l-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (3B) id="p-506" id="p-506" id="p-506" id="p-506" id="p-506" id="p-506" id="p-506" id="p-506" id="p-506"

[0506]To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (80 mg, 0.20 mmol) in toluene (mL) was added 5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazole (49 mg, 0.39 mmol) followed by PPh(102 mg, 0.39 mmol) and DIAD (79 mg, 0.39 mmol) under N2 atmosphere at 0 °C and the reaction mixture was stirred at 60 °C for 16 hrs. The mixture was concentrated to dryness and the residue was purified by prep-TLC (PE: EtOAc= 1: 1) to give compound 3A(20 mg, yield 19.9 %) and compound 3B(40 mg, yield 39.7 %) as white solid. LC/MS (ESI) m/z: 516 (M+H)+. The 224 WO 2022/034568 PCT/IB2021/059266 configuration of two isolated products was confirmed in the next reaction. Step 3: 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-2H-l,2,3,4-tetrazol-2-yl]methyl}-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid [0507]To a solution of methyl 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l- yl]methyl }-I-methyl-1H-1, 2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperi din-3- yl]acetate (20 mg, 0.04 mmol) in THF (4 mL), MeOH (1 mL) and water (1 mL) was added LiOH (16 mg, 0.39 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (10 mL). The mixture was washed with EtOAc (2x3 mL) and the aqueous layer was acidified with IM aq.HCl to pH = 4 and extracted with DCM (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10- 95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (5 mg, 25.7% yield) as white solid. LC/MS (ESI) m/z: 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.90 (d, J= 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 6.65 (s, 2H), 4.24 (s, 3H), 3.28-3.19 (m, 2H), 3.13-3.01 (m, 1H), 2.91 (q, J= 7.6 Hz, 2H), 2.73 (d, J= 7.0 Hz, 2H), 2.64 - 2.55 (m, 1H), 2.54 - 2.45 (m, 1H), 2.44 - 2.36 (m, 2H), 2.31 -2.26 (m, 1H), 1.80 - 1.63 (m, 1H), 1.29 (t,J=7.6Hz, 3H), 1.12 - 1.00 (m, 1H), 0.56 - 0.45 (m, 2H), 0.22 - 0.17 (m, 2H). Example 138: 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid id="p-508" id="p-508" id="p-508" id="p-508" id="p-508" id="p-508" id="p-508" id="p-508" id="p-508"

[0508]The title compound was prepared using the same method for the synthesis of example 137. LC/MS (ESI) m/z: 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.94 (d, J= 8.3 Hz, 1H), 7.62 (d, J= 8.4 Hz, 1H), 6.43 (d, J= 8.8 Hz, 2H), 4.09 (s, 3H), 3.22-3.13 (m, 2H), 3.06 - 2.99 (m, 1H), 3.90 - 2.88 (m, 2H), 2.71 (d, J= 7.0 Hz, 2H), 2.58 - 2.50 (m, 1H), 2.48-2.40 (m, 1H), 2.34-2.(m, 2H), 2.28 - 2.17 (m, 1H), 1.72 - 1.57 (m, 1H), 1.16 (t, J = 7.5 Hz, 3H), 0.91 - 0.82 (m, 1H), 0.43 - 0.38 (m, 2H), 0.02 - 0.00 (m, 2H). Example 139: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetic acid 225 WO 2022/034568 PCT/IB2021/059266 Step 1Pyrdine DCM LiOHTHF/MeOH/H2OStep 3 Example 139 Step 1: Methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetate [0509]To a mixture of methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (350 mg, 0.89 mmol) and 4-nitrophenyl chloroformate (535 mg, 2.67 mmol) in DCM (15 mL) was added pyridine (348 mg, 4.41 mmol) and the reaction was stirred at r.t. for 1 hr. The mixture was diluted with DCM (20 mL) and was washed with saturated aq.NaHCO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified via silica gel chromatography (eluted with PE: EtOAc=5: to 3: 1) to give the title compound (460 mg, 92.8% yield) as yellow solid. LC/MS (ESI) (m/z): 5(M+H)+. Step 2: Methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetate id="p-510" id="p-510" id="p-510" id="p-510" id="p-510" id="p-510" id="p-510" id="p-510" id="p-510"

[0510]To a solution of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (120 mg, 0.21 mmol) in THF(10 mL) was added DIPEA (135 mg, 1.04 mmol) followed by methyl(propyl)amine (76 mg, 1.04 mmol) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with IM aq.NaOH solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-TLC (50% EtOAc in PE) to give the title compound (55 mg, 52.0% yield) as yellow solid. LC/MS (ESI) (m/z): 495 (M+H)+. Step 3: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetic acid 226 WO 2022/034568 PCT/IB2021/059266 id="p-511" id="p-511" id="p-511" id="p-511" id="p-511" id="p-511" id="p-511" id="p-511" id="p-511"

[0511]To a solution of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetate (55 mg, 0.11 mmol) in THF (4 mL) /H2O (4 mL)/MeOH (4 mL) was added LiOH.H2O (47 mg, 1.11 mmol) and the reaction mixture was stirred at r.t. for 2 hrs. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc (2x5 mL), acidified with IN aq.HCl to pH~4 and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (28.7 mg, 53.8% yield) as white solid. LC/MS (ESI) (m/z): 481 (M+H)+. 1H NMR (400 MHz, CD:OD) 5 7.82 (d, J = 8.3 Hz, 1H), 7.53 (d, J= 8.3 Hz, 1H), 5.70 (d, J= 5.1 Hz, 2H), 4.17 (s, 3H), 3.30 - 3.20 (m, 3H), 3.15 - 3.00 (m, 2H), 2.84 (d, J =20.0 Hz, 3H), 2.64 - 2.57 (m, 1H), 2.56 (s, 3H), 2.54 - 2.46 (m, 1H), 2.44 - 2.38 (m, 2H), 2.36 - 2.25 (m, 1H), 1.82 - 1.64 (m, 1H), 1.59 - 1.32 (m, 2H), 0.89 - 0.(m, 3H). The Examples in the following table were synthesized according to the procedures described as the synthesis of example from appropriate starting materials. Ex# Structure & name Analytical data Method140N n^t^o^ N-N^(S)-2-(l-(6-(5-((((cyclopropylmethyl)(methyl) carbamoyl)oxy)methyl)- 1 - methyl-1H-1, 2,3-triazol-4-yl)- 2-methylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI ) (m/z): 493, (M+H)+. 1H NMR (400 MHz, CD3OD) 7.82 (d, J= 8.0 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 5.70 (s, 2H), 3.29 - 3.23 (m, 2H), 3.17 - 3.01 (m, 3H), 2.91 (d, J= 16.2 Hz, 3H), 2.65 - 2.48 (m, 2H), 2.56 (s, 3H), 2.45 - 2.37 (m, 2H), 2.35 - 2.25 (m, 1H), 1.84- 1.65 (m, 1H), 1.05-0.(m, 1H), 0.40-0.12 (m, 4H).

Example 139 141N 1 0N"M-M /N^b> (S)-2-(l-(6-(5-((((cyclopropylmethyl)(methyl) carbamoyl)oxy)methyl)- 1 - methyl-1H-1, 2,3-triazol-4-yl)- 2-ethylpyridin-3-yl)-5,5- LC/MS (ESI) (m/z): 506, (M+H)+. 1H NMR (400 MHz, CD3OD) 7.85 (d, J= 8.3 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 5.76 (d, J= 9.0 Hz, 2H), 4.19 (s, 3H), 3.27 - 3.18 (m, 2H), 3.16-3.00 (m, 3H), 2.97- 2.87 (m, 5H), 2.63 -2.55 (m, 1H), 2.55 - 2.45 (m, 1H), 2.43 - 2.(m, 2H), 2.35 -2.25 (m, 1H), 1.- 1.64 (m, 1H), 1.34 (t, J= 7.4 Hz, Example 139 227 WO 2022/034568 PCT/IB2021/059266 difluoropiperi din-3-yl)acetic acid3H), 1.04 - 0.72 (m, 1H), 0.55 - 0.01 (m, 1H).142 pVyVn V ° ''nJ n —n n^V(S)-2-(l-(6-(5-(((cyclobutyl(methyl)carbamoy l)oxy)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 493 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J= 8.4 Hz, 1H), 7.53 (d, J= 8.Hz, 1H), 5.69 (s, 2H), 4.17 (s, 3H), 3.29 - 3.24 (m, 2H), 3. 15- 3.(m, 1H), 2.81 (s, 3H), 2.64 - 2.(m, 2H), 2.55 (s, 3H), 2.44 - 2.(m, 3H), 2.18 - 1.87 (m, 4H), 1.- 1.50 (m, 3H), 1.17 (t,J= 7.1 Hz, 1H).

Example 139 143 j״r I 0 (S)-2-(l-(6-(5-(((cyclobutyl(methyl)carbamoy l)oxy)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 507 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J= 8.3 Hz, 1H), 7.56 (d, J= 8.Hz, 1H), 5.75 (s, 2H), 4.17 (s, 3H), 3.27-3.19 (m, 2H), 3.13-3.(m, 1H), 2.93 (q, J= 7.4 Hz, 2H), 2.81 (s, 3H), 2.63 - 2.57 (m, 1H), 2.51 (s, 1H), 2.43 - 2.38 (m, 2H), 2.36 - 2.24 (m, 1H), 2.23 - 1.(m, 4H), 1.69 (d, J= 29.6 Hz, 3H), 1.33 (t, J =7.5 Hz, 3H).

Example 139 144N Aa- (R)-2-(l-(2-methyl-6-(l- methyl-5-(((methyl(propyl)carbamoyl)ox y )m ethyl)- 1H-1,2,3 -tri azol-4- yl)pyridin-3 -yl)piperidin-3 - yl)acetic acid LC/MS (ESI) m/z: 445 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J= 8.3 Hz, 1H), 7.47 (d, J= 8.Hz, 1H), 5.69 (s, 2H), 4.17 (s, 3H), 3.25-3.19 (m, 2H), 3.13 - 3.(m, 2H), 2.88 - 2.78 (m, 3H), 2.- 2.67 (m, 1H), 2.54 (s, 3H), 2.47 - 2.39 (m, 1H), 2.32-2.19 (m, 3H), 1.94- 1.74 (m, 3H), 1.60-1.(m, 1H), 1.41 - 1.32 (m, 1H), 1.-1.16(m, 1H), 0.90-0.66 (m, 3H).

Example 139 228 WO 2022/034568 PCT/IB2021/059266 145u ° N-N p x/(R)-2-(l -(2-ethyl-6-( 1 -methyl- 5- (((methyl(propyl)carbamoyl)ox y )m ethyl)- 1H-1,2,3 -tri azol-4- yl)pyridin-3 -yl)piperidin-3 - yl)acetic acid LC/MS (ESI) m/z: 459 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.(d, J = 8.2 Hz, 1H), 7.49 (d, J = 8.Hz, 1H), 5.75 (s, 2H), 4.18 (s, 3H), 3.24 - 3.00 (m, 4H), 2.90 (q, J = 7.Hz, 2H), 2.83 (d, J = 17.4 Hz, 3H), 2.76 - 2.66 (m, 1H), 2.48 - 2.(m, 1H), 2.36-2.18 (m, 3H), 1.-1.74 (m, 3H), 1.61-1.50 (m, 1H), 1.38-1.31 (m, 1H), 1.34 (t, J = 7.1 Hz, 3H) 1.27- 1.17 (m, 1H), 0.77 (dt, 1 = 77.5, 7.1Hz, 3H).

Example 139 146 FVyVH V 0 /x ImON" N-N^(S)-2-(l-(2-ethyl-6-(l-methyl- 5-(((methyl(propyl)carbamoyl)ox y )m ethyl)- 1H-1,2,3 -tri azol-4- yl)pyridin-3-yl)-5,5- difluoropiperi din-3-yl)acetic acid LC/MS (ESI) m/z: 459 (M+H)+1H NMR (400 MHz, CD3OD) 5 7.(d, J= 7.8 Hz, 1H), 7.56 (d, J= 7.Hz, 1H), 5.76 (s, 2H), 4.18 (s, 3H), 3.26-3.18 (m, 3H), 3.14-3.(m, 2H), 2.94 (q, J= 7.2 Hz, 2H), 2.83 (d, J= 17.3 Hz, 3H), 2.65 - 2.46 (m, 2H), 2.39 - 2.28 (m, 3H), 1.78- 1.64 (m, 1H), 1.60-1.(m, 1H), 1.34 (t, J= 7.5 Hz, 3H), 0.78 (dt,J= 14.2, 6.5 Hz, 3H).

Example 139 Example 147 and 148: (S) and (R)-l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3- carboxylic acid Example 147 and 148 Stereochemisry not assigned Step 1: Methyl l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate [0512]To a mixture of Methyl 5,5-difh1oro-l-((6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-methylpyridin-3-yl)methyl)piperidine-3-carboxylate (50 mg, 0.13 mmol) and 2-chloro-4- cyclobutylpyrimidine (21 mg, 0.13 mmol) in DMF (5 mL) was added t-BuOK (0.25 mL, 0.25 mmol, 1.0 M in THF) drop-wisely at 0 °C and the reaction was stirred at 0 °C for 2 hrs. The mixture was 229 WO 2022/034568 PCT/IB2021/059266 quenched with saturated aq.NH4Cl solution at 0 °C and acidified with IN aq.HCl to pH~4. The mixture was extracted with EtOAc (3x5 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (40 mg, 60.0% yield) as yellow solid. LC/MS (ESI) (m/z): 528 (M+H)+. Step 2: (S) or (R)-l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid and (R) or (S)-l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid [0513]To a solution of methyl l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-1H- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (40 mg, 0.076 mmol) in THE (4 mL)/H20 (4 mL)/MeOH (4 mL) was added LiOH.H2O (32 mg, 0.76 mmol) and the reaction was stirred at r.t. for 2 hrs. Volatiles were removed under vacuum and the residue was diluted with H2O (5 mL). The mixture was adjusted with IN aq.HCl to pH~4 and extracted with EtOAc (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was firstly purified by prep- HPLC (Cl 8, 5-95%, MeCN in H2O with 0.1% HCOOH) and further purified by chiral SFC to give example 147(Peak 1, retention time: 6.433 min) (6.5 mg, 16.7% yield) as white solid and example 148(Peak 2, retention time: 6.662 min) (5.5 mg, 14.1% yield) as white solid. Absolute stereochemistry of these two isomers has not been assigned. [0514] Example 147:LC/MS (ESI) (m/z): 514 (M+H)+. 1H NMR (400 MHz, DMSO-d6) 5 8.(d, J = 5.0 Hz, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.09 (d, J = 5.1 Hz, 1H), 6.(d, J = 1.6 Hz, 2H), 4.22 (s, 3H), 3.67 (s, 2H), 3.61 - 3.54 (m, 2H), 3.05 - 2.95 (m, 2H), 2.76 - 2.67 (m, 1H), 2.44 (s, 3H), 2.25 - 2.20 (m, 2H), 2.27 - 2.20 (m, 4H), 2.05 - 1.93 (m, 2H), 1.83 - 1.74 (m, 1H). [0515] Example 148:LC/MS (ESI) (m/z): 514 (M+H)+. 1H NMR (400 MHz, DMSO-d6) 5 8.(d,J = 5.0 Hz, 1H), 7.97 (d, J= 7.9 Hz, 1H), 7.79 (d, J= 7.9 Hz, 1H), 7.09 (d, J= 5.1 Hz, 1H), 6.24 - 6.08 (m, 2H), 4.22 (s, 3H), 3.67 (s, 2H), 3.62 - 3.55 (m, 2H), 3.04 - 2.96 (m, 2H), 2.76 - 2.70 (m, 1H), 2.44 (s, 3H), 2.34 - 2.28 (m, 2H), 2.26 - 2.20 (m, 4H), 2.06 - 1.95 (m, 2H), 1.82 - 1.75 (m, 1H).SFC condition: Column: ChiralPak AD, 250x21.2 mm I.D., 5 pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 30%; Flow rate: 50 mL /min; Column temperature: °C. 230 WO 2022/034568 PCT/IB2021/059266 Example 149 and 150: (S) and (R)-l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid Example 149 and 150 Stereochemisry not assigned Step 1: Methyl l-((2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate id="p-516" id="p-516" id="p-516" id="p-516" id="p-516" id="p-516" id="p-516" id="p-516" id="p-516"

[0516]To a solution of methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (100 mg, 0.25 mmol ) in DCM (mL) were added TEA (51 mg, 0.51 mmol) and MsCl (43 mg, 0.38 mmol) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The crude product was used in the next reaction without further purification. LC/MS (ESI) (m/z): 4(M+H)+. Step 2: Methyl l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate [0517] To a mixture of methyl l-((2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (90 mg, 0.190 mmol) and 4-propylpyridin-2(lH)-one (39 mg, 0.285 mmol) in toluene (5 mL)/H20 (1 mL) was added K2CO3 (53 mg, 0.380 mmol) followed by TBAF (5 mg, 0.019 mmol) and the reaction mixture was stirred at 100 °C for 16 hrs. The mixture was partitioned between EtOAc (10 mL) and water (mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 40% EtOAc in PE) to give the title compound (75 mg, 76.7% yield) as yellow solid. LC/MS (ESI) (m/z): 5(M+H)+. Step 3: (S) or (R)-l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid and (R) or (S)-l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid id="p-518" id="p-518" id="p-518" id="p-518" id="p-518" id="p-518" id="p-518" id="p-518" id="p-518"

[0518]The title compounds were synthesized according the same procedure as example 147 and 148.The final product was purified by chiral SECto give example 149(Peak 1, retention time: 231 WO 2022/034568 PCT/IB2021/059266 3.513 min) (6.5 mg, 28.5% yield) as white solid and example 150(Peak 2, retention time: 3.8min) (4.4 mg, 19.3% yield) as white solid. [0519] Example 149:LC/MS (ESI) (m/z): 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.90 (d, J= 7.8 Hz, 1H), 7.80 (d, J= 7.8 Hz, 1H), 7.70 (d, J= 2.4 Hz, 1H), 7.39 (dd, J= 9.2, 2.4 Hz, 1H), 6.53 (d, J= 9.2 Hz, 1H), 5.91 (s, 2H), 3.70 (d,J=4.4 Hz, 2H), 3.14 - 3.02 (m, 1H), 3.00 (t, J = 7.5 Hz, 2H), 3.04 - 2.92 (m, 1H), 2.88 - 2.66 (m, 1H), 2.38 - 2.28 (m, 2H), 2.21 (t, J= 7.6 Hz, 2H), 1.38 (q, J= 14.7, 7.4 Hz, 2H), 1.30 (t, J= 7.5 Hz, 3H), 0.75 (t, J= 7.4 Hz, 3H). [0520] Example 150:LC/MS (ESI) (m/z): 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.90 (d, J= 7.9 Hz, 1H), 7.80 (d, J= 8.0 Hz, 1H), 7.70 (s, 1H), 7.39 (dd, J= 9.2, 2.5 Hz, 1H), 6.53 (d, J = 9.2 Hz, 1H), 5.91 (s, 2H), 4.17 (s, 3H), 3.70 (s, 2H), 3.14 - 3.09 (m, 1H), 2.99 (t, J= 7.4 Hz, 2H), 2.99 - 2.94 (m, 1H),2.82 - 2.74 (m, 1H), 2.50 - 2.30 (m, 3H), 2.21 (t, J= 7.4 Hz, 2H), 2.05 - 1.(m, 1H), 1.38 (q, J= 7.4 Hz, 2H), 1.30 (t, J= 7.4 Hz, 3H), 0.75 (t, J= 7.4 Hz, 3H).SEC condition: Column: ChiralPak IG, 250x21. 2mm I.D., 5pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 30%; Flow rate: 50 mL /min; Column temperature: 35 Example 151: l-((6-(5-(((4-cyclopropylpyrimidin-2-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid LiOHTHE, MeOHH2OStep 4 Example 151 DIPEA, NMPStep 3 Step 1: Methyl l-((6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3- yl)methyl)-5,5-difluoropiperidine-3-carboxylate id="p-521" id="p-521" id="p-521" id="p-521" id="p-521" id="p-521" id="p-521" id="p-521" id="p-521"

[0521]To a solution of methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (300 mg, 0.62 mmol) in DMF (mL) was added NaN3 (60 mg, 0.923 mmol) and the reaction was stirred at 60 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with water and brine, dried over 232 WO 2022/034568 PCT/IB2021/059266 anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 30% EtOAc in PE) to give the title compound (208 mg, 77.8% yield) as yellow solid. LC/MS (ESI) (m/z): 435 (M+H)+. 1H NMR (400 MHz, CDC13) 8.03 (d, J= 7.9 Hz, 1H), 7.66 (d, J= 7.9 Hz, 1H), 5.17 (s, 2H), 4.13 (s, 3H), 3.69 (s, 3H), 3.64 - 3.60 (m, 2H), 3.13 - 2.99 (m, 2H), 2.92 (q, J= 7.4 Hz, 2H), 2.94 - 2.89 (m, 1H), 2.46 - 2.37 (m״ 1H), 2.35 -2.25 (m, 1H), 2.23 - 2.21(m, 1H), 2.0 2- 1.98 (m, 1H), 1.36 (t, J = 7.4, 3H). Step 2: Methyl l-((6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3- yl)methyl)-5,5-difluoropiperidine-3-carboxylate id="p-522" id="p-522" id="p-522" id="p-522" id="p-522" id="p-522" id="p-522" id="p-522" id="p-522"

[0522]To a solution of methyl l-((6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (200 mg, 0.46 mmol) in EtOAc (mb) was added 10% Pd/C (40 mg, 0.038 mmol) and the mixture was degassed under N2 for three times and stirred under a H2 balloon at r.t. for 2 hrs. The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated to dryness to give the title compound (190 mg, 100% yield), which was used in the next step without further purification. LC/MS (ESI) (m/z): 4(M+H)+. Step 3: Methyl l-((6-(5-(((4-cyclopropylpyrimidin-2-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate id="p-523" id="p-523" id="p-523" id="p-523" id="p-523" id="p-523" id="p-523" id="p-523" id="p-523"

[0523]To a mixture of methyl l-((6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (70 mg, 0.17 mmol) and 2-chloro- 4-cyclobutylpyrimidine (29 mg, 0.17 mmol) in NMP (2 mL) was added DIPEA (44 mg, 0.mmol) and the reaction was stirred in a CEM microwave reactor at 150 °C for 2 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by perp-TLC (40% EtOAc in PE) to give the title compound (50 mg, 54.0% yield) as yellow oil. LC/MS (ESI) (m/z): 527 (M+H)+. Step 4: methyl l-((6-(5-(((4-cyclopropylpyrimidin-2-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate [0524]The title compound was synthesized according to the same procedure as Example 149. LC/MS (ESI)(m/z): 513 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 8.02 (d, J= 5.2 Hz, 1H), 7.(d, 8.0 Hz, 1H), 7.77 (d, J= 8.0 Hz, 1H), 6.51 (d, J= 5.2 Hz, 1H), 5.06 (s, 2H), 4.23 (s, 3H),3.70 (s, 2H), 3.14-3.09 (m, 1H), 3.05 - 2.99 (q, J= 15 Hz, 2H), 3.00 - 2.94 (m, 1H), 2.83 - 2.(m, 1H), 2.50 - 2.38 (m, 1H), 2.36 - 2.26 (m, 2H), 2.04 - 1.88 (m, 1H), 1.87 - 1.80 (m, 1H), 1.(t, J= 15 Hz, 3H), 0.94 - 0.86 (m, 4H).The Examples in the below Table were synthesized and separated by chiral SEC by the same 233 WO 2022/034568 PCT/IB2021/059266 methods exemplified by the preparation of the examples as indicated. As a convertion, the fatser- eluting enantiomer is always listed as enantiomer Pl and the slower-eluting enantiomer is listed as enantiomer P2. The symbol * at the chiral centre denotes that this chiral center has been resolved and the absolute stereochemistry at that center has not been determined.

Ex# Structure & name Analytical data Method152HO^O A N^JA 1L / 0A A N-N^ enantiomer Pl:(S) or (R)-l-((6-(5-(((4- cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5- difluoropiperi dine-3-carboxylic acid LC/MS (ESI) (m/z): 528 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.40 (d, J= 5.1 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.75 (d, J= 8.1 Hz, 1H), 6.98 (d, J= 5.1 Hz, 1H), 6.(s, 2H), 4.24 (s, 3H), 3.68 - 3.(m, 2H), 3.54-3.48 (m, 2H), 3.-3.11 (m, 1H), 3.03 -2.92 (m, 1H), 2.87 (q, J= 7.5 Hz, 2H), 2.- 2.64 (m, 1H), 2.42 - 2.28(m, 2H), 2.27 - 2.18 (m, 5H), 2.06 - 1.(m, 1H), 1.84-1.71 (m, 1H), 1.(t, 7= 7.5 Hz, 3H).

Example 147 153HO^O A, 1 N-AJ/ / t' / 0A A N-N N-^X enantiomer P2: (R) or (S)-l-((6- (5-(((4-cyclobutylpyrimidin-2- yl)oxy)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5- difluoropiperi dine-3-carboxylic acid LC/MS (ESI) (m/z): 528 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.40 (d, J= 5.1 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.75 (d, J= 7.8 Hz, 1H), 6.98 (d, J= 5.1 Hz, 1H), 6.(s, 2H), 4.24 (s, 3H), 3.66 (d, J = 4.1 Hz, 2H), 3.58 - 3.46 (m, 2H), 3.15-3.10 (m, 1H), 3.00-2.(m, 1H), 2.88 (q, J= 7.5 Hz, 2H), 2.82 - 2.65 (m, 1H), 2.41 - 2.(m, 2H), 2.27 -2.16 (m, 5H), 2.- 1.98 (m, 1H), 1.82- 1.72 (m, 1H), 1.21 (t, J= 7.5 Hz, 3H).

Example 147 154־ 1A A oN־ A enantiomer Pl : (S) or (R)-l-((2- ethyl-6-(5-((5-isobutyl-2-oxopyridin- 1 (2H)-yl)m ethyl)- 1 - LC/MS (ESI) (m/z): 529 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.90 (d, J= 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.65 (d,7=2.1 Hz, 1H), 7.36 (dd, J= 9.2, 2.1 Hz, 1H), 6.53 (d, J= 9.2 Hz, 1H), 5.92 (s, 2H), 4.18 (s, 3H), 3.70 (s, 2H), 3.- 3.10 (m, 1H), 2.99 (q, J= 7.6 Hz, 2H), 2.97 - 2.91 (m, 1H), 2.85 - 2.67 (m, 1H), 2.49 - 2.28 (m, 3H), 2.09 (d, J= 6.6 Hz, 2H), 2.02 - 1.85 (m, 1H), 1.62- 1.55 (m, 1H), 1.30 (t, J= 7.4 Hz, 6H), 1.02 (t, J= Example 148 234 WO 2022/034568 PCT/IB2021/059266 methyl- 1H-1,2,3 -tri azol-4- yl)pyridin-3-yl)methyl)-5,5- difluoropiperi dine-3-carboxylic acid 7.4 Hz, 1H), 0.72 (d, J= 6.6 Hz, 6H). 155A 1 O N־ O enantiomer P2: (R) or (S)-l-((2- ethyl-6-(5-((5-isobutyl-2-oxopyridin- 1 (2H)-yl)m ethyl)- 1 - methyl- 1H-1,2,3 -tri azol-4- yl)pyridin-3-yl)methyl)-5,5- difluoropiperi dine-3-carboxylic acid LC/MS (ESI) (m/z): 529 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.90 (d, J= 7.9 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.65 (d, J= 2.0 Hz, 1H), 7.36 (dd, J= 9.2, 2.0 Hz, 1H), 6.53 (d, J= 9.2 Hz, 1H), 5.92 (s, 2H), 4.18 (s, 3H), 3.70 (s, 2H), 3.- 3.07 (m, 1H), 2.99 (q, J= 7.5 Hz, 3H), 2.97 - 2.90 (m, 1H), 2.86 - 2.74 (m, 1H), 2.49 - 2.26 (m, 3H), 2.09 (d, J= 7.1 Hz, 2H), 2.04 - 1.89 (m, 1H), 1.62 - 1.55 (m, 1H), 1.30 (t, 7=7.1 Hz, 1H), 0.72 (d, J= 6.6 Hz, 6H).

Example 149 156HO^O A 1 0N־ o enantiomer Pl:(S) or (R)-5,5-difluoro-l-((2- methyl-6-(l-methyl-5-((2-oxo-5- propylpyridin-l(2H)-yl)methyl)- 1H-1,2,3-tri azol-4-yl)pyri din-3- yl)methyl)piperidine-3- carboxylic acid LC/MS (ESI) (m/z): 501 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.88 (d, 7= 2.1 Hz, 1H), 7.86 (d, = 7.9 Hz, 1H), 7.75 (d, 7= 8.0 Hz, 1H), 7.36 (dd, 7= 9.2, 2.5 Hz, 1H), 6.47 (d, 7= 9.2 Hz, 1H), 5.79 (s, 2H), 4.24 (s, 3H), 3.68 (s, 2H), 3.- 3.06 (m, 1H),3.OO - 2.92 (m, 1H), 2.83 - 2.74 (m, 1H), 2.67 (s, 3H), 2.48 - 2.38 (m, 1H), 2.36 - 2.(m, 2H), 2.25 (t, 7= 7.5 Hz, 2H), 2.04- 1.89 (m, 1H), 1.45 - 1.(m, 2H), 0.77 (t, 7= 7.3 Hz, 3H).

Example 149 157HO^O A 1 0N־ o LC/MS (ESI) (m/z): 501 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.89 (d, 7= 2.3 Hz, 1H), 7.86 (d, = 8.0 Hz, 1H), 7.76 (d, 7= 8.0 Hz, 1H), 7.37 (dd, 7= 9.2, 2.5 Hz, 1H), 6.48 (d, 7= 9.2 Hz, 1H), 5.79 (s, 2H), 4.24 (s, 3H), 3.67 (d, 7= 8.Hz, 2H), 3.15 - 3.07 (m, 1H), 3.-2.91 (m, 1H), 2.79-2.71 (m, 1H), 2.67 (s, 3H), 2.47 - 2.37 (m, Example 149 235 WO 2022/034568 PCT/IB2021/059266 enantiomer P2: (R) or (S)-5,5- difluoro- 1 -((2-methyl-6-( 1 - methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- 1H-1,2,3-tri azol-4-yl)pyri din-3- yl)methyl)piperidine-3-carboxylic acid 1H), 2.36 - 2.29 (m, 2H), 2.27 - 2.21 (m, 2H), 2.05 - 2.00 (m, 1H), 1.4=4 - 1.38 (m, 2H), 0.78 (t, J= Hz, 3H). 158HO^OA 1 0 N־ enantiomer Pl: (S) or (R)-5,5- difluoro- 1 -((2-methyl-6-( 1 - methyl-5-((6-oxo-4-propylpyridazin- 1 (6H)- yl)methyl)-lH- 1,2,3-tri azol -4- yl)pyri din-3-yl)methyl)piperidine-3- carboxylic acid LC/MS (ESI) (m/z): 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.78 (d, J= 7.9 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.68 (s, 1H), 6.83 - 6.69 (m, 1H), 5.91 (s, 2H), 4.16 (s, 3H), 3.61 (q, J= 13.7 Hz, 2H), 3.-3.03 (m, 1H), 2.97-2.88 (m, 1H), 2.76 - 2.66 (m, 1H), 2.52 (s, 3H), 2.50 - 2.43 (m, 2H), 2.42 - 2.21 (m, 3H), 1.99 - 1.82 (m, 1H), 1.65 - 1.54 (m, 2H), 0.93 (t, J= 7.Hz, 3H).

Example 149 159HO^O A 1 0 N-N ׳ /) enantiomer P2: (R) or (S)-5,5- difluoro- 1 -((2-methyl-6-( 1 - methyl-5-((6-oxo-4- propylpyridazin- 1 (6H)- yl)methyl)-lH- 1,2,3-tri azol -4- yl)pyri din-3-yl)methyl)piperidine-3- carboxylic acid LC/MS (ESI) (m/z): 502 (M+H)+. 1H NMR (400 MHz, CD3OD) 7.79 (d, J= 7.9 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.68 (s, 2H), 6.82 - 6.68 (m, 1H), 5.91 (s, 2H), 4.16 (s, 3H), 3.62 (d, J=3.6Hz, 2H), 3.- 2.99 (m, 1H), 2.98 - 2.87 (m, 1H), 2.82 - 2.70 (m, 1H), 2.52 (s, 3H), 2.49 - 2.44 (m, 2H), 2.42 - 2.25 (m, 3H), 2.02 - 1.84 (m, 1H), 1.65 - 1.55 (m, 2H), 0.93 (t, J= 7.Hz, 3H).

Example 149 236 WO 2022/034568 PCT/IB2021/059266 160HU^U N^N JI 0 N־ o enantiomer Pl: (S) or (R)-l-((4- ethyl-2-(l-methyl-5-((2-oxo-5- propylpyridin-l(2H)-yl)methyl)- lH-pyrazol-4-yl)pyrimidin-5- yl)methyl)-5,5-difluoropiperi dine-3-carboxylic acid LC/MS (ESI) (m/z): 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.54 (s, 1H), 8.20 (s, 1H), 7.51 (d, J = 2.5 Hz, 1H), 7.40 (dd, J= 9.1, 2.Hz, 1H), 6.55 (d, J= 9.1 Hz, 1H), 5.88 (s, 2H), 3.93 (s, 3H), 3.67 (s, 2H), 3.10 - 3.03 (m, 1H), 2.92 (q, J = 7.5 Hz, 3H), 2.80 - 2.75 (m, 1H), 2.51-2.39 (m, 1H), 2.37-2.(m, 2H), 2.23 (t, J = 7.5 Hz, 2H), 2.10-1.85 (m, 1H), 1.44-1.(m, 2H), 1.26 (t, J = 7.5 Hz, 3H), 0.76 (t, J= 7.5 Hz, 3H).

Example 149 161 N^NJI nX.n ־ O enantiomer 2:(R) or (S)-l-((4-ethyl-2-(l- methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-pyrazol-4-yl)pyrimidin-5- yl)methyl)-5,5-difluoropiperi dine-3-carboxylic acid LC/MS (ESI) (m/z): 515 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.54 (s, 1H), 8.20 (s, 1H), 7.51 (d, J = 2.5 Hz, 1H), 7.40 (dd, J= 9.2, 2.Hz, 1H), 6.55 (d, J= 9.2 Hz, 1H), 5.88 (s, 2H), 3.93 (s, 3H), 3.67 (s, 2H), 3.10-3.03 (m, 1H), 2.99- 2.93 (m, 1H), 2.92 (q, J= 7.4 Hz, 2H), 2.80 - 2.71 (m, 1H), 2.52 - 2.39 (m, 1H), 2.38 - 2.30 (m, 1H), 2.23 (t,J=7.4Hz, 2H), 2.10- 1.(m, 1H), 1.45 - 1.35 (m, 1H), 1.(t, J= 7.4 Hz, 3H), 0.76 (t, J= 7.Hz, 3H).

Example 149 162HO^O I*,.N^J^ r f"-״Hq T n*xN-N H N X—। enantiomer Pl: (S) or (R)-l-((6- (5-(((4-cyclobutylpyrimidin-2- yl)amino)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)methyl)-5,5- LC/MS (ESI) (m/z): 527 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.15 (d,J=4.8Hz, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.77 (d, J= 8.0 Hz, 1H), 6.54 (d, J= 4.8 Hz, 1H), 5.(s, 2H), 4.30 (s, 3H), 3.70 (d, J= 2.2 Hz, 2H), 3.49 - 3.40 (m, 1H), 3.14-3.10 (m, 1H), 3.05(q, J= 7.Hz, 2H), 3.01 - 2.95 (m, 1H), 2.- 2.73 (m, 1H), 2.48 - 2.38 (m, 1H), 2.37 - 2.29 (m, 2H), 2.27 - 2.19 (m, 4H), 2.07-2.01 (m, 1H), 2.00- 1.89 (m, 1H), 1.86-1.(m, 1H), 1.38 (t, J= 7.5 Hz, 3H).

Example 151 237 WO 2022/034568 PCT/IB2021/059266 difluoropiperi dine-3-carboxylic acid163HO^O J*N^^-F r f Tn,VnAJ N-N H N । enantiomer P2: (R) or (S)-l-((6- (5-(((4-cyclobutylpyrimidin-2- yl)amino)methyl)- 1 -methyl- 1H- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5- difluoropiperi dine-3-carboxylic acid LC/MS (ESI) (m/z): 527 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.05 (d, J= 5.4 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.67 (d, J= 7.9 Hz, 1H), 6.44 (d, J= 5.4 Hz, 1H), 4.(s, 2H), 4.20 (s, 3H), 3.61 (d, J = 2.2 Hz, 2H), 3.37-3.31 (m, 1H), 3.05 - 3.01 (m, 1H), 2.95 (q, J= 7.6 Hz, 2H), 2.91 - 2.80 (m, 1H), 2.74 - 2.57 (m, 1H), 2.37 - 2.(m, 1H), 2.27 -2.18 (m, 2H), 2.-2.08 (m, 4H), 2.00-1.91 (m, 1H), 1.91 - 1.79 (m, 1H), 1.76- 1.69 (m, 1H), 1.28 (t, J= 7.5 Hz, 3H).

Example 151 Example 164 and 165: (S) and (R)-l-((2-ethyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5- difluoropiperidine-3-carboxylic acid DIPEA THFStep 2 LiOHTHF, MeOHH2Ochiral separationStep 3 O^OH Example 164 and 165 Stereochemisry not assigned Step 1: Methyl l-((2-ethyl-6-(l-methyl-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate id="p-525" id="p-525" id="p-525" id="p-525" id="p-525" id="p-525" id="p-525" id="p-525" id="p-525"

[0525]To a mixture of methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (120 mg, 0.29 mmol) and 4- nitrophenyl chloroformate (177 mg, 0.88 mmol) in DCM (5 mL) was added pyridine (116 mg, 1.mmol) and the reaction was stirred at r.t. for 1 hr. The mixture was diluted with DCM (10 mL) and 238 WO 2022/034568 PCT/IB2021/059266 was washed with saturated aq.NaHCO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (170 mg, 100% yield). The crude product was used in the next step without further purification. LC/MS (ESI) (m/z): 575 (M+H)+. Step 2: Methyl l-((2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate id="p-526" id="p-526" id="p-526" id="p-526" id="p-526" id="p-526" id="p-526" id="p-526" id="p-526"

[0526]To a solution of methyl l-((2-ethyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy )methyl)-1H- 1,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5, 5- difluoropiperidine-3-carboxylate (120 mg, 0.21 mmol) in THF(10 mL) was added DIPEA (1mg, 1.04 mmol) followed by methyl(propyl)amine (76 mg, 1.04 mmol) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with IM aq.NaOH solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-TLC (50% EtOAc in PE) to give the title compound (23 mg, 21.7% yield) as yellow solid. LC/MS (ESI) (m/z): 509 (M+H)+. Step 3: (S) and (R)-l-((2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid id="p-527" id="p-527" id="p-527" id="p-527" id="p-527" id="p-527" id="p-527" id="p-527" id="p-527"

[0527]The title compound was synthesized according the same procedure as example 147. Example 164:(Peak 1, retention time: 6.385 min) (7.5 mg, 19.2% yield). LC/MS (ESI) (m/z): 495 (M+H)+. 1HNMR (400 MHz, CD3OD) 5 7.84 (d, J= 8.0 Hz, 1H), 7.74 (d, J= 8.0 Hz, 1H), 5.78 (s, 2H), 4.19 (s, 3H), 3.67 (d, J = 5.2 Hz, 2H), 3.25 - 3.17 (m, 1H), 3.13 - 3.08 (m, 2H), 3.00 - 2.97 (m, 1H), 2.95 (q, J= 15 Hz, 2H), 2.82 (d,J=25.1 Hz, 3H), 2.77 - 2.68 (m, 1H), 2.44-2.36 (m, 1H), 2.30 (t, J= 15 Hz, 2H), 2.00 - 1.85 (m, 1H), 1.60- 1.50 (m, 1H), 1.38- 1.30 (m, 1H), 1.35 (t, 7.5 Hz, 3H), 0.76 (dt, J= 81.3, 7.5 Hz, 3H). Example 165:(Peak 2, retention time: 6.663 min) (7 mg, 18.3% yield) as white solid. 1H NMR (400 MHz, CD3OD) 7.84 (d, J= 7.9 Hz, 1H), 7.74 (d, J= 7.9 Hz, 1H), 5.78 (s, 2H), 4.19 (s, 3H), 3.67 (d, J= 4.5 Hz, 2H), 3.25 - 3.17 (m, 1H), 3.14 - 3.07 (m, 2H), 3.00 - 2.92 (m, 1H), 2.95 (q, J= 1A Hz, 2H), 2.82 (d, J= 25.1 Hz, 3H), 2.76 - 2.70 (m, 1H), 2.44 - 2.35 (m, 1H), 2.31 (t, J= 7.2 Hz, 2H), 2.- 1.85 (m, 1H), 1.42 - 1.36 (m, 1H), 1.35 (t, 7.4 Hz, 3H), 0.76 (dt, J= 81.6, 7.2 Hz, 3H). SEC condition: Column: ChiralPak IG-H, 250x4.6 mm I.D., 5 pm; Mobile phase: A for CO2 and B for Methanol (0.05% NH4OH); Gradient: B 5%-40%; Flow rate: 50 mL /min; Column temperature: °C.

Example 166: 4-((2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)morpholine-2-carboxylic acid 239 WO 2022/034568 PCT/IB2021/059266 7 Example 166 Step 1: methyl 6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylnicotinate id="p-528" id="p-528" id="p-528" id="p-528" id="p-528" id="p-528" id="p-528" id="p-528" id="p-528"

[0528]To a solution of methyl 2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy )methyl)- lH-l,2,3-triazol-4-yl)nicotinate (500 mg, 1.44 mmol) in MeOH (10 mL) was added PPTS (1mg, 0.72 mmol) and the mixture was stirred at 50 °C for 3 hrs. The mixture was diluted with EtOAc (20 mL), washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (290 mg, 76.6% yield) as white solid. LC/MS (ESI) (m/z): 379 (M+H)+. Step 2: methyl 2-methyl-6- (l-methyl-5- ((((4-nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)nicotinate id="p-529" id="p-529" id="p-529" id="p-529" id="p-529" id="p-529" id="p-529" id="p-529" id="p-529"

[0529]To a solution of methyl 6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylnicotinate (290 mg, 1.1 mmol) in DCM (10 mL) was added pyridine (1.47 g, 5.53 mmol) followed by 4-Nitrophenyl chloroformate (669 mg, 3.32 mmol) at 0 °C and the mixture was stirred at r.t. for 3 hrs. The solvent was removed to give the title compound (450 mg, 95.2% yield) as yellow oil, which was used directly in the next step. LC/MS (ESI) (m/z): 428 (M+H)+. Step 3: methyl 2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)nicotinate id="p-530" id="p-530" id="p-530" id="p-530" id="p-530" id="p-530" id="p-530" id="p-530" id="p-530"

[0530]To a solution of methyl 2-methyl-6- (l-methyl-5- ((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)nicotinate (450 mg, 1.05 mmol) in THE (10 mL) was added DIPEA (0.52 ml, 3.16 mmol) followed by methyl (propyl)amine (154 mg, 2.mmol) and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (20 mL), washed IN aq.NaOH solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, ~ 60% EtOAc in PE) to give the title compound (320 mg, 84.1% yield) as yellow oil. LC/MS (ESI) (m/z): 362 (M+H)+. 240 WO 2022/034568 PCT/IB2021/059266 Step 4: (4-(5-(hydroxymethyl)-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methyl (propyl)carbamate id="p-531" id="p-531" id="p-531" id="p-531" id="p-531" id="p-531" id="p-531" id="p-531" id="p-531"

[0531]To a solution of methyl 2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)nicotinate (320 mg, 0.89 mmol) in THF (mL) was added LiBH4 (1.11 mL, 2.21 mmol, 2M in THF) drop-wisely at 0 °C. After addition, the reaction was stirred at 55 °C for 3 hrs. The mixture was poured into saturated aq.NH4Cl solution and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (250 mg, 84.7% yield) as yellow oil. LC/MS (ESI) (m/z): 334 (M+H)+. Step 5: (4-(5-formyl-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methyl(propyl)carbamate id="p-532" id="p-532" id="p-532" id="p-532" id="p-532" id="p-532" id="p-532" id="p-532" id="p-532"

[0532]To a solution of (4-(5-(hydroxymethyl)-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol- 5-yl)methyl methyl (propyl)carbamate (250 mg, 0.75 mmol) in DCM (10 mL) was added Dess- Martin periodinane (477 mg, 1.12 mmol) at 0 °C. The reaction was stirred at r.t. for 3 hrs. The mixture was washed with saturated aq.NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 30% EtOAc in PE) to give the title compound (180 mg, 72.4% yield) as yellow solid. LC/MS (ESI) (m/z): 332 (M+H)+. Step 6: methyl 4-((2-methyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)morpholine-2-carboxylate id="p-533" id="p-533" id="p-533" id="p-533" id="p-533" id="p-533" id="p-533" id="p-533" id="p-533"

[0533]To a solution of (4-(5-formyl-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl methyl(propyl)carbamate (100 mg, 0.30 mmol) in DCE (6 mL) was added methyl morpholine-2-carboxylate (87 mg, 0.60 mmol) followed by NaBH(OAc)3 (191 mg, 0.90 mmol) at °C and the reaction mixture was stirred at r.t. for 16 hrs. The mixture was diluted with DCM (mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (30 mg, 21.6% yield) as yellow solid. LC/MS (ESI) (m/z): 4(M+H)+. Step 7: 4-((2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)methyl)morpholine-2-carboxylic acid id="p-534" id="p-534" id="p-534" id="p-534" id="p-534" id="p-534" id="p-534" id="p-534" id="p-534"

[0534]To a solution of methyl 4-((2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)morpholine- 2-carboxylate (30 mg, 0.065 mmol) in THF (2 mL) /H2O (1 mL) /MeOH (41 mL) was added 241 WO 2022/034568 PCT/IB2021/059266 LiOH.H2O (27 mg, 0.65 mmol) and the reaction was stirred at r.t. for 2 hrs. Volatiles were removed under vacuum and the residue was diluted with H2O (5 mL). The mixture was adjusted with IN aq.HCl to pH~4 and extracted with EtOAc (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 5-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (13 mg, 44.7% yield) as white solid. LC/MS (ESI) (m/z): 447 (M+H)+. 1HNMR (4MHz, CD3OD) 5 7.84 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 7.9 Hz, 1H), 5.73 (s, 2H), 4.19 (s, 3H), 4.- 4.12 (m, 1H), 4.01 - 3.95 (m, 1H), 3.76 - 3.70 (m, 1H), 3.69 - 3.62 (m, 2H), 3.25 - 3.19 (m, 1H), 3.17 - 3.09 (m, 1H), 3.00 - 2.94 (m, 1H), 2.89 - 2.80 (m, 3H), 2.70 - 2.64 (m, 1H), 2.62 (s, 3H), 2.52 - 2.39 (m, 2H), 1.57 - 1.36 (m, 2H), 0.93 - 0.65 (m, 3H). Example 167& 168& 169: (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-1,2,3-triazol-2- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3- yl)acetic acid & (R)-2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid & (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid Step 3 LiOH MeOH/THF/H2O Example 167 Example 169 Step 1: ethyl (R)-2-(l-(2-(difluoromethyl)-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate id="p-535" id="p-535" id="p-535" id="p-535" id="p-535" id="p-535" id="p-535" id="p-535" id="p-535"

[0535]To a mixture of ethyl (R)-2-(l-(2-(difluoromethyl)-6-(5-(hydroxymethyl)-l-methyl-lH- l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (68 mg, 0.17 mmol), TEA (60 mg, 0.6 mmol) in DCM (5 mL) was added drop-wisely MsCl (28 mg, 0.25 mmol) at 0 °C. After the addition, the resulting solution was stirred at r.t. for another 2 hrs. The mixture was diluted with DCM (10 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (75 mg, 92.8% yield) as colorless oil, which was directly used in the next reaction without purification. LC-MS (ESI) m/z: 488 (M+l) +. 242 WO 2022/034568 PCT/IB2021/059266 Step 2: ethyl (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate (3) & ethyl (R)- 2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate (3a) & ethyl (R)-2-(l-(6-(5-((4- (cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- (difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate (3b) id="p-536" id="p-536" id="p-536" id="p-536" id="p-536" id="p-536" id="p-536" id="p-536" id="p-536"

[0536]To a mixture of ethyl (R)-2-(l-(2-(difluoromethyl)-6-(l-methyl-5- (((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (75 mg, 0.15 mmol), 4-(cyclopropylmethyl)-2H-l,2,3-triazole (19 mg, 0.15 mmol) in MeCN (2 mL) was added DBU (45.6 mg, 0.3 mmol) and the mixture was stirred in a CEM microwave reactor at 1°C for 1 hr. The mixture was diluted with DCM (10 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-40% of EtOAc in PE) to give compound 3(22 mg, 27.8% yield) and a mixture of compound 3a and 3b(50 mg, 63.1% yield) as colorless oil. LC-MS(ESI) m/z: 515 (M+l) +. Step 3: (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid id="p-537" id="p-537" id="p-537" id="p-537" id="p-537" id="p-537" id="p-537" id="p-537" id="p-537"

[0537]To a solution of ethyl 2-[(3R)-l-[6-(5-{[4-(cyclopropylmethyl)-2H-l,2,3-triazol-2- yl]methyl}-l-methyl-lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl]piperidin-3-yl]acetate (22 mg, 0.04 mmol) in MeOH (1 mL), water (1 mL) and THE (2 mL) was added LiOH (13 mg, 0.4 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl to pH~3 and extracted with DCM (2x3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (5.2 mg, 30.6% yield) as white solid. LC/MS (ESI) m/z: 487 (M+l) +. 1HNMR (400 MHz, CD3OD) 5 8.00 (d, J= 8.6 Hz, 1H), 7.66 (d, J= 8.Hz, 1H), 7.36 (s, 1H), 6.91 (t, J= 54.4 Hz, 1H), 6.25 (s, 2H), 3.90 (s, 3H), 3.06 (d, J= 9.7 Hz, 1H), 2.97 (d, J= 11.8 Hz, 1H), 2.71 -2.61 (m, 1H), 2.47-2.41 (m, 1H), 2.38 (d, J = 7.0 Hz, 2H), 2.(d, J=6.3Hz, 2H), 2.13 -2.03 (m, 1H), 1.76 (d, J= 12.8 Hz, 1H), 1.72- 1.58 (m, 2H), 1.13-1.(m, 1H), 0.89 - 0.76 (m, 1H), 0.38 - 0.30 (m, 2H), 0.06 - 0.03 (m, 2H).

Example 168:(R)-2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid and example 169:(R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid were prepared as the same manner of example 167,the absolute configuration was confirmed by NOE. 243 WO 2022/034568 PCT/IB2021/059266 Example 168:LC/MS (ESI) m/z: 487 (M+l) +. 1HNMR (400 MHz, CD3OD) 5 8.22 (d, J= 8.Hz, 1H), 7.84 (d, J= 8.6 Hz, 1H), 7.63 (s, 1H), 7.13 (t, J= 54.4 Hz, 1H), 6.35 (s, 2H), 4.14 (s, 3H), 3.21 (d, J= 11.3 Hz, 1H), 3.16-3.07 (m, 1H), 2.83 (td,J= 11.2, 3.6 Hz, 1H), 2.63-2.(m, 3H), 2.31 (d, =6.5 Hz, 2H), 2.29 - 2.20 (m, 1H), 1.96- 1.88 (m, 1H), 1.88- 1.71 (m, 2H), 1.27 - 1.18 (m, 1H), 0.94 - 0.85 (m, 1H), 0.54 - 0.44 (m, 2H), 0.09 - 0.02 (m, 2H).

Example 169:LC/MS (ESI) m/z: 487 (M+l) +. 1HNMR (400 MHz, CD3OD) 5 8.22 (t, J= 4.Hz, 2H), 7.86 (d, J= 8.6 Hz, 1H), 7.23 (t, J= 54.4 Hz, 1H), 6.23 (s, 2H), 4.33 (s, 3H), 3.23 (d, J = 11.3 Hz, 1H), 3.17-3.10 (m, 1H), 2.89 - 2.78 (m, 1H), 2.65 - 2.58 (m, 1H), 2.55 (d, J= 7.0 Hz, 2H), 2.35 - 2.31 (m, 2H), 2.30 - 2.22 (m, 1H), 1.97 - 1.78 (m, 3H), 1.28-1.17 (m, 1H), 1.00 - 0.90 (m, 1H), 0.54 - 0.44 (m, 2H), 0.20 -0.11 (m, 2H).

Example 170: 2-(4-(2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetic acid Step 1: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate id="p-538" id="p-538" id="p-538" id="p-538" id="p-538" id="p-538" id="p-538" id="p-538" id="p-538"

[0538]To a mixture of 3-bromo-2-ethyl-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine (760 mg, 2.0 mmol), ethyl 2-[(3R)-piperidin-3-yl]acetate (210 mg, 2.0 mmol) and Cs2CO3 (1.9 g, 5.9 mmol) in 1,4-dioxane (20 mL) was added RuPhos (46 mg, 0.1 mmol) and Ruphos-Pd-G3 (80 mg, 0.1 mmol) under N2 atmosphere. The resulting mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-30% of EtOAc in PE) to give the title compound (810 mg, 85.8% yield) as colorless oil. LC/MS (ESI) m/z: 474 (M+H)+. 1HNMR (400 MHz, CDC13) 5 7.99 (d, J= 8.3 Hz, 1H), 131 (d, J= 8.4 Hz, 1H), 5. 244 WO 2022/034568 PCT/IB2021/059266 - 5.31 (m, 2H), 4.76 - 4.71 (m, 1H), 4.20 - 4.16 (m, 2H), 4.15 (s, 3H), 4.03 - 3.96 (m, 1H), 3.92 - 3.83 (m, 2H), 3.51 (d,J=4.5 Hz, 1H), 3.11 - 3.02 (m, 1H), 2.95 - 2.80 (m, 4H), 2.68 - 2.56 (m, 2H), 2.52 - 2.43 (m, 1H), 1.82 - 1.68 (m, 3H), 1.55 - 1.50 (m, 3 H), 1.36 (t, J= 7.5 Hz, 3H), 1.(t,J=7.1Hz, 3H), 1.17 (d, J =6.1 Hz, 1H), 1.01 (d,J=6.0Hz, 1H). Step 2: ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)pyridin-3- yl)morpholin-2-yl)acetate [0539]To a mixture of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (810 mg, 1.7 mmol) in MeOH (10 mL) was added PPTS (610 mg, 4 mmol) and the mixture was stirred at 60 °C for hrs. The reaction mixture was diluted with DCM (20 mL), washed with saturated aq.NaHCOsolution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-50% of EtOAc in PE) to give the title compound (520 mg, 78.1% yield) as white solid. LC/MS (ESI) m/z: 390 (M+H)+. Step 3: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate [0540]To a mixture of ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate (60 mg, 0.15 mmol) and pyridine (200 mg, 0.75 mmol) in DCM (5 mL) was added a solution of 4-nitrophenyl chloroformate (90 mg, 0.45 mmol) in DCM (1 mL) drop-wisely at 0 °C and the mixture was stirred at r.t. for 3 hrs. The reaction mixture was diluted with DCM (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (80 mg, 92.3% yield) as yellow solid. LC/MS (ESI) m/z: 555 (M+H)+. Step 4: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate id="p-541" id="p-541" id="p-541" id="p-541" id="p-541" id="p-541" id="p-541" id="p-541" id="p-541"

[0541]To a mixture of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (80 mg, 0.14 mmol) and DIEA (190 mg, 0.15 mmol) in THE (4 mL) was added methyl(propyl)amine (22 mg, 0.3 mmol) at 0 °C and the reaction mixture was stirred at r.t. for hrs. The mixture was diluted with EtOAc (10 mL), washed with IN aq.NaOH solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (mg, 71.0% yield) as white solid. LC/MS (ESI) m/z: 489 (M+H)+. Step 5: 2-(4-(2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetic acid id="p-542" id="p-542" id="p-542" id="p-542" id="p-542" id="p-542" id="p-542" id="p-542" id="p-542"

[0542]To a solution of ethyl 2-[(3R)-l-{2-ethyl-6-[l-methyl-5- 245 WO 2022/034568 PCT/IB2021/059266 ({[methyl(propyl)carbamoyl]oxy}methyl)-lH-l,2,3-triazol-4-yl]pyridin-3-yl}piperidin-3- yl]acetate (50 mg, 0.11 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (18 mg, 0.5 mmol) and the mixture was stirred at 25 °C for 1 hr. The mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc twice and acidified with IN aq.HCl to pH= 3. The mixture was extracted with EtOAc (3x5 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (20.1 mg, 42.6% yield) as white solid. LC/MS (ESI) m/z: 461 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.84 (d, J= 8.Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 5.76 (s, 2H), 4.18 (s, 3H), 4.15 - 4.08 (m, 1H), 4.00 -3.94 (m, 1H), 3.88 - 3.80 (m, 1H), 3.22 (t, J= 7.0 Hz, 1H), 3.12 (dd, J= 13.0, 7.3 Hz, 2H), 2.99 - 2.88 (m, 4H), 2.83 (d, J= 17.1 Hz, 3H), 2.66 - 2.58 (m, 1H), 2.57 - 2.46 (m, 2H), 1.59 - 1.49 (m, 1H), 1.- 1.33 (m, 4H), 0.78 (dt, J= 74.8, 7.2 Hz, 3H). Example 171: 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)morpholin-2-yl)acetic acid Step 1: ethyl 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-ethylpyridin-3-yl)morpholin-2-yl)acetate [0543]To a mixture of ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate (50 mg, 0.13 mmol) and 2-chloro-4-cyclobutylpyrimidine (32.5 mg, 0.19 mmol) in THF (2 mL) was added t-BuOK (0.26 mL, 0.26 mmol, IM in THF) drop- wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with ice- water and extracted with EtOAc (2x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (mg, 89.6% yield) as yellow solid, which was used in the next step directly. LC/MS (ESI) m/z: 5(M+H)+. Step 2: 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)- 2-ethylpyridin-3-yl)morpholin-2-yl)acetic acid [0544]To a solution of ethyl 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-1H- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)morpholin-2-yl)acetate (60 mg, 0.12 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (24 mg, 0.6 mmol) and the mixture was stirred at r.t. for 2 hrs. The reaction mixture was concentrated to dryness and the residue was 246 WO 2022/034568 PCT/IB2021/059266 dissolved in water. The mixture was washed with EtOAc twice, acidified with IN aq.HCl to pH = and extracted with EtOAc (3x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (11.mg, 20% yield) as white solid. LC/MS (ESI) m/z: 494 (M+H)+. 1H NMR (400 MHz, CD3OD) 8.41 (d, J= 5.1 Hz, 1H), 7.88 (d, J= 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 6.99 (d, J= 5.1 Hz, 1H), 6.20 (s, 2H), 4.23 (s, 3H), 4.13 - 4.06 (m, 1H), 3.99 - 3.93 (m, 1H), 3.87 - 3.79 (m, 1H), 3.- 3.47 (m, 1H), 3.15 - 3.09 (m, 1H), 2.95 - 2.83 (m, 4H), 2.65 - 2.58 (m, 1H), 2.56 - 2.46 (m, 2H), 2.28-2.18 (m, 4H), 2.08 - 1.97 (m, 1H), 1.85 -1.76 (m, 1H), 1.24 (t, J = 7.5 Hz, 3H).

Example 172: 2-(4-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetic acid Step 1: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate [0545]To a solution of ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate (60 mg, 0.154 mmol) in DCM (2 mL) was added TEA (mg, 0.46 mmol) followed by MsCl (35 mg, 0.3 mmol) at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with DCM (5 mL), washed with saturated aq.NaHCO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (mg, 81.9% yield) as yellow solid, which was directly used in the next reaction without purification. LC/MS (ESI) m/z: 468 (M+H)+. Step 2: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate [0546]To a solution of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (59 mg, 0.13 mmol) in toluene (3 mL) and 247 WO 2022/034568 PCT/IB2021/059266 H2O (0.5 mL) was added 5-propyl-l,2-dihydropyridin-2-one (35 mg, 0.25 mmol), K2CO3 (52 mg, 0.38 mmol) and TBAF (5 mg, cat.) and the mixture was stirred at 110 °C for 3 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (55 mg, 85.7% yield) as yellow solid, which was directly used in the next step. LC/MS (ESI) m/z: 509 (M+H)+. Step 3: 2-[(2R)-4-(2-ethyl-6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]- lH-l,2,3-triazol-4-yl}pyridin-3-yl)morpholin-2-yl]acetic acid [0547]To a solution of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (55 mg, 0.11 mmol) in THF (4 mL) was added MeOH (1 mL), water (1 mL), LiOH (26 mg, 1.08 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was acidified with IN aq.HCl to pH~4 and extracted with EtOAc (3x3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by pre.HPLC to give the title compound (20 mg, 38.5% yield) as white solid. LC/MS (ESI) m/z: 481 (M+H)+. 1H NMR (400 MHz, CD3OD) 5 7.90 (d, J= 8.4 Hz, 1H), 7.69 -7.65 (m, 1H), 7.61 (d, J= 8.4 Hz, 1H), 7.-131 (m, 1H), 6.54 (d, J= 9.2 Hz, 1H), 5.89 (s, 2H), 4.17 (s, 3H), 4.15-4.10 (m, 1H), 4.03-3.(m, 1H), 3.91 - 3.83 (m, 1H), 3.20 - 3.12 (m, 1H), 3.04 - 2.93 (m, 4H), 2.69 - 2.61 (m, 1H), 2.59 - 2.50 (m, 2H), 2.23 (t, J= 7.5 Hz, 2H), 1.41 - 1.32 (m, 5H), 0.78 (t, J= 13 Hz, 3H).

BIOLOGICAL ASSAYS LPA1 Calcium Flux Assays [0548]The effectiveness of compounds of the present invention as LPA1 inhibitors can be determined in an LPA1 functional antagonist assay as follows: [0549]PathHunter® CHO-K1 EDG2 P־Arrestin Cell Line (Eurofins DiscoverX Corporation, Cat#93-0644C2) were plated overnight (11,500 cells/well) in poly-D-lysine coated 384-well microplates (Corning, Cat#3 56697) in Assay Complete Cell Plating 35 Reagent (Eurofins DiscoverX Corporation, Cat#93-0563R35). Following overnight culture, cells were loaded with calcium indicator dye from the HitHunter Calcium No WashPLUS Assay kit (Eurofins DiscoverX Corporation, Cat#93-0091) for 45 minutes at 37°C. Test compounds solubilized in DMSO (Sigma, Cat#276855) on 384-well polypropylene microplates (Greiner bio-one, Cat#781280) were then diluted to intermediate concentration with assay buffer [IX HBSS calcium/magnesium (Coming, Cat#2 1-023-CM) and 20mMHEPES (Coming, Cat#25-060-Cl)] 248 WO 2022/034568 PCT/IB2021/059266 before addition to cells by Agilent Velocity 11 with a final concentration of 0.4% DMSO. After compound addition, assay plates were equilibrated to room temperature for 30 minutes. Cells were then stimulated by addition of EC80 concentration of LPA (Cat#, 10010093) in assay buffer containing [1XHBSS calcium/magnesium (Coming, Cat#2 1-023-CM), 20mMHEPES (Corning, Cat#25-060-Cl), and 0.1% BSA (Sigma, Cat#A8806)] using Molecular Devices FLIPR Tetra PLUS®. IC50 values were determined by Chemical and Biological Information System from Chemlnnovation Software, Inc. [0550]The compounds of this invention were tested for their activity to inhibit LPA1 as determined in an LPA1 functional antagonist assay as described herein. Results of LPA1 assay are given in Table 1. Table 1. Activity data in LPA1 assay* * A: <100 nM; B:100 ~ 500 nM; C: 500 ~ 5000 nM; D: 5000 nM ~ 10 pM Example No. LPA1IC50 1 C 2 C 3 c 4 B D 6 A 7 C 8 D 9 D B 11 D 12 A 13 A 14 A A 249 WO 2022/034568 PCT/IB2021/059266 16 A 17 A 18 C 19 D D 21 C 22 B 23 D 24 A B 26 B 27 C 28 C 29 B C 31 D 32 C 33 D 34 C B 36 B 37 D 38 D 39 C 40 C 41 B 42 C 250 WO 2022/034568 PCT/IB2021/059266 43 D 44 D 45 B 46 D 47 D 48 D 49 D 50 D 51 D 52 C 53 D 54 D 55 D 56 D 57 D 58 A 59 A 60 A 61 C 62 C 63 B 64 C 65 D 66 A 67 B 68 C 69 C 251 WO 2022/034568 PCT/IB2021/059266 70 D 71 D 72 D 73 D 74 A 75 C 76 A 77 B 78 A 79 A 80 A 81 D 82 A 83 B 84 A 85 A 86 B 87 A 88 B 89 A 90 A 91 D 92 D 93 B 94 C 95 A 96 B 252 WO 2022/034568 PCT/IB2021/059266 97 B 98 B 99 A 100 B 101 A 102 A 103 A 104 A 105 A 106 D 107 D 108 C 109 C 110 D 111 D 112 C 113 C 114 D 115 D 116 A 117 B 118 D 119 B 120 C 121 C 122 B 123 B 253 WO 2022/034568 PCT/IB2021/059266 124 A 125 A 126 B 127 B 128 B 129 A 130 A 131 B 132 A 133 B 134 B 135 D 136 B 137 B 138 B 139 B 140 B 141 B 142 B 143 A 144 C 145 C 146 D 147 A 148 A 149 B 150 B 254 WO 2022/034568 PCT/IB2021/059266 151 C 152 A 153 C 154 B 155 C 156 B 157 C 158 D 159 D 160 C 161 C 162 A 163 B 164 D 165 B 166 D 167 A 168 A 169 B 170 C 171 A

Claims

WO 2022/034568 PCT/IB2021/059266 WE CLAIM:

1. A compound of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups; L2 is a covalent bond or (CR7R7)P; L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond; Q is C(=O)NR9R10, C(=O)OR10, or a ring selected from a 5- or 6-membered heteroaryl group or a 5- or 6-membered heterocyclyl group, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or an oxo group attached to a ring member, and wherein the ring is substituted with (R3)n and one R4; X1 is N, O or CR6a; X2 is N or NR6; X3 is N, NR6 or CR6, wherein the dashed circle denotes bonds forming a five-membered aromatic ring; Y1, Y2, Y3 and Y4 are each independently N or CR5, provided that at least one but no more than two of Y1, Y2, Y3 and Y4 are N; Z is CH2 or O; 256 WO 2022/034568 PCT/IB2021/059266 R1 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- calkyl-OH, C1-6alkoxy, haloC1-6alkoxy, CN, C3-7cycloalkyl, NRaRb, C1-ealkyl-NRaRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O; R2 is (CR7R7)q-R8; R3 at each occurrence is independently hydrogen, halogen, CN, C1-6alkyl, or C3-7cycloalkyl; R4is independently hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci- ealkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3- 7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7- membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R5 at each occurrence is independently hydrogen, halogen, C1-6alkyl, haloCi-ealkyl, OH, Ci- 6alkyl-OH, C1-6alkoxy, C1-6alkyl-C1-6alkoxy, haloCi-alkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- ealkyl-NRaRb; each occurrence of R6a and R6 is independently hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R7 at each occurrence is independently hydrogen, C1-4alkyl, C3-5cycloalkyl, or twoR7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; R8 is C(=O)OR7, C(=O)NRaRb, CN, C(=O)NHC(=O)R7, C(=O)NHS(=O)2R7, I ״N C(=O)NHS(=O)R7, S(=O)2R7, P(=O)(OH)2, or n'N ; each occurrence of R9 and R10 is independently hydrogen, C1-6alkyl substituted with 1-4 R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 257 WO 2022/034568 PCT/IB2021/059266 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; R11 at each occurrence is independently hydrogen, C1-6alkyl, haloCi-ealkyl, C2-6alkenyl, C2- ealkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- ?cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)p-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy; R12 at each occurrence is independently hydrogen, C1-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or C1-6alkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of C1-4alkyl, phenyl and benzyl; m is 1, or 2; n is 0, 1, or 2; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.

2. The compound of Claim 1, wherein Z is CH2.

3. The compound of Claim 1, wherein Z is O.

4. The compound of any one of Claims 1-3, wherein L1 is a covalent bond.

5. The compound of any one of Claims 1-3, wherein L1 is CH2 optionally substituted with 1or 2 methyl groups.

6. The compound of any one of Claims 1-3, wherein L1 is CH2.

7. The compound of any one of Claims 1-6, wherein each occurrence of R1 is independentlyhydrogen.

8. The compound of any one of Claims 1-6, wherein each occurrence of R1 is independently halogen. 258 WO 2022/034568 PCT/IB2021/059266

9. The compound of any one of Claims 1-6, wherein m is 2, one R1 is hydrogen, and the other R1 is halogen.

10. The compound of any one of Claims 1-6, wherein m is 2, one R1 is hydrogen, and the other R1 is F.

11. The compound of any one of Claims 1-6, wherein m is 2, each occurrence of R1 is F.

12. The compound of any one of Claims 1-11, wherein Y2 is N, and each of Y1, Y3 and Y4 isindependently CR5.

13. The compound of any one of Claims 1-11, wherein Y1 is CR5, Y2 is N, and each of Y3 and Y4is independently CH.

14. The compound of any one of Claims 1-11, wherein Y1 is CR5, Y2 is N, Y3 is N, and YCH.

15. The compound of any one of Claims 1-14, wherein R5 at each occurrence is independently hydrogen, methyl or ethyl.

16. The compound of any one of Claims 1-14, wherein R5 at each occurrence is independently hydrogen, CHF2 or CF3.

17. The compound of any one of Claims 1-14, wherein R5 at each occurrence is independently hydrogen, or CN.

18. The compound of any one of Claims 1-17, wherein X1 is N, X2 is N, and X3 is NR6.

19. The compound of any one of Claims 1-17, wherein X1 is CH, X2 is N, and X3 is NR6.

20. The compound of any one of Claims 1-17, wherein X1 is O, X2 is N, and X3 is CR6.

21. The compound of any one of Claims 1-20, wherein R6 is methyl.

22. The compound of any one of Claims 1-21, wherein L2 is a covalent bond.

23. The compound of any one of Claims 1-21, wherein L2 is (CR7R7)P.

24. The compound of any one of Claims 1-21, wherein L2 is CH2.

25. The compound of any one of Claims 1-24, wherein L3 is a covalent bond.

26. The compound of any one of Claims 1-24, wherein L3 is O.

27. The compound of any one of Claims 1-24, wherein L3 is NR7.

28. The compound of any one of Claims 1-27, wherein q is 0.

29. The compound of any one of Claims 1-27, wherein q is 1.

30. The compound of any one of Claims 1-27, wherein q is 2.

31. The compound of any one of Claims 1-30, wherein R8 is COOH.

32. The compound of any one of Claims 1-31, wherein R9 is C1-4alkyl.

33. The compound of any one of Claims 1-32, wherein R10 is C1-6alkyl substituted with 1-R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted 259 WO 2022/034568 PCT/IB2021/059266 with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11.

34. The compound of any one of Claims 1-33, wherein R10 is C1-6alkyl.

35. The compound of any one of Claims 1-33, wherein R10 is (CH2)p-C3-7cycloalkyl.

36. The compound of any one of Claims 1-33, wherein R9 and R10, together with the nitrogenatom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.

37. The compound of any one of Claims 1-36, wherein Q is C(=O)NR9R10.

38. The compound of any one of Claims 1-36, wherein Q is a ring selected from 5-memberedheteroaryl or heterocyclyl and 6-membered heteroaryl or heterocyclyl, wherein the ring comprises at least on carbon atom, at least one nitrogen atom and optionally 1-heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or a carbonyl attached to a ring member, and wherein the ring is substituted with (R3)n and R4.

39. The compound of Claim 38, wherein Q is: is substituted with (R3)n and one R4 at any available carbon or nitrogen position.

40. The compound of Claim 38, wherein Q is: which is substituted with (R3)n and one R4 at any available carbon or nitrogen position. 260 WO 2022/034568 PCT/IB2021/059266

41. The compound of any one of Claims 1-40, wherein each occurrence of R3 is independently hydrogen, halogen, or C1-4alkyl.42. The compound of any one of Claims 1-40, wherein each occurrence of R3 is independently C1-4alkyl.43. The compound of any one of Claims 1-40, wherein each occurrence of R3 is independently methyl.44. The compound of any one of Claims 1-43, wherein R4 is independently hydrogen, Ci- ealkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy.45. The compound of any one of Claims 1-43, wherein R4 is independently (CH2)q-5-6- membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11.46. The compound of any one of Claims 1-43, wherein R4 is independently C1-6alkyl, C2- 6alkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, or C2- 6alkenyl-C3-7cycloalkyl.47. The compound of any one of Claims 1-46, having a structure of Formula (II), wherein:

42.Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein oxygen may be a ring 261

43.WO 2022/034568 PCT/IB2021/059266 member and/or an oxo attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;

44.X1 is N, or CR6a;

45.R6a is hydrogen, or methyl;

46.R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;

47.R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; and t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1; and further provided that when Lis CH2 optionally substituted with 1 or 2 methyl groups, w is 0.

48. The compound of Claim 47, wherein Z is CH2.

49. The compound of Claim 47, wherein Z is O.

50. The compound of any one of Claims 47-49, wherein L1 is a covalent bond.

51. The compound of any one of Claims 47-49, wherein L1 is CH2 optionally substituted with1-2 methyl.

52. The compound of any one of Claims 47-49, wherein L1 is CH2.

53. The compound of any one of Claims 47-52, wherein each occurrence of R1 isindependently hydrogen.

54. The compound of any one of Claims 47-52, wherein each occurrence of R1 is independently halogen.

55. The compound of any one of Claims 47-52, wherein one R1 is hydrogen, and the other Ris halogen.

56. The compound of any one of Claims 47-52, wherein one R1 is hydrogen, and the other Ris F.

57. The compound of any one of Claims 47-52, wherein each occurrence of R1 is independently F.

58. The compound of any one of Claims 47-57, wherein the moiety59. The compound of any one of Claims 47-58, wherein each R5 is independently hydrogen, halogen, C1-6alkyl or haloCi-ealkyl. 262

59.WO 2022/034568 PCT/IB2021/059266

60. The compound of any one of Claims 47-58, wherein each R5 is independently C1-6alkyl.

61. The compound of any one of Claims 47-58, wherein each R5 is independently methyl orethyl.

62. The compound of any one of Claims 47-58, wherein each R5 is independently CHF2 or CF3.

63. The compound of any one of Claims 47-62, wherein X1 is N.

64. The compound of any one of Claims 47-62, wherein X1 is CH.

65. The compound of any one of Claims 47-64, wherein R6 is methyl.

66. The compound of any one of Claims 47-65, wherein L2 is a (CR7R7)P.

67. The compound of any one of Claims 47-65, wherein L2 is a CH2.

68. The compound of any one of Claims 47-65, wherein L3 is a covalent bond.

69. The compound of any one of Claims 47-65, wherein L3 is O.

70. The compound of any one of Claims 47-65, wherein L3 is NR7.

71. The compound of any one of Claims 47-70, wherein Q is: substituted with (R3)n and one R4 at any available carbon or nitrogen position, and n is 0, 1 or 2.

72. The compound of Claim 71, wherein Q is substituted with (R3)n and one R4 atavailable any carbon or nitrogen position, and n is 0, 1 or 2.73. The compound of any one of Claims 47-70, wherein Q is: 263

73.WO 2022/034568 PCT/IB2021/059266 which is substituted with (R3)n and one R4 at available any carbon or nitrogen position, and n is 0, 1 or 2.

74. The compound of any one of Claims 47-73, wherein each occurrence of R3 is independently hydrogen, halogen, or C1-4alkyl.

75. The compound of any one of Claims 47-73, wherein each occurrence of R3 is independently C1-4alkyl.

76. The compound of any one of Claims 47-73, wherein each occurrence of R3 is independently methyl.

77. The compound of any one of Claims 47-76, wherein R4 is independently hydrogen, Ci- ealkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, C1-6alkyl, or C1-6alkoxy.

78. The compound of any one of Claims 47-76, wherein R4 is independently (CH2)q-5-6- membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11.

79. The compound of any one of Claims 47-76, wherein R4 is independently C1-6alkyl, C2- 6alkynyl, C1-6alkoxy, (CH2)p-C1-6alkoxy, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, or C2-alkynyl-C3-7cycloalkyl. . R1R13

80. The compound of any one of Claims 47-79, wherein the O moiety isR1

81. The compound of any one of Claims 47-80, wherein R13 is hydrogen.

82. The compound of any one of Claims 47-80, wherein R13 is methyl.

83. The compound of any one of Claims 47-80, wherein R13 is cyclopropyl.

84. The compound of any one of Claims 1-46 or 48-83, having the structure of Formula (III), 264 WO 2022/034568 PCT/IB2021/059266 (HI), wherein: X1 is N, or CR6a; R6a is hydrogen, or methyl; R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; R13 at each occurrence is independently hydrogen, C1-4alkyl, or C3-5cycloalkyl; and t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1, and further provided that when Lis CH2 optionally substituted with 1 or 2 methyl groups, w is 0;.

85. The compound of Claim 84, wherein Z is CH2.

86. The compound of Claim 84, wherein Z is O.

87. The compound of any one of Claims 84-86, wherein L1 is a covalent bond.

88. The compound of any one of Claims 84-86, wherein L1 is CH2 optionally substituted with1-2 methyl.

89. The compound of any one of Claims 84-86, wherein L1 is CH2.

90. The compound of any one of Claims 84-89, wherein each occurrence of R1 isindependently hydrogen.

91. The compound of any one of Claims 84-89, wherein each occurrence of R1 is independently halogen.

92. The compound of any one of Claims 84-89, wherein one R1 is hydrogen, and the other Ris halogen. 265 WO 2022/034568 PCT/IB2021/059266

93. The compound of any one of Claims 84-89, wherein one R1 is hydrogen, and the other Ris F.

94. The compound of any one of Claims 84-89, wherein each occurrence of R1 is independently F. JWV >AA/V n ־r(R5)t II 1

95. The compound of any one of Claims 84-94, wherein the moiety is .

96. The compound of any one of Claims 84-95, wherein each R5 is independently hydrogen, halogen, or C1-6alkyl.

97. The compound of any one of Claims 84-95, wherein each R5 is independently C1-6alkyl.

98. The compound of any one of Claims 81-95, wherein each R5 is independently methyl orethyl.

99. The compound of any one of Claims 84-98, wherein X1 is N.

100. The compound of any one of Claims 84-98, wherein X1 is CH.

101. The compound of any one of Claims 84-100, wherein R6 is methyl.

102. The compound of any one of Claims 84-101, wherein L2 is a (CR7R7)P.

103. The compound of any one of Claims 84-101, wherein L2 is a CH2.

104. The compound of any one of Claims 84-101, wherein L3 is a covalent bond.

105. The compound of any one of Claims 84-101, wherein L3 is O.

106. The compound of any one of Claims 84-101, wherein L3 is NR7.

107. The compound of any one of Claims 84-106, wherein R9 is C1-4alkyl.

108. The compound of any one of Claims 84-107, wherein R10 is C1-6alkyl substituted with 1- R11, (CR12R12)q-C2-6alkenyl substituted with 1-4 R11, (CR12R12)q-C2-6alkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11.

109. The compound of any one of Claims 84-107, wherein R10 is C1-6alkyl.

110. The compound of any one of Claims 84-107, wherein R10 is (CH2)q-C3-7cycloalkyl.

111. The compound of any one of Claims 84-107, wherein R9 and R10, together with thenitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. 266 WO 2022/034568 PCT/IB2021/059266

112. The compound of any one of Claims 84-111, wherein the moiety is

113. The compound of any one of Claims 84-112, wherein R13 is hydrogen.

114. The compound of any one of Claims 84-112, wherein R13 is methyl.

115. The compound of any one of Claims 84-112, wherein R13 is cyclopropyl.

116. The compound of Claim 1, selected from:

117. The compound of Claim 1, selected from: 267 WO 2022/034568 PCT/IB2021/059266

118. The compound of Claim 1, selected from: 268 WO 2022/034568 PCT/IB2021/059266

119. The compound of Claim 1, selected from:

120. A pharmaceutical composition comprising the compound of any one of Claims 1-119, and a pharmaceutically acceptable carrier.

121. A method for treating or preventing a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi) in a subject in need thereof, comprising administering an effective amount of a compound of any one of claims 1-119 to the subject.

122. The method of Claim 121, wherein the disease is pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, dernal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis 269 WO 2022/034568 PCT/IB2021/059266 (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis. 270